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ABSTRACT 
 
The objectives of this research were to test treatment and survival differences 
between women and men with lung cancer as there is minimal investigation in the 
literature.  Three research questions were developed with statistical testing for gender 
differences based on similar cancer type, stage, treatment assignment and survival.  Data 
for 44,863 primary lung cancer cases were collected from eight U.S. state-based cancer 
registries to investigate the research questions.  The lung cancer incidence data included 
the morphological cell-types of adenocarcinoma (AC); squamous cell carcinoma (SCC); 
large cell carcinoma (LCC) and small cell carcinoma (SCC).  Stage, grade, treatment 
type, as well as, individual characteristics such as gender, age at diagnosis, marital status 
at diagnosis and race were other variables obtained to be included in the statistical 
models.   
Reporting the overall effect for lung cancer gender specific treatment differences 
or survival has not been demonstrated in the literature to the author’s knowledge.  By 
convention, main effects and interaction effects are reported in the literature; without 
including an evaluation the overall effect of a variable on the outcome, possible 
misinterpretations could be made.  For example, utilizing the Cox’s Proportional Hazards 
model when the interaction effect of gender and treatment type received was examined, 
females were at an increased risk for death by as much 29% as compared to males (HR = 
1.18, 95% CI 1.09 – 1.29).  But when the gender effect on survival was assessed, there 
was an increase in females survivorship as compared to males by as much as 28% (HR =  
xvi 
0.80, 95% CI 0.72 – 0.97 ).   
In conclusion, by using a unique statistical approach, statistically significant Odds 
Ratios and Hazard Ratios were demonstrated for the research data set when the overall 
interaction effect on the outcome was examined.  Recommendations to health care 
practitioners include adhering to current guidelines, e.g. American Medical Association, 
for lung cancer treatments. Standard treatment protocols were not always followed for 
early stage disease, e.g. females versus males with stage I lung cancer were 1.71 times 
more likely to receive chemotherapy in combination with radiation therapy versus a 
standard first treatment course of surgery (OR = 1.71, 95% CI 1.06 – 2.78).  Also, 
depending on the lung cancer morphology and lung cancer treatment, females as 
compared to males could exhibit an increase in survivorship by as much as 28%.  To 
improve the results of medical care decisions for lung cancer, clinicians may find the 
information presented in this study useful and encourage further research on which 
treatment increases survival for both men and women.  
 
1 
CHAPTER I: INTRODUCTION 
Background 
There are many histological types of lung cancer and finding an optimum 
treatment regimen is a challenge.  Lung cancer typically is classified into two major 
divisions: small cell lung cancer (SCLC or oat cell carcinoma) and non-small cell lung 
cancer (NSCLC) 
2-5
.  SCLC accounts for approximately 20% of all the lung cancer cases, 
whereas about 80% of all lung cancer cases are NSCLC.  There are many types of 
NSCLC but the three major histological classifications are adenocarcinoma, large cell 
carcinoma, and squamous cell carcinoma 
6, 7
.  The treatment modalities for small cell 
lung cancer versus non-small lung cancer are different due to the biological response of 
the particular cancer cell type to various treatment regimens 
8-11
.  The medical 
interventions for each histological type can include any combination of treatment 
modalities such as surgery, radiation therapy, and/or chemotherapy.  Adding to the 
complexity of lung cancer is that the incidence, prevalence, and survival rates are also 
dissimilar for the specific histological type 
1, 2, 12, 13
.  
One prognostic factor for lung cancer ―in terms of treatment treatment/modality 
received‖ that requires further exploration is the relationship between lung cancer 
treatment(s) and gender.  There is limited research regarding if the treatment modality, 
e.g. radiation therapy, surgery, chemotherapy, received is dependent upon being a woman 
with lung cancer as compared to a man with lung cancer.  This is of particular interest  
because of all the various types of cancers and treatments available, lung cancer has 
2 
become the leading cause of death for women as there has been a 600% increase for 
women with lung cancer from 1930 to 1997 
44
.  Any effect which gender exerts in the 
decision regarding which lung cancer treatment modality decided upon must be 
disentangled from other prognostic factors.  The study question(s) of this research 
attempted to enumerate the risk of being a woman with lung cancer and type of treatment 
received compared to a man with lung cancer and the type of treatment modality that he 
receives.  An assessment was made to determine if a statistically significant association 
between gender and treatment modality exists.  Another aspect of gender differences that 
was investigated included the impact on survivorship between women and men with lung 
cancer.  Stratified analysis was based on the histological type, stage, grade, gender and 
the treatment modality or treatment modalities received in an attempt to investigate 
treatment effects on survival.  Much of the scientific literature on lung cancer research 
does not address survival and the relationship gender has to play due to the effects of 
specific histological lung cancer types, stage or progression of LC, and grade on gender 
and survival.  The purpose of this research study is to provide a quantitative assessment 
of the outcome (survival) for women as compared to men based on the particular 
treatment received for lung cancer 
14-17
.  
Minorities will also be included in the subject selection; it is important not to 
exclude minorities as they can provide valuable epidemiologic information.  In an 
attempt to facilitate minority research, United States government agencies, e.g. the 
National Cancer Institute (NCI), now mandate the inclusion of women, children, and 
3 
minorities if government funding is provided for the study 
18-20
.  For the purposes of this 
research, minorities are being included since the treatment modality selected for the 
treatment of lung cancer may be dependent upon race as well as gender 
21
.  In other 
words, race may or may not play a role in the treatment modality utilized for lung cancer.  
Although this research is primarily focused on what treatment modalities are 
utilized for men as compared to women, the impact of gender on lung cancer survival 
will also be considered. There are several reasons why is gender important as risk factor 
for lung cancer. First, according to the 2001 report by the Surgeon General 
44
, female 
lung cancer mortality increasing by 600% since 1930 noting that this is a ―full blown 
epidemic‖ 44. Secondly, the causal pathways of lung cancer development are blurred for 
women
 8, 13
.  For example, the causes of lung cancer among women seemingly different 
from men, are still not resolved 
3, 8, 13
.  One possible answer to this question is much of 
the current knowledge and treatment patterns for lung cancer are based on research 
primarily done on men.  Previously, the association between being a woman and the risk 
of lung cancer was considered negligible as reported in the 1964 Report of the Advisory 
Committee to the Surgeon General DHEW Publication Number PHS 1103
23
.  But as 
behavior and other temporal changes, such as cigarette smoking have occurred over the 
past several decades for women, lung cancer incidence and increased mortality rates of 
lung cancer 
24, 76, 77
.  Women historically have been excluded from clinical trials or if 
included, the data was not analyzed
22
.  If women are at a greater risk for lung cancer than 
men at the same level of smoking one result of women being excluded historically from 
4 
research studies is even there is no evidence in the literature to support this; results have 
been conflicting and limited 
22
.  A 1964 report of the ―Surgeon General on Women and 
Smoking‖ 23 did not reach any conclusions concerning what role gender difference may 
play in the development of lung cancer.  The 1964 report did conclude that although 
smoking was risk factor for lung cancer in men, smoking was not a risk factor for lung 
cancer in women as there was not enough scientific evidence to establish causality 
24
.  
What was not known at the time of the 1964 report was the temporal effect due to when 
women started smoking on a large scale and the development of lung cancer (lag time of 
approximately twenty years).  
Hypotheses have been developed based on possible physiological responses to 
carcinogens and hormonal related differences in women as compared to men but 
inconsistent results in the literature remains 
8, 15, 17, 25-27
.  Lung cancer is the leading cause 
of death of all cancers in both men and women in the United States 
28
.  The overall 
lifetime risk in women is 1 in 17 and for men 1 in 13 for lung cancer development 
27, 29, 
30
. Lung cancer has an extremely low 5 year survival rate of 15%.  The primary cause of 
lung cancer is due to smoking cigarettes; smoking is estimated as being a causal factor in 
80 – 90 % of all lung cancer cases 14, 15.   Some of the literature reports the susceptibility 
for lung cancer in women is different when compared to men with women by 
demonstrating an increased risk for lung cancer  
8, 14, 15, 31, 32
.  Another source for concern 
for women is second hand smoke; of the individuals that die from that exposure, 65 % are 
women 
33
.  This could possibly indicate hormonal differences may make women more 
5 
susceptible to smoke.  Sex differences in survival and susceptibility have been linked to 
estrogen as a lung cancer risk factor 
229
.   
 
Research Questions 
Given what present day research has and has not found concerning the treatment 
of lung cancer and the role gender has played in the selection of the treatment modality, 
the following research questions will be addressed in this dissertation:  
Question One: Do men and women with the same histological type and 
stage/grade of lung cancer receive the same treatment modality? 
Question Two: Are there differences in survival between men and women 
regardless of the treatment modality received? 
Question Three: Do men and women with the same histological type, stage/grade 
of lung cancer, and same treatment modality, have comparable survival? 
 
As stated in the abstract and in the background, the study or research question(s) 
will focus on the association between the treatment received by women with lung cancer 
as compared to that received by men. The study will investigate the overall survival 
patterns based on the treatment that a woman with lung cancer receives versus a man.  
 
 
 
6 
CHAPTER TWO: LITERATURE REVIEW 
Overview of the Lungs 
Anatomy and Physiology 
The lungs, part of the respiratory system, are coned shaped, sponge-like, and 
highly elastic organs located in the chest.  The functions of the respiratory system and in 
particular, the lungs, include gas exchange, moisturizing the inhaled air, stabilizing the 
temperature of all air to body temperature, and filtering harmful substances 
34, 35
.  As 
shown in Figure 5, the respiratory system includes the nasal cavity, the windpipe or 
trachea, and two lungs.  The upper tract of the respiratory system includes the mouth or 
oral cavity, the nasal cavity, and the trachea 
36
.  The lower tract of the respiratory system 
consists of lungs, bronchi, and alveoli. Inspiration and expiration are the two phases of 
respiration or breathing.  During each phase of respiration, the volume or dimensions of 
the chest cavity is changed, i.e. increased lung volume (inspiration) or decreased lung 
volume (expiration) 
36, 37
.  
Air entering into the body via the nose or mouth, contains approximately 21% 
oxygen with no carbon dioxide.  The air is drawn into the trachea and bronchi, and then 
enters the lungs through the left or right bronchi.  Air entering into the main branch of the 
bronchi will travel into smaller bronchi which further divide into smaller, complex tubes 
called the bronchioles 
36, 37
.  Mucus is secreted by the inner lining of the larger bronchial 
tubes.  One of the purposes of the secretion is to filter or trap dirt from the air.   In a 
continuous, sweeping process, the mucus is expelled from the lungs by cilia; cilia are 
7 
similar to hair or brush-like structures 
38
.  Coughing is another method by which mucus is 
removed from the lungs.  The final or most distal ends of the bronchioles are connected 
to small air sacs called alveoli.  The exchange of gases occurs in the alveoli. T he alveoli 
are very thinly walled, balloon-like structures that expand upon inspiration and relax or 
deflate upon expiration 
37, 38
.  Each alveolus is surrounded by small blood vessels called 
capillaries.  When the concentration of dissolved oxygen is greater in the alveoli than in 
the capillaries, oxygen diffuses across the alveoli walls into the blood plasma contained 
in the capillaries.  An increased concentration of CO2 in the blood results in carbon 
dioxide diffusing from the capillaries into the alveoli.  At the time air is exhaled, it 
contains approximately 16% oxygen and 4.5% carbon dioxide 
37, 38
.  
As previously described, the exchange of oxygen and carbon dioxide occurs in the 
lungs.  Each lung is identified by the apex, lobes, and base.  The left lung is comprised of 
2 lobe or sections; typically weighing 625 grams 
34, 39
.  The right lung has three lobes, 
approximately 567 grams.  The left lung is smaller than the right to accommodate the 
heart and other structures in the mediastinum.  The lungs have a surface area 
approximately equal to the size of a tennis court and while at rest, the entire body blood 
supply or blood volume, five liters, passes through the lungs each minute 
38
.   
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Figure 1: The Respiratory System          
             Source: webschoolsolutions.com/patts/systems/lungs.htm 
 
 
The Disease of Interest: Lung Cancer 
Any obstruction of air flow through the bronchial tree or at the alveoli can cause 
serious functional limitations or even death 
37, 38
.  Besides the various diseases which can 
obstruct airflow and affect the cellular respiration, the lungs can become cancerous 
10
.  
Physiological changes in the lung tissue where the lung becomes cancerous can be 
defined as an uncontrolled cell growth in the lung forming clumps of tissue referred to as 
malignant tumors 
37
.  Exposure to carcinogens, such as those present in tobacco smoke, 
immediately causes changes to the tissue lining the bronchi of the lungs (the bronchial 
mucous membrane), the more cumulative damage to the lung tissue, the greater the 
probability a tumor will develop 
9, 10
.  The non-small cell lung cancers (NSCLC) are 
grouped together because their prognosis and management is roughly identical 
2, 9, 54
.  
9 
There are 3 major subtypes of NSCLC: squamous, large cell, and adenocarcinoma 
1, 2, 55
.  
Squamous cell carcinoma starts in the larger breathing tubes but grows slower, this means 
that the size of these tumors vary when the diagnosis is made.  Adenocarcinoma (the 
slower growing type forms alveolar cell cancer) starts near the gas-exchanging surface of 
the lung 
56
.  It is less closely associated with smoking.  Large cell carcinoma is a fast-
growing form that grows near the surface of the lung 
4, 57
.  It is primarily a diagnosis of 
exclusion, and when more investigation is done, it is usually reclassified to squamous cell 
carcinoma or adenocarcinoma 
56
.  Small cell carcinoma (SCLC, also called "oat cell 
carcinoma") is the less common form of lung cancer.  Approximately 20% of all primary 
lung cancer diagnosed are small cell lung cancer and account for 30,000 to 35,000 cases 
per year in the United States 
13, 28
.  Small cell LC tends to start in the larger breathing 
tubes and progresses rapidly becoming quite large 
6, 10, 58, 59
.  SCLC is more sensitive to 
chemotherapy, but carries a worse prognosis and is often metastatic at presentation 
2, 3, 33
.  
This type of lung cancer is strongly associated with smoking 
4
.  Exposure to carcinogens, 
such as those present in tobacco smoke, immediately causes cumulative changes to the 
tissue lining the bronchi of the lungs (the bronchial mucous membrane) and the more 
tissue that gets damaged, the greater the probability a tumor will develop 
4, 37
.  Squamous 
cell carcinoma usually is diagnosed after the disease has spread 
1, 5, 12, 13
. The overall 
prognosis for all non-small cell lung cancers is poor, with a five-year survival rate of 
about 15% 
11, 13, 60
.  The survival rate is higher (close to 50%) when the cancer is detected 
and treated early 
13
.  Survival rates after surgery vary 
7, 43, 54, 61-63
.  For those with stage I 
10 
disease, the five-year survival rate is about 47% 
13, 64
.  For those with stage III disease, 
the five-year survival rate is 8% 
2, 13, 33, 64
.  Even when surgery and other therapies are 
initially successful, there is a high risk of the cancer reoccurring 
4, 27, 32, 65
.  This reflects 
the fact that squamous cell carcinoma is rarely restricted to just one area.  Squamous cell 
carcinoma readily spreads to other parts of the body 
4, 30, 66
.  
Cancer is a multistep progression of changes or phases that occur in the genes 
43, 
52, 67-71
.  The genotypic changes are characterized by the loss of normal cellular 
differentiation and an alteration in tissue morphology due to an increase of unrepaired 
DNA damage  and the formation of abnormal genomic variants 
10
.  Lung cancer can 
result from an exposure of a susceptible host to carcinogenic agents; these exposures 
cause progressive changes in the cell from metaplasia, to atypia and dysplasia, then 
developing into a carcinoma in situ and invasive cancer 
72
.  The changes that occur on the 
cellular level are variable from individual to individual, and not all neoplasms follow the 
same progress 
4
.  Metaplasia, the first phase of cancer development, is the transformation 
of a mature differentiated cell type into a different mature differentiated cell type 
4
.  This 
transformation is in response to an injury or insult at a cellular level which can make the 
tissues more susceptible to a malignant alteration.  Atypia is defined as an abnormality 
associated with a precancerous process.  An atypical cell (atypia) can also be an 
indication of an infection or irritation 
4, 37
.  Atypia can be caused by a chronic irritation 
and this has been shown increases the probability of premalignant lesions 
9
.  Dysplasia is 
typically an irreversible condition or change in the cell that is a precursor of invasive 
11 
epithelial tumors.  There levels or grades of dysplasia and high grade dysplasia can be 
difficult to distinguish from carcinoma in situ during histologic examination 
4, 37
.  
 
Exposures of Interest: Gender and Lung Cancer Treatment Modality 
There is limited research regarding the survival of women with lung cancer and 
the treatment received compared to the survival of men with lung cancer and the 
treatment men receive 
12, 40-45
.  Presently, there are no quantitative results that show 
whether there is a statistically significant difference regarding survival due to a particular 
treatment for women as compared to men having the same histological type and stage of 
lung cancer 
46-48
.  The goal of this research is to investigate the exposures, gender and 
treatment modality and their effect on the outcome, survival.  Several research questions 
must be answered in order to evaluate the relationship between these variables.  Belani 
et.al., 2007, in the article ―Women and lung cancer: Epidemiology, tumor biology, and 
emerging trends in clinical research‖, noted that ―emerging findings in the scientific 
literature reveal gender specific differences in cancer prognosis‖ 41.  The authors 
expressed an urgent need to increase research and funding to improve lung cancer care, 
women in particular 
41
.   Ringer et al. (2005) in the article "Influence of sex on lung 
cancer histology, stage, and survival in a Midwestern United States Tumor Registry." 
identified differences between men and women with regard to lung cancer type, stage at 
diagnosis, and survival in a single hospital system cancer registry.  The study design was 
a retrospective cohort with a target population based on case information from a lung 
12 
cancer tumor registry at a single hospital system composed of 2 independent hospitals in 
the Midwestern United States
27
.  This database included all patients from 1996 to 2002 
with known lung cancer or abnormal findings on chest radiography or computed 
tomography (N=2618).  Patients with adenocarcinoma or squamous cell, small-cell, or 
large-cell carcinoma were included in the study.  A total of 1216 men and 997 women 
were included in the study.  The authors found no significant difference in age between 
sexes at diagnosis
27
.  Women were significantly more likely to have adenocarcinoma or 
small-cell carcinoma but less likely to have squamous cell carcinoma compared with 
men.  There were no significant differences between sexes in the incidence of large-cell 
carcinoma.  No significant differences were found between men and women in terms of 
cancer stage at diagnosis 
27
.  There were significant differences in survival between the 
histologic types at years 3, 4, and 5.  Only patients with stage I disease showed a 
difference between sexes and only for years 2, 3, 4, and 5.  This study did not investigate 
the impact of treatment modality on survival, gender, histological type and stage of lung 
cancer.  Women were found to have a decreased survival with late stage lung cancer as 
compared to men 
27
 but there was no expansion of the results based on the type of 
treatment received for women and men.  
In the article by Ouellette, et. al. (1998), ―Lung Cancer in Women as Compared to 
Men: Stage, Treatment, and Survival‖ 8, gender differences in survival were examined.  
The authors
8
 cited several articles that reported on cardiovascular disease and the survival 
advantage for men as compared to women; Ouellette, et. al.’s research attempted to 
13 
identify gender disparities in lung cancer survival.  To test the hypothesis of a gender 
difference in lung cancer survival, a retrospective cohort study of 104 women and 104 
men was conducted.  Women were found to have a higher incidence of small cell lung 
cancer (25% versus 12% as compared to men); whereas men had a greater percentage of 
squamous cell carcinoma (51% versus 38% as compared to women) 
8
.  The authors noted 
there were no statistically significant survival differences between women and men but 
women were found to live, on average, 6 months longer then men (mean survivalwomen = 
24 months, mean survivalmen = 18 months).  Ouellette, et. al. reported when stratified 
analysis based on the stage of  lung cancer (Stage I, II, IIIa, IIIb, and IV)  was assessed, ― 
these two groups with a coefficient according to stage, there was a survival advantage in 
women, and they seem to live 12 months longer than men‖ 8.  The authors reported that 
this increase in women’s survivorship may be contributed to an intrinsic factor, e.g. 
hormones.  Ouellette, et. al. concluded the overall survival between men and women was 
not statistically significant but that there was a significant survival difference between 
men and women with lung cancer when stratified on stage. 
 The question about gender differences and lung cancer survival has not been 
resolved in the literature as conflicting results still exist 
40, 41, 49-52
.  A recently published 
article investigating gender differences and survival by Wisnivesky and Halm, 2007, 
―Sex-Differences in Lung Cancer Survival: Do Tumors Behave Differently in Elderly 
Women‖ examined women’s responses to treatment and their survival as compared to 
men 
53
.  The study was based on SEER data collected from men and women diagnosed 
14 
between 1991 and 1999 (N = 18,967) with stage I and stage II non-small cell lung cancer.  
It was shown that for early stages of lung cancer, that women have a better overall and 
relative survival as compared to men (p = 0.001).  The authors noted women as compared 
to men had a greater probability of being diagnosed with adenocarcinoma, tended to be 
diagnosed at an earlier age, and when the disease had not metastized (localized) 
53
.  
 
Epidemiology 
Epidemiology is utilized to monitoring the consequences of an intervention and is 
used in the development of hypotheses for risk factors 
73, 74
.  Epidemiological methods 
are used to study lung cancer for the identification of the disease frequency, determinants, 
and distribution of lung cancer in human populations 
73, 74
.  For example, there has been 
an increase of 600% in mortality for women with lung cancer since 1930 
28, 40, 60
 and 
without monitoring or the identification of the disease frequency in epidemiological 
terms ―this epidemic rise in lung cancer mortality44‖ 24, 75-77 may not have been identified.  
Alberg et. al, (2005) reported that in the 20
th
 century of the United States the lung cancer 
epidemic ―peaked and began to declined by century’s end, a decline that continues today‖  
40
.  The rates of lung cancer in women were shown to have a differential increase in lung 
cancer incidence and mortality over time as compared to men 
40
.  Lung cancer rates have 
peaked for men but the rates for women are still increasing in many regions of the world 
5, 16, 30, 65, 78, 79
.  While the gap between lung cancer gender differences is narrowing, the 
differences for in incidence and mortality rates are declining 
45, 46, 66, 80, 81
.  According to 
15 
the International Agency for Research on Cancer (IARC), rates of all lung cancer types 
among women and adenocarcinoma of the lung in men continue to rise in many Western 
countries 
5
.  Worldwide, lung cancer is the 10th leading cause of death and is the leading 
cause of death for all types of cancer 
5
.  The 5-year relative survival remains low; 
approximately 10% in Europe. In Developing Countries, the incidence of smoking-
related lung cancer is rising rapidly 
5, 30, 82
.  Countries such as China are expected to see a 
marked increase in lung cancer cases as smoking is exceedingly common 
5, 78
.  Devesa 
and Bray, 2005, reported recent total lung cancer incidence rates among males varied by 
4-fold, from 83.6 among U.S. Blacks to 21.1 in Sweden 
30
.  Rates in the Nordic countries, 
which varied by 2-fold from a high in Denmark to a low in Sweden, still were generally 
lower than in other parts of Europe, where the incidence rate was highest in the 
Netherlands 
30
.  Lung cancer rates in Italy, Slovenia and France were higher as compared 
to U.S. Whites or Canadian LC incidence.  The authors also noted that among females, 
recent incidence rates varied by almost 8-fold, with the highest among U.S. Blacks (35.8) 
and the lowest in Spain (4.6) 
30
.  The ranking of rates among females paralleled that in 
males, with the exception of Switzerland.  Lung cancer rates everywhere were higher 
among males than females 
30
. Male to female rate ratios varied from less than 2 in 
Iceland, U.S. Whites, Canada, Denmark and Sweden to more than 6 in Slovenia, Italy, 
and France and more than 10 in Spain 
13, 30
.  Henschke et. al. (2006) reported that the US 
cancer rates for men and women in their research showed a dose (pack-years) – incidence 
(lung cancer) threshold as there was a biological gradient associated with increased pack-
16 
years with an increased risk of lung cancer 
174
.    
In the United States, the American Cancer Society estimated that there were 
92,305 new cases of lung cancer in men and 79,544 new cases among women in 2006 
2
.  
The majority of cancer deaths among women and men are attributed to lung cancer 
2
. 
According to the American Cancer Society, approximately 60% of newly diagnosed lung 
cancer cases die within the first year of diagnosis 
2
.  The 5- year relative survival rate is 
approximately 15% in the United States.  The prevalence rates of smoking as reflected in 
the National Health Interviews, Current Population Survey, notes that smoking 
attributable cancer mortality for males is approximately 90% and 78% for females 
84-86
.  
Current literature about smoking habits (age when started smoking, number of cigarettes 
daily, duration frequency of inhalation, use of dark tobacco, and non-filter cigarettes) 
87-
89
, notes that a smoker is twenty two times more likely to die from lung cancer than a 
nonsmoker 
86
.  In Chapter Three ―The Descriptive Epidemiology of Lung Cancer‖ from 
the book Epidemiology of Lung Cancer: Academic Press; 1998, a study from the 
Saskatchewan Cancer Foundation (a population based cancer registry) was referenced by 
Thomas J. Mason.  He noted endogenous and exogenous factors may contribute to the 
development of primary lung cancer in women 
83
.  Endogenous factors can be produced 
or can be synthesized within an organ in the body; exogenous factors are agents or factors 
from outside the body (cigarette smoke) 
37
.   
Zang and Wynder conducted a hospital-based prospective, case-control study on 
data collected from 1995 through 1995 that included 21,057 males as controls and 14,448 
17 
female controls that were originally diagnosed with non-smoking related diseases 
81
.  The 
authors found that at the same level of lifelong exposure to cigarette smoke, women had a 
1.5 times greater risk of developing lung cancer as compared to men 
90
.  There was a 
statistically significant difference in the incidence of adenocarcinoma; females were at a 
higher risk of developing adenocarcinoma versus males independent of tar yield per 
cigarette 
90
.  Zang and Wynder noted a statistically significant difference between 
squamous cell carcinoma for women as compared to men, dependent upon the level of 
total tar per cigarette (> 6 kg). Women were found to develop primary lung cancer at 
earlier age as compared to men, yet women smoked fewer cigarettes for a shorter time 
than men 
81
.  
Smoking patterns have changed over the past thirty years and the change in the 
dominant histologic lung cancer classifications, possible differences between gender 
emerges 
83
.  Lung cancer has a multivariable etiology and there are specific risks 
associated with the type of lung cancer 
3, 91-95
.  These secular trends can provide a clue to 
the understanding of lung cancer and future research for the impact on diagnosis, 
treatment, and outcome 
48
.  Other studies that identify patterns of risk by the histologic 
types include an article by Devesa, et al., 2005, utilizing data from the International 
Agency for Research on Cancer (IARC) databases 
30
.  Morphology-specific incidence 
data noted that the rates of all lung cancer types are increasing for women and 
adenocarcinoma is rising for men 
30
.  This trend continues even with the decrease in 
prevalence of smoking and the use of filtered and low tar cigarettes 
13
.  These finding are 
18 
consistent with current literature as the secular trends in histologic type with the annual 
rise in the incidence of adenocarcinoma 
10, 96-98
.  Govindan et al., 2006 in the article 
―Changing Epidemiology of Small-Cell Lung Cancer in the United States over the Last 
30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database‖, found 
that the proportion of women with SCLC increased from 28% in 1973 to 50% in 2002 
99
.   
When SCLC was compared to all lung cancer histologic types there was a decreased of 
SCLC from 17% in 1986 to 13% in 2002 
99
.  The authors also noted that although there 
was an overall decrease in small cell carcinoma, survival had not improved. Stockwell, et 
al., 1990, found the histological type of lung cancer varied by age, sex and the use of 
cigarettes; this was based on observations from a population based cancer registry in 
Florida 
96
.  A dose threshold for the amount of cigarettes smoked and the risk of lung 
cancer was not statistically significant.  The authors noted that adenocarcinomas were 
more frequent in the younger aged population (< 60 years of age) for both genders.  Men 
who smoked had a higher risk for squamous cell carcinoma whereas females very more at 
risk for small cell carcinoma 
96
.  Adenocarcinoma was the most frequently encountered 
histological type for women who were nonsmokers 
96
.  
 As there are differences in the incidence of histologic lung cancer types 
based on smoking patterns, the rates of incidence and mortality for lung cancer differ 
according to regional areas across the United States 
4
.  Geographic mapping of lung 
cancer incidence and mortality was introduced by Mason in the 1960’s while at the 
National Cancer Institute in Atlanta, Georgia 
83
.  This novel approach allowed for the 
19 
identification of regional differences in lung cancer rates; with this information Public 
Health resources were directed to areas with increased rates for purposes of prevention 
and monitoring of trends.  There are differences in smoking attributable risk between 
males (>90%) and females (<80%) although ratio between male smoking rates and 
female smoking rate approach unity 
83
.  These homogeneous and heterogeneous patterns 
of lung cancer etiology require further identification of factors other than smoking as to 
quantify the risk for the four major histologic types of lung cancer.  
Currently, lung cancer incidence in women is approximately equal to that of men 
as reported by the American Cancer Society (see Figure 6 below) 
2
.   Lung cancer in the 
United States is the most common cause of cancer death in women; today the mortality 
rate is more than two times what it was 25 years ago 
2
.  In Figure 7 below, the estimated 
number of U.S. lung cancer deaths is given for 2006.  Cancer of the lung and bronchus is 
the most common and most fatal cancer in men (31%), followed by prostate cancer 
(10%), and colon & rectum cancer (10%) 
2
.   The major killer of women from a cancer 
specific cause is lung cancer (27%), breast cancer (15%), and colon & rectum (10%) are 
the leading sites of cancer death 
2
.  
As women began smoking in increasing numbers during the 1930’s and 1940’s, 
the death rate due to lung cancer steadily increased with a dramatic rise in mortality rates 
in 1965 (see Figure 8) 
2-4, 79, 100, 101
.  Lung cancer mortality rates in women have reached a 
plateau since 1998 
102
.  As shown in the Figure 9 below, the death rate from lung cancer 
appears to have peaked in 1990 for men 
2
.  The age-adjusted lung cancer death rate in 
20 
men has been decreasing since 1990.  Prior to 1990, the major increase in cancer death 
rates for men was attributable to lung cancer 
2
.  When comparing the mortality rates 
between men and women (Figure 8 and Figure 9), the temporal effect of gender specific 
smoking patterns associated with the increase in lung cancer mortality is clearly 
demonstrated 
2, 102
.  
2006 Estimated US Cancer Cases*
*Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.
Source: American Cancer Society, 2006
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Figure 2: 2006 Estimated US Cancer Cases 
 
 
Figure 3: 2006 Estimated US Cancer Deaths 
 
 
21 
Cancer Death Rates*, for US Women, 
1930-2001
*Age-adjusted to the 2000 US standard population.
Source:  US Mortality Public Use Data Tapes 1960-2001, US Mortality Volumes 1930-1959,
National Center for Health Statistics, Centers for Disease Control and Prevention, 2004.
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Figure 4: US Women Cancer Death Rates 
 
Cancer Death Rates*, for US Men,
1930-2001
*Age-adjusted to the 2000 US standard population.
Source: US Mortality Public Use Data Tapes 1960-2001, US Mortality Volumes 1930-1959, 
National Center for Health Statistics, Centers for Disease Control and Prevention, 2004.
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Figure 5: US Men Cancer Death Rates 
 
There are many other aspects of the association of the risk factor (gender) to the 
outcome of lung cancer.  These aspects of a woman’s overall susceptibility to lung cancer 
can include but are not limited to: smoking patterns (cigarette type, depth of inhalation, 
number of pack years), gender, occupation, dietary factors, nutrition, hormonal factors, 
air pollution, obesity, and radiation effects 
45, 49, 62, 67, 81, 103-110
.  Incidence and prevalence 
22 
rates are used in the evaluation of the overall disease (lung cancer) trends.  These 
statistics are available on government sponsored data bases such as the National Cancer 
Registry SEER registries, state cancer registries, e.g. members of the North American 
Association of Central Cancer Registries, Inc. or other state registries, such as the 
Washington State Department of Health Occupational Mortality Data Base 
1, 13
. 
 
Impact on Health Care Resources 
Lung cancer has a devastating impact an individual’s quality of life but has also 
has direct and indirect costs associated with lung cancer diagnosis and treatment.  Some 
of the direct costs are medical care which include hospitalization, doctors visits, home 
health care, hospice care, and treatment modalities such as radiation therapy, surgery, and 
chemotherapy 
10
.  Direct non-medical costs associated with lung cancer can consist of 
transportation to and from the hospital/physician’s office, housekeeping services and any 
additional costs incurred due to changes necessary in the living conditions of the patient.  
Other considerations are the indirect costs which can be difficult to grasp the scope of 
exactly what can be involved with patient care 
111-113
.  These costs such as time spent 
seeking medical attention, time lost from work (lost productivity), or job replacement 
costs cannot be directly measured in some instances 
111-113
.  The costs associated with 
lung cancer care are enormous according to the National Heart Lung & Blood Institute 
(NHLBI).  In 2003, there were 1.5 million deaths representing 47% of all deaths in the 
United States 
111, 113, 114
.  These deaths were as result mainly of three disease processes; 
lung, cardiovascular, and blood diagnosis.  By 2006, these three diseases are expected to 
23 
exceed $560 billion of medical costs 
115
.  Lung cancer costs in 2004, shows medical 
expenditures as approximately 10 billion annually, according to the Centers for Medicare 
and Medicaid Services (CMS) 
115
.  Lung cancer represents over 13% of the total cancer 
care costs for 2004.  The non medical total or personal care exceeded 250 billion for the 
same time period.  
Lung cancer is one cancer which is more expensive to diagnose and treat because 
of the histologic types 
64, 116-118
.  Many successfully treated cancer types have an early 
detection program or screening program for the early diagnosis of cancer 
4, 117, 119
. 
Unfortunately, lung cancer does not have an effective screening tool and typically is not 
diagnosed until it has spread outside the diseased organ 
64, 116-118
.  As the majority of lung 
cancer is diagnosed at later stages, the associated healthcare costs and resources required 
are increased 
111, 113
.  In 2007, it is estimated that the total healthcare cost (HCC) for lung 
cancer will be 21 billion. According to CMS, lung cancer care and treatment accounts for 
10% of the total US healthcare costs 
115
.  The United States Federal Office of the Actuary 
estimates that by 2016 every 20 cents of every dollar will go towards health care by 2016 
115, 120
.  The annual forecast by a division of the Centers for Medicare and Medicaid 
Services (CMS) predicts a 10-year increase of approximately 2 trillion dollars (2.1 trillion 
to $4 trillion) for spending on health care in the United States 
115, 120
.  This represents an 
ever increase amount of healthcare resources going to the detection and treatment of lung 
cancer.  Using the estimated 4 trillion which is expected in 2016 with the total HCC 
being 400 billion, the lung cancer portion of 13.3% would make the projected lung cancer 
24 
portion over 53 billion 
115
.  If the same relationship as seen in medical costs, estimated 
non medical costs could exceed over 1 trillion.  The projected lung cancer incidence and 
mortality rates are expected to increase as 77 million baby boomers will move into their 
60’s; the age that has the highest risk for lung cancer incidence. This march to retirement 
of those who were heavy tobacco use will be responsible for even higher costs after 2016 
115, 120
. 
 
Origin 
The site of origin of lung cancer refers to the type of tissue from which the cancer 
cells develops 
9, 121
.  Lung cancer is categorized by site of origin into hilar and peripheral 
types; as the structures where the disease originates are different 
37
.  The majority of early 
cancers in the hilar region are squamous cell types, whereas many early stage lung 
cancers in the peripheral areas are adenocarcinoma 
121
.  Adenocarcinoma originates in 
glandular tissue; whereas a carcinoma originates in the tissue that lines the organs and 
tubes of the lungs called epithelial tissue 
122
.  NSCLC adenocarcinoma and large cell 
carcinoma typically are located in the peripheral of the lungs and can present as solitary 
nodules or masses 
37
.  Squamous cell carcinoma and small cell carcinoma are normally 
found in the central portion of the lungs and can be misdiagnosed as a collapsed lung 
(atelectasis) or pneumonia (an inflammation of the lungs) 
37
.  Small cell carcinoma is 
normally located in the mainstem bronchi; this cancer originates in the Kulchitsky’ cells 
which are a component of the bronchial epithelium 
35
.   
25 
The tissue layers are comprised of cells that are similar in their structure and 
perform common functions.  The intercellular material, e.g. RNA, DNA, are contained 
within the cells; genetic material is found within the intercellular material for that cell 
type.  As a human embryo develops, three primary germ layers provide the basis for body 
tissue and organ formation 
35
.   The three germ layers are the ectoderm, the endoderm, 
and the mesoderm.  The ectoderm and endoderm layers are considered epithelial tissue.  
The epithelial tissue from the endoderm lines the respiratory tract (the lungs and the air 
passageways from the pharynx to the lungs).    
 
Clinical Signs and Symptoms of Lung Cancer 
 Early detection of cancer is credited with an increased survival; unfortunately for 
lung cancer, there is no early detection program that has clinically proven long-term 
success 
4, 117, 118, 123
.  One impact due to the lack of early detection for lung cancer is that 
lung cancer has become one of the most lethal of all cancers; mortality rates for lung 
cancer have surpassed colorectal, breast and prostate cancer combined 
4
.  The main 
difficulty in the diagnosis of lung cancer is that the majority of lung cancer cases do not 
have symptoms (asymptomatic) until the disease has progressed to an advanced stage 
4, 64, 
119, 124
.  It is estimated by the American Cancer Society that only 15% of all lung cancer 
cases are diagnosed in the early stage, i.e. Stage I 
4
.  The average five year survival rate 
for lung cancer patients is 15%, this low survival rate is consistent with the current lack 
of an early diagnosis program 
4, 64, 119, 124
.     
26 
Common clinical lung cancer symptoms include a new or persistent cough, 
hemoptysis or blood in the sputum, chest pain, wheezing, hoarseness, shortness of breath, 
and repeated respiratory infections, e.g. bronchitis, pneumonia 
4
.  The symptoms of lung 
cancer can vary according to the tumor type and the extent of the disease or metastases. 
Recent articles in the literature have identified another area of concern in the diagnosis of 
lung cancer 
4, 9, 125-128
.  Lung cancer diagnosis is currently done based on the symptomatic 
criteria outlined in textbooks that were written ten to twenty years ago 
125
.  As physicians 
may not be aware of the changing patterns of lung cancer, this may add to the difficultly 
of a diagnosis, let alone an early diagnosis 
125
.  Collins, et. al., 2007, noted that there have 
been epidemiologic changes or differences in the lung cancer patient population 
4
.  Some 
of the current differences include an increased number of females with lung cancer; the 
most frequently encountered histological lung cancer type for males and females has 
changed to adenocarcinoma, and temporal differences in the age of diagnosis 
4, 10
.  These 
epidemiologic differences may decrease the identification of specific symptomatic 
patterns in lung cancer cases which in turn could negatively impact the rate of early 
diagnosis 
4
.   
Approximately thirty to forty percent of lung cancer cases that are diagnosed have 
symptoms of metastatic disease 
28
; some of the most common organs that the cancer 
spreads to are the liver, the brain, the bones, spinal cord, and the adrenal glands. The 
symptoms of metastatic disease include bone pain, personality changes, confusion, 
elevated alkaline phosphatase level, seizures, weakness, weight loss, nausea, vomiting, 
27 
and palpable lymphadenopathy 
4
.  There are several clinical manifestations of the skeletal 
and endocrine systems due to lung cancer spread. Some of the endocrine manifestations 
include Cushing’s syndrome and hypercalcemia.  Common clinical symptoms of the 
skeletal system consist of digital clubbing and hypertrophic pulmonary osteoarthropathy; 
these symptoms occurs in approximately ten percent of lung cancer cases 
4
.  
Clinical presentation and radiographic results are first steps in the differentiation 
or diagnosis of lung cancer type, i.e. small cell lung cancer (SCLC) or non-small call lung 
cancer (NSCLC) 
9
.  Small cell lung cancer is recognized by lymphadenopathy or the 
swelling of the lymph nodes and tumor invasion of the mediastinum 
9
.  A characteristic of 
small cell lung cancer is the tumor or mass is seen in the hilum in approximately 78% of 
the cases.  Patients with small cell lung cancer can present with paraneoplastic 
syndromes.  Paraneoplastic syndromes are a collection of clinical signs and symptoms 
resulting from the byproducts of the tumor interrupting normal biological function 
4
.   
Some of the syndromes resulting from small cell lung cancer include Lambert-Eaton 
syndrome (muscle weakness), inappropriate antidiuretic hormone, and ectopic 
adrenocorticotrophic hormone production 
9
.  
 
Procedures for Diagnosing Lung Cancer 
Early detection and treatment is credited with increased survival for early stage 
lung cancer 
13, 28
.  Early stage lung cancer is defined ICD-9 code as Stage I; which is less 
than 3 cm and with no evidence that the disease has may has spread outside the lung.  There are 
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several early detection technologies providing diagnosis of lung cancer.  These include are 
Computerized Tomography (CT), Magnetic Resonance Imaging (MRI) and Positron 
Emission Tomography (PET) Scans 
113, 129
.  Early treatment choices for lung cancer include 
chemotherapy, surgery, Radiation Therapy and combined modalities 
4, 48, 130
.   In 
Radiation Therapy, there have been advancements in computer technology allowing the 
scanning results of CT, MRI and PET to be merged into a three dimensional (3-D) treatment 
planning system for more precise Radiation Therapy treatments 
72
.  The technological 
treatment advancement of Intensity Modulated Radiation Therapy can focus the radiation 
beam into very specific treatment fields that are created or simulated on the treatment 
planning system by using CT scan and/or by merging of CT and PET scans 
72
.  Literature 
has shown that staging of cancer patients has vastly improved with the aid of PET 
131-133
.  In 
many instances, the patient treatment plan has been changed drastically. Cancer patient cases 
thought to be primary and hence the patient would have received a very aggressive treatment 
become palliative with less cost, physically, emotionally and economically, to the patient and 
community at large 
131-133
. 
The gold standard for diagnosing lung cancer is with a tissue diagnosis.  There are 
several diagnostic methods in order to obtain a tissue which include 1) sputum cytology, 
2) a thoracentesis, 3) excisional biopsy of an accessible node, 4) flexible bronchoscopy 
with or without transbronchial needle aspiration, 5) transthoracic needle aspiration, 6) 
video-assisted thoracoscopy, and 6) thoracotomy 
4
.  In order to select the most 
appropriate test or procedure the physician, e.g. pulmonologist, interventional radiologist, 
29 
or thoracic surgeon, must make a determination of which lung cancer type is suspected.   
Patients with suspected early stage non small cell lung cancer who are surgical 
candidates, commonly have a surgical procedure known as a thoracotomy 
4, 9, 54, 59, 125, 134, 
135
.  A patient can be staged as well as having a tissue diagnosis from this procedure 
4, 9
.   
Sputum cytology involves the collection of at least three samples of sputum; it is 
noninvasive, but if the results are negative, further testing may be required 
4, 9, 135
.  This 
technique is recommended if the patient has hemoptysis; sputum cytology is indicated for 
centrally located tumors in the chest cavity.  The specificity for this test is 99% and the 
sensitivity for central tumors is 71%, peripheral tumors are less than 50% 
4, 125, 127
.  If the 
patient has pleural effusion (fluid between the lung and the chest cavity); a thoracentesis 
can be performed.  Sampling of the fluid can give an indication of the presence of lung 
cancer.  The sensitivity for this procedure is 80% with a specificity of less than 90%. In 
the case of palpable lymphadenopathy, a biopsy of an accessible node can be a method to 
obtain a tissue sample.  Sputum cytology, flexible bronchoscopy, and transthoracic 
needle aspiration are procedures employed when the stage and the cancer type are 
unclear.  Flexible bronchoscopy involves passing a scope along the bronchial tract and 
taking samples of tissue via bronchial washings and/or biopsies.  The sensitivity of this 
procedure or ability to correctly detect the presence of the disease is 88%.  Computerized 
tomography (CT) of fluoroscopic guidance can be utilized while placing the catheter into 
the patient’s lungs.  The sensitivity and specificity of this test depends upon where the 
tumor is located or where the tissue sample is taken.  The sensitivity for diagnosis of 
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centrally located tumors utilizing flexible bronchoscopy is 88% and the specificity is 
90%.  The sensitivity for peripheral tumors drops to 60 to 70% with this technique.  The 
procedure of choice for peripheral tumors (sensitivity of 90%) under CT or fluoroscopic 
guidance is the transthoracic needle aspiration; its’ specificity is 97%.  It is indicated in 
nonsurgical candidates with peripheral tumors when the transbronchial needle aspiration 
is inconclusive.  One drawback or complication of this procedure is a pneumothorax 
(collapsed lung) in 25 to 30% of the patients undergoing the procedure 
4, 9
.  Video-
assisted thoracoscopy is a more recent procedure 
4
 and is used for small peripheral tumors 
less than 2 centimeters in diameter, pleural effusion , or pleural tumors.  The major 
advantage of a video-assisted thoracoscopy is it can prevent an unnecessary surgical 
procedure, i.e. the thoracotomy.  Lastly, the surgical procedure recommended for the 
treatment and the diagnosis of early stage non-small cell lung cancer is a thoracotomy in 
cases with a clearly resectable tumor 
4, 9, 126, 136
.   
 
Screening 
There are many histological types of lung cancer and finding a single biomarker 
or screening tool is a challenge.  Several biomarkers are being evaluated as screening or 
predictors for lung cancer.  An effective screening program for lung cancer is important for 
early detection of the disease which could increase survival.  One of the research projects at 
the Moffitt Cancer Research Center, has the objective of finding a biomarker that will be 
used to develop an early screening and detection program for those people at risk for lung 
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cancer 
137, 138
.  Present research includes microscopic examination of sputum sample 
staining patterns.  One of the possible biomarkers is monoclonal antibodies (Mabs).  The 
pattern and stain intensity of the Mabs and varying cell characteristics are being 
investigated as a possible screening tool.  The understanding of tumor biology has 
increased with the recognition of genetic and protein markers which precede malignancy 
137
.   Mutations of particular genes contribute to the process of epithelial carcinogenesis.  
These mutations modify the control of abnormal cell growth.  Heterogeneous nuclear 
ribonucleoprotein (hnRNP) has been linked as a marker with sputum cytology for early 
detection of lung carcinogenesis.  Data demonstrate that hnRNP is expressed in most lung 
cancer cases before any morphologic abnormality.  
Other biological markers that are found in lung tumors include: tumor suppressor 
genes (p53, Rb, p16, p21), proto-oncogenes (K-ras, c-myc, c-erB-1 and 2, HGF, HER-2), 
Telomerase (hTERT), hypermethylation and growth factors (GRP/BN, TGF-b, FDGF, 
PTHrP, IGF-I and II), apoptosis and angiogenesis (Bcl-2, VEGF), and gene amplification 
(HER-2) 
137
.  These molecular markers can be important markers for pulmonary 
carcinogenesis, used as an early diagnosis tools, and can be determinants in prognosis of 
a lung cancer treatment regimen.  As shown in the Table 1 (Chart 2) below from Duarte, 
et. al, 2005, several biological markers are found with greater frequency with respect to 
the tumor type 
139
.  The molecular marker Rb is found 30% in NSCLC but approximately 
100% of the time it is detected in SCLC.  
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Table 1: Molecular Biomarker for Lung Cancer (LC) 
 
Presently, the National Cancer Institute is conducting a large scale clinical trial 
known as the Prostate, Lung, Colorectal, and Ovarian Screening Trial (PLCO) 
140, 141
.  
The objective of this study is to determine the efficacy of screening tools utilized during 
the trial and evaluate the death or mortality rate associated with that particular cancer 
under study 
142
.  The major disadvantage with this trial for the early detection of lung 
cancer is the screening tool, a conventional chest x-ray, does not detect lung neoplasms at 
early stages 
140
.  Another research study known as the National Lung Screening Trial 
(NLST) is sponsored by the National Cancer Institute for women and men and women at 
risk for lung cancer.  This particular trial is comparing spiral CT scans and conventional 
chest x-rays and making a determination which is a more effective screening tool in an 
effort to reduce death due to lung cancer.  Spiral CT scans are effective in the 
visualization of lung nodules that cannot be seen in conventional chest x-rays; this does 
creates moral and ethical issue as a spiral CT is proven to detect lung cancer in the early 
stages as compared to a chest x-ray 
143
.  Presently, the literature does not show that a 
spiral CT scan or a conventional chest x-ray has not been demonstrated in the literature to 
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reduce the risk of lung cancer mortality 
9, 135, 140, 144
.  
 
Pathology/Histology 
There are two major categories of lung cancer; small cell carcinoma and non-small cell 
carcinoma. NSCLC includes adenocarcinoma, squamous cell carcinoma and large-cell 
undifferentiated carcinoma 
3, 40
.  Each histological type has its own medical intervention 
that can include any combination of surgery, radiation therapy, and/or chemotherapy 
7, 51, 67
.  
The incidence and survival rates are also different for the lung cancer type.  There are many 
causal factors for lung cancer such as lifestyle, occupational risks, and environmental 
factors 
10
.  The primary cause of lung cancer is smoking 
9, 13, 145-151
.  Lung cancer remains a 
major public health problem lacking an early prevention and intervention program 
4, 9, 125, 136
.  
As far as Public Health consequences, lung cancer is the most lethal of all cancers as it has 
the highest mortality rate both among men and women 
2, 13
 with the average ―5 Year 
Survival Rate‖ of 13 percent.  
The four major types of lung cancer are adenocarcinoma, squamous cell 
carcinoma, large cell, carcinoma, and small cell carcinoma.  The four major lung cancer 
types comprise 95% of a lung cancer cases 
72
.  Adenocarcinoma is a malignant neoplasm; 
it originates in the epithelial cells of glandular tissue, and forms glandular structures.  
This particular cancer is very commonly found in the periphery and accounts for 30 - 
40% of all lung cancer types.   Squamous cell carcinoma accounts for 20-30% of lung 
tumors and the origin is usually hilar 
7, 152
.  95% of all small cell lung cancer is attributed 
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to smoking. SCLC metastasizes early and has a five year survival rate of less than 15%.  
Large cell carcinomas account for 10-15% of all lung neoplasms and are comprised of 
undifferentiated or immature cells.  Large cell is the most aggressive of the NSCLC as 
they difficult to diagnose due to its’ undifferentiated nature.  These are commonly located 
in the central portion of the lung.  
The ICD-O code for lung cancer pathology is classified by the morphology code 
and the topography code as shown below in Figure 6. 
 
 
 
 
 
 
 
 
 
Figure 6: Structure of a Morphology Code 
Source: http://training.seer.cancer.gov 
 
The topography code identifies the site and the sub-site for the disease of interest.  
The complete ICD-O code contains ten digits with the first four digits being the topography 
and the last six digits the morphology identifiers.  Figure 7 is an example of the coding 
scheme for a squamous cell lung cancer.  
 
Diagnostic term: 
Poorly differentiated squamous cell 
carcinoma, upper lobe of lung 
 
C34.1   M-8070/33 
 
Figure 7: Structure of a Complete ICD-O Code 
Source: http://training.seer.cancer.gov 
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The complete site specific topography code for lung cancer is shown in Figure 8 
from SEER.  Figure 9 displays the anatomy of the lungs with the associated ICD-O code.  
The codes range from C34.0 as found in the main bronchus to C34.9 NOS (not otherwise 
specified). 
ICD-O TERM 
C34.0 Main bronchus  
C34.1 Upper lobe, lung  
C34.2 Middle lobe, lung (RIGHT LUNG ONLY) 
C34.3 Lower lobe, lung  
C34.8 Overlapping lesion of lung  
C34.9 Lung, NOS  
C33.9 Trachea, NOS  
Prior to the Second Edition of ICD-O, trachea and lung had the same ICD-O 
code. With the advent of ICD-O-2, trachea has a separate code (C33.9) from lung (C34._). The ICD-O 
four-digit subsites of C33.9 through C34.9 are considered part of a single primary site. Since lung is a 
paired organ, laterality must be coded.  
 
        Figure 8: ICD-O-3 Site (Lung) Codes  
Source: http://training.seer.cancer.gov/ss_module03_lung/unit03_sec01_icdo_codes.html                
 
 
 
 
 
 
 
 
Figure 9: Lung Anatomy with ICD-O-2/3 Codes 
Source: http://training.seer.cancer.gov/ss_module03_lung/unit03_sec01_icdo_codes.html 
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Staging/Extent of Disease 
There are several purposes why it is necessary to stage a cancer case.  First, the 
medical professional must assess the extent of the disease adequately 
1, 4, 40
.   Correct 
ascertainment of the extent of the disease is crucial as the appropriate treatment regimen 
must be determined 
10
.  A curative or palliative approach in disease management will be 
based on the stage of lung cancer the patient has.  Secondly, staging can one of the 
indicators of patient’s prognosis and projected survival.  Other indicators of prognosis 
include tumor histology, grade of disease, and patient demographics, e.g. age, gender, 
race, socioeconomic status, and martial status 
55, 139, 153, 154
.  Finally, with a 
comprehensive and standardized staging protocol, the exchange of information between 
the scientific communities can be accomplished.  Staging or coding data are use for 
research and general health care information.  The extent of the disease can be classified 
by the use of a number or coding system with increasing values representative of 
increasing disease severity.  The anatomic coding system allows for analysis of similar 
cases with comparable characteristics based on disease extent 
11
.  Cancer cases are 
described by the site of origin called the primary site and how far the cancer has spread 
from the primary site.  Other essential variables include tumor size, the number of tumors 
(multiplicity), the depth of the tumor invasion, regional or distant tissue extension, 
regional lymph node involvement, and distant metastases 
13
.    
Coding information began on an international level in 1893 for mortality data.  
The League of Nations’ World Health Organization (WHO) introduced the concept of 
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staging a disease in 1929.  One of the first descriptions of the extent or the stage of the 
disease was for carcinoma of the cervix 
13
.  After World War II, the World Health 
Organization established guidelines for the classification of disease.  In 1948 the 
International Statistical Classification of Diseases, Injuries, and Causes of Death (ICD), 
manual was published; the coding scheme was used to code and tabulate morbidity and 
mortality data.  The American Cancer Society 
2
, in 1951, developed the first code manual 
for the classification of tumor morphology.  The tumor codes were comprised of the first 
two numbers being the indicator of the tumor type with a third number representing the 
behavior of the neoplasm 
2, 29
.  WHO adopted a coding system based on the ACS in 1956 
2, 29
.  The International Agency for Research on Cancer (IARC) was commissioned by the 
World Health Organization to help develop a world wide classification scheme for 
oncology.   The first edition of this manual was in 1976 called the International 
Classification of Disease for Oncology (ICD-O) 
2, 29
.  There have been several updates 
and revision for the classification scheme but morphology code uses standardized three- 
and four- character categories 
1, 2, 29
.  
In the United States, the Surveillance, Epidemiology, and End Results (SEER) 
Program of the National Cancer Institute routinely gathers data on cancer statistics from 
designated population based cancer registries 
11, 13, 60
.  SEER has developed a two stage 
classification system, extent of the disease and a summary stage.  Summary staging is 
based in how the cancer advances or grows and there are five main categories 
11
.  The 
Commission on Cancer (CoC) of the American College of Surgeons uses the American 
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Joint Committee on Cancer (AJCC) staging system.  An earlier version of the AJCC 
classification scheme was first introduced in 1958 by the Union Internationale Contre le 
Cancer (UICC) 
29
.  In 1959, the American Joint Committee on Cancer Staging and End 
Results Reporting (AJC) was organized and adopted the UICC coding system 
29
.  The 
AJC changed their name to The American Joint Committee on Cancer in 1980.  This 
system classifies the tumor in terms of the primary tumor (T), the regional lymph nodes 
(N), and distant metastasis 
155
.  T is the indication for size and the invasiveness of the 
primary tumor.  It (T) describes the size of the tumor in millimeters or centimeters with 
the extension of the disease into the adjacent tissue, e.g. mucosa, submucosa, muscularis, 
subserosa, serosa.  T0 indicates there is no tumor; T1 indicates carcinoma in situ and 
limited to surface cells, and T1-4 reflects increasing tumor size and disease extension 
1, 11
.  
The N component is indicative of nodal involvement or no lymph node involvement.  An 
increasing numerical value represents increasing disease extension into the lymph nodes.  
M is used in the identification of metastatic disease and distant lymph node involvement 
1, 11
.  
Another numeric system commonly in cancer registries used to describe or 
classify the extent of the disease is Stage 0 through Stage IV 
1, 11
.  Stage 0 limits the 
disease to the surface and is also known as cancer in situ, Stage I confines the cancer 
growth to the tissue of origin and gives evidence of cancer growth, Stage II describes the 
cancer as limited local spread, Stage III is extensive local and regional spread, and Stage 
IV is used to classify distant metastasis 
29
.  
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The ICD-O coding system uses a morphology code based on the histology (cell 
type), behavior code, and grade 
1, 11
.  The behavior indicates if the tumor is malignant, 
benign, in situ, or if the diagnosis is uncertain. Grading is determined by microscopic 
examination of the tumor cells 
1, 11
.  The cells are classified Grade I through Grade IV; 
Grade I, the cells are slightly abnormal and well differentiated, Grade II cells are 
moderately differentiated and the cells appear more abnormal, Grade III cells are very 
abnormal and poorly differentiated, and Grade IV are undifferentiated and immature.  
Immature or primitive cells are undifferentiated and highly abnormal in appearance.  If a 
cell is well differentiated, it can appear like a mature or specialized cell.  Table 2 below 
summarizes the AJCC staging system originally based on clinical data or surgical 
findings 
11
. 
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Table 2: AJCC TNM Staging System for Lung Tumors 
American Joint Committee on Cancer (AJCC) TNM Staging System for Lung Tumors 
 
Tx Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum 
or bronchial washings but not visualized by imaging or bronchoscopy 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without 
bronchoscopic evidence of invasion more proximal than the lobar bronchus† i.e., not in the main 
bronchus 
T2 Tumor with any of the following features of size or extent: 
• More than 3 cm in greatest dimension 
• Involves main bronchus, 2 cm or more distal to the carina 
• Invades the visceral pleura 
• Associated with atelectasis or obstructive pneumonitis that extends to the hilar region 
but does not involve the entire lung 
T3 Tumor of any size that directly invades any of the following: chest wall (including superior 
sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main 
bronchus less than 2 cm distal to the carina, but without involvement of the carina; or associated 
atelectasis or obstructive pneumonitis of the entire lung 
T4 Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, 
esophagus, vertebral body, carina; or separate tumor nodules in the same lobe; or tumor with a 
malignant pleural effusion‡ 
†The uncommon superficial tumor of any size with its invasive component limited to the 
bronchial wall, which may extend proximal to the main bronchus, is also classified T1. ‡Most 
pleural effusions associated with lung cancer are due to tumor. However, in a few patients, 
multiple cytopathologic examinations of pleural are negative for tumor. In these cases, fluid is 
not bloody and is not an exudate. Such patients may be further evaluated by videothoracoscopy 
(VATS) and direct pleural biopsies. When these elements and clinical judgment dictate that the 
effusion is not related to the tumor, the effusion should be excluded a staging element and the 
patient should be staged T1, T2, or T3. §M1 includes separate tumor nodule(s) in a different lobe 
(ipsilateral or contralateral). 
NX: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes 
N2: Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s)  
N3: Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or 
supraclavicular lymph node(s) 
Stage 0: Carcinoma in situ 
Stage IA: T1, N0, M0 
Stage IB: T2, N0, M0 
Stage IIA: T1, N1, M0 
Stage IIB: T2, N1, M0, T3, N0, M0 
Stage IIIA: T1, N2, M0, T2, N2, M0, T3, N1, M0, T3, N2, M0 
Stage IIIB: T4, N0, M0, T4, N1, M0, T4, N2, M0, T1, N3, M0, T2, N3, M0, T3, N3, M0, T4, N3, M0 
Stage IV: Any T, any N, M1 
Source: American Joint Committee on Cancer (AJCC) 
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Lung Cancer Prognosis 
There are certain factors that affect prognosis, i.e. quality of life, chance of 
recovery, survival, for a disease.  In particular, the prognostic factor of interest for this 
research is to expand the scientific knowledge concerning gender differences in women 
and men with lung cancer and survival.  The literature has cited several prognostic factors 
that affect lung cancer survival 
49, 55, 139, 154
.   The prognosis can be dependent upon 1) the 
stage of lung cancer (the size of the tumor, whether the cancer is confined to the lungs or 
has spread to other places in the body, i.e. metastized), 2) the histologic type of lung 
cancer, 3) if there are respiratory symptoms, e.g. coughing, difficulty breathing, and 4) 
the patient’s general health or well-being 4.  Early stage disease (Stage I, Stage II, 
resectable Stage III) prognostic factors most critical to decreased survival have been 
shown to include large tumor size and presence of lymph node metastasis, male gender, 
age greater than 60 years, and having a wedge resection versus a lobectomy or 
pnumonectomy 
55, 61, 156
.  In advanced stage lung cancer, poor performance status, weight 
loss, male gender, elevated serum lactate dehydrogenase, and liver/bone metastasis are 
key prognostic factor for poor survival 
17, 61, 157, 158
. 
Clinical research has identified more than 150 risk or prognostic factors according 
to Blanchon, et. al., 2006 
153
.  Prognostic factors investigated by Blanchon, et. al., 2006’s 
research included age, gender, socioeconomic status, possibility of occupational origin of 
the cancer, stage of cancer at time of diagnosis, smoking history (pack-years, duration, 
discontinuation, date of discontinuation),  geographic location, histology, stage, vital 
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status, treatment modality, and performance status at time of diagnosis 
153
.  Performance 
status was based on the classification as given by the Eastern Cooperative Oncology 
Group 
158, 159
, based on a 0 to 4 scale.  The final univariate model included age, sex, 
performance status, histologic types, and stage of disease.  Patients younger than 50 years 
had a greater probability of survival as compared to those greater than 70 years.  Men had 
a decreased survival (Hazard Ratio (HR) = 1.17; 95% CI: 1.05-1.31) versus women.  The 
HR for risk of death increased with increasing stage of disease (Stage IV HR = 3.53; 95% 
CI 3.05-4.09) and performance status (Performance Status 4 HR = 4.97; 95% CI: 3.83-
6.43) 
153
.  These five predictor variables served as the most important prognostic factors 
for Blanchon’s research.  Other medical research has reported similar individual 
characteristics (prognostic factors) such as gender, sex, stage of disease, performance 
status, molecular biologic markers, marital status, smoking status, and psychosocial 
factors as predictors for lung cancer survival 
61, 156, 157, 160, 161
; similar to  Blanchon et al. 
(2006).  
In the article ―The Lung Cancer Database Project at the National Cancer Center, 
Japan: Study Design, Corresponding Rate and Profiles of Cohort‖, Nakaya, et. al., 2006, 
reported the importance of having a database with available prognostic factors for lung 
cancer survival 
160
.  The authors stressed the epidemiologic, psychosocial, and molecular 
biology data as to improve lung cancer patient outcome by increase treatment efficiency.  
In this particular study, biologic material was collected and several questioners at 
baseline and subsequent follow-up intervals 
160
.  
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Epidemiologic studies have shown that there is a causal relationship between 
smoking and lung cancer 
149, 162, 163
.  Smoking patterns and status serves as a prognostic 
factor in survival after the diagnosis of lung cancer but the majority of heavy smokers do 
not develop lung cancer 
139
.  Duarte, et. al. 2005 has suggested that genetic factors affect 
an individual’s susceptibility to the development of lung cancer.  Molecular changes in 
lung cancer may serve as an indicator (prognostic factor) for survival.  Several genetic 
factors have been investigated, but presently there is no evidence that a single parameter 
has sufficient treatment efficiency 
139, 153
.  Principle molecular markers primarily found in 
lung cancer will be expanded upon in the section on Genetic Risk Factors in this chapter.  
Biologic or molecular markers can be important as prognostic variables but also in the 
identification of treatments targeting the cancer cell based on the patient’s genetic code 
for an effective cancer cell kill. This is becoming increasingly important for the treatment 
of lung cancer and survival 
 
Lung Cancer Survival and Risk Factors 
Gender 
Why is gender important as risk factor for lung cancer survival?  Although lung 
cancer mortality has reached epidemic levels for women (an increase of 600 % since the 
1950’s), the causal pathways are blurred for women 40.  The exact etiology of a woman’s 
susceptibility (reported in the literature as different from men ) to lung cancer, still not 
resolved 
49
.  One potential reason for the current deficit of knowledge for gender 
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differences in the etiology and subsequent susceptibility is that the treatment patterns for 
lung cancer are based on research done on men.  Previously, the association between 
being a woman and the risk of lung cancer was considered negligible by the medical 
community as referenced by published reports by the US Surgeon General 
24, 76
 .  But as 
behavior and other temporal changes, such as cigarette smoking have occurred over the 
past several decades, the incidence of lung cancer has increased with a resultant increase 
in mortality 
2, 29
.  Women historically have been excluded from clinical trails or if 
included, the data was not analyzed 
18
.  As one result of this disparity of being excluded 
from research studies, women may be at a greater risk of lung cancer than men at the 
same level of smoking but the evidence in the literature has be conflicting and is limited 
22
.  A report of the Surgeon General 
24, 76
 on women and smoking did not reach any 
conclusions concerning what role gender difference may play in the development of lung 
cancer (US Department of Health, and Human Services, 2001).  Hypotheses have been 
developed based on possible response to carcinogens and hormonal related differences in 
women as compared to men (Ryberg et al., 1994) but conflict in the literature remains 
27, 
40, 45, 50, 107, 164
. 
Lung cancer incidence and mortality rates are higher in men as compared to 
women 
3, 10
.  The fact that women have a lower prevalence of smoking may account for 
this difference.  The primary cause of lung cancer in women and men is due to smoking 
tobacco products, in particular cigarettes 
23, 75, 165, 166
.  In 2006, it is estimated lung cancer 
will account for 30 percent of all cancer deaths in the United States.  Among men, lung 
45 
cancer incidence and mortality have been declining since the early 1980s and 1990s. The 
peak death rate in men in the 1990s coincided with a lag period of approximately 25 
years after the highest per capita cigarette consumption.  Women started smoking 
approximately 20 years after men, lung cancer incidence rates did not begin to fall in 
women until 1998.  For the first time in 1995, mortality rates in women have stabilized, 
after increasing for several decades.  There has been an increase of 600% in mortality for 
women with lung cancer since 1930 
28, 40, 60
.  Lung cancer has overtaken breast cancer as 
the number one cause of cancer related deaths of women in the United States.  
In the next several articles cited in this chapter, epidemiological studies were 
designed to quantify the differences in lung cancer risk between men versus women 
8, 15,
 
17, 27, 167  
.  In the paper, "Lung cancer in women compared with men: stage, treatment, and 
survival", Ouellette et al., 1998, conducted a retrospective cohort study, to test the 
hypothesis of a survival difference among men and women with lung cancer 
8
.  The target 
population consisted of 104 women and 104 men with incident cases of lung cancer 
diagnosed between March 1998 and June 1990 at a university hospital in Montreal, 
Canada.  The authors concluded there was no difference in mean age of lung cancer 
diagnosis for females (60.97+ 10.89 years of age) and for male patients (61.49 +10.29 
years of age).  There was a statistically significant difference in the distribution of the 
different histologic types of lung cancer between men and women (p = 0.028).  When 
Ouellette et. al. stratified on lung cancer stage, the stage of the disease positively 
influenced survival between the women and men 
8
.  After adjustment, women appeared 
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to live 12 months longer than men at any stage and a statistically significant survival 
advantage in women was found (p = 0.02) 
167
.  
The authors (Ouellette et. al. ) found that women did received less surgical 
interventions than men; although not statistically significant 
8
.  Twenty-four women 
received chemotherapy compared with fourteen men, although this was not found to be 
statistically significant according to the authors. A limitation in this study could be due to 
the small number of lung cancer cases contributing to the non-significant finding 
(decreased power).  Ouellette et al., 1998 reported men and women received similar 
treatments for their disease in this study.  This differs from studies on coronary artery 
disease in which it was thought that physicians may pursue less aggressive management 
in women as noted by Steingart et al., 1991 
8
.  Unlike Ouellette, et. al., 1998, Aitakov et. 
al., 1998, found that more men in Russia underwent surgery with a ratio of men to 
women of 7.4:1.0 
167
.  Ouellette et al. did not find such a disparity; the ratio was 1.17:1.0 
men to women, and noted that is probably reflected the tendency to offer similar 
treatments to both sexes in the Western world.   
A population-based study by Radzikowska et al., (2002), investigated 
demographic factors (gender, age, and smoking) and factors connected with the disease 
(histology, performance status, stage, treatment and survival) for lung cancer patients.  
The target population was comprised of members of community-based cancer registries.  
Approximately 20,561 lung cancer cases from all parts of Poland, from 1995 to 1998, 
were registered with the National Tuberculosis and Lung Diseases Research Institute 
47 
(NTLDRI), as well as being registered with the Polish Cancer Register.  From this 
population, 2,875 women and 17,686 men were selected 
15
.  It was determined that 
women developed lung cancer at a younger age, were more likely to be lifetime non-
smokers, consumed fewer cigarettes per day and smoked for a short period of time 
15
.  
The authors commented that all those factors suggested that women are more susceptible 
to the carcinogenic compounds of cigarette smoke and environmental noxious conditions 
that possibly damaged the genetic distribution for the population 
15
.  Women were found 
to be more likely to have adenocarcinoma and SCLC as compared to men.  Squamous 
cancer was the predominant type of lung cancer among men, and less than ten percent of 
men had adenocarcinoma.  Different patterns of histological types of lung cancer were 
observed in Poland as compared to the USA, China or Denmark, where over-
representation of adenocarcinoma has been noted.  The distribution of main histological 
types of lung cancer in Poland was similar to that described in Finland and Scotland.  The 
most important prognostic factors for lung cancer patients were performance status, 
clinical stage of the disease and surgical treatment.  The authors did not evaluate different 
treatment modalities and the effect on survival. Radzikowska et al., found that females 
with lung cancer had a survival benefit compared with males, taking into account age, 
histology, performance status, extension of the disease and treatment.  This overall 
survival advantage of women was described first in data based on Danish Register 
information.  Although Radzikowska, et al., found an increased survival based on gender 
the other researchers found the opposite. Kirsh et al., in their 1982 article ―Carcinoma of 
48 
the Lung in Women‖ found that the survival among women in a younger age group was 
significantly lower than for both groups of women in the older age group (p = 0.0335) 
and men in the younger age group (p = 0.0033).  This was believed to be due to the 
higher incidence of both Stage III disease and adenocarcinoma in younger women.  
Visbal et al. (2004) "Gender differences in non-small-cell lung cancer survival: an 
analysis of 4,618 patients diagnosed between 1997 and 2002 evaluated the magnitude of 
the gender effect on non-small-cell lung cancer (NSCLC) survival across disease stage, 
tumor histology, and therapies 
17
.  The target population of 4,618 newly diagnosed 
NSCLC were patients at the Mayo Clinic in Olmsted County, Minnesota between 1997 
and 2002.  There were 2,724 men (59%) and 1,894 women (41%), with a median age at 
diagnosis of 68 years in men and 66 in women (p < 0.01).  Women were diagnosed on 
average two years younger than men 
17
.  As compared to men, women began smoking at 
a later age, smoked less cigarettes per day and fewer years.  More men smoked and were 
heavier smokers than women
17
.  Adenocarcinoma was the common subtype in both 
genders; 59.5% of the women and 48.2% of men. The difference between women and 
men with adenocarcinoma was significant with a p-value of <0.001.  For the other 
histological types (squamous, unclassified NSCLC, large cell, adenosquamous) of lung 
cancer the difference was not significant between men and women with. The estimated 
relative survival in men was 51% (95% CI: 49%, 53%) at one year and 15% (95% CI: 
12%, 17%) at five years.  The estimated one year relative survival in women was 60% 
(95% CI: 58%, 62%) and 19% (95% CI: 16%, 22%) at five years 
17
.  Men were at a 
49 
significantly increased risk of mortality compared to women following a diagnosis of 
NSCLC (adjusted relative risk: 1.20, 95% CI: 1.11, 1.30), particularly for patients with 
stage III/IV disease or adenocarcinoma.  Male gender was found an independent 
unfavorable prognostic indicator for NSCLC survival 
17
. This particular study by Visbal 
et. al. was of interest to this research as Visbal  studied treatment types, stage and 
histology of the disease; as noted previously reports on stage, grade, histology, and 
treatment are limited. Some of the weaknesses of this study included the lack of 
interaction terms in the model as without evaluating interaction any significant effects 
could be masked.  
The 2005 article by Ringer et al., ―Influences of Sex on Lung Cancer Histology, 
Stage, and Survival in a Midwestern Untied States Tumor Registry‖ 27 attempted to 
expand the current knowledge of gender differences in men and women with lung cancer 
and survival (N= 2618).  Squamous cell carcinoma was the predominant histologic type 
of lung cancer for men; women had an increased likelihood of having adenocarcinoma or 
small cell lung cancer.  There was no statistically significant difference for men with 
large call carcinoma versus women with large call carcinoma.  The stage of disease at 
diagnosis for men as compared to women was not significant
27
.   Differences in survival 
were demonstrated between the lung cancer types during the cutpoints of 3, 4, and 5 
years.  A very pronounced survival difference existed between men and women for stage 
IV squamous cell carcinoma (274 mean days for men versus 153 mean days for women, 
p = 0.005).  Women diagnosed with squamous cell carcinoma stage II again had 
50 
decreased survival versus men (636 mean days for men, 379 mean days for women, p = 
0.043).  This study demonstrated the important effect histologic type and stage at 
diagnosis plays in overall survival when comparing gender differences 
27
.  It has been 
hypothesized that women are more susceptible to tobacco products as compared to men.  
 
Tobacco 
The number one cause of lung cancer, approximately 80% of lung cancer cases 
can be attributed to smoking tobacco products, and the subsequent decrease in survival 
for lung cancer cases is due to tobacco smoke 
10, 168
.  The etiology of lung cancer is multi-
causal with a complex pathway of development that includes carcinogen exposure, 
metabolism, and genetics 
48
.  Tobacco smoke is recognized as the chief risk factor for 
lung cancer 
25, 67, 92, 169
.  It has been estimated by the International Agency for Research 
on Cancer (IARC) to contain at least 80 known mutagens and carcinogens, e.g. 
polycyclic aromatic hydrocarbons (PAH’s), N-nitro amines, and aromatic amines.  Yach 
and Wipfli stress the importance of tobacco-control efforts as tobacco kills five million 
people annually with an estimated increase of 100% (10 million) by mid 2020 
170
.  Today 
the population attributable risk percent (PARP) for men is approximately 90% and for 
women the PARP is approximately 80% 
10
.  The effects of tobacco smoking were 
demonstrated in the 1950’s with an epidemic rise of lung cancer in US males.  The 
increase in lung cancer rates were first attributed to factors other than tobacco smoke 
such as atmospheric pollution 
170
.  As the rise in lung cancer rates and the increase in 
51 
mortality rates for lung cancer, clinical evidence and case series were reported in the 
literature during the 1930’s for a suspected link between tobacco smoke and an increased 
risk of lung cancer.  In 1938, Raymond Pearl, M.D. from Johns Hopkins University 
reported that smokers do not live as long as nonsmokers 
170
.  There were two classic 
epidemiologic studies that demonstrated a strong association between the risk of lung 
cancer and smoking by 1) Sir Richard Doll and 2) Sir Bradford Hill 
10
.  Sir Richard Doll 
conducted a case control study in 1947 and compared hospitalized patients with and 
without lung cancer.  He collected information on smoking history and found a greater 
than 20 percent increased risk for lung cancer.  Zang and Wynder found that women were 
at an increased risk (1.2 to 1.7 times) for lung cancer than men independent of tobacco 
smoking level 
171
 with an associated decrease in survival.  
Passive smoke, also known as second hand smoke or environmental tobacco 
smoke (ETS) has been shown to increase the risk of lung cancer 
10, 172
.   Stockwell et al. 
(1992) demonstrated an increased risk, OR = 2.4; 95%CI = 1.1-5.3, for women with 40 or 
more smoke-years of household (ETS) exposure as an adult.  The authors also found a 
statistically significant association with women exposed to ETS during childhood or 
during adolescence for 22 smoke-years with an OR = 2.4; 95%CI = 1.1-5.4 
173
.  
Investigators for the International Early Lung Cancer Action Program found that women 
have an increase susceptibility to lung cancer as compared to men, OR = 1.9; 95%CI = 
1.5-2.5 yet women had a decrease hazard ratio for survival versus men, HR = 0.48; 
95%CI= 0.25-0.89 
174
.   The study population was comprised of 1202 men and women 
52 
from New York City undergoing a baseline screening at Weill Medical College of 
Cornell University 
174
.  
 
Race and Ethnicity 
 Worldwide statistics for lung cancer obtained from the International 
Agency for Research on Cancer, IARC,  and GLOBOCAN 2002 demonstrate that lung 
cancer incidence and mortality rates are less in women than men 
5
.  The decreased rates 
for women are not dependent upon ethnicity and race as reported by IARC.   Some of the 
variation in the incidence rates may be attributed to the quality of the data collected by 
the cancer registries and diagnostic methods employed.   
Gadgeel and Kalemkerian (2005) reported that race is not a biologically relevant 
parameter but racial differences in lung cancer characteristics and outcomes have been 
reported 
21
.  Blacks consistently have higher rates of lung cancer incidence as compared 
to whites.  African-Americans in the United States have the greatest incidence of lung 
cancer (8.5% risk of lung cancer diagnosis); they also have the highest lung cancer 
mortality rates (7.6% risk of death form lung cancer) 
10
.  Racial differences in smoking 
habit sand SES, have been associated with an increased risk of lung cancer 
21
.  
Willsie and Foreman (2006) in the article ―Disparities in Lung Cancer: Focus on 
Asian Americans and Pacific Islanders, American Indians and Alaska Natives, and 
Hispanics and Latinos‖ evaluated lung cancer incidence and mortality based on racial and 
ethnic groups 
175
.  The authors noted racial and ethnic differences in smoking habits, 
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presentation, stage at diagnosis, metabolism of nicotine, treatment received, and 
outcomes will impact lung cancer survival and health care over the next several decades 
in the United States 
175
.  
The identification of ethnic groups is an important aspect of lung cancer research 
for possible gender differences based on ethnicity and lung cancer survival.  The 
Multiethnic/ Minority Cohort study was established to study diet and cancer in the United 
States 
176
.  The data can be and is utilized to evaluate lung cancer patterns of incidence 
and mortality and the effect gender, race, and ethnicity play.  The cohort consisted of 
215, 251 living in California (primarily in Los Angeles County) and Hawaii with the 
cohort consisting of 16.3% African-American, 22.0% Latino, 26.4% Japanese-American, 
6.5% Native Hawaiian, 22.9% White, and 5.8% of other ancestry. African American had 
the highest rate of smoking, 28.5%, followed by Native Hawaiian at 20.1%.  The lowest 
groups of smokers were Japanese Americans, 15.5%, and whites, 15.9%.  Both females 
and male African American and Native Hawaiian females had the highest prevalence of 
smoking as compared to male and female Japanese Americans and Latinas.  Lung cancer 
incidence was 54.0% lower for Japanese American men (p-value < 0.001) and 71.0% 
lower for Latina women (p-value < 0.001) as compared to African Americans 
176
.   
 
Genetics 
Prior to 1970, scientific evidence about the etiology of lung cancer was 
unavailable.  A pathway of understanding the complex route of lung cancer development 
54 
with the consequent effects of gender differences and survival became accessible with 
advances in molecular genetics 
83
.  Cancer is a complex process which involves an initial 
damage of the genetic material (DNA, RNA) of a cell; this leads to a mutation or change 
in the chromosomes
19, 67, 69, 71, 177-180
.  The mutations can be inherited (germ cells) or may 
occur ―somatically‖ in the stem cells; resulting in clone cells of the original cell that may 
become cancerous (malignant and uncontrolled cell growth).  Although identification of 
biologic materials provides evidence of genetic susceptibility; inter-individual variation 
can modify the effects of carcinogenic exposures and the resultant effects.  For an 
example, the majority of long term smokers will not develop lung cancer.  A predictive 
model for lung cancer genetic susceptibility among smokers was developed by Bach et al. 
(2003) 
92, 117, 118
.  Utilizing data from the CARET trial, 18, 172 individuals, the statistical 
model predicted only a quarter of the lung cancer cases based on genetics predisposition; 
individual variation of metabolism, DNA repair, cell cycle, inflammation and 
microenvironment would be a possible explanation for the inability to calculate an 
accurate and precise model of behavior 
92
.    
Several genetic and epigenetic mutations of tumor suppressor genes have been 
observed in lung cancer 
48
.  Thomas et al. (2006) noted in 95% of small cell lung cancers 
and 40 to 70% of NSCLC, the most frequently encountered genetic alteration was p53.  
The p53 affects the biological pathway in G1 and G2 cell cycle regulation; p53 stops the 
cell division that occurs when there is damage to the DNA 
48
.  The p53 mutation leads the 
formation of DNA adducts (abnormal piece of DNA bonded to a cancer causing agent) as 
55 
a response to the effects of smoking; this mutation inhibits the normal cell repair and is 
involved in carcinogenesis.  Women have been found to have increased DNA adducts per 
pack years versus men. K-ras (a proto-oncogene) is another biomarker and forms DNA 
adducts when damaged; women are three times more likely than men to have the K-ras 
mutation; this mutation is associated with adenocarcinoma.  
 
Family History 
Another risk factor impacting lung cancer survival can be associated with family 
history or familial aggregation 
10, 172
.   Familial aggregation can serve as a surrogate 
(indirect measure) for lung cancer etiology and resultant survival rates based on genetic 
predisposition 
181
.  Etzel et al. (2003) examined risks for smoking related cancers for 
relatives of lung cancer patients 
169
.  Siblings were found to have a statistically significant 
association, RR = 1.85; p-value = 0.003, of lung cancer risks as well as an increased risk 
for smoking-related cancers, RR = 1.29; p-value = 0.01 
169
.  When stratification on age of 
disease onset was done, there was no association between familial aggregation and lung 
cancer risk for ages less than 55 years.  The authors did find evidence of familial 
aggregation, RR = 1.71; p-value < 0.001, for lung cancer risk between relatives of late-
onset cases of lung cancer.  Schwartz et al. (1999) found evidence that common 
susceptibility genes may increase the risk for lung cancer among relatives of nonsmoking 
lung cancer cases 
182
.  The study population was obtained from families of nonsmoking 
lung cancer cases (257 population-based) and nonsmoking controls (277 population-
56 
based), residing in metropolitan Detroit.  The first-degree nonsmoking lung cancer cases 
relatives were (OR = 1.5; 95% CI = 1.02-2.27) at increased risk for cancer of the 
digestive system after adjustment for each relative's gender, race, age, and smoking 
status.  There was an elevated OR of 1.12 for an increased risk for lung cancer for first 
degree relatives but the findings were not statistically significant, i.e. 95% CI = 0.65-1.93 
182
.  
 
Genetics and the Environment 
A powerful design to disentangle the interplay between genetics and 
environmental influences in the studies of human disease incidence, mortality, and 
survival can be accomplished by the use of twin studies 
10, 172
.  Twin studies serve to 
separate the affects of an individual’s biological makeup and environmental influences. 
Identical twins (monozygotic (MZ)) develop from fission of single fertilized egg and 
have inherited identical genetic material; fraternal (dizygotic (DZ)) twins derive from two 
distinct fertilized eggs meaning they have the same genetic makeup comparable to 
siblings 
10, 172
.  Genetic effects would be determined significant if there was concordance 
for cancer among MZ twins as compared to DZ twins (on average share 50% of their 
separated genes).  Environmental factors would be the determining factor for increased 
lung cancer risk if the concordance was similar for both types of twins 
183
.  Lichtenstein 
et al, (2000) combined data from three different national twin and cancer registries 
(44,788 pairs of twins from Swedish, Danish, and Finnish twin registries) 
183
.  The 
57 
authors found that there were statistically significant risks associated with colon and 
breast cancer, lung cancer was not.  This implies the inherited genetic factors do not 
make an individual susceptible to lung cancer and survival but environmental factors play 
the major role 
183
.  
Braun et al. (1995) concluded that genetic susceptibility had influence on lung 
cancer mortality 
184
 in men.  There was an excess risk of lung cancer mortality for 
dizygotic twin pairs (DZ SMR = 2.2; 95%CI = 1.3-3.4) but the risk was not statistically 
significant for monozygotic twin pairs (MZ SMR = 2.1; 95%CI = 1.0-3.7).  This suggests 
a predisposition for lung cancer in males.  
 
Geographic Variation 
Survival rates based on lung cancer incidence and mortality cluster in geographic 
regions that have a high prevalence of smoking 
10
.  Devesa et al. (1999) examined data 
from the IARC cancer registries of morphology specific lung cancer.  Squamous cell 
carcinoma had declined by 30% in North America 
30
.  Rates in the Nordic countries, 
which varied by 2-fold from a high in Denmark to a low in Sweden, still were generally 
lower than in other parts of Europe, where the rate was highest in the Netherlands 
30
.  The 
lung cancer incidence rates among males varied by 4-fold: 83.6 among U.S. Blacks to 
21.1 in Sweden.  Among females, recent rates varied by almost 8-fold, with the highest 
among U.S. Blacks (35.8) and the lowest in Spain (4.6).  Incidence rates among females 
paralleled that in males, with the exception of Switzerland.  Rates everywhere were 
58 
higher among males than females.  Male to female rate ratios varied from less than 2 in 
Iceland, U.S. Whites, Canada, Denmark and Sweden to more than 6 in Slovenia, Italy, 
and France and more than 10 in Spain.  
Developing countries demonstrate a higher ratio of lung cancer incidence and 
mortality for men versus women.  As shown below in Table 3, developing countries, 
have a higher ratio of male and female lung cancer incidence and mortality rates. 
 
 
Table 3: Incidence and Mortality Rates 
Incidence and Mortality Rates, Crude and Age-Standardized (World) rates, per 100,000 
 
Country/Region 
Incidence Mortality 
Cases 
Crude 
Rate ASR(W) Deaths 
Crude 
Rate ASR(W) 
World 1352132 43.5 47.6 1178918 37.8 41.5 
More developed 
regions 676681 114.7 72 584979 99.2 61.2 
Less developed 
regions 672221 26.7 35.3 591162 23.4 31.2 
Females       
World 386891 12.6 12.1 330786 10.7 10.3 
More developed 
regions 194731 31.7 17.1 161472 26.3 13.6 
Less developed 
regions 191192 7.8 9.4 168481 6.8 8.3 
Males       
World 965241 30.9 35.5 848132 27.1 31.2 
More developed 
regions 481950 83 54.9 423507 72.9 47.6 
Less developed 
regions 481029 18.9 25.9 422681 16.6 22.9 
Source: GLOBOCAN 2002, IARC 
 
In the United States, Kentucky had the highest incidence of lung cancer, 40 per 
100,000, and lung cancer mortality, 115 per 100,000 for the years 1997-2001 for males 
59 
10
.  Utah has the lowest incidence and mortality rates for lung cancer for males and 
females based on data from the American Cancer Society.  
 
Alcohol 
 Another risk factor associated gender differences and lung cancer survival is 
alcohol 
10
.  The causal relationship between lung cancer and alcohol is complicated and 
remains controversial 
10
.  Confounding by smoking is a major consideration and tobacco 
smoking commonly exists in setting where alcohol is consumed 
185
.  Nine studies were 
identified by Wakai et al. (2007) and in the authors’  examination of alcohol and lung 
cancer; they found only five of the studies adjusted for smoking 
185
.  This meta-analysis 
concluded that methodological issues explain the elevated risks in the studies of alcohol 
as misclassification errors based of smoking status were common in the nine studies.  
Prescott et al. (1999) found a protective association between lung cancer risk and 
wine drinking 
186
.  This was based on the results of three prospective cohort studies in 
Denmark.  Men who consumed more than 13 glasses of wine per week had an RR of 
0.78; 95%CI 0.63-0.97 compared to nondrinkers of wine.  The RR’s were elevated and 
statistically significant for beer drinkers (RR = 1.36; 95%CI 1.02 -1.82) and ―spirits‖ 
(more than 41 drinks per week RR = 1.57; 95%CI 1.06-2.33).  The study made the 
determination that the type of alcohol consumed impacted the association between lung 
cancer and alcohol after adjustment for smoking status 
186
.    
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Diet and Micronutrients 
 Scientific evidence from the literature exists pointing to dietary factors as 
protectors against lung cancer induction 
83, 187, 188
.  This risk factor, diet, may prove to 
increase survival as it may serve as a protector against lung cancer for men and women.  
Some of the dietary factors include fruits, vegetables, carotenoids, vitamin C, phenols, 
flavones, vitamin E, selenium, isothiocyanates, folate, fat, and alcohol 
10
.  The article by 
Smith-Warner et al., 2003, ―Fruits, Vegetables and Lung Cancer: A Pooled Analysis of 
Cohort Studies‖ found that after controlling for smoking, there was a sixteen to twenty-
three percent reduction in lung cancer risk (RR = 0.77; 95% CI 0.67-0.87; p-value (test 
for trend) =0.001) for men and women that had an increased consumption of vegetables 
and fruits versus study participants that had a limited intake of fruits and vegetables.  
Table 4 (Table 1 from Smith-Warner et al. (2003)), lists the prospective cohort studies 
used in the pooled analysis used for the research. 
The American Institute for Cancer Research presented a summary of seventeen 
case-control and seven cohort studies and concluded evidence existed that with an 
increased intake of fruits, vegetables, and in particular dark, leafy, green vegetables,  lung 
cancer risk was decreased 
189
.  Brennan et al., 2005 studied whether cruciferous 
vegetables were protective against lung cancer in a case-control study 
190
.  Cruciferous 
vegetables contain isothiocyanates, non-nutrient compounds found to be effective 
inhibitors of tumorigenesis 
10
 .  The authors found that weekly consumption of 
cruciferous vegetables decreased lung cancer (OR = 0.78; 95% CI 0.64-0.96) as 
61 
compared to men and women that consumed cruciferous vegetables less than monthly 
190
. 
One of the weaknesses of the study by Brennan et al., was there was no identification or 
analysis by gender and the possible gender effect of cruciferous vegetables consumption 
on lung cancer. 
Insufficient adjustment for smoking has been examined as a possible residual 
confounder 
191
 to explain the protective effects demonstrated by an increased intake of 
fruits and vegetables for a decreased lung cancer risk and subsequent increase in survival.   
The results of the research done by Skuladottir et al., 2004, found that there was an 
inverse relationship between an increased intake of fruits, vegetables, and lung cancer 
risk even after the influences of smoking as a confounder analyzed via stratified analysis.  
Men and women in the highest quartile of intake of fruits and vegetables demonstrated a 
thirty-five percent lower risk of lung cancer as compared to individuals in the lowest 
quartile of fruits and vegetable intake 
191
.  The lung cancer risk and fruits and vegetable 
intake association was decreased when stepwise adjustment for smoking status, duration 
of smoking, and the number of cigarettes smoked per day was done but the relationship 
remained statistically significant for study participants that had the highest intake of all 
plant food (fully-adjusted rate ratio = 0.65; 95% CI 0.46-0.94) 
191
.  
 Dietary carotenoids have been identified as the possible micronutrients in fruits 
and vegetables that may decrease lung cancer risk 
84, 192-195
.  When this effect was tested 
utilizing clinical trials with high doses of carotenoids, in particular beta-carotene, a 
reduction in lung cancer risk was not demonstrated 
196, 197
.  One particular clinical trial, 
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the Alpha-Tocopherol, Beta-Carotene Cancer Prevention 
198
 Trial, was stopped early due 
to the unexpected result of a statistically significant increase of lung cancer after 
receiving beta-carotene as compared to participants receiving the placebo 
197, 198
.  Stram 
et al., 2002 suggested that biases introduced from the method of smoking assessment 
resulted in the failure of three prospective beta-carotene clinical trials: CARET, ATBC, 
and the PHS 
199-202
.    
Gender specific lung cancer survival may be influence by a dietary factor, fat.  
There has been extensive research into the association between dietary fat and lung 
cancer risk 
203-211
.  Alavanja et al. (2001), Goodman, et al. (1992), and De Stefani et al. 
(1997) (study restricted to men) reported an elevated risk of lung cancer with an 
increased consumption of fat 
204, 206, 212
.  A non-statistically significant association was 
demonstrated by Swanson et al., 1997
210
 for intake of red meats and increased lung 
cancer risk after adjusting for confounders.  Conflicting results in the literature as cited in 
this chapter could be suggestive of inaccurate reporting and possible recall bias 
10
.   
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Table 4: Lung Cancer and Food Intake Cohort Studies 
 
 
Obesity and Body Mass Index (BMI) 
The major controversies concerning the exposure disease relationship between 
gender, obesity, BMI, lung cancer risk and lung cancer survival exist in the literature.  
There are conflicting opinions in the scientific community concerning the association 
40, 
213
 of low BMI and elevated lung cancer risk.  In case-control studies, the literature 
26, 108, 
214-219
 cite that low body mass index or ―leanness‖ is associated with the increased risk of 
lung cancer. The scientific unit for BMI is 1 kg/m
2 220
.  The three levels of exposure are: 
low BMI (> 25 kg/m
2
), normal or the reference group BMI (> 21.9 kg/m
2
to <25 kg/m
2
), 
and the high BMI group (> 25 kg/m
2
).  As noted in a report from the January-February 
2005 FDA Consumer Report, the average or median BMI has increased from 25 kg/m
2
 in 
1960 to 28 kg/m
2 
in 2002 for the general US population. BMI can serve as a proxy 
64 
measure for overweight and obesity.  It is widely cited in the literature 
220
 that a high BMI 
(> 25 kg/m
2
) is associated with an increased risk to hypertension, diabetes mellitus, 
ischemic heart disease and in particular most cancers.  A contradiction exists with lung 
cancer and low BMI (> 25 kg/m
2
) 
40, 218, 219
 where there is an inverse relationship.  As 
pointed out previously, the evidence based on BMI and cancer is blurred due to the 
progression of lung cancer and that effect on mortality 
106, 220
.  Weight loss may occur 
(which affects BMI) due to the cancer process prior to the disease being diagnosed 
adding to the difficulty associated with making a definitive causal inference in the 
BMI/Lung Cancer association 
5, 106, 108, 220, 221
. 
Some of the limitations of previous obesity, BMI, and lung cancer risk study 
designs may have served to mask a true association.  Kanashiki 
218
 mentioned in his 
article that the previous case-control studies investigating the relationship between low 
BMI and lung cancer were based on participants with symptomatic lung cancer.  This 
may have caused a misinterpretation of the relationship between the exposure and the 
disease because weight loss may be a sign or clinical symptom of the disease, lung 
cancer.  Kanashiki 
218
 further reported that there is a statistically significant association 
between low BMI and lung cancer for men; women did not demonstrate a statistically 
significant association between low BMI and lung cancer (increased lung cancer risk).  
Previous cohort studies 
108, 219, 222
 such as Kabat and Wynder used self-reported body size 
during data collection.  Using a method of self-reported body size has been noted to be 
problematic in the literature 
223
; as overestimates of height and underestimates of weight 
65 
can be reported with this method.  As noted by Henley 
213
, another issue with all previous 
prospective studies is that the numbers were not large enough to exclude those that were 
smokers or that have preexisting diseases that may reduce body weight. This may have 
resulted in a spurious association between low BMI and lung cancer.  The main effect of 
BMI and lung cancer has been shown by Rauscher 
26
 to have an increased Odds Ratio of 
1.33 (95% CI 1.13, 1.57) in matched analysis for men and women with high BMI and 
being a non-smoker.  This conflicts with other studies that associate a low BMI with an 
increase in the risk of cancer as compared to a normal BMI group.  These conflicting 
results serve as an example for the need for the additional clarification that the proposed 
research study will provide.  Biologic plausibility defined by Gordis 
224
 as a consistency 
of the epidemiologic findings with existing biologic knowledge.  Therefore, without 
biologic plausibility, interpreting the data or making a definitive statement about the 
association between the exposure and the disease becomes problematic.  In the case of 
suspect biologic plausibility, Gordis 
224
 suggests that the requirements for the sample size 
and the significance of any differences that may be observed may have to be  escalated, 
e.g. increase the sample size to decrease the variability in the sample 
155
.  Hennekens 
73
 
states that biologic plausibility is a causal criterion for an association and that a known 
biologically plausible mechanism enhances the cause and effect relationship.  
From the literature review in the section above, the disease process in lung cancer 
has been shown to influence BMI levels or visa versa.  Changes in the association 
between the exposure and the disease, for example, could be a result of changes in 
66 
physiology during the preclinical phase of the disease; which would provide a 
biologically plausible mechanism.  The ―exact‖ biological mechanism of how lung cancer 
changes BMI or how BMI influences lung cancer has not been clearly established.  
 
Occupation 
 Several occupational exposures are known carcinogens and have been classified 
by IARC (an international agency) and the Occupational Safety and Health 
Administration (OSHA) in conjunction with the National Institute of Safety and Health (a 
US based agency) 
225
.  The list of substances considered by NIOSH include arsenic and 
inorganic arsenic compounds, dintrotoluenes, beryllium and beryllium compounds, 
cadmium compounds, nickel compounds, and crystalline forms of silica 
225
.  Diesel 
exhaust, coal tar pitch volatiles, coke oven emissions, and environmental tobacco smoke 
are other substances of variable chemical composition and are considered carcinogens by 
NIOSH.  Other occupational risk factors (agents) include radon, vinyl chloride, 
polycyclic aromatic compounds, asbestos, and bischoloromethyl ether 
10
.  Epidemiologic 
studies estimate a range of attributable risk percent associated with lung cancer and 
occupational exposure of 9% to 15% 
10
.  Hessing and Hartung explored the excessive 
rates of respiratory cancers for European underground metal miners in 1879 
226
.  Radford 
and Renard (1984) examined the increased dose-response relationship for radiation and 
lung cancer 
227
.  The expected death rate for nonsmoking miners with lung cancer was 1.8 
but the observed mortality rate for nonsmoking miners  due to lung cancer was 18 
227
.  
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Deposits of uranium and radium and the subsequent by-products of radioactive decay 
(radon) were determined to be the causative agent for the development of lung cancer for 
miners.  Other occupational investigational studies included Doll (1952) who  
demonstrated an increased risk of lung cancer for gas workers and  Morgan (1992) 
reported that mortality from lung cancer had a standardized mortality ratio SMR of 1.65 
226
.  Hinds et al. (1985) determined risk factors for lung cancer based on excessive 
relative risks for a number of occupational groups exposed to coal and tar pitch, diesel 
fuel and exhaust, arsenic, chromium, asbestos, nickel, and beryllium 
228
. 
 
Hormones  
 Sex differences in susceptibility and survival have been attributed to estrogen as a 
lung cancer risk factor and prognostic factor 
229
.  Gender specific estrogen receptor 
(ER) expression may offer a biologically plausible influence in female lung 
carcinogenesis 
230
.  Schwartz et al. (2005) conducted a study of lung cancer tissue 
samples from two population based, case-control studies (214 women and 64 men) 
229
. 
Normal lung tissue was obtained for comparison from subject during autopsy that did not 
have lung cancer.  The association between the ER receptor status, subject characteristics, 
and survival were analyzed.  The lung tissue was tested for the presence of nuclear 
estrogen receptor (ER)-alpha and ER beta with immunohistochemistry.  Lung tissue 
sample for tumor and normal tissue did not stain positive for ER. Nuclear ER 
receptors were found in 61% of the lung tumor samples (70% of the men and 58% of the 
68 
women) and in 20% of normal tissue.  Females were less likely to have positive ER 
tumors than males (OR = 0.54; 95%CI = 0.27-1.08).  When the analysis was stratified on 
histologic type, women with adenocarcinoma were less likely to have positive ER 
tumors than males ((OR = 0.40; 95%CI = 0.18-0.89).  
Han et al. (2005) found that the gender specific estrogen receptor  (Er) may 
offer a plausible explanation that inter-individual difference in Er expression (present in 
the lung) impact carcinogen metabolism and mutation. The research was based on 
genome studies of genes (CYP1A1, CYP1B1) key in carcinogen metabolism; those genes 
were the most responsive to cigarette smoke extract (CSE) in normal bronchial epithelial 
(NHBE) cells 
230
. 
 
Socioeconomic Status 
The risk of lung cancer and socioeconomic status patterns can be dependent upon 
a country’s industrialization.  In Canada, Mao et al. (2001) reported males with a lower 
socioeconomic status had an increased risk of lung cancer as compared to individuals at a 
higher SES level 
231
.  Females did not show an association between lung cancer risk and 
SES after adjustment for occupation, education level, income, and social class was made 
10
.  Singh et al. (2002) reported on changing US area socioeconomic patterns for lung 
cancer mortality for the years 1950 through 1998 
232
.  Temporal changes in the 
distribution of lung cancer mortality were shown for women in all age groups with a 7 
times increased risk between 1950 and 1998 with an overall higher mortality of women 
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with lung cancer in higher socioeconomic groups.  Lung cancer mortality for men (25-64 
years) was 56% (95%CI = 49%-64%) higher in the lowest socioeconomic groups 
232
.  
The authors concluded that lung cancer mortality risk based on socioeconomics reversed 
for males from 1950 to 1998 with women demonstrating an increased risk for lung cancer 
mortality independent of socioeconomic status 
232
.  
 
Environment 
 Environmental factors play a distinct role in lung cancer etiology and 
survival patterns.  Passive or environmental tobacco smoke (ETS) and occupational 
exposures are risk factors for lung cancer and causal associations have been established.  
Veneis et al. (2007) investigated ETS and traffic related air pollution 
233
.  Attributable 
risk percents for the proportion of lung cancer cases of never smokers and former 
smokers were 16 to 24%.  The authors concluded that a reduction in air pollution levels, 
as measured by nitrogen dioxide (NO2) levels less than 30 g/m
3
, would prevent 5 to 7 % 
of all lung cancer cases 
233
.  Indoor air pollutants have been studied as risk factors for 
lung cancer in developed and developing countries 
234
.  In a recent article by 
Ramanakumar et al. (1997) the risk of lung cancer and residential heating and cooking 
fuels was assessed for a North American population.  The odds ratio for women as 
compared to men exposed to both traditional cooking and heating sources was 2.5; 95% 
CI = 1.5-3.6.  Oriental women have been shown to be at increased risk for lung cancer, in 
particular adenocarcinoma, which is attributed to prolonged and concentrated exposures 
70 
to cooking and heating sources 
172, 234
.  
 
Diseases Associated with Lung Cancer 
An individual’s previous history of respiratory disease has been shown to modify 
the risk of lung cancer incidence and mortality 
10, 235
.  Cigarette smoking and chronic 
respiratory diseases play a key role is carcinogenesis due to a continued cycle of injury 
and repair.  Schabath et al. (2005) compared the medical histories of 1,375 health 
controls and 1,553 lung cancer cases in a case control study (1995 through 2003) with a 
focus on respiratory diseases (asthma, emphysema, bronchitis, hay fever, pneumonia, and 
TB).  Two biologically relevant biomarkers for lung cancer, polymorphic genes (matrix 
metalloproteinase-1 and myeloperoxidase) were also assessed.  Those with emphysema 
had an elevated for the risk of lung cancer (OR = 2.87; 95%CI = 2.20-3.76).  Individuals’ 
positive for the adverse genotype had a significantly higher risk of lung cancer; OR 
metalloproteinase-1 + = 4.98; 95%CI = 2.94-8.44) and OR myeloperoxidase + = 4.23; 95%CI = 1.84-
9.73 
235
.  A previous history of hay fever was found to be protective with an OR of 0.32; 
95%CI = 0.21-0.50. 
Alavanja et al. (1992) examined preexisting lung disease in nonsmoking women 
and the risk of lung cancer.  The OR = 1.7 for the risk of adenocarcinoma and previous 
lung disease; the overall OR for all lung cancer types was 1.8.  The OR’s for nonsmokers 
were significant for lung cancer risk; OR asthma = 2.7and OR pneumonia = 1.5.  The OR for 
emphysema was 2.6 and tuberculosis, OR = 2.0, for former smokers.  The authors found 
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an attributable risk percent (16%) among women that were nonsmokers and had a 
previous history of emphysema, asthma, pneumonia, and tuberculosis 
235
.  Further 
investigation is warranted as the biologic role of respiratory diseases in lung cancer 
etiology is unclear as the evidence is not consistent. 
 
Treatments for Lung Cancer 
How lung cancer spreads throughout the body can be classified into three 
categories: intrathoracic (local), lymphatic (regional), and hematogenous (distant).  The 
sequence of the cancer growth is sporadic and does not necessarily follow any particular 
order 
72
.  Small cell carcinoma (oat cell) has the greatest probability of distant spread as 
compared to non small cell lung cancer; adenocarcinoma of the three NSCLC types has 
the highest incidence of distant spread or metastasis 
2, 4, 40
.  Depending upon the diagnosis 
of the lung cancer histologic type, stage, grade and the health of the patient, a clinical 
decision is made by the physician how the treatment will proceed.  These treatment 
decisions are based on years of empirical data, research, and clinical trials; the standards 
of care established by the medical community are overseen by several organizations such 
as the American Medical Association, the American College of Surgeons, the National 
Cancer Institute, and the American College of Radiology 
33
.  
 
Confined to the Lungs 
NSCLC confined to the lung is considered early stage disease and is treated with a 
72 
surgical resection 
72
.  Postoperative radiation therapy with or without chemotherapy is 
recommended for the treatment of microscopic disease 
135
.  The patient’s health and co-
morbidities are other considerations if the patient is a surgical candidate.  Radiation 
Therapy is then the treatment of choice if the patient cannot tolerate surgery.  Early stage 
small cell lung cancer is considered limited disease spread and the primary treatment is 
chemotherapy plus concurrent radiation therapy.  There has been current interest in 
surgical procedures for limited stage SCLC; according to Anraku and Waddell (2006) when 
the disease is confined, surgery improves the local control and increases survival 
54
.  The authors 
also note that continued research via clinical trials is warranted to confirm long term results. 
Local Spread 
Once the tumor has spread beyond the hemithorax and there is mediastinal lymph 
node metastasis, the treatment options include chemotherapy and radiation therapy; at 
this stage surgery is contraindicated.  Surgery could be an option in cases of limited 
mediastinal lymph node involvement in combination with chemotherapy or radiation 
therapy 
72
.  Prior to the advent of CT scans and the ability to detect mediastinal lymph 
node metastasis, it has been estimated in the literature that 30% of all NSCLC patients 
would have received a surgical resection unnecessarily by current medical standards 
72
.  
 
Distant Spread 
Extrathoracic, distant, or hematogenous spread involves the growth of lung cancer 
into multiple organs.  Treatment of extensive disease for non small cell lung cancer and 
73 
small cell lung cancer is chemotherapy alone 
135
.  The anticancer agents treat the disease 
systemically or throughout the body.  The future direction for treatments includes 
targeting therapies, i.e. the treatment of cancer cells treated with bio-agents that attack the 
cells at the molecular level 
135
.  
 
Lung Cancer Relapse 
In the case a lung cancer relapse, the stage, grade, histologic type, and patient 
condition once again determines next steps in treatment options. Angeletti, et. al. (1995), 
noted that surgery is warranted in the case of an early stage lung cancer relapse or a 
second locally confined primary in the lung 
236
.  Although long term survival and local 
control has not been validated, the authors suggest this as a viable option to increase 
patient survival.  Another approach suggested by Johnson, et. al. (1990) suggested a 
combination of cyclophosphamide, doxorubicin, and vincristine or etoposide or both 
vincristine and etoposide for SCLC.  
 
Complications of Lung Cancer 
The lungs are highly vascular and are supplied by a system of lymphatic glands so 
the greatest complication of lung cancer is the spread of cancer through different tissue 
and organs of the body (metastasis).  Another major complication of lung cancer is the 
reappearance of the disease in the form of another primary neoplasm or the development 
of a secondary tumor 
72
.  According to the American Cancer Society, lung cancer relapse 
74 
commonly occurs within two years even in the event of a positive treatment course 
2
.  
Complications are associated with each treatment regimen; in particular chemotherapy 
agents have been shown to decrease survival resulting in the early termination of clinical 
trials 
237
.  Venuta, et al., 2006, found in a retrospective study based on one hundred and 
thirty-nine patients (100 males and 39 females), preoperative functional parameters, type 
of operation, associated disorders, staging, induction regimen (chemotherapy alone or 
combined with radiation therapy), all added to the complication rate for surgical 
procedures 
238
.  After multivariate analysis for morbidity and mortality and controlling 
for age and lung functional volume; the results were not statistically significant.  
The complications for radiation therapy lung cancer treatments include decreased 
ventilation function, hemoptysis, and local relapse.  Historically, the major disadvantage 
to the use of radiation therapy was the amount normal tissue that had to be irradiated 
thereby reducing lung function in a lung already compromised by cancer.  Advances in 
radiation therapy treatment modalities, e.g. Intensity Modulated Ration Therapy (IMRT), 
Image Guided Radiation Therapy (IGRT), Respiratory Gated Radiation Therapy 
(RGRT), all allow for techniques to minimize motion and to increase the precision of the 
target or tumor coverage 
239-241
.  Underberg, et. al., 2005 found a 50% reduction in the 
primary tumor volume irradiated with the new treatment techniques.  This means that the 
newer radiation therapy techniques can offer a consistently smaller irradiation volume so 
decreased toxicity can be expected; any longer term effect on survival would have to be 
investigated 
242
. 
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Lung Cancer Treatment Modalities 
 The type of lung cancer treatment modality is dependent upon several factors that 
include the histological type of lung cancer, the size of the tumor, the location, extent or 
degree of regional spread of the disease, and the general condition of the patient.  Many 
of the treatment modalities, e.g. radiation therapy, surgery, chemotherapy, photodynamic 
therapy, can be used separately or combined to treat the cancer
239-241
.  As there are 
several treatment options, there are at the very least two main goals that are anticipated 
upon completion of the treatments.  First, there is an expectation that if a complete cure is 
not achieved, the progression of the tumor has been confined.  This should have an 
overall effect of increased survival.  Secondly, there is an expectation that the symptoms 
of the disease will be diminished for the patient, thereby improving quality of life issues.  
In the next several sections in this chapter, current and emergent technologies will be 
expanded upon. 
 
Radiation Therapy 
Radiation therapy or radiotherapy utilizes high energy rays to kill cancer cells 
4,
 
47
.  The radiation is delivered to a very specific region of the diseased lung, with the goal 
of a minimal radiation dose given to normal tissue.  Prior to a surgical procedure, 
radiation can be given to decrease the tumor size and destroy peripheral, microscopic 
disease surrounding the tumor 
4, 239-241
.  Radiation therapy can also be used for the relief 
of lung cancer symptoms, such as shortness of breath.  There are several radiation therapy 
76 
treatment options for lung cancer; external beam therapy and radioisotope therapy 
(brachytherapy) 
6
.  External beam is the application of a radiation beam from an external 
source, e.g. linear accelerator, cyclotron, to the affect site of cancer.  Recent 
advancements as discussed in ―Complication of Lung Cancer‖ section of this chapter 
reviewed the newer technologies to reduce radiation damage of the normal tissue, thereby 
preserving lung function 
72
.  One of the newest and most costly (1.2 billion US dollars) 
radiation therapy treatment involves treating with a proton beam to reduce radiation 
induced morbidities.  Protons deposit their energy maximally at a specific distance from 
the patient surface 
72
.  This maximum deposition occurs at the Bragg Peak of the proton; 
the amount of radiation deposited is dependent upon the energy of the proton (a charged 
ionizing particle) and the medium or material of interaction.  There is minimal interaction 
with normal tissue and decreased lung function toxicity. 
 Endobronchial brachytherapy involves the application of a radioactive material to 
the affect site in the lung; a commonly used radioisotope is Iridium-192 
72
.  Normally the 
treatment is done for a more circumscribed area of the lung (less than 10 centimeters in 
length) as compared to external beam radiation.  The application of the radioactive source 
can be done by two methods; either a high dose rate application (taking several minutes) 
or by the low dose method (can take several hours) 
72
.  For the high dose rate (HDR) 
method, the radioactive source is introduced into the lung tumor via a flexible catheter.  
This catheter is place prior to the HDR during a bronchoscopic procedure.  The treatment 
goal is to minimize any normal tissue damage and deliver a therapeutic dose (3 to 10 
77 
Gray per fraction) 
72
.  The advantage of this technique is an increased local control of the 
tumor progression and it is less invasive than a surgical procedure with the associated 
postoperative morbidities.  The main disadvantages to this technique is fistula formation 
and fatal hemoptysis 
243
.  
 
Chemotherapy 
Chemotherapy is another lung cancer treatment option, as shown in Table 5, 
which uses drugs to obliterate cancer cells.  The purpose of chemotherapy is to kill the 
cancerous cell or interrupt the cancer cell cycle, thereby preventing the growth of the 
tumor.  One of the harmful effects of chemotherapy agents is the drug(s) destroy normal 
cells in the process of destroying the cancer cells.  The destruction of normal cells/tissue 
can cause various side effects that include nausea, vomiting, diarrhea, increased 
susceptibility to infections, and in some instances, death 
9
.  The various chemotherapy 
drugs are administered either by infusion, orally, or as a combination of both during a 
treatment. NSCLC and SCLC can both be treated with chemotherapy agents; the 
optimum or most effective drugs for the treatment of lung cancer are platinum-based 
drugs, cisplatin and carboplatin 
135
.  Other non-platinum based chemotherapy agents 
include docetaxel, paclitaxel, gemcitabine, and irinotecan; these can be used in 
conjunction with cisplatin and carboplatin during the treatment regimen.  For further 
information, Appendix III Table 75 contains a listing with chemotherapy drugs typically 
used in the treatment of lung cancer, the type of agent, and major side or adverse effects.  
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Typically, chemotherapy is used as an adjunct or secondary treatment to surgery 
or radiation therapy, dependent upon the histological type and stage of the disease.  In the 
case of small cell lung cancer, chemotherapy is the treatment of choice because the 
procession of the disease is typically widespread throughout the body when the diagnosis 
of lung cancer is made 
4, 135
.  Small cell lung cancer accounts for approximately 20 to 
25% of incident lung cancer cases diagnosed 
13
.  Of all SCLC diagnosed, only 40% of the 
cases have the disease limited to the chest cavity (thorax).  The regimen of choice is 
chemotherapy plus radiation therapy.  In some instances, prophylactic irradiation of the 
brain is given to treat micrometastasis; which is the early spread of the cancer to the 
brain.  The five year survival rate for limited stage SCLC is 15 – 25%.  The median 
survival for patients that do not receive chemotherapy in combination with radiation 
therapy is 6 to 12 weeks 
237
.  If the SCLC has developed into an extensive stage, the 
recommendation is to use chemotherapy alone; these cases account for 60% of all the 
newly diagnosed SCLC 
237
.  When a case of SCLC is diagnosed at this stage, the disease 
has normally progressed or metastized to the brain, liver, bone, and/or bone marrow.  
According to Carney in his New England Journal of Medicine article,‖ Lung Cancer -
Time to Move on from Chemotherapy‖, he states that over the past twenty years, all the 
chemotherapy drugs combinations and varying treatment regimens, the most significant 
improvement in survival was on average two months 
244
.  At advanced stages of lung 
cancer, clinical trials are still being evaluated for efficacy 
54, 59, 245-249
.  
Gerold Bepler of the H. Lee Moffitt Cancer Center and Research Institute, noted 
79 
that there is a renewed interest in the development of new strategies for chemotherapy to 
increase survival for NSCLC patients 
250, 251
.  This has come about due to advances in 
genetic research and the identification of genes on the chromosomes that have been 
identified as prognostic factors in the treatment of lung cancer.  The level of the genetic 
material present in a lung cancer case’s biological makeup can determine which specific 
chemotherapy drug or combination of chemotherapy drugs will be most effective to treat 
the cancer 
250
.  An increased level of two genes, RRM1 and ERCC1, has been shown to 
decrease the effectiveness of chemotherapeutic drugs 
251
.  In the clinical trial, the 
International Adjuvant Lung Cancer Trial, Olaussen et al. (2006), demonstrated that 
patients with ERCC1- negative tumors had increased survival (adjusted hazard ratio = 
0.65, 95% CI 0.50 – 0.86; p-value = 0.002); whereas patients with ERCC1 – positive 
tumors (adjusted hazard ratio = 1.14; 95% CI 0.84 – 1.55; p-value = 0.40) 252.  
Table 5 gives a summary of the recommendations found in Collins, et al 2007
4
 
and describes the primary or first choice of treatment for a particular lung cancer type, i.e. 
Non Small Cell Lung Cancer and Small Cell Lung Cancer, and stage of the disease.  The 
secondary treatment modality recommendations and the associated five year survival 
rates are also listed in Table 5.  
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Table 5: Lung Cancer Treatment Recommendations 
 
 
Stage 
Primary 
Treatment 
Modality 
Secondary 
Treatment  
Modality 
 
Survival Rate  
 
Non Small Cell Lung Cancer (NSCLC) 
I Surgery 
(Resection) 
Chemotherapy† 5-Yr survival rate, 
> 60 – 70% 
II Surgery 
(Resection) 
Chemotherapy 
with or without  
Radiation 
Therapy† 
5-Yr survival rate, 
> 40 – 50% 
III A (resectable) Preoperative 
chemotherapy followed 
by surgical resection 
(preferable) or surgical 
resection 
Chemotherapy 
with or without  
Radiation Therapy 
5-Yr survival rate, 
15 -30% 
III A (unresectable) 
 
Chemotherapy plus 
concurrent radiotherapy 
(preferable) or 
chemotherapy followed 
by radiotherapy 
 
None 
5-Yr survival rate, 
10 – 20% 
III B (pleural effusion) 
or IV 
Chemotherapy with 2 
agents for 3 or 
4 cycles (preferable) 
 
Surgical resection of 
solitary brain metastasis 
and surgical resection of 
primary (T1) lesion 
 
None 
 
 
 
 
None 
Median survival, 8–10 mo 
1-Yr survival rate, 30–35% 
2-Yr survival rate, 10–15% 
 
 
5-Yr survival rate , 10–15% 
 
Small Cell Lung Cancer (SCLC) 
Limited Disease‡ Chemotherapy and 
concurrent Radiation 
Therapy 
 
None 
5-Yr survival rate, 
15 – 25% 
Extensive Disease‡ Chemotherapy None 5-Yr survival rate, 
< 5% 
* All chemotherapy regimens include either cisplatin or carboplatin. A complete list of clinical trials is available at 
http://www.cancer.gov. and up-to-date approaches to the treatment of non–small-cell and small-cell lung cancer are 
available from the National Comprehensive Cancer Network at http://www.nccn.org. 
† This regimen is based on data from the International Adjuvant Lung Cancer Trial, which demonstrated a small but 
significant survival advantage with cisplatin-based adjuvant therapy. Physicians should strongly consider such therapy 
for appropriate patients. 
‡ Prophylactic cranial irradiation is recommended for all patients with a complete response to initial therapy. 
Source: Adapted from Collins, et. al., 2007 
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Surgery 
 Surgery removes lung cancer or the tumor during an operation.  The operation or 
surgical procedure is based on the histology or type of lung cancer and where the tumor is 
located.  A surgical procedure is not recommended for small cell lung cancer, unless the 
disease is very circumscribed and is not too advanced at the time of diagnosis 
4
.  Surgery 
is recommended by the American College of Chest Physicians and the American Joint 
Commission on Cancer 
4, 9, 253
 for NSCLC.  According to Rivera, et. al., (2003), Stage I 
and Stage II have the optimum prognosis, with a average five year survival rate of 60% to 
70% for Stage I and a greater than 40 – 50% for Stage II 9.  Other considerations for a 
surgical procedure for the excision of a lung tumor include the location of the tumor, i.e. 
the tumor may be too close to the heart or the trachea, if the patient is a surgical candidate 
and can withstand the surgical intervention, and the stage or extent of the disease 
135
.  If 
the disease is too extensive throughout the body, a surgical procedure to remove the lung 
tumor is not recommended. Radiation Therapy and/or chemotherapy may be other 
options if surgery is not indicated 
4, 9, 135
.  
 Different types of surgical procedures include 1) wedge resection, 2) 
segmentectomy, 3) lobectomy, 4) lymph node removal, and 5) pnumonectomy.  A wedge 
resection consists of the removal of part of the lung; it is used when the tumor is confined 
to a particular location in the lung.  When the tumor is removed, a portion of the healthy 
or non diseased lung is also removed.  This is done in an attempt to eliminate any 
microscopic disease around the periphery of the tumor bed.  A segmentectomy is the 
82 
procedure where a greater margin is taken around the tumor bed.  A lobectomy entails the 
removal of one of the five lobes of the lung; the right lung has three lobes and the left 
lung has two lobes.  This type of surgical resection involves the surgeon making an 
incision on the patient’s side between the ribs.  Once the incision has been made the 
surgeon then spreads the ribs apart; this makes the lung tumor accessible for removal.  A 
video-assisted lobectomy (VATS) employs a small video camera (a thorascope) inserted 
into the chest cavity; the images received form the thorascope guides the surgeon to the 
operative area in the chest.  This particular procedure minimizes the bleeding and 
complications of the surgery; the patient stay is reduced from five to seven days to two to 
three days.  A lymphectomy or lymph node removal can be accomplished during the 
surgical procedure.  The lymph nodes are examined by the pathologist for signs of 
disease; if the nodes were positive, this would be an indication of disease spread.  In the 
case of positive nodes, the surgeon may opt not to remove any of the tissue as the stage of 
the disease has progressed and surgery is not an indication 
4, 54, 59, 253
.  
 A pnumonectomy is the complete removal of the entire lung.  This procedure can 
only be performed if the patient’s physical condition and breathing capacity can tolerate 
this extensive surgical procedure and would not compromise the patient’s quality of life.  
A pnumonectomy is recommended for centrally located tumors and tumors that involve 
more then one lobe.  The removal of the lung is warranted when the tumor has spread 
throughout the lung but has not metastized to other parts of the body.  The complications 
from surgery may include internal bleeding, infection, lymohocytopenia (low white 
83 
count), and possible reoccurrence of the disease. 
 
Combination Therapy 
 Treatment modalities are combined in an effort to increase the length of survival 
for lung cancer patients.  The standard of practice for small cell lung carcinoma with 
limited disease (no evidence of spread) is chemotherapy drugs concurrent with radiation 
therapy 
4, 135
.  According to Anraku and Waddell (2006), surgery can be warranted under 
certain conditions for early stage SCLC.  Chemotherapy with a combination of surgery 
for patients with T1-2 N0 SCLC may enhance local control but the authors also note that 
clinical trials are needed to validate these results 
54
.  Surgery and chemotherapy can be 
offered to patients that have a mixed tumor type (SCLC and NSCLC components) as the 
anticancer agents are less effective against NSCLC in the limited or early stages of the 
disease 
54
.  Stage I and Stage II NSCLC use the combination of surgical resection, 
radiation therapy, and/or chemotherapy.  Surgery is the primary treatment with radiation 
and/or chemotherapy as the adjuvant therapy.  Other treatment regimens include surgery 
with or without preoperative chemotherapy for resectable Stage IIIA with the adjuvant 
therapy of chemotherapy with or without radiation therapy.  The five year survival rate is 
15 to 30% for this course of therapy
4, 9
.  The recommendation for Stage IIIA unresectable 
NSCLC is chemotherapy with concurrent radiation therapy or radiation therapy 
treatments after the course of chemotherapy treatments.  The five year survival rate 
declines for this combination of modalities to 10 to 20% 
4, 9, 135
.  Patients with Stage IIIB 
84 
(pleural effusion) or IV are given chemotherapy, resection of a primary T1 tumor and 
primary brain metastasis.  
 
Emergent Modalities 
The optimum treatment for lung cancer is based on stage and grade of the 
disease
4, 144, 243, 249, 253, 254
.  There are several recently developed endoscopic modalities for 
the treatment of early stage lung cancer. 
243
.  Although the newer treatment techniques 
offer a less invasive technique, decreased perioperative morbidity and reduced cost as 
compared to conventional modalities, the techniques and methods require validation 
4, 243
.   
Endoscopic therapies such as photodynamic therapy, brachytherapy, neodymium yttrium 
aluminum garnet laser, electrocautery, and cryotherapy; offer an alternative in the 
treatment of early stage lung cancer.  These modalities can be applied during a procedure 
known as a fluorescence bronchoscopy.  Pathological changes in the appearance of 
normal lung tissue can be detected during bronchoscopy utilizing fluorescence.  Normal 
tissue fluoresces (emission of light) at varying energy levels when compared to cancerous 
tissue; this difference in energy levels is seen by the human eye as differences in color 
243
.    The main disadvantage to this detection method is the high false-positive rate; 
inflammatory processes or trauma can cause changes in the light patterns that could be 
perceived as cancerous 
243, 255
.   Lam, et al., 1993, reported a sensitivity of 72.5% and a 
specificity of 94% in the detection of advanced dysplasia 
243, 255
.  When comparing 
fluorescence bronchoscopy to conventional bronchoscopy, the conventional technique 
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had a sensitivity of 48.4% 
255
.  A multicenter trial comparing the two techniques found 
fluorescence bronchoscopy detection rate of invasive lung carcinoma of 95% as 
compared to conventional bronchoscopy with a 65% detection rate 
256
.  Photodynamic 
therapy (PDT), as a treatment for lung cancer, has been used in conjunction with 
fluorescence bronchoscopy 
243
.  PDT involves targeting the lung tumor cells with a 
photo-sensitizing agent and an application laser light to the affected area during a 
bronchoscopy.  The laser light, typically 630 nanometers, activates the chemical 
sensitizer producing a photochemical reaction at the cellular level.  This results in the 
destruction of the tumor cells by an oxidative process 
243
.  
Lung cancer treatments can be done by a neodymium yttrium aluminum garnet 
(Nd: YAG) laser.  This treatment has been done for palliation purposes but the literature 
does not support a significant contribution in the treatment of early stage lung cancer 
243
.   
Gerasin et al. (1990), did report success with this technique for early stage lung cancer in 
the contralateral lung when a lobectomy is contraindicated 
257
.  
Scientific advancements in the fields of chemotherapy, surgery, and radiation 
therapy involving tumor development (carcinogenesis) and lung cancer progression have 
been possible with the discovery of genetic materials that are involved in the disease 
process 
4, 9
.  There has been recent evidence that a drug, epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor, has been effective in the treatment of bronchialveolar 
cell carcinoma (a NSCLC type).  This particular cancer type is common in women and in 
non smokers.  The drug causes the shutdown of the epidermal growth factor receptor 
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protein, thereby preventing the development of the cancer.  
 
Conclusions and Assessment of the Literature 
 The purpose of this research is to test the hypothesis of a survival 
difference in women with lung cancer as compared to men, dependent upon treatment 
modality (surgery, chemotherapy, radiation, or combination), histological type, and stage 
of disease.  An extensive literature search and review was preformed to investigate the 
variables that could be involved in the associated lung cancer treatment received and how 
that treatment decision influences women’s survival as compared to men.  There is 
limited research regarding the risk of being a woman with lung cancer and the treatment 
received as compared to men.  As described in the literature review, there are no studies 
combining the specific treatment modality received or combinations of treatment 
received, gender, stage, grade, morphology and demographic factors with respect to 
survivorship. Visbal et.al. (2004) noted the Relative Risks between males and females 
and survival adjusting for stage, histological, and treatment type.  Although there were 
significant results for stage (Stage IIIB RR = 1.22, 95% CI = 1.02, 1.46 and Stage IV RR 
= 1.29, 95% CI = 1.15, 1.44), there was no significant results for treatment type received. 
Also the authors did not mention if there were any combined treatments of chemotherapy, 
radiation, or surgery 
17
.  In the article by Radzikowska et. al. (2002), (n = 11,479) a 
multivariate survival analysis was performed based on age (categorized into two groups; 
group I < 50 years old, group II > 50 years old), gender, performance status, clinical 
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stage of lung cancer (four stages), histology (adenocarcinoma, squamous, SCLC, and 
other) and two treatment types (surgery and non-surgical) 
15
. In the Cox-Proportional 
Hazard’s model, the relative risk of death was adjusted to age, gender, histological type 
of lung cancer, performance status, and stage of the disease.  The RR’s were given with 
no confidence intervals; any truly significant results could not be evaluated. The reported 
RR’s were all greater than 1.0 (squamous cell RR = 1.09, SCLC RR = 1.42, Other 
Histological Type RR = 1.46) with the exception of the reference group (RR = 1.0). 
There were significant p-values, all values < 0.004 with the exception of the histological 
type for squamous cell (p-value = 0.29). Lung cancer was six times more frequent in 
males versus females and women with lung cancer were younger and smoked less than 
males with lung cancer.  
There are many histological types of lung cancer, finding an optimum treatment 
regimen that will increase survival for a particular lung cancer type is challenging.  Each 
histological type has its own medical intervention that can include any combination of 
surgery, radiation therapy, and/or chemotherapy.  Gender-specific incidence and survival 
rates were shown to be different for the lung cancer types.  In the article by Thomas et. al.  
(2005), ―Lung Cancer in Women: emerging differences in epidemiology, biology, and 
therapy‖ 48, as the authors noted ―women are at an increased risk for lung cancer than 
men‖. The gender differences placing women at a greater risk were reported to include 
molecular variables such as different metabolism of tobacco-related carcinogens, possible 
association with human papilloma virus (HPV) infection, and that women have less DNA 
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repair capacity (DRC); the authors also noted that women had better survival outcomes 
stage for stage than men 
48
.  
Presently, there are no published quantitative results that show whether there is a 
statistically significant difference regarding survival due to a particular treatment for 
women as compared to men having the same histological type, grade and stage of lung 
cancer.  The statistical methods performed in the articles cited in the literature review did 
not evaluate interaction effects of the independent variables; this is a major limitation as 
any gender specific differences based on any moderating variables could not be 
evaluated. Performing this research provides the scientific evidence to answer the 
question concerning gender, stage, grade, morphology, age, martial status and race and 
their impact on survival. Findings of treatment differences by major histological types are 
presented in this dissertation. In conclusion, the goal of this research was to provide a 
statistical and biologically plausible model demonstrating gender differences in lung 
cancer survival exist based on the treatment received. 
 
 
 
 
 
 
 
89 
CHAPTER III: PROCEDURES AND METHODS 
Introduction 
The purpose of the research presented in this dissertation was to determine if 
gender differences exist for a treatment(s) utilized for lung cancer and if that treatment(s) 
received impacts gender specific survival.  The epidemiologic study design was based on 
a historical cohort of lung cancer cases drawn from population based state-wide cancer 
registries. Each cancer registry were members of the North American Association of 
Central Cancer Registries, NAACCR 
258
.  The participants were men and women with 
newly diagnosed/incident primary lung cancer diagnosed between January 1, 2000 and 
December 31, 2004.  All lung cancer cases selected were pathologically confirmed and 
classified on the four major histological types of the disease, i.e. adenocarcinoma, 
squamous cell carcinoma, large cell carcinoma and small cell carcinoma.  
 
Aims/Hypothesis 
Aim 1:  The first aim was to determine if men and women with the same 
histologic type, stage, and grade of lung cancer received the same treatment type.  Any 
effect, such as any interaction that the covariates (histologic type, stage, and grade) may 
exert on the relationship between gender and treatment received must be evaluated.  It 
was important to establish if there were treatment differences’ dependent upon gender.   
If the lung cancer treatment is gender dependent, this may impact gender specific 
survivorship.  
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Hypothesis 1:  Women with the same histological type, stage and grade of lung 
cancer will receive the same treatment modality as compared to men with the same 
histological type, stage and grade of lung cancer.  
Aim 2:  The second aim is to evaluate the overall relationship between survival 
and gender for the lung cancer cases.  The goal is to obtain an assessment of the overall 
survivorship by gender. 
Hypothesis 2:  There is a statistically significant difference in survival in women 
with lung cancer as compared to men with lung cancer.  
Aim 3: The third aim of this study is to expand the investigation of treatment 
modality differences and gender-specific survival.  The goal is to determine if men and 
women with lung cancer grouped or stratified by treatment modality, histologic type, 
stage, and grade exhibit or demonstrate gender-specific survivorship.  
Hypothesis 3:  Women with the same histological type, stage, grade of lung 
cancer, and the same treatment modality differ significantly in survival as compared to 
men with the same histological type, stage, and grade of lung cancer, and the same 
treatment modality.  
 
Participant Description and Case Identification 
The study participants in this research are primary lung cancer cases drawn from 
population based state-wide cancer registries.  Data on cancer cases and cancer deaths are 
collected, managed, and analyzed by a system of state-based cancer registries 
1
.  The 
91 
majority of state cancer registries are members of the National Program of Cancer 
Registries 
259
; the NPCR was established in 1992 by the Cancer Registries Amendment 
Act 
259
.  The NPCR is administered by the Centers for Disease Control and Prevention 
(CDC) and is under the Division of Cancer Prevention and Control 
259
.  Prior to the 
establishment of the National Program of Cancer Registries, there were ten states with no 
cancer registry; today there are forty-five states with cancer registries to include the 
Virgin Islands, the Republic of Palau, Puerto Rico, and the District of Columbia 
258
.  
Another international cancer registry organization that certifies NPCR is the North 
American Association of Central Cancer Registries 
258
.  NAACCR was established in 
1987; it represents state cancer registries and professional organizations such as the 
American College of Surgeons, the American Cancer Society, and the Public Health 
Agency of Canada 
258
.  Other responsibilities of the NAACCR or known as the ―central 
cancer registry‖ are to monitor and certify state cancer registries; this ensures the data 
collection methods used by each state registry are complete, accurate, and done on a 
timely basis.  The each state registry that is a member of NAACCR submits cancer case 
data obtained from medical facilities, e.g. hospitals, surgical centers, laboratories, 
outpatient facilities, physician offices, and radiation therapy centers, to the central cancer 
registry.  Cancer information is collected or abstracted in a standardized format into 
highly specified field arrangements 
258
.  The standardization of field information allows 
for the intercomparison of data within the state, with other states, and on a national level 
258, 259
.  
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One of the first steps in the selection of the primary lung cancer cases for this 
research study was to identify the eligible cancer registries. The criteria for the state/state 
cancer registries selected had to be established.  Each selection parameter or criterion was 
critical; the ultimate goal being selection criteria that could be utilized to generate a 
dataset free from bias.  The criteria for selection of a state/state cancer registry (Table 6) 
for this research were as follows: 
Table 6: Criteria for State/State Cancer Registry Selection 
1. The registry must exist in a state in the United States of America,  
2. The registry must be population based,  
3. Each registry must be selected from the four US regions as defined by the US Census 
Bureau,  
4. The individual lung cancer cases must be randomly selected, as each lung cancer case 
in the state cancer registry must have an equal chance of being included or excluded 
in the registry, 
5. The cancer registry must be defined as a ―passive‖ registry,  
6. The data must include primary lung cancer cases diagnosed between 1-1-2000 and 
12-31-2004, a five year time frame,  
7. The state registry must be a member of NAACCR,  
8. Each state registry must meet the criteria of the ―Standards for Cancer Registries: 
Standards for Completeness, Quality, Analysis, and Management of Data‖ 258 , and  
9. The state cancer registry must have achieved NAACCR certification (a  minimum of 
3 years gold certification and maximum of 2 years silver certification – see Table 6. 
10. Each state must be randomly selected as not to introduce selection bias,  
11. The data must be accessible and retrievable to the researcher conducting the study. 
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The NAACCR guidelines for certification are measurable standards and each year 
state registries obtaining the goals for ―Completeness of Data‖ are awarded a gold or 
silver designation (if the goals were achieved) by NAACCR.  The selection of states for 
the research study began with a process as outlined in Figure 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: State Selection Process 
 
 
37 USA States 
(50 – 13 SEER States) 
 
 
50 USA States 
 
 
 
29 USA NAACCR States 
(Reporting – Non-Reporting States) 
 
 
14 USA States 
(Meet Certification Guidelines) 
 
 
8 USA States 
(Randomly Selected) 
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This goal of this research ―selection criteria‖ protocol was designed to minimize 
bias. If one state is selected over another state it must be purely by chance thereby 
eliminating any possible influences or bias.  In other words, each state cancer registry 
must have an equally likelihood of being selected; one state may be inherently different 
and this difference would tend to diminish with the having all the states randomly 
selected.  Another source of bias may be introduced by the investigator if that 
investigator selected a particular state over another state due to personal or unscientific 
reasons – the random process would be invalid.  
.  The first text box of Figure 10 represents individual lung cancer cases from the 
fifty US states which serve as the population from which the final research data set 
(Criterion 1) was drawn.  The research protocol was developed as to include lung cancer 
cases selected from population based cancer registries (Criterion 2).  The fifty states are 
sub-divided into geographic regions by the US Census Bureau (Criterion 3).  The Bureau 
identifies four major US regions (South, Midwest, West, and the Northeast) which 
correspond to regional populations from which the lung cancer cases will be selected.  As 
discussed in the literature, population characteristics can differ with geographic location 
155, 260-262
 and it is critical that the individuals selected are randomly selected lung cancer 
cases as not to introduce bias (Criterion 4).  
Of the 50 states, 13 states were excluded (text box 2 of Figure 6), leaving 37 
NAACCR states.  The states excluded were members of SEER and those SEER states 
were: 1 - Connecticut, 2 - Hawaii, 3 - Iowa, 4 - Louisiana, 5 - New Jersey, 6 - New 
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Mexico, 7 - Utah, 8 - Georgia (multi-country areas of Atlanta & rural Georgia), 9 - 
Michigan (Detroit), 10 - California (San Francisco-Oakland, San Jose-Monterey, Los 
Angeles county, remaining counties of California), 11 - Washington (Seattle-Puget 
Sound), 12 - Arizona (American Indians), and 13 - Alaska (Alaskan Natives).  SEER is 
an active registry system and those states under SEER do not meet selection criterion 5.  
This is important as there are two main types of cancer registries, passive and active, that 
differ in the method data are collected.  An active cancer registry collects the data from 
the medical facilities whereas a passive registry has the data sent to the registry from the 
medical facilities (reporting facilities) that are part of the state wide system.  An example 
of an active state cancer registry would be a member of SEER such as the Kansas Cancer 
Registry. NAACCR cancer registries are passive; some of the state cancer registries are 
listed in.  In this research, passive registries were only selected (Criterion 5). Having only 
passive registries served the following purpose: the ―passive‖ classification aided in the 
standardization of the states selected; this helped to minimize selection bias by only 
selecting states that have a similar reporting mechanism and reporting criteria.   
The thirty-seven states were evaluated (text box 3 Figure 10.) for their NAACCR 
status.  Eight of the thirty-seven states were not members of NAACCR for a portion of 
the years under study (2000-2004), thereby excluding them from participation in this 
research; 29 US NAACCR states remained (Criteria 6 and 7).  Selection Criterion 6, 
restricting the time period under study (a 5 year range), will help to reduce any temporal 
differences associated with lung cancer treatments.  A temporal bias may be introduced 
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when studying extended time periods or ranges.  Treatment modalities have drastically 
changed over the past 20 years, and trying to determine treatment effects over that 20 
year time period would be more difficult to ascertain.  Survival differences during this 5 
year range are of particular concern; the treatment modality utilized to treat the lung 
cancer case should be more consistent and this could impact survivorship.  Therefore, the 
date/time range established for lung cancer case data inclusion starts January 1, 2000 and 
ends December 31, 2004.   
The reporting system used for the cancer registries of interest for this research is 
based on the ―Criteria and Standards for Eligibility of NAACCR Registry Certification 
and CINA Combined Rates‖ (Criterion 8).  The criteria and the standards are displayed 
below in Table 7.  Using this criterion, fifteen (15) states, as shown in Table 8., were 
excluded and fourteen (14) NAACCR states remained from the 29 states (text box 4 of 
Figure 10.).  The selection criteria for state inclusion were based on the grading scales 
established by the central cancer registry as outlined in Table 7 below (NAACCR Criteria 
and Standards for Gold/Silver Certification). NAACCR certifies for ―High Quality 
Incidence Data‖ and the exact protocol followed by the central cancer registry is 
contained in the North American Association of Central Cancer Registries, Inc. Standards 
for Cancer Registries Volume III, ―Standards for Completeness, Quality, Analysis, and 
Management of Data‖.  For example, the criteria and standards are used to evaluate 
characteristic variables of the tumor such as tumor morphology (histology and behavior), 
stage, grade, and the method of diagnostic confirmation.  The standards are used to assess 
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the quality of the information in the individual state cancer registry, completeness of the 
data reported, and timeliness of reporting 
258
.  In summary, a total of fifteen (15) of the 
twenty-nine (29) states did not meet the selection criteria as outlined in Criterion 9; 
thereby excluding those states from participation (see Table 7). 
 
 
Table 7: NAACCR Criteria and Standards for Gold/Silver Certification 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Standards for NAACCR Cancer Registries: Standards for Completeness, 
Quality, Analysis, and Management of Data 
Note: DCO = Death Certificate Only 
 
Table 8 lists the twenty nine NAACCR states from the four US Census Bureau 
defined regions and their certification status over the study 5 year time period (2000 – 
2004).  
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Table 8: Annual NAACCR Certification Designation 
Five Years of Certification - States (29) by Region (4)  
 
REGION 
 
STATE 
 
2000 
 
2001 
 
2002 
 
2003 
 
2004 
 
Annual  
Incidence 
 
Average  
Annual 
Cases 
 
 
 
WEST 
COLORADO gold silver gold gold gold 54.9 2011 
IDAHO gold gold gold gold gold 55.2 683 
MONTANA silver silver silver gold gold 66.5 663 
NEVADA gold gold gold gold gold 76.9 1622 
OREGON gold gold gold gold gold 69 2489 
 
 
 
 
 
 
 
SOUTH 
ALABAMA silver silver gold silver gold 75.2 3569 
ARKANSAS   silver   silver silver 81.1 2404 
DELAWARE     silver gold gold 76.6 649 
FLORIDA gold gold gold gold gold 74.6 15838 
NORTH 
CAROLINA gold silver silver silver gold 68.5 5611 
OKLAHOMA     gold gold gold 83.9 3068 
SOUTH 
CAROLINA silver silver gold gold gold 74.7 3111 
TEXAS       gold gold 68 12162 
WEST VIRGINIA gold gold gold gold gold 87.7 1915 
 
 
 
 
 
 
 
MIDWEST 
ILLINOIS gold gold gold gold gold 72.8 8836 
INDIANA silver gold gold silver gold 80.6 4931 
KANSAS gold gold   gold gold 66.5 1841 
MINNESOTA gold gold gold gold   58.8 2843 
MISSOURI gold silver gold gold gold 78.6 4731 
NEBRASKA gold gold gold gold gold 62.4 1118 
OHIO silver silver silver   silver 74.6 8993 
SOUTH DAKOTA       gold silver 58.7 486 
WISCONSIN gold gold gold gold   65.9 3700 
 
 
 
 
NORTHEAST 
MAINE   gold gold gold gold 79.1 1183 
MASSACHUSETTS gold gold gold gold gold 70.5 4764 
NEW HAMPSHIRE gold gold gold silver gold 67.7 860 
PENNSYLVANIA gold   gold gold gold 70.4 10292 
RHODE ISLAND gold gold gold gold gold 73.8 860 
VERMONT       silver gold 63.9 418 
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Of the 29 states, 15 states were excluded as the state had to meet at a minimum 
three years of gold certification and a maximum of 2 years of the silver certification as 
defined the NAACCR criteria (see Table 7.) for the five year time frame under study 
(Criterion 9).  Table 9 lists the final 14 states; the minimum number of states in a region 
(the South and the Northeast) was three with a maximum number of states of four in the 
West and Midwest.  
Table 9: Annual NAACCR Certification Designation by Region and State (14) 
 
 
REGION 
 
STATE 
 
2000 
 
2001 
 
2002 
 
2003 
 
2004 
 
Annual  
Incidence 
 
Average  
Annual 
Cases 
 
 
WEST 
COLORADO gold silver gold gold gold 54.9 2011 
IDAHO gold gold gold gold gold 55.2 683 
NEVADA gold gold gold gold gold 76.9 1622 
OREGON gold gold gold gold gold 69 2489 
 
 
SOUTH 
FLORIDA gold gold gold gold gold 74.6 15838 
SOUTH CAROLINA silver silver gold gold gold 74.7 3111 
WEST VIRGINIA gold gold gold gold gold 87.7 1915 
 
 
MIDWEST 
ILLINOIS gold gold gold gold gold 72.8 8836 
INDIANA silver gold gold silver gold 80.6 4931 
MISSOURI gold silver gold gold gold 78.6 4731 
NEBRASKA gold gold gold gold gold 62.4 1118 
 
 
NORTHEAST 
MASSACHUSETTS gold gold gold gold gold 70.5 4764 
NEW HAMPSHIRE gold gold gold silver gold 67.7 860 
RHODE ISLAND gold gold gold gold gold 73.8 860 
 
The fourteen states were distributed from the four US geographic regions – from 
each region the intent was to randomly select two states (Criterion 10).  As stated 
previously, the states were selected at random as not to introduce bias.  The reasons for 
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selecting two states from each region were: 
1. At least two states were needed from each region to measure or account for variability 
within the regions. 
2. Including all fourteen states was not feasible due to limited resources, e.g. cost 
considerations, manpower, and time constraints.  
In the selection of the states from the four US geographic regions, a random 
sample selection was made utilizing a SAS program; these samples represent the 
population from which they were drawn (all US primary lung cancer cases).  To account 
for any variability of the population within each region, more than one state for the region 
had to be selected.  At a minimum, at least two states from each region must be selected 
in order to account for any variability within the region.  
As part of the selection criteria the data must be accessible (Criterion 11); not all 
states consented to having the data distributed to an outside individual.  Logistical issues, 
such as data unavailability would prevent the selection of a state registry.  An additional 
logistical issue that could be encountered could be - although a particular state registry 
may meet NAACCR requirement for certification, the state reporting system may not 
report a variable needed for the research under study.  The final step was to call each of 
the state registries and request the procedure the particular state registry utilized for a data 
request (Criterion 11).  West Virginia was hesitant to participate due to concerns for the 
protection of patient privacy and was requiring the author to send the author’s 
Curriculum Vitae (CV), the committee members CV’s, and the complete IRB application 
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that was submitted to the University of South Florida (the application contained 
confidential information about the author and committee members); the registry would 
not accept the official IRB approval letter.  Also, West Virginia does not/did not report 
the complete date listed for ―date of last contact‖ a variable of interest in this research; 
the date is reported by year and does not include the day and month.  As West Virginia 
did not meet selection Criterion 11, South Carolina was selected to participate; the 
resultant 8 states selected are given in Table 10.  Additionally, after fourteen months of 
requesting data from the Missouri Cancer Registry with no data forthcoming and in the 
interest of completing this research, a decision was made to randomly select a different 
state from the Midwest region, Nebraska was selected. 
Table 10: Final NAACCR Eight State Cancer Registries 
 
 
REGION 
 
STATE 
 
2000 
 
2001 
 
2002 
 
2003 
 
2004 
 
Annual  
Incidence 
 
Average  
Annual 
Cases 
 
WEST 
OREGON gold gold gold gold gold 69 2489 
IDAHO gold gold gold gold gold 55.2 683 
 
SOUTH FLORIDA gold gold gold gold gold 74.6 15838 
 SOUTH 
CAROLINA silver silver gold gold gold 74.7 3111 
 INDIANA silver gold gold silver gold 80.6 4931 
MIDWEST NEBRASKA gold silver gold gold gold 78.6 4731 
 MASSACHUSETTS gold gold gold gold gold 70.5 4764 
NORTHEAST RHODE ISLAND gold gold gold gold gold 73.8 860 
 
In summary, the selection criterion for this research utilized a process to minimize 
selection bias.  For example, Criterion 4, the state registry must use passive reporting 
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methods as outlined by NAACCR and not use other methods for reporting as in SEER 
State registries.  Possible geographic differences in the population under study are 
addressed with selection criterion 3.  It is critical to get a fair comparison of lung cancer 
cases; selecting cases just from the Northeast could introduce bias possibly invalidating 
several study results.  The 10
th
 item for selecting a state (registry) is the selection cannot 
be done by the researcher in a biased manner; the selection must be made by a random 
assignment.  The last criterion, Item 11, (selection of the state based cancer registry) is 
that the data must be available for acquisition.  If the data cannot be acquired from a state 
registry by the author that state cancer registry will be excluded from selection.  The 
seventh criterion is that the state registry must be a member of NAACCR.   The 
NAACCR has standardized guidelines for abstracting data.  Data can only be compared if 
the methods and information collected are consistent and complete.  Deviations from a 
standardized format can introduce error into the study results affecting internal validity 
and external validity.  
 
Variables of Interest (Inclusion and Exclusion Criteria) 
Inclusion Criteria 
Primary lung cancer cases from state population based cancer registries that are a 
member of the North American Association of Central Cancer Registries were identified.  
A primary site classification (NAACCR Code 400) is made by the state cancer registry 
based on site of tumor origin and specified in the medical record. In this research the 
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primary site code is specified by ―Code 36‖ for lung.  This classification is made in 
accordance with ICD-O coding schemes.  Cases that were diagnosed between January 1, 
2000 and December 31, 2004 were selected.  An extensive inclusion criteria are listed in 
this Chapter (Three) under the section ―Variables of Interest‖; some of the inclusion 
criteria include a known date of diagnosis, that the case must be confirmed from a tissue 
or cell sample and in terms of the case assessment: the primary lung cancer case was 
classified as analytic 
1, 258
.  In order to perform survival analysis, it is critical to have an 
origin or beginning (date of diagnosis will serve as the origin), an observed time range, 
and an endpoint/conclusion for the study or a valid analysis cannot be completed.  Also, 
for this research, a lung cancer case must be diagnostically confirmed by means of a 
positive histology from the tumor tissue or a positive cytology (cells examined 
microscopically) as not to bias any subsequent results with the addition of histologically 
unconfirmed primary lung cancer cases in the data set.  The descriptions of ―Diagnostic 
Confirmation‖ codes are listed in Table 3.10.; those codes include 1, 2, 4, 5 - the codes 
describe the methods of a diagnostic technique with a lung tissue/cell sample of the 
tumor.  An analytic lung cancer case classification code denotes that part of the diagnosis 
and/or treatment of the lung cancer case was performed at the reporting (cancer registry) 
facility.  An analytic case can further be defined under the NAACCR classification 
variable known as the ―Class of Case‖.  Class of Case (NAACCR Code 610) describes 
the criterion for inclusion as an analytic case with the codes 0-2 as shown in Table 3.12.  
Non-analytic cases (codes 3 through 9) are cases that can have a greater chance of error 
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as the information is abstracted from case information not directly associated with the 
reporting facility.  The data from non-analytic lung cancer cases can be subject to bias 
when the information is provided by a patient (recall bias) that had the diagnosis and 
treatment at a facility different from the reporting facility.  The decision was made to 
include only analytic cases for this research.  
 
Exclusion Criteria 
As only primary lung cancer cases are included in this study, secondary or 
recurrent lung cancer case will be excluded.  The variables of interest such as gender 
include codes or categories that are not of interest in this research; those data are 
excluded.  These gender codes include 3= hermaphrodite, 4 = transsexual, or 9 = 
unknown/not stated 
258, 263
.  Other variable codes of interest that have a code category not 
known or not stated (code = 9) must be identified during exploratory analysis.  The 
number of missing values (codes for the sex of an individual cancer case) can possibly 
impact the research results.  These values can provide information and knowing the exact 
number of individuals not represented in the final data set is important as it can decrease 
the validity of the results (increases the uncertainty) if the number of missing values is 
large.  Some of the other variables that include the not know or not stated category (code 
= 9) are primary site, histology, stage, grade, treatment type (chemotherapy, surgery, 
radiation therapy), tobacco use, marital status, and vital status.  It was important to 
address the missing values and record the number for each category as to assess the 
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impact those missing values on the study results. 
In the next section ―Variable Identification and Coding‖ (Chapter Three), each of 
the research patient parameters or variables of interest will be described.  The central 
cancer registry information/data variables that were requested by the investigator for each 
state cancer registry are listed in Table 11.  
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Table 11: NAACCR Variable Code and Description 
 
NAACCR 
Code  Description of Variable 
 
 
 
NAACCR 
 Code Description of Variable 
      
1 20 Patient ID Number 
 
24 480 
Morphology Coding  
System - Original 
2 150 Marital Status at DX  25 490 Diagnostic Confirmation 
3 160 Race 1  26 500 Type of Reporting Source 
4 161 Race 2  27 560 Sequence Number - Hospital 
5 162 Race 3  28 580 Date of 1st Contact 
6 163 Race 4  29 610 Class of Case 
7 164 Race 5  30 630 Primary Payor at DX 
8 190 Spanish/Hispanic Origin  31 759 SEER Summary Stage 2000 
9 220 Sex  32 760 SEER Summary Stage 1977 
10 230 Age at Diagnosis 
 
33 1200 
Record Date of  
First Surgery 
11 240 Birth Date  
 
34 1210 
Record Date of  
First Radiation 
12 250 Birthplace 
 
35 1220 
Record Date of  
First Chemotherapy 
13 340 Tobacco History 
 
36 1290 
Record Summary  
Surgical Primary  Site 
14 390 Date of Diagnosis 
 
37 1360 
Record Summary  
Radiation 
15 400 Primary Site 
 
38 1390 
Record Summary  
Chemotherapy 
16 410 Laterality  39 1750 Date of Last Contact 
17 419 
Morphology Type and 
Behavior ICD-O-2 
 
40 1760 Vital Status 
18 420 Histology (92-00) ICD-O-2 
 41 1910 Cause of Death 
19 430 Behavior (92-00) ICD-O-2  42 1930 Autopsy 
20 521 
Morphology Type and 
Behavior ICD-O-3 
 
43 1940 Place of Death 
21 522 Histology (92-00) ICD-O-3 
 44 2090 Date Case Completed 
22 523 Behavior (92-00) ICD-O-3  45 2110 Date Case Exported 
23 440 Grade 
 
46 3000 
Derived AJCC Stage 
Summary 
 
 
Some of the research variables (independent or explanatory and dependent or 
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outcome) include the individual lung cancer case identifier assigned by the cancer 
registry (this number was de-identified to the researcher of this study), the cancer registry 
identification number, the date of first contact (the date may be representative of a 
physician’s visit, biopsy, x-ray, or laboratory test), the treatment modality received 
(radiation, surgery, chemotherapy), and the type of reporting source, e.g. hospital, 
outpatient facility.  It should be noted that the date of lung cancer diagnosis, NAACCR 
recommends that the best approximation for the date of diagnosis should be used versus 
coding the date as unknown (9) 
258
.  Therefore in the situation of the year of diagnosis 
being known but no other information on the month or day is given, the general 
abstracting instruction is to use June 15 for the year indicated.  If the year and month are 
available but not the day, the 15
th
 of the month is entered.  The other patient demographic 
variables of interest include gender, race, marital status at time of diagnosis, primary 
insurance payer at diagnosis, a birthplace Geocode, and birth date.  Table 11 includes 
NAACCR variable names and the associated NAACCR item number to that variable.  
Table 11 provides the complete list of patient or individual lung cancer case information 
that was intended to be utilized in this study.  Tumor information or data are collected to 
describe the cancer case; this descriptive information includes the tumor histology, tumor 
type and stage, date of diagnosis, and how the diagnosis was made.  The individual lung 
cancer case data that identifies dates that can be used for an origin or beginning of the 
study time period and stop or end date are required for survival analysis.  All variables 
such as the date of diagnosis, vital status (alive or dead), date of last contact or date of 
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death, were used to answer the research questions as it pertains to survival in conjunction 
with gender, treatment type, and/or tumor descriptor variables. 
 
Variable Identification and Coding 
 
Patient Identification (ID) Number  
NAACCR Designated Item Number = 20 
 
The identification number is a unique NAACCR number assigned to a particular 
individual (patient).  The ID number serves several functions and purposes as a unique 
identifier for a particular individual.  It is the recommendation of NAACCR, that a 
previously assigned patient ID number is never reused or reissued if a patient file is 
deleted.  This number will follow the patient assigned a unique Patient Identification (ID) 
Number.  Different state cancer registries may report tumor information on the same 
patient to NAACCR or commonly referred to as the central registry. In this instance, the 
central registry will identify that individual, verify any duplicate records, and then assign 
a unique patient ID number, exclusive to that patient.  This number assignment serves to 
follow the individual patient throughout his/her cancer history regardless of any 
subsequent tumors that are reported for the patient.  
Marital Status at Diagnosis (DX) 
NAACCR Designated Item Number = 150 
 
When the tumor information is reported, the patient’s marital status on the 
diagnosis date is recorded.  The martial status can be different depending upon the tumor 
being reported, as an individual may have different tumor sites.  This variable is 
important as the incidence and survival has been shown to vary by marital status with 
109 
particular cancer types 
264, 265
 .  The codes used by the central registry for marital status 
are 1) Single (never married), 2) Married (including common law), 3) Separated, 4) 
Divorced, 5) Widowed, 9) Unknown. 
Race 1 
NAACCR Designated Item Number = 160 
 
The Race coding used by NAACCR is taken from the 2000 US Census Bureau 
definitions for race, see Table 12 below.  
Table 12: NAACCR Code and Description of Race 
 
Code NAACCR Designation Code NAACCR Designation 
01 White 20 Micronesian, NOS 
02 Black 21 Chamorran 
03 American Indian, Aleutian, or 
Eskimo (includes all indigenous 
populations of the Western 
hemisphere) 
 
22 
 
Guamanian, NOS 
 
 
04 Chinese 25 Polynesian, NOS 
05 Japanese 26 Tahitian 
06 Filipino 27 Samoan 
07 Hawaiian 28 Tongan 
08 Korean 30 Melanesian, NOS 
09 Asian Indian, Pakistani 31 Fiji Islander 
10 Vietnamese 32 New Guinean 
11 Laotian 
 
96 Other Asian, including Asian, 
NOS and Oriental, NOS 
12 Hmong 97 Pacific Islander, NOS 
13 Kampuchean 98 Other 
14 Thai 99 Unknown 
15 Micronesian, NOS   
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
 
 
 
Race 2 
NAACCR Designated Item Number = 161 
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When an individual is multiracial, Race 2 through Race 5 is coded and prior to 
2000 Race 2 through 5 was blank.  The acceptable coding for each race designation is 
shown in Table 12 under Race 1. 
Race 3 
NAACCR Designated Item Number = 162 
 
Race 4 
NAACCR Designated Item Number = 163 
 
Race 5 
NAACCR Designated Item Number = 164 
 
Spanish/Hispanic Origin 
NAACCR Designated Item Number = 190 
 
Spanish or Hispanic origin does not use the same code as Race 1 through Race 5. 
Origin as defined by the Census Bureau is the ―heritage, national group, lineage, or 
country of birth of the person or the person’s parents or ancestors before their arrival in 
the United States.  The NAACCR Coding Manual states that people who identify their 
origin as Spanish, Hispanic, or Latino, may be of any race 
266
.  This particular item 
variable was used in an attempt by the US Census Bureau to increase the reporting 
accuracy of the data.  
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Table 13: NAACCR Code and Description of Spanish/Hispanic Origin 
 
Code Description of Spanish/Hispanic Origin 
0 Non-Spanish; non-Hispanic 
1 Mexican (includes Chicano) 
2 Puerto Rican 
3 Cuban 
4 South or Central American (except Brazil) 
5 Other specified Spanish/Hispanic origin (includes European; excludes 
Dominican Republic) 
6 Spanish, NOS 
7 Hispanic, NOS 
8 Latino, NOS 
9 'unknown whether Spanish or not' should be used 
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
 
Sex 
NAACCR Designated Item Number = 220 
 
This variable is one of the key variables under study for gender differences 
research. Under the coding scheme of NAACCR, there are 5 codes for this classification: 
1) 1 = Male, 2) 2 = Female 3) 3 = Other (Hermaphrodite), 4) 4 = Transsexual and 5) 9 = 
Not Stated or Unknown. 
Age at Diagnosis 
NAACCR Designated Item Number = 230 
 
The patient’s age at the time of tumor diagnosis is recorded in years. The coding 
scheme is shown in actual years of age, e.g. a 57 year old would be coded as 057.  Other 
examples of age coding are given as 000 for less than 1 year old, 001 for 1 year old, but 
less than 2 years, 002 represents 2 years of age, 101 for 101 years, 120 for 120 years old, 
and 999 for an unknown age.  
Birth Date 
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NAACCR Designated Item Number = 240 
 
The NAACCR format is given as MMDDCCYY, where MM is the month (01 - 
12), DD the day (01 – 31) and CCYY, the year.  The birth date is coded in an 8 character 
format as either a valid date in the NAACCR format or 99999999 (8 characters) if 
unknown.  The North American Association of Central Cancer Registries Standards for 
Cancer Registries Volume II Data Standards and Data Dictionary recommends that if the 
birth year is unknown, the birth date can be calculated from the age of diagnosis and the 
year of diagnosis.  The coding for the month and the day would be 9999 as unknown but 
the calculated year would be used.  The NAACCR Standards further state an estimated 
birth date is better than an unknown value. 
Birthplace 
NAACCR Designated Item Number = 250 
 
The coding of the birthplace of an individual is found in the SEER Program Code 
Manual Appendix B.  This variable is of interest as variations in disease patterns, genetic 
and socioeconomic characteristics have been demonstrated in the literature varying on 
place of birth 
82, 261, 267
. 
Tobacco History 
NAACCR Designated Item Number =340 
 
NAACCR does not have a designated code for tobacco use or tobacco history. 
Coding schemes for tobacco use varies across state cancer registries.  
Date of Diagnosis 
NAACCR Designated Item Number = 390 
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The date of diagnosis is the initial date the primary lung tumor was identified. The 
coding of the date is done with the same ―date‖ format as the variable, Birth Date (240). 
Primary Site 
NAACCR Designated Item Number = 400 
 
The primary tumor site for this particular research is 36, lung. The coding used by 
NAACCR is designated by the International Classification of Disease – Oncology.  
Laterality 
NAACCR Designated Item Number = 410 
 
Laterality is used for paired organs and describes which lung (left or right) has 
been diagnosed with the primary tumor (Table 14).  
Table 14: NAACCR Code and Description of Laterality 
Code Description of Laterality 
0 Not a paired site 
1 Right: origin of primary 
2 Left: origin of primary 
3 Only one side involved, right or left origin unspecified 
4 Bilateral involvement, lateral origin unknown; stated to be single 
primary; including both ovaries 
9 Paired site, but no information concerning laterality, midline tumor 
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
 
 
Morphology Type and Behavior ICD-O-2 
NAACCR Designated Item Number = 420 
 
The morphology code is representative of the cell type and the biological activity 
the tumor presents.  The ICD-O coding system uses a morphology code based on the 
histology (cell type), behavior code, and grade; the codes are given in Table 15.  The first 
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four digits of the morphology code denote the cell histology, the fifth digit is the behavior 
and the last digit is the grade. The ICD-O-2/3 terms include 1) C34.0 for the main 
bronchus, 2) C34.1 for the upper lobe of the lung, 3) C34.2 for the middle lung lobe (this 
can be for the right lung only), 4) C34.3 lower lobe, lung, 5) C34.8 an overlapping lesion 
of lung, and 6) C34.9 Lung, NOS. The histologic and behavior codes vary as a function 
of the lung cancer type.   
Table 15: NAACCR Code and Description of LC Morphology 
 
Lung Cancer Type 
ICD-O  
Morphology Codes 
 
Lung Cancer Type 
ICD-O  
Morphology Codes 
Small Cell  
Lung Cancers 
 80413 
 80423 
 80433 
 80443, 
 80453 
Large Cell 
Carcinoma 
80123 
Squamous or 
Epidermoid 
807_3 Adenosquamous 
Carcinoma 
85603 
Adenocarcinoma 814_3 Non-Small Cell 
Carcinoma 
80463 
Bronchi alveolar 82503   
Source: Florida Cancer Data System November 2003 Monthly Memo 
 
 
Histology (92-00) ICD-O-2 
NAACCR Designated Item Number = 420 
 
There are three parts of the coding scheme for the morphology code and the tumor 
type is classified under ―histology‖ which is the first part (first 4 digits) of the 
morphology code.  A complete explanation of the history classification scheme was given 
in Chapter Two under the Pathology/Histology section.  As shown in Table 15, the first 
four digits are representative of the coding used for lung cancer cases. Each lung cancer 
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type is classified and coded by standardized methods, as discussed in Chapter Two. 
Behavior (92-00) ICD-O-2 
NAACCR Designated Item Number = 430 
 
The behavior of a tumor is the way or the mode of tumor growth or progression 
within the human body.  The physician, normally a pathologist, observes the tumor 
behavior and classifies the growth pattern.  It would be important to select or include 
cases with the behavior code of ―3‖ (see Table 16.) 
Table 16: NAACCR Code and Description of LC Behavior 
Code Description of Behavior 
/0 Benign 
/1 Uncertain whether benign or malignant, borderline malignancy, low 
malignant potential, uncertain malignant potential 
/2 Carcinoma in situ, intraepithelial, non-infiltrating, non-invasive 
/3 Malignant, primary site 
/6 Malignant, metastatic or secondary site 
/9 Uncertain whether primary or metastatic site 
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
 
Morphology Type and Behavior ICD-O-3 
NAACCR Designated Item Number = 521 
 
Coding for the lung cancer type or morphology essentially did not change from 
ICD-O-2 to ICD-O-3; for other tumor types and disease classifications, the ICD-O coding 
did change.  As part of the quality assurance procedure, ICD-O-2 lung cancer cases will 
be compared to the ICD-O-3 cases, to ensure that the data are consistent.  Another 
method to identify any errors or errors in duplication will be to utilize the NAACCR 
variable (code 480) ―Morphology Coding System – Original‖.  There should be 
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consistency between Morphology Type and Behavior ICD-O-2, Morphology Type and 
Behavior ICD-O-, and Morphology Coding System – Original. 
Histology (92-00) ICD-O-3 
NAACCR Designated Item Number = 522 
  
ICD-O-3 Histology or cell/tumor type designation is the same coding scheme as 
Histology ICD-O-2. 
 
Behavior (92-00) ICD-O-3 
NAACCR Designated Item Number = 522 
 
 The ICD-O-3 Behavior or cell growth pattern designation is the same 
coding scheme as described in Behavior IDC-O-2.  
Grade 
NAACCR Designated Item Number = 440 
 
The code for grade describes the cells of the tumor.  Grades I through IV (codes 1 
– 4 as shown in Table 17) are utilized and the other grades listed in that table below are 
not applicable to this research. 
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Table 17: NAACCR Code and Description for Grade 
 
Code Description of Grade Equivalent Term* 
1 
 
Grade I 
Grade I; grade 1; Well differentiated; Differentiated, 
NOS 
 
 
2 
 
 
 
 
 
 
 
Grade II 
 
 
 
 
 
Grade II; grade 2; Moderately differentiated; 
Moderately well differentiated; Intermediate 
differentiation; Low grade; 
Partially well differentiated; 
Relatively well differentiated; 
Generally well differentiated; 
Fairly well differentiated; 
Intermediate differentiation; 
Grade I of 3 category system; 
Grade I-II; Trabecular 
3 
 
 
 
 
 
Grade III 
 
 
 
 
Grade III, grade 3; Poorly differentiated; 
Dedifferentiated; Medium grade; Moderately 
undifferentiated; Relatively undifferentiated; 
Relatively poorly differentiated; Grade II of 3 
category system; Grade II-III 
4 
 
Grade IV 
 
Grade IV; grade 4; Undifferentiated; 
Anaplastic; High grade; Grade III of 3 category 
system; Grade III-III 
5 T-cell  
6  B-cell  
7 Null cell  
8 NK (natural killer) cell  
9 
 
 
Grade/differentiation 
unknown, not stated, or 
not applicable 
Cell type not determined, not stated or not applicable; 
No grade/differentiation in the primary site even if a 
grade is given for a metastatic site. 
Source: The North American Association of Central Cancer Registries Standards for 
Cancer Registries Volume II Data Standards and Data Dictionary 2007 
 *Source: Florida Cancer Data System Data Acquisition Manual 2006  
 
Morphology Coding System – Original 
NAACCR Designated Item Number = 480 
 
The morphology coding system originally used will be utilized as a second check 
to ensure data quality in the reporting and data received from the cancer registries.  
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Diagnostic Confirmation 
NAACCR Designated Item Number = 490 
 
Diagnostic confirmation is essential for verification of a particular tumor type.  
This confirmation can be made utilizing various methods such as an examination by a 
pathologist or cytologist of tissues or cells via the microscope.  For this research, certain 
criteria for the variables of interest must be used when evaluating a particular tumor type, 
in particular, in the study of lung cancer.  One criterion to know is the specific scientific 
method used to diagnosis the tumor type.  Biological confirmation of the cancer type is 
the gold standard in the medical community.  In the NAACCR coding scheme, other 
diagnostic confirmation methods other than biologic confirmation such as direct 
visualization of the tumor are included and are shown in Table 18.  The codes for the 
reporting method for confirming a particular tumor type in this research will only include 
biologically confirmed methods: 1) positive histology, 2) positive cytology, no positive 
histology, 4) positive microscopic confirmation, method not specified, and 5) Positive 
laboratory test/marker study as shown in Table 18. 
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Table 18: NAACCR Code and Description Diagnostic Confirmation 
 
Code 
 
Description of Diagnostic Confirmation 
 
1 Positive histology 
2 Positive cytology, no positive histology 
4 Positive microscopic confirmation, method not specified 
5 Positive laboratory test/marker study 
6 Direct visualization without microscopic confirmation 
7 
Radiography and other imaging techniques without microscopic 
confirmation 
8 Clinical diagnosis only (other than 5, 6, or 7) 
9 Unknown whether or not microscopically confirmed 
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
 
 
Type of Reporting Source 
NAACCR Designated Item Number = 500 
 
The tumor information is contained in many different records at different 
facilities.  As the data are abstracted or collected in a standardized manner, it is necessary 
to identify where the information was obtained from.  As an example, information from 
laboratory reports identified from the medical record in a medical oncology center would 
have the reporting center coded as 2 – see Table 19.  It is well documented in the 
literature 
57, 229
 that death certificates many have incomplete information and may not 
represent a complete picture of the patient’s medical history.  It would be important to the 
investigator to be aware that reporting source with a code of 7 as to address any 
discrepancies during the analysis.  
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Table 19: NAACCR Code and Description for Reporting Source Type 
 
Code 
 
Description of Type of Reporting Source 
 
1 Hospital inpatient; Managed health plans with comprehensive, unified 
medical records  
2 Radiation Treatment Centers or Medical Oncology Centers  
(hospital-affiliated or independent)  
3 Laboratory only (hospital-affiliated or independent)  
4 Physician's office/private medical practitioner (LMD)  
5 Nursing/convalescent home/hospice  
6 Autopsy only  
7 Death certificate only  
8 Other hospital outpatient units/surgery centers  
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
 
 
Sequence Number 
NAACCR Designated Item Number = 560 
This code is used by the cancer registry to identify primary, secondary, or 
multiple lung tumors.  As this research is focused on primary lung cancer cases, this 
designation is 00 and codes other than the 00 will be identified. 
Date of Admission or First (Adm/1
st
) Contact 
NAACCR Designated Item Number = 580 
 
This variable designates the date the first time a case was contacted either as an 
outpatient or inpatient.  The coding of the date is done with the same ―date‖ format as the 
variable, Birth Date (240).  The date may be representative of an outpatient procedure, an 
x-ray, or pathology report associated with the diagnosis of the tumor. 
Class of Case 
NAACCR Designated Item Number = 610 
 
Class of case describes the location of the reporting facility where the diagnosis 
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was made and the codes for Class of Case are described in Table 20.  Analytic cases are 
those that are diagnosed at the reporting facility and include the codes 0 through 2.  The 
other codes include nonanalytic cases that are identified at the reporting facility but were 
diagnosed and treated at a different facility.  These cases also include those diagnosed at 
autopsy.  
Table 20: NAACCR Code and Description for Class of Case 
 
Codes Description of Class of Case 
 
Analytic Cases 
0 Diagnosis at the reporting facility and the entire first course of treatment 
was performed elsewhere or the decision not to treat was made at another 
facility. 
1 Diagnosis at the reporting facility, and all or part of the first course of 
treatment was performed at the reporting facility. 
2 Diagnosis elsewhere, and all or part of the first course of treatment was 
performed at the reporting facility. 
Non-analytic Cases 
3 Diagnosis and the entire first course of treatment were performed 
elsewhere. Presents at your facility with recurrence or persistent disease. 
4 Diagnosis and/or first course of treatment were performed at the reporting 
facility prior to the reference date of the registry. 
5 Diagnosed at autopsy 
6 Diagnosis and the entire first course of treatment were completed by the 
same staff physician in an office setting. ―Staff physician‖ is any medical 
staff with admitting privileges at the reporting facility. 
7 Pathology report only. Patient does not enter the reporting facility at any 
time for diagnosis or treatment. This category excludes tumors diagnosed at 
autopsy. 
8 Diagnosis was established by death certificate only. Used by central 
registries only. 
9 Unknown. Sufficient detail for determining Class of Case is not stated in 
patient record. Used by central registries only. 
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
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Primary Payor at Diagnosis 
NAACCR Designated Item Number = 630 
 
Information about the insurance carrier at the time of diagnosis can be an 
important variable.  Possible treatment disparities between minority groups with lung 
cancer and the association between the types of insurance coverage could be of interest.  
Table 21 lists the codes that are associated with the particular payor at the time of lung 
cancer diagnosis.  
 
Table 21: NAACCR Code and Description for Payor at Diagnosis 
 
Code  Description of Primary Payor at Diagnosis 
01 Not insured 
02 Not insured, self-pay 
10 Insurance, NOS 
20 Private Insurance: Managed care, HMO, or PPO 
21 Private Insurance: Fee-for-Service 
31 Medicaid 
35 Medicaid -Administered through a Managed Care plan 
60 Medicare/Medicare, NOS 
61 Medicare with supplement, NOS 
62 Medicare - Administered through a Managed Care plan 
63 Medicare with private supplement 
64 Medicare with Medicaid eligibility 
65 TRICARE 
66 Military 
67 Veterans Affairs 
68 Indian/Public Health Service 
99 Insurance status unknown 
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
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SEER Summary Stage 1977 
NAACCR Designated Item Number = 760 
 
The coding scheme for SEER Summary Stage 1977 (Table 22) is used at the time 
of initial primary tumor diagnosis.  Stage was a variable that was historically monitored 
for time trends.   
Table 22: NAACCR Code and Description SEER Summary Stage 1977 
 
Codes Description of SEER Summary Stage 1977 
0 In situ 
1 Localized 
2 Regional, direct extension only 
3 Regional, regional lymph nodes only 
4 Regional, direct extension and regional lymph nodes 
5 Regional, NOS 
7 Distant 
8 Not applicable 
9 Unstaged 
 Source: The North American Association of Central Cancer Registries Standards for  
Cancer Registries Volume II Data Standards and Data Dictionary 2007 
 
 
SEER Summary Stage 2000 
NAACCR Designated Item Number = 2000 
 
SEER Summary Stage 2000 at initial diagnosis is a variable that includes the 
description of the reportable tumor.  Table 23 exhibits the site-specific single-digit coding 
scheme explicit to the tumor location. 
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Table 23: NAACCR Code and Description SEER Summary Stage 2000 
 
Codes Description of SEER Summary Stage 2000 
0 In situ 
1 Localized 
2 Regional, direct extension only 
3 Regional, regional lymph nodes only 
4 Regional, direct extension and regional lymph nodes 
5 Regional, NOS 
7 Distant 
8 Not applicable 
9 Unstaged 
Source: The North American Association of Central Cancer Registries Standards for Cancer 
Registries Volume II Data Standards and Data Dictionary 2007 
 
 
Record (RX) Date of First Surgery 
NAACCR Designated Item Number = 1200 
 
The date of the first surgery for the primary tumor is coded with the NAACCR 
format given as MMDDCCYY, where MM is the month (01 - 12), DD the day (01 – 31) 
and CCYY, the year.  The surgical date is coded in an 8 character format as either a valid 
date in the NAACCR format or 99999999 (8 characters) if it is unknown if any surgical 
procedure was performed.  If there was no surgical procedure performed or if the 
individual was an autopsy-only case, the code would be 00000000.  
Record (RX) Date of First Radiation 
NAACCR Designated Item Number = 1210 
 
This is the date that the treatment modality, radiation therapy began at any 
radiation therapy facility, e.g. hospital, outpatient center, for the patient’s first course of 
their treatment.  The coding for this variable is the NAACCR format MMDDCCYY, 
where MM is the month (01 - 12), DD the day (01 – 31) and CCYY is the year.  Other 
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variations include 00000000 when radiation therapy is not administered; autopsy-only 
case, 88888888 if radiation therapy was scheduled as part of the first course of therapy, 
but was not started at the time and 99999999 if the date was unknown, it was unknown 
whether any radiation therapy was administered; or if the case was only identified by 
death certificate. 
Record (RX) Date of First Chemotherapy 
NAACCR Designated Item Number = 1220 
 
This designation is the date that chemotherapy was first started. The format used 
by NAACCR is the same as in ―Birth Date‖.  The other codes admissible include 
00000000 when chemotherapy is not administered or in the case of an autopsy.   
Record (RX) Summary of Surgery for Primary Site 
NAACCR Designated Item Number = 1290 
 
The summary of the surgery performed for the primary tumor site is given below 
in Table 24. As the disease of interest for this research is lung cancer, all surgical sites 
will be specific to regions of the lung. 
 
Table 24: NAACCR Code and Description of Surgical Primary Site 
 
Code Description of Record (RX) Summary of Surgery for Primary Site 
00 None 
10-19 Site-specific code; tumor destruction 
20-80 Site-specific codes; resection 
90 Surgery, NOS 
98 Site specific codes; special 
99 Unknown 
Source: The North American Association of Central Cancer Registries Standards for Cancer 
Registries Volume II Data Standards and Data Dictionary 2007 
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Record (RX) Summary of Radiation 
NAACCR Designated Item Number = 1360 
 
The coding for ―Record Summary of Radiation‖ described in Table 25 with an 
explanation the type of radiation treatment the lung cancer case received. 
 
Table 25: NAACCR Code and Description of Radiation Treatment 
 
Code Description of Radiation Treatment 
0 None 
1 Beam radiation 
2 Radioactive implants 
3 Radioisotopes 
4 Combination of 1 with 2 or 3 
5 Radiation, NOS—method or source not specified 
6 Currently allowable for historic cases only; see Note 
below 
7 Patient or patient’s guardian refused* 
8 Radiation recommended, unknown if administered* 
9 Unknown if radiation administered 
Source: The North American Association of Central Cancer Registries Standards for Cancer 
Registries Volume II Data Standards and Data Dictionary 2007 
“Note: In the SEER program, a code 2 for other radiation was used between 1973 and 1987. 
When the radiation codes were expanded to add codes '2' radioactive implants  
and '3' radioisotopes, all cases with a code '2' and diagnosed in 1973-1987 were converted to a 
code '6' radiation other than beam radiation.‖ 
 
 
Record (RX) Summary of Chemotherapy 
NAACCR Designated Item Number = 1390 
 
The chemotherapy codes used for the NAACCR Designated (Item Number = 
1390) Record Summary of Chemotherapy are listed in Table 26.  The code is specified 
when a chemotherapy agent/drug is received or not administered to an individual case as 
part of the first treatment for lung cancer.  Also a code is given to identify when it is 
unknown if the lung cancer case received chemotherapy, i.e. codes 88 and 99.  
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Table 26: NAACCR Code and Description for Chemotherapy 
 
Code Description of Chemotherapy Treatment 
00 None, chemotherapy was not part of the planned first course of therapy. 
01 Chemotherapy, NOS 
02 Chemotherapy, single agent. 
03 Chemotherapy, multiple agents. 
82 Chemotherapy was not recommended nor administered because it was 
contraindicated due to patient risk factors, i.e., comorbid conditions, advanced 
age. 
85 Chemotherapy was not administered because the patient died prior to planned 
or recommended therapy. 
86 Chemotherapy was not administered. It was recommended by the patient’s 
physician, but was not administered as part of first-course therapy. No reason 
was stated in the patient record. 
87 Chemotherapy was not administered; it was recommended by the patient’s 
physician, but this treatment was refused by the patient, the patient’s family 
member, or the patient’s guardian. The refusal was noted in the patient record. 
88 Chemotherapy was recommended, but it is unknown if it was administered. 
99 It is unknown whether a chemotherapeutic agent(s) was recommended or 
administered because it is not stated in patient record; death certificate-only 
cases. 
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
 
 
Derived AJCC Stage Group  
NAACCR Designated Item Number =3000 
 
This variable, Derived AJCC Stage Group, encompasses all stage designations 
from the AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER 
Summary Stage 2000 and complies the different coding into this one item number, 3000.  
The coding designation, shown in Table 27 came into effect as a result of a joint task 
force so a common, uniform set of rules and coding will be available.  Representatives 
from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC collaborated on the coding 
designation to standardize the grouping of disease stage. 
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Table 27: Derived AJCC Stage Group 
 
AJCC 
Code 
Display 
String 
 
Comments 
00 0 Stage 0 
01 0a Stage 0a 
02 0is Stage 0is 
10 I Stage I 
11 INOS Stage I NOS 
12 IA Stage IA 
13 IA1 Stage IA1 
14 IA2 Stage IA2 
15 IB Stage IB 
16 IB1 Stage IB1 
17 IB2 Stage IB2 
18 IC Stage IC 
19 IS Stage IS 
23 ISA Stage ISA (lymphoma only) 
24 ISB Stage ISB (lymphoma only) 
20 IEA Stage IEA (lymphoma only) 
21 IEB Stage IEB (lymphoma only) 
22 IE Stage IE (lymphoma only) 
30 II Stage II 
31 IINOS Stage II NOS 
32 IIA Stage IIA 
33 IIB Stage IIB 
34 IIC Stage IIC 
35 IIEA Stage IIEA (lymphoma only) 
36 IIEB Stage IIEB (lymphoma only) 
37 IIE Stage IIE (lymphoma only) 
38 IISA Stage IISA (lymphoma only) 
39 IISB Stage IISB (lymphoma only) 
40 IIS Stage IIS (lymphoma only) 
41 IIESA Stage IIESA (lymphoma only) 
42 IIESB Stage IIESB (lymphoma only) 
43 IIES Stage IIES (lymphoma only) 
50 III Stage III 
51 IIINOS Stage III NOS 
52 IIIA Stage IIIA 
53 IIIB Stage IIIB 
54 IIIC Stage IIIC 
55 IIIEA Stage IIIEA (lymphoma only) 
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56 IIIEB Stage IIIEB (lymphoma only) 
57 IIIE Stage IIIE (lymphoma only) 
AJCC 
Code 
Display 
String 
Comments 
58 IIISA Stage IIISA (lymphoma only) 
59 IIISB Stage IIISB (lymphoma only) 
60 IIIS Stage IIIS (lymphoma only) 
61 IIIESA Stage IIIESA (lymphoma only) 
62 IIIESB Stage IIIESB (lymphoma only) 
63 IIIES Stage IIIES (lymphoma only) 
70 IV Stage IV 
71 IVNOS Stage IV NOS 
72 IVA Stage IVA 
73 IVB Stage IVB 
74 IVC Stage IVC 
88 NA Not applicable 
90 OCCULT Stage Occult 
99 UNK Stage Unknown 
Source: The North American Association of Central Cancer Registries  
Standards for Cancer Registries Volume II Data Standards and Data Dictionary  
2007 
 
 
Date Case Report Received 
NAACCR Designated Item Number = 2111 
 
The ―Date Case Report Received‖ is the date that the source record is submitted 
and received by the central cancer registry 
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.  In the event of multiple reports on the 
same individual and one date is needed, the protocol is to use the first date the record was 
received.  This variable can be used to evaluate the reporting timeliness of the cancer 
registries.  This variable may also be used to measure how long the individual cancer 
registry takes to submit the data when the date the report (2111) is received is compared 
to the date of first contact (580).  
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Date of Last Contact 
NAACCR Designated Item Number =1750 
 
The Date of Last Contact is the last date of known contact but also can represent 
the date of death.  The date is obtained from either an active or a passive follow-up.  The 
sources include the state registries date of last contact or death (passive) or from an active 
state SEER registry or the National Death Index.  The date coding follows the NAACCR 
format of MMDDCCYY, where MM is the month (01 - 12), DD the day (01 – 31) and 
CCYY is the year.  The main purpose of this variable is to record the date of last contact 
or date of death. 
Vital Status 
NAACCR Designated Item Number =1760 
 
The vital status of the individual as given by the NAACCR is 0 for dead, 1 for 
alive, 4 for dead.  A code of 0 is obtained from states that report based on the guidelines 
of the Commission on Cancer (passive registry) and a code of 4 is based on information 
obtained from a SEER state (active registry). 
Follow-Up Source 
NAACCR Designated Item Number =1790 
 
The source is given for the most currently recorded information for an individual.  
Any discrepancies in the record can be reviewed and cross-checked with other variable 
coding.  Table 28 lists the sources or the contributors to the follow-up data.  It includes 
information reported from the Department of Motor Vehicles, death certificate 
information, patient or physician reporting, Medicare/Medicaid files, and if the data is 
unknown, not stated in the patient record. 
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Table 28: NAACCR Code and Description of Follow-Up Sources  
 
Code Description of Follow-Up Source 
0 Reported hospitalization 
1 Readmission 
2 Physician 
3 Patient 
4 Department of Motor Vehicles 
5 Medicare/Medicaid file 
7 Death certificate 
8 Other 
9 Unknown, not stated in patient record 
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries 
Volume II Data Standards and Data Dictionary 2007 
 
 
Autopsy 
NAACCR Designated Item Number =1930 
 
This designation is the indicator if an autopsy was performed or not.  This 
information could be use to verify the correctness of the coding for other variables.  For 
example, the coding for this NAACCR designated item number, 1930, could be 
compared to a patient status code for a particular individual to check for agreement.  A 
case could not be alive if an autopsy was performed. 
 
Table 29: NAACCR Code and Description of Autopsy 
 
Code Description of Autopsy 
0 Not applicable; patient alive 
1 Autopsy performed 
2 No autopsy performed 
9 Patient expired, unknown if autopsy performed 
Source: The North American Association of Central Cancer Registries Standards 
for Cancer Registries Volume II Data Standards and Data Dictionary 2007 
Place of Death 
NAACCR Designated Item Number = 1940 
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This variable is useful to correlate to the date of last contact.  If the patient is 
coded as alive and a place of death is documented, further investigation is warranted. 
Date Case Completed 
NAACCR Designated Item Number = 2090 
 
The date can be used to assess the quality and timeliness of reporting for the data.  
Date Case Exported 
NAACCR Designated Item Number = 2110 
 
The date can be used to assess the quality and timeliness of reporting for the data.  
Derived AJCC Stage Summary 
NAACCR Designated Item Number = 3000 
 
This variable is used to compare stage information.  
 
Epidemiologic Research Design 
The epidemiologic study design for this research was based on a historical cohort 
of primary lung cancer case.  Female lung cancer cases were compared to male lung 
cancer cases and this comparison between genders included the histological type, stage, 
and grade of lung cancer and the treatment received (chemotherapy, radiation therapy, 
surgery, or combination) as variables of interest. Some of the strengths of this study 
design are multiple effects of the exposure were assessed simultaneously.  Historically, a 
weakness of a retrospective or historical study design is it can be prone to bias due to 
recall or information bias.  This particular limitation or weakness was minimized as the 
data were collected by a standardized, controlled method utilizing trained cancer registry 
abstractors; information was provided by medical records and non-analytic cases were 
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excluded, e.g. information provided by the patient or members of the family.  As the 
majority of the states are mandated by law to report cancer case information; non-
compliance is minimal and monitored by the NAACCR; therefore the case information is 
assumed to be complete. 
 
Data Collection Methods 
Prior to the collection of any lung cancer case information, approval from the 
University of South Florida Internal Review Board Data (IRB) was sought by the 
principle investigator, PI.  The chief concern of the IRB was that the case information 
could not be used to identify any one particular individual.  The research data acquired 
for primary lung cancer cases for this study are cases from state cancer registries that are 
members of NAACCR.  Initially, there were two main approaches to collecting the lung 
cancer case information.  The first method was to contact the eight states selected (Table 
10). As stated previously, West Virginia was randomly selected but the cancer registry 
was unable to comply with the data research request.  Table 30 outlines the contact 
process followed for the cancer registries and the contact information.  The data set 
acquisitions was done in accordance to protocol and procedures outlined by each state 
based cancer registry. 
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Table 30: State Cancer Registry Contact Information 
 
State 
 
Contact Information 
 
Requirements for the Release of Data 
Oregon 
 
 
 
 
 
 
 
 
Catherine Riddell (great resource) 
Research Analyst 
Oregon State Cancer Registry 
Phone: (971) 673-1113 
FAX: (971) 673-0996 
catherine.a.riddell@state.or.us 
 
 
Requested Lung Cancer Data and sent the following three 
files: 
1. The PDF file of the approval letter from the IRB at the 
University of South Florida concerning my dissertation 
research. 
2. The variables of interests are outlined in "NAACCR 
VARIABLE" (the data will be utilized as part of my 
dissertation/research project). 
3. The eight state cancer registries selected to participate in 
my dissertation research project that includes Oregon. 
Idaho 
 
 
 
Cancer Data Registry of Idaho  
615 N. 7th Street 
P.O. Box 1278 
Boise, Idaho 83701 
http://www.idcancer.org/generalinfo.html 
 
The Cancer Data Registry of Idaho has a release requirement 
and form that must be submitted prior to the release of any 
data. 
 
 
Florida 
 
 
 
Florida Cancer Data System 
http://fcds.med.miami.edu/ 
 
 
The FCDS has a release requirement and form that must be 
submitted prior to the release of any data. The data request 
forms are located on the FCDS website at: 
http://fcds.med.miami.edu/inc/datarequest.shtml 
 
 
 
South Carolina 
 
 
 
 
S.C. Department of Health & Environmental 
Control  
S.C. Central Cancer Registry 
810 Dutch Square Blvd., Ste. 220  
Columbia, SC 29210 
 
The South Carolina Central Cancer Registry has a release 
requirement and form that must be submitted prior to the 
release of any data. 
Telephone # (803) 731-1419  
Fax # (803) 731-1455 
Indiana 
 
 
Indiana State Department of Health  
Epidemiology Resource Center  
2 North Meridian, 5K  
Indianapolis, IN 46204  
317-233-7807  
317-234-2812 FAX 
The Indiana State Department of Health has a release 
requirement and form that must be submitted prior to the 
release of any data. 
 
 
Massachusetts 
 
 
 
 
 
 
 
Massachusetts Cancer Registry 
250 Washington Street, 6th Floor 
Boston, MA 02108 
Phone: (617) 624-5642 
Fax: (617) 624-5695 
 
Annie McMillan (great resource and 
extremely helpful)  
The Massachusetts Cancer Registry has a release requirement 
and form that must be submitted prior to the release of any 
data. 
Confidential Data Officer Privacy and Data Access Office 
Massachusetts Department of Public Health 
250 Washington Street, 2nd Floor 
Boston, MA  02108-4619 
TEL: (617) 624-5229 
FAX: (617) 624-5234 
 
Nebraska 
 
 
Nebraska Cancer Registry 
Nebraska Comprehensive Cancer Control 
Program 
Janis Singleton (very nice) 
IRB approval process 
DHHS, Division of Public Health 
301 Centennial Mall South 
Lincoln NE 68509 
Rhode Island 
 
 
 
3 Capitol Hill 
Providence, RI 02908 
(401)222-1172 
Fax: 222-3551 
http://www.health.ri.gov/disease/cancer/regis
try.php 
 
The Rhode Island Cancer Registry has a release requirement 
and form that must be submitted prior to the release of any 
data. 
Main Contact (extremely helpful): John P. Fulton, PhD, RI 
Department of Health: 401-277-1394 x115  
135 
The other or second method of data case acquisition was attempted through the 
central cancer registry, NAACCR, for the states of interest (Table 9).  To answer the 
research questions, data from the eight states was required.  It was considered a viable 
option that collecting the data from a centralized data bank, like NAACCR, would 
streamline the data collection process.  The second option was pursued via multiple data 
requests made directly to NAACCR.  The complete approval/disapproval process for data 
release took over a year and after multiple requests and multiple re-submissions for the 
lung cancer data, NAACCR determined they would provide the information to the 
researcher.  Within 1 month of receiving the NAACCR approval letter, the investigator 
was again contacted by NAACCR and was told more approvals by another NAACCR 
committee were required and the approval was withdrawn.  Ultimately, after several more 
months, a letter was received by the investigator and was told by NAACCR the data 
would not be provided to the researcher; multiple reasons were given.  During this 
process of awaiting the second NAACCR approval, the investigator was contacted by 
telephone by one of the NAACCR committee members; that particular committee 
member said that the dissertation research did not serve any scientific merit.  NAACCR 
can be contacted via the URL http://www.naaccr.org/ .  Any other future attempts to use 
the NAACCR data base were deemed unproductive therefore method one of contacting 
the states directly was utilized for the primary lung cancer case data collection. 
When the data sets were acquired from each state cancer registry, the data set was 
assessed for completeness of information, i.e. that the variables of interest were included.  
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Also the categories for the variables of interest were evaluated for coding as the format 
would have to be similar as outlined by the standard NAACCR protocols.  The 
comparison of results from state based registries for lung cancer cases would not be 
possible without this standardization.  When each state cancer registry was contacted, 
each state representative was particularly interested in how the data are used for the 
specified or requested research project and that patient confidentiality would not be 
compromised.  Additionally, it was requested that the database not shared with anyone 
other than the researchers identified on the data request form (the researchers must attest 
to this; in some instances the state data request form had to be notarized), and any 
confidential patient information inadvertently discovered must be kept confidential.   
 
Statistical Procedures 
Prior to any statistical procedures, complete assessment of the study design 
methods was completed. The methods outlined in the selection criteria for cases 
identification and state cancer registry selections were based on epidemiological 
principles so ultimately valid assessments could be made after utilizing the most 
appropriate statistical procedures.  In other words, data sets that contain inherent flaws 
due to bias would never result in invalid conclusions regardless of the statistical methods 
applied.  For example, randomization during the selection of the regional state based 
cancer registry was part of the initial selection process.  Any bias that may have been 
introduced by the selection of a state in theory was minimized by that randomization 
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process. In the previous sections, the importance of the data selection or variables of 
interest (inclusion and exclusion criteria) was discussed.  Collecting data from cancer 
registries that utilize a standardized format 
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 was critical.  Data not collected in such a 
manner could be subject to bias resulting in erroneous results.  Each lung cancer case 
acquired from each state cancer registry was assessed for completeness of the data.  In 
other words, all the variables of interest should be included in the case information and 
the categories for the variables of interest should be coded in a similar manner as outlined 
by the standard NAACCR protocols.  The comparison of results from state based 
registries for lung cancer cases would not be possible without the standardization of the 
variables of interest. 
The selection of the most appropriate statistical model that best represented and 
accounted for the behavior of the data was critical in the evaluation of the three research 
questions.  The statistical procedures applicable to each research question are discussed 
and reviewed in the following section; these procedures are utilized so that the research 
questions were answered appropriately.  Each of the eight state based primary lung 
cancer case data was concatenated into one data set; this data set was used to answer the 
research questions.  The lung cancer case information from each state is representative of 
the lung cancer cases that state (Idaho, Oregon, Florida, South Carolina, Indiana, 
Massachusetts, Nebraska, and Rhode Island) as each case within the state cancer registry 
has as likely a chance to be included in the state registry as another.  The ability to 
identify which state the individual lung cancer case originated from in the merged data 
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set will be done by means of a generated variable (code).  This coding enabled the 
researcher to not only look at the aggregate population statistics but also by state and 
region.  
One of the first statistical procedures performed on the data sets was exploratory 
analysis.  These descriptive procedures enabled the investigator to identify any 
differences, as well as the similarities of the patient population under study.  This was 
accomplished by the PROC FREQ statistical procedure in SAS and univariate analysis by 
investigating the resultant means of the continuous variable age; results of the testing are 
given in Chapter Four.  For example, it was useful to examine the difference between 
men and women, age of diagnosis, and state/region.  Several studies recently published, 
suggest that the age at diagnosis of lung cancer is less for women versus men 
40, 15
 and the 
opportunity to compare the results of this data set analysis served to increase the validity 
of this research.  Any differences in the lung cancer case population were determined for 
the number of men and women in each particular variable category such as morphology 
(histology and behavior) group, treatment group, or the age at tumor diagnosis categories.  
The results of the SAS PROC FREQ statistical procedure were examined for the other 
research variables of stage, grade, marital status at the time of diagnosis, race, vital status 
and state.  The statistical procedures were used to count the frequencies of the data 
variables and calculated percentages.  In summary, all categorical variables are displayed 
in Chapter Four tables and were also classified according to gender (male and female).  
The continuous variable of age at diagnosis was evaluated by the SAS PROC 
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UNIVARIATE procedure and described in terms of the mean, medians and ranges 
comparing to males and females.  Age was categorized into five age groups and those 
categorical classifications were used in the subsequent analysis to answer the three 
research questions. 
 
Study Question One  
 
Null Hypothesis: Females receive the same treatment as men regardless of the 
histological type, stage and grade of lung cancer.  The outcome variable is treatment, the 
exposure is gender (a main effect), and the variables classified as other main effect 
variables include stage, grade, and histological type; the demographic independent 
variables included age group at diagnosis, marital status at diagnosis and race.  The 
statistical model used to examine the relationship between the dependent and independent 
variable, gender, will be the multinomial logistic regression model (MLRM).  The 
multinomial logistic regression model facilitates the examination of the categorical 
outcome variable (Treatment Group) and the relationship between the independent 
variables.  In this research, the outcome variable is multinomial or polychotomous and is 
coded on a nominal level.   Each treatment type or treatment group (txgrp) or 
combination of treatments is categorized on a nominal scale meaning the levels (scale) do 
not represent a better or worse category.  These nominal outcome levels and the 
independent variables were modeled or ―fitted‖ to a multinomial logistic regression 
model.  There are eight treatment types (outcome variable levels) 1) radiation, 2) surgery, 
3) chemotherapy, 4) radiation combined with surgery, 5) radiation combined with 
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chemotherapy, 6) surgery combined with chemotherapy, 7) radiation combined with 
chemotherapy and surgery, and 8) no treatment received that were analyzed to answer 
question one. 
A representative equation for the full model is listed below and is defined as:  
 Pr (yi=1) = G (0 + 1xi1 + 2xi2 +…+ kxik) 
Where                        is the cumulative distribution function for a logistic variable and 
upon transformation is referred to as the logit model. This model makes the assumption the 
chance (odds) of an outcome given a response level (in this case, a particular treatment 
modality received) are constant regardless of which level (treatment type) selected.   For 
nominal outcome logistic models with k + 1 possible levels for the outcome variable, the 
logistic model can be extended to a multinomial model called a generalized or baseline-
category logit model, and is shown below: 
 ln     (Pr(Y = i| x))/ (Pr(Y = k+1| x))  = i + ’ixi, where i= 1,……,k 
Where the 1, …, k  are the k intercept parameters and the 1, …., k are the k vectors of 
the slope parameters; these models are designated as a special case of the discrete choice 
or conditional logit model. The coefficients resulting from multinomial logistic 
regression upon exponentiation are commonly referred to as an Odds Ratio. 
As gender was one of the main interests of this research, the effect that gender had 
w
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on the selection of the treatment received classified gender as the primary ―main effect‖ 
variable for this particular research question (Question I).  Each covariate, gender, stage, 
grade, morphology, age group, race, and marital status had different coding or levels 
within the particular variable and was discussed in the ―Variable of Interest‖ section of 
this chapter.  The statistical results including the Odds Ratios and 95% Confidence 
Intervals generated by the MLRM included the main effects, interaction effects, and the 
overall gender effect on the outcome, i.e. treatment type received, are included in the 
overall assessment to answer Question One.  In summary, the multinomial logistic 
regression model utilizing categorical variables was used as the statistical model to test 
Hypothesis I in order to answer question one.    
Additionally, a random effect model utilizing the SAS PROC GLIMMIX 
procedure with a link function to the generalized logit model was included to evaluate 
any effect state had the outcome as compared to another state.  The identification of each 
state in the data set was important with respect to the study of any random effects 
introduced by a state on the relationship between the outcome (lung cancer treatment) 
and the independent variables.  A random effect model was useful in the identification of 
one state that behaved differently (in the statistical sense) or having variability as 
compared to another state.  As an example, a possible contributor to the ―random effect 
of state‖ would be that Florida is known as a retirement state. Florida’s population has an 
overrepresentation of individuals with a greater probability of cancer incidence.  Statistics 
based on the treatment of Florida lung cancer female and male cases when compared to 
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another state such as Nebraska (different population base) may lead to variability in the 
relationship of lung cancer treatment and the independent variables dependent upon state.    
 
Study Question Two  
The statistical procedures to address the second study question (Is there a 
statistically significant difference in survival in women with lung cancer as compared to 
men with lung cancer regardless of the treatment modality received?) included the 
Kaplan-Meier and the Life Table methods for overall lung cancer survival analysis between 
men and women.  The log-rank statistical test was utilized to test for survival differences 
between women and men by examining for any statistical significance.  Survival was defined 
in this study as the time (in months) from the diagnosis of lung cancer to death or to the date 
of last contact when the individual was reported as alive – a cutoff date of 12-31-2004 was 
used to censor individuals that had a date of last contact greater than 12-31-2004.   
 
Study Question Three  
 
The third research question, ―Do women with the same histological type, 
stage/grade of lung cancer, and the same treatment modality differ significantly in 
survival as compared to men with the same histological type, stage/grade of lung cancer, 
and the same treatment modality‖ utilized the Cox Proportional Hazards model.  The Cox 
Proportional Hazards model estimated the relative risk or hazard ratio for death for women as 
compared to men.  This model was used to address gender differences in overall survival 
while adjusting for the primary main effects, demographic main effects and interaction term 
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moderation.  The effect of gender on survival was examined by determining the estimated 
relative risk (hazards ratio) of death for women as compared to men by adjusting by stage, 
histology, grade, treatment type, race, marital status, and age group as well as interaction 
terms with the adjusted Cox Proportional Hazards model.  The proportionality assumption of 
the Cox’s Proportional Hazard model for each variable was tested by evaluating the graphs of 
the survival function and noting that the distance between the levels or strata of a variable did 
not change (increase or decrease) over time or cross.  In each case, the proportionality 
assumption held with the exception of the variable, treatment groups.  In this case there was 
crossover between two of the treatment groups suggestive of limitations in the analysis. 
Residual analysis was completed for the final model, there were some trends demonstrated in 
the Martingale Residuals over time but the majority of the residuals were varying about zero 
as expected - demonstrating no trends. 
 
Preliminary Statistical Analysis 
Initially, a study was conducted by the investigator to determine if there were 
statistically significant differences between females versus males and the treatment 
received prior to the development of this dissertation.  The data set was drawn from the 
Florida Cancer Data System 
1
 in which Commercial File 4505  had 2,393,853 cancer 
cases from the years 1981 through 2003.  The lung cancer cases (n = 139,926) were 
categorized by the International Classification of Diseases – Oncology (ICD-O) and 
included the four major histological lung cancer types: adenocarcinoma, squamous cell 
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carcinoma, large-cell carcinoma, and small-cell carcinoma.  Other FCDS gender 
categories: 3 = Other (Hermaphrodite), 4) 4 = Transsexual and 5) 9 = Not Stated or 
Unknown, were excluded from the analysis as those particular gender categories did not 
contribute to the research question.  The major treatment modalities (chemotherapy, 
surgery, hormone use, and radiation therapy) for FCDS lung cancer cases were included; 
other treatment modalities were excluded as this research focused on the major treatment 
modalities used to treat cancer.   The major races/ethnic groups were selected based on 
the overall FCDS statistics; white and African-American were selected as the two 
racial/ethnic groups.  Inclusion criteria for smoking status consisted of never smoking, 
past history of smoking, and presently smoking as referenced to the date of lung cancer 
diagnosis.  The mean age for FCDS males (n = 88,248) was 68.96 years of age and for 
FCDS females (n = 51,678) 68.66 years of age was calculated with the SAS PROC 
UNIVARIATE program.   Variable frequencies classified by gender were determined 
with the SAS PROC FREQ procedure.  The majority of the FCDS women were married 
(14.2%), had a history of smoking (90.43%), and were white (n = 49,227 (95.26%)).   
Adjusted Odds Ratios were derived from the logistic regression model utilizing 
SAS Institute Inc., Cary, NC, USA Version 9.1 software.  Based on a the statistics 
generated by a logistic regression model, there were statistically significant differences 
between gender and the treatment modality after adjusting for race, age and tobacco use. 
FCDS females had a decrease odds of receiving radiation therapy (OR = 0.939 (95%CI = 
0.919, 0.961)) and surgery (OR = 0.940 (95%CI = 0.915, 0.966)) as compared to FCDS 
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men.  Additionally, there was decrease in the odds of having radiation therapy as a 
treatment modality for lung cancer for white FCDS females as compared to African-
American females (OR = 0.806 (95%CI = 0.771, 0.841)).  FCDS African-American 
females had a decrease odds of receiving surgery as a treatment modality (OR = 0.605 
(95%CI = 0.569, 0.643)) and chemotherapy (OR = 0.790 (95%CI = 0.751, 0.831)) for 
lung cancer as compared FCDS white women.  FCDS females had a greater probability 
or risk of adenocarcinoma and small cell carcinoma as compared to FCDS males.  Some 
of the limitations of investigator’s initial FCDS study were that the treatment groups were 
not stratified to examine a combination of receiving more than one treatment type nor 
were interaction terms considered in the relationship between treatment and gender.  
 
Summary 
Initially, this research was based on a preliminary investigation of primary lung 
cancer cases for the Florida Cancer Data System 
1
 that studied if the treatment modality 
selected to treat a lung cancer case was based on gender. This research expanded the 
concept of lung cancer treatment differences based on gender to include the 
determination of survival differences in women as compared to men dependent upon the 
treatment modality received.  The initial study objective was to investigate differences in 
major treatment modalities by gender, all four major histological lung cancer types 
combined by gender, and the major histological lung cancer types by gender.   The 
relationship between treatment modalities and other variables (race, smoking status, vital 
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status, and marital status) was evaluated.  In particular, race was investigated to 
determine if any disparities between race and treatment type existed for FCDS women.   
This research expands on the preliminary findings and the patient population by 
including other NAACCR associated cancer registry lung cancer data in an attempt to 
determine if the particular treatment modality used to treat a woman with lung cancer 
affects her survival as compared to a man.  As statistically significant differences in the 
association between gender and treatment have been demonstrated previously in the 
preliminary findings of this research, it was important to address these findings during the 
next phase of gender differences in lung cancer survival research.  This study is a first 
step in the determination of survival in women with lung cancer and differences in 
treatment patterns as compared to men utilizing the data from state registries that are 
members of NAACCR.  Results from this newly combined database will be in an attempt 
to quantify the extent of a gender specific treatment effect and the impact of this effect on 
survival.  Another novel statistical approach in the study of gender differences in 
treatment selection and gender specific survival is the addition of interaction terms in the 
analysis. Also with the inclusion of interaction terms, the calculation of an overall gender 
effect of the treatment outcome and on survival could be possible. In the literature 
reviewed and cited throughout this dissertation, this approach has not been demonstrated.  
This approach adds another dimension in the study of gender differences for lung cancer 
treatments and survival as statistically significant results were demonstrated.  
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CHAPTER IV: PRESENTATION AND ANALYSIS OF DATA 
Introduction 
 This chapter presents the study findings. The study population consisted of 
lung cancer cases drawn from state based passive cancer registries in the United States.  
The lung cancer cases that were selected from each state cancer registry were intended to 
be representative of all the lung cancer cases for that particular state. For each state, the 
lung cancer case had equally as likely a chance of being included or excluded from the 
cancer registry.  The study individuals were selected from state cancer registry lung 
cancer cases diagnosed during a five year time period, 1-1-2000 through 12-31-2004.  
The time or date of diagnosis served a dual purpose as that date was also used to specify 
the origin or start date for subsequent Survival Analysis.  As previously stated in Chapter 
Three, the eight state cancer registries with the lung cancer cases were randomly selected 
from NAACCR US state cancer registries in four geographic regions. The reason for 
selecting cancer registries from four different geographic regions in the United States was 
reduce or eliminate any biases, e.g. selection, treatment, that may have been introduced 
by selecting cases from only one geographic region.  The overall intent was to account 
for any differences in the population characteristics.   
Forty-six variables for each lung cancer case were requested from the eight 
NAACCR cancer registries.  Each state reviewed the requested information and provided 
data that was consistent with their Internal Review Board (IRB) protocol, policies, and 
procedures.  While some of the individual states did not provide information on all 46 
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variables requested, the data provided by each state, did allow for a complete assessment 
so that the three research questions proposed in this study could be answered.  Many of 
the study variables requested were intended to be utilized in a quality of data assessment. 
For example, evaluating the number of autopsies reported and comparing that frequency 
with Vital Status (alive versus dead) could be used to check the integrity of the data.  As 
some data were either incomplete or unavailable to the researcher, a quality assessment or 
test could not be completed.  Additionally, in the original request for specific variables, a 
number of states would not provide the variable information that they (the state registry) 
determined could possibly compromise the confidentially of a particular lung cancer case. 
Some of the state cancer registries made the determination of the variables or variables 
that were needed to answer the three research questions and provided only that 
information.  As an example, the variables, ―date of diagnosis‖ and the ―date of last 
contact or date of death‖, were not provided in the South Carolina data set.  Rather than 
providing the date of death, the South Carolina Cancer Registry computed ―survival 
time‖ for those lung cancer cases that were either died or alive.  Survival time was 
calculated as the number of months from date of diagnosis to date of death or censure 
time (12/31/2004).  
Of the original 46 variables requested from the cancer registries, eleven variables 
were chosen to answer the three research questions.  The list of variables in Table 31 
include gender, stage of disease, grade of lung cancer, morphology (histology and 
behavior), treatment group, age at diagnosis, age group at the time of diagnosis, race, 
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marital status at diagnosis, state of the cancer registry, vital status, and survival time 
(number of months from the date of diagnosis to date of death or censure time 
(12/31/2004)).  Four variables of the original forty-six variables were selected as primary 
variables and are listed below in the Table 31.  The primary independent variables are 
gender, morphology, stage, and grade and all four are included in the analysis to answer 
research questions one and three.  When Hypothesis II for question two was tested, 
gender was used as the primary independent variable.  
Table 31 – Final Data Lung Cancer Set Variables 
 
 Description of Variables 
Gender 
Morphology (Type and Behavior)  
Stage 
Grade 
Marital Status at Diagnosis 
Race 
Age at Diagnosis Group 
Vital Status 
Survival Time*  
Treatment Group 
State 
*Survival time in months: from date of diagnosis 
to date of death or censure time (12/31/2004) 
 
From the originally requested 46 variables, several variables were intended to be 
used as quality indicators, be evaluated as possible confounders and to test for interaction 
effects.  For the scope of this research, these are referred to as ―secondary‖ variables. 
Table 31 secondary variables include race, marital status at the time of diagnosis, and age 
group at the time of diagnosis.  Treatment Group was used as a response variable for 
testing Hypothesis I and as an independent variable for testing Hypothesis III.  Table 32 
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provides clarification and gives a description of the independent and outcome variables 
used to answer each of the research questions via hypothesis testing. 
 
Table 32: Classification of Variables for Hypothesis Testing 
 Independent Variables 
(Predictor) 
 Dependent Variables 
(Response) 
 
Hypothesis I 
 
Gender, Stage, Grade, 
Morphology, Race, Marital 
Status, Age Group, and State*   
  
Treatment Group 
 
Hypothesis II 
 
 
Gender 
  
Survival Time, Vital 
Status 
 
 
Hypothesis III 
Gender, Stage, Grade, 
Morphology, Race, Marital 
Status, Age Group, Treatment 
Group,  
  
 
Survival Time, Vital 
Status 
*State was used in a separate model when testing for any random effect, i.e. any effect that state 
could have on the relationship between the outcome and the independent variables. 
 
In conclusion, eleven variables were utilized for the final analysis in order to 
answer the three research questions via hypothesis testing.  The list of variables include 
gender, stage of disease, grade of lung cancer, morphology (histology and behavior), 
treatment group, age at diagnosis, race, marital status at diagnosis, state of the cancer 
registry, vital status, and survival time (number of months from date of diagnosis to date 
of death or censure time (12/31/2004)). 
 
151 
Population Characteristics 
Demographics 
The demographic characteristics of the population under study from each state are 
given in Tables 33 through 36.  There were a total of 44, 863 primary lung cancer cases 
included in the analysis after the study selection criteria for inclusion and exclusion were 
met and as outlined in Chapter Three.  Briefly, the combined primary and secondary 
variable data set consisted of lung cancer cases that excluded individuals that were not 
diagnostically confirmed lung cancer, e.g. a diagnosis made by a cell/tissue sample or 
that were not analytic.  For a lung cancer case to be considered analytic, one of three 
criterion must be met: (1) the diagnosis at the reporting facility and the entire first course 
of treatment was performed elsewhere or the decision not to treat was made at another 
facility, (2) the diagnosis at the reporting facility, and all or part of the first course of 
treatment was performed at the reporting facility, and (3) the diagnosis was made 
elsewhere, and all or part of the first course of treatment was performed at the reporting 
facility.  Also, for each individual lung cancer, any missing or NOS (not otherwise 
specified) values for the primary and secondary variables were excluded.  
As shown in Table 33 below, Florida provided the major contribution of lung 
cancer cases at 24,602 (55.5% of all females, 54.9% of all males) with the overall data set 
minimum for lung cancer cases from Idaho (2.0% of all females, 2.0% of all males).  As 
expected, for all states, there were a higher percentage of males with lung cancer as 
compared to females with lung cancer.  Overall, the data set has 19,994 females (44.6% 
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of the total lung cancer cases) and 24,869 males (55.4% of the total lung cancer cases) – 
shown in Table 36. 
Table 33: State Cancer Registries versus Gender  
Lung Cancer Distribution from the Eight State Cancer Registries 
 
 Females Males  
 
 
State Cancer Registry 
Frequency Percent Frequency 
 
Percentage 
 
Total 
 
Florida 11089 55.5 13513 54.9 24602 
Idaho 400 2.0 496 2.0 896 
Indiana 2333 11.7 3107 12.5 5440 
Massachusetts 2823 14.1 2992 12.0 5815 
Nebraska 702 3.5 1018 3.5 1720 
Oregon 735 3.7 824 3.3 1559 
Rhode Island 459 2.3 666 2.7 1125 
South Carolina 1453 7.3 2253 9.1 3706 
Total 19994 100.0 24869 100.0 44863 
 
The demographic characteristics for the lung cancer cases (gender, vital status, 
race, age group, and marital status at diagnosis) are listed in Table 24.  The ages for the 
combined data set (primary lung cancer cases diagnosed between 1/1/2000 – 12/31/04) 
ranged from 40 - 89 years old.  The mean age for the data set (N = 44,863) was 67.9 
years, SD+10.2; for females (Nfemale = 19,994) the mean age was 67.9 years, SD + 10.4 
and for males (Nmale = 24,869), the mean equaled 68 years, SD+10.0.  For hypothesis 
testing, the continuous variable ―Age at Diagnosis‖ was classified into age groups 
(categorical variables); five ―Age Group-at-Diagnosis‖ strata or intervals were generated 
and are described in Table 24. The Age at Diagnosis (in years) Group 7 (> 70 - < 80) had 
greatest frequency of lung cancer cases with 16,404 (36.6 %), followed by Group 6 (> 60 
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- < 70) with 13,536 (30.2 %), Group 5 (> 50 - < 60) 7,179 (16.0 %), and the minimum 
number in an age group was the > 40 - < 50 age interval, Group 4 with 2, 352 (5.2 %). 
Table 34: Lung Cancer Distribution 
Gender, Vital Status, Race, Age Group, and Marital Status at Diagnosis 
 
 Frequency Percent 
Variable   
Gender   
Female 19994 44.6 
Male 24869 55.4 
Total 44863 100 
Vital Status     
Dead 31869 71.0 
Alive 12994 29.0 
Total 44863 100 
Race     
White 41458 92.4 
Black 3042 6.8 
Other 363 0.8 
Total 44863 100 
Age Group at Diagnosis      
   
> 40 - < 50 yrs 2352 5.2 
> 50 - < 60 yrs 7179 16.0 
> 60 - < 70 yrs 13536 30.2 
> 70 - < 80 yrs 16404 36.6 
> 80 - < 90 yrs 5392 12.0 
Total 44863 100 
Marital Status at Diagnosis     
Single 4427 9.9 
Married 26759 59.6 
Separated 367 0.8 
Divorced 4920 11.0 
Widowed 8390 18.7 
Total 44863 100 
 
Originally, there were ten ―Age Group at Diagnosis‖ levels. Those age range 
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groups not listed in Table 34 were > 0 - <10 years old, > 10 - <20 years old, > 20 - <30 
years old, > 90 - <100 years old, and > 100 years old. The decision was made to limit the 
number of age groups based on the following: first, there were limited numbers of lung 
cancer cases that were younger than 40 and older than 90.  The cumulative percent was 
less than 1% for the lung cancer data set for those lung cancer cases less than forty years 
of age and for those cases greater than 90 years old.  An analysis and subsequent results 
would be subject error due to the limited sample size (decreased power or lack of ability 
to detect the ―effect‖ under study).  Secondly, the population for the extremely young and 
extremely old, as referenced to lung cancer, is different and would not contribute to the 
relevance of the lung cancer cases selected for this research.   In summary, the decision 
was made to exclude these age range groups.  
Seventy-one percent of the lung cancer cases (31,869) were classified under the 
variable ―Vital Status‖ as dead and 12,994 cases (29.0 %) were coded as alive.  The study 
set, under Race, consisted mainly of ―White‖ lung cancer cases (41,458 (92.4 %)), with 
3,042 (6.8 %) ―Black‖ and 363 (0.8%) cases were coded as ―Other‖.  Table 34 also 
displays marital status at the time of lung cancer diagnosis.  Approximately 60 percent of 
all the lung cancer cases (26,759, 59.6%) were classified as married at the time of 
diagnosis.  The next classification with the greatest frequency was windowed (8,390, 
18.7%) followed by divorced (4,920, 11.0%) and single (4,427, 9.9%) with the minimum 
number classified as separated of 367 (0.8%).  
The primary research variables (main effect) listed in Table 35 includes stage, 
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grade, and morphology.  Morphology coding, as previously stated in Chapter Three, 
includes coding for the histological type of lung cancer combined with the behavior code 
of the disease.  All the primary lung cancer cases in this data set have a behavior code of 
3, meaning all lung cancer cases in this data set were classified as malignant. 
Table 35: Lung Cancer Distribution  
Stage, Grade, and Morphology 
 
 Frequency Percent 
Variable   
 
Stage     
I 12028 26.8 
II 4107 9.2 
III 10359 23.1 
IV 18369 40.9 
Total 44863 100 
Grade     
I 3153 7.0 
II 12715 28.3 
III 22417 50.0 
IV 6578 14.7 
Total 44863 100 
Morphology     
Adenocarcinoma 16139 36.0 
Squamous 13425 29.9 
Large Cell 8473 18.9 
Small Cell 6826 15.2 
Total 44863 100 
 
Stage IV lung cancer accounts for 40.9 % of the total four stage classification 
scheme with the minimum number of cases found with Stage II at 9.2 %.  
Adenocarcinoma was the major morphological type with 16,139 cases (36.0 %), 
squamous cell had the second highest frequency with 13, 425 (29.0 %), followed by large 
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cell carcinoma with 8,473 (18.9 %) cases, and lastly, small cell carcinoma having 6,826 
cases made up 15.2 % of the total four different stages of the lung cancer data base (N =  
44,863).  The grade of lung cancer (Table 35) consists of four classifications, most 
commonly found was Grade III (22,417, 50.0%); the Grade II lung cancers consisted of 
12,715 (28.3%) cases, Grade IV (6,578, 14.7%), and Grade I had the minimum number 
of lung cancer cases of 3,153 (7.0%).  
One of the last tables of demographic data, Table 36-a, consists of the frequency 
and percent for state each cancer registry and the treatment groups.  Of the eight states 
listed, Florida was the major contributor of the lung cancer cases as expected due to a 
greater number of residents – see Table 36-b for the 2000 – 2004 annual estimated 
population.  Additional demographics for each state are provided in Appendix I in Tables 
70 through Table 77. There are eight treatment classifications in Table 36-a which 
include a single treatment modality (Radiation Therapy (I), Chemotherapy (II), or 
Surgery (III)) treatment group, combinations of treatment modalities received (Radiation 
and Surgery (IV), Radiation and Chemotherapy (V), Surgery and Chemotherapy (VI), or 
Radiation combined with Surgery and Chemotherapy (VII) and the last classification 
consisted of lung cancer cases that received no treatment (Treatment Group VIII). 
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Table 36-a: Lung Cancer Treatment Group and State  
Lung Cancer Distribution (Frequency and Percent) 
 
 Frequency Percent 
Variable   
State     
Florida 24602 54.8 
Idaho 896 2.0 
Indiana 5440 12.1 
Massachusetts 5815 13.0 
Nebraska 1720 3.8 
Oregon 1559 3.5 
Rhode Island 1125 2.5 
South Carolina 3706 8.3 
Total 44863 100 
Treatment Group     
Radiation  4351 9.7 
Chemotherapy  6472 14.4 
Surgery  12728 28.4 
Radiation + Surgery 1063 2.4 
Radiation + Chemotherapy 7955 17.7 
Surgery + Chemotherapy 1249 2.8 
Radiation + Surgery + Chemotherapy 1348 3.0 
No Treatment 9697 21.6 
Total 44863 100 
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Table 36-b: Total Population for the Eight States* 
 
 Males Females Total 
 N % n % N % 
State        
Florida 7,797,715 48.8 8,184,663 51.2 15,982,378 40.00 
Idaho 648,660 50.1 645,293 49.9 1,293,953 3.24 
Indiana 2,982,474 49.0 3,098,011 51.0 6,080,485 15.24 
Massachusetts 3,058,816 48.2 3,290,281 51.8 6,349,097 15.91 
Nebraska 843,351 49.3 867,912 50.7 1,711,263 4.29 
Oregon 1,696,550 49.6 1,724,849 50.4 3,421,399 8.58 
Rhode Island 503,635 48.0 544,684 52.0 1,048,319 2.63 
South Carolina 1,948,929 48.6 2,063,083 51.4 4,012,012 10.06 
Total 19,480,130 100 20,418,776 100 39,898,906 100 
*Source: U.S. Census Bureau, Census 2000, and used as most current source of population 
statisitics for estimate purposes only 
 
Although this research was focused primarily on specific treatment modalities, a 
proportion of lung cancer cases received no treatment (no radiation, chemotherapy, 
and/or surgery) were classified as Treatment Group VIII (Table 36-a).  This classification 
allowed for the investigation of lung cancer cases that received no treatment by 
comparing the no treatment group to the other levels of the treatment groups.  Treatment 
Group VIII had the second largest number of lung cancer cases as shown in Table 36-a 
with 9,697 (21.6%) subjects.  One concern regarding the utilizing this treatment group 
(VIII) would be a possible bias being introduced from utilization of the ―no treatment 
received group‖ as the reference group during the statistical testing/analysis.  For 
example, utilizing Treatment Group VIII as the reference group could introduce a 
differential classification bias.  This bias would be resultant from using a set/group of 
lung cancer cases (VIII) that were different from all the other lung cancer cases 
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(Treatment Group I - VII) as they (VIII) never received any treatment, i.e. radiation, 
chemotherapy, surgery, radiation + chemotherapy, radiation + surgery, chemotherapy + 
surgery, or radiation + chemotherapy + surgery.  This could bias the null in any direction 
and any effect from the comparison of other treatment groups could be masked.  Simply 
stated, the category of no treatment group used as a reference group cannot be lung 
cancer cases that are comprised from a different population.  The population 
characteristics of the eight treatment groups were compared; there were no observable 
trends that suggested that Group VIII had any observable differences suggesting a 
dissimilar population mix.  The following tables, Table 37 through Table 40, contain the 
assessment of the primary variable by the individual treatment groups.  Each treatment 
group was evaluated for any dissimilarity or variability in gender, morphological type, 
stage, and grade of lung cancer. Table 37 displays the lung cancer distribution between 
the Treatment Groups versus Gender. In Table 37 for all treatment groups, the frequency 
of males with lung cancer is greater than females with lung cancer.  When evaluating the 
eight treatment groups versus gender, the greatest number of males with lung cancer is 
found in Treatment Group III (Surgery only) with 6,718 cases.  The minimum number of 
male lung cancer cases (612) was documented for Treatment Group IV (Radiation and 
Surgery).  The maximum number of females (6010) was found in Treatment Group III 
(Surgery only) with the minimum number of female lung cancer cases (451) in Table 37 
receiving a combination of Radiation and Surgery (Treatment Group IV).   
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Table 37: Lung Cancer Distribution – Treatment Group vs. Gender 
 
Treatment Group Gender Frequency Percent 
Radiation 
I  Female 1772 40.7 
  Male 2579 59.3 
Chemotherapy 
II  Female 2946 45.5 
  Male 3526 54.5 
Surgery 
 III Female 6010 47.2 
  Male 6718 52.8 
Radiation + Surgery 
 IV Female 451 42.4 
  Male 612 57.6 
Radiation + Chemotherapy 
 V Female 3346 42.1 
  Male 4609 57.9 
Surgery + Chemotherapy 
VI  Female 585 46.8 
  Male 664 53.2 
Radiation + Surgery +  
Chemotherapy 
 VII Female 608 45.1 
  Male 740 54.9 
No Radiation, Surgery,  
and/or Chemotherapy 
VIII  Female 4276 44.1 
  Male 5421 55.9 
Note: During statistical testing surgery was designated as the reference Treatment Group 
(VIII), the No Radiation , Surgery, and/or Chemotherapy Group (No Treatment Group) was 
designated as Treatment Group III 
 
 
The next three tables compare the eight treatment groups with the primary 
variables of stage (Table 38), grade (Table 39) and morphology (Table 40). 
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Table 38: Lung Cancer Distribution – Treatment Group vs. Stage 
 
Treatment Group Stage Frequency Percent 
 Radiation I 658 15.1 
 I II 278 6.4 
  III 820 18.9 
  IV 2595 59.6 
 Chemotherapy I 337 5.2 
 II II 277 4.3 
  III 1224 18.9 
  IV 4634 71.6 
 Surgery I 8332 65.5 
 III II 1847 14.5 
  III 1972 15.5 
  IV 577 4.5 
 Radiation + Surgery I 195 18.3 
 IV II 200 18.8 
  III 482 45.3 
  IV 186 17.5 
 Radiation + Chemotherapy I 585 7.4 
 V II 551 6.9 
  III 2677 33.7 
  IV 4142 52.1 
 Surgery + Chemotherapy I 334 26.7 
 VI II 163 13.1 
  III 551 44.1 
  IV 201 16.1 
 Radiation +Surgery+ Chemotherapy I 119 8.8 
 VII II 160 11.9 
  III 816 60.5 
  IV 253 18.8 
No Radiation, Surgery, I 1468 15.1 
and/or Chemotherapy  II 631 6.5 
VIII  III 1817 18.7 
   IV 5781 59.6 
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The purpose of Table 38 was to compare the eight different treatment groups with the 
four stages of lung cancer.  There were four treatment groups having the greatest percent of Stage 
IV lung cancer, Group I Radiation (59.6%), Group II Chemotherapy (71.6%), Group V Radiation 
and Chemotherapy (52.1%), and Group VIII (59.6%).   One treatment group, the surgical 
treatment group, Group III, had the greatest percent (65.5%) for Stage I.  Stage three lung cancers 
had the highest percentage in Group IV (Radiation and Surgery) at 45.3%, Group VI Surgery and 
Chemotherapy (44.1%) and Treatment Group VIII which combined all three treatment 
modalities: Radiation, Surgery, and Chemotherapy. 
Seven of the eight treatment groups (Table 39) had the highest percentage of lung 
cancers considered Grade III as compared to the other three grades:  Treatment Group I 
(58.7%), Treatment Group II (47.5%), Group IV (52.5%), Group V (53.3%), Group VI 
(49.6%), Group VII (59.4%), and Group VIII (55.5%).  There was only one treatment group 
(those receiving surgery only, Treatment Group III) in which the highest proportion (44.8%) 
of lung cancer cases were Grade II.  In Table 40,  Adenocarcinoma was the most frequent 
histological type of lung cancer for Treatment Groups III (46.2%), IV (45.6%), VI 
(46.3%), and VIII (33.7%).  Squamous cell lung cancer was most common in Groups I 
(36.7%) and V (27.3%).  Lastly, the most common histologic type of lung cancer for 
Group II Chemotherapy (38.5%) was Small Cell Lung Cancer (SCLC). 
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Table 39: Lung Cancer Distribution - Treatment Group vs. Grade 
Treatment Group Grade Frequency Percent 
 Radiation I 244 5.6 
 I II 1171 26.9 
  III 2553 58.7 
  IV 383 8.8 
 Chemotherapy I 216 3.3 
 II II 926 14.3 
  III 3072 47.5 
  IV 2258 34.9 
 Surgery I 1627 12.8 
 III II 5697 44.8 
  III 5194 40.8 
  IV 210 1.7 
 Radiation + Surgery I 63 5.9 
 IV II 418 39.3 
  III 558 52.5 
  IV 24 2.3 
 Radiation + Chemotherapy I 280 3.5 
 V II 1496 18.8 
  III 4239 53.3 
  IV 1940 24.4 
 Surgery + Chemotherapy I 103 8.3 
 VI II 463 37.1 
  III 619 49.6 
  IV 64 5.1 
 Radiation +Surgery 
+ Chemotherapy I 52 3.9 
 VII II 429 31.8 
  III 801 59.4 
  IV 66 4.9 
No Radiation, Surgery, I 568 5.9 
and/or Chemotherapy  II 2115 21.8 
VIII  III 5381 55.5 
   IV 1633 16.8 
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Table 40: Lung Cancer Distribution – Treatment Group vs. Morphology 
Treatment 
Group Morphology Frequency Percent 
Radiation Adenocarcinoma 1430 32.9 
 I Squamous 1596 36.7 
  Large Cell 980 22.5 
 Small Cell 345 7.9 
Chemotherapy  Adenocarcinoma 1747 27.0 
II Squamous 1087 16.8 
  Large Cell 1145 17.7 
  Small Cell 2493 38.5 
 Surgery Adenocarcinoma 5880 46.2 
 III Squamous 4610 36.2 
 Large Cell 2142 16.8 
  Small Cell 96 0.8 
Radiation + Surgery Adenocarcinoma 485 45.6 
  IV Squamous 426 40.1 
 Large Cell 144 13.6 
 Small Cell 8 0.8 
Radiation + Chemotherapy  Adenocarcinoma 2106 26.5 
V Squamous 2171 27.3 
  Large Cell 1597 20.1 
  Small Cell 2081 26.2 
 Surgery + Chemotherapy Adenocarcinoma 602 48.2 
 VI Squamous 350 28.0 
  Large Cell 238 19.1 
  Small Cell 59 4.7 
Radiation + Surgery +   Adenocarcinoma 624 46.3 
Chemotherapy Squamous 419 31.1 
 VII Large Cell 241 17.9 
  Small Cell 64 4.8 
 No Treatment  Adenocarcinoma 3265 33.7 
 VIII Squamous 2766 28.5 
 Large Cell 1986 20.5 
 Small Cell 1680 17.3 
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The tables and results of the analysis by treatment group versus the secondary 
variables are located in Appendix II - Tables 41 through 43.  The tables display a 
comparison of the treatment groups versus age race (Table 41), marital status group at 
diagnosis (Table 42), and age group at the time of lung cancer diagnosis (Table 43). 
There were no obvious differences in treatment groups versus and distribution of race, 
Table 41 in Appendix II. The majority of lung cancer cases are White ranging from 
91.3% of all lung cancer cases in Group V (Radiation and Chemotherapy) to 94% of all 
lung cancer cases in Group III (Surgery).  The classification of ―Other‖ for race contained 
the least amount of lung cancer cases for each treatment group with each Treatment 
Group having a minimum of approximately one percent within each treatment 
classification (I – VIII).  All treatment groups in Table 42 (Treatment Group vs. Marital 
Status at Diagnosis) have the greatest percentage of the lung cancer cases classified as 
married at the time of diagnosis ranging from 52.2 percent for Treatment Group VIII (no 
treatment) to maximum percentage of 69.9 percent for surgical and chemotherapy, Group 
VI. Lastly, each treatment group was evaluated for Age Group at Diagnosis.  The 
treatment groups, I - VII did not display that Treatment Group VIII was any different or 
displayed any trends that would suggest that the patient population was not comparable to the 
other seven treatment groups.  It was determined that the lung cancer cases in Group VIII were 
just as likely to receive a treatment modality or combination of treatment modalities when 
comparing the treatment patterns for Groups I through VII.   The decision was made to 
include Group VIII for the analysis. 
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Testing the Hypotheses 
Hypothesis I  
Women with the same histological type, stage and grade of lung cancer received the 
same treatment modality as compared to men with the same histological type, stage and 
grade of lung cancer.  
Introduction 
The first aim was to determine if men and women stratified by histologic type, 
stage, and grade of lung cancer received the same treatment type.  The relationship 
between gender and the treatment modality received was evaluated including other 
independent variables and interaction terms.  Interaction terms were included in the 
model to assess the role of moderating variables.  A moderating variable can change the 
association (Odds Ratios) between the independent variable and the outcome variable at 
different levels of that moderator.  It was important to establish if different treatments, 
e.g. radiation therapy, chemotherapy, surgery, were received based on gender; this has 
not been addressed specifically in the literature.  Also after determining if the type of 
lung cancer treatment received was gender dependent, further analysis or study of that 
impact on gender specific survivorship could be addressed in Hypotheses II and III.  As 
stated in Chapter Three, the statistical model selected to examine the relationship 
between the outcome variable (treatment group) and the independent variables was the 
multinomial, polychotomous or polytomous logistic regression model.  The multinomial 
logistic regression or ―logit‖ models an outcome variable that has more than two 
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outcomes; the research outcome variable, treatment group, was comprised of eight 
categories or eight different treatment selections.   
Table 44 lists the variables used during the testing of Hypothesis I; the variables 
were coded as categorical variables and were classified on the nominal scale.  Also 
shown in Table 44 are the reference groups, for example Group VIII (Surgery) was 
utilized as the reference group during statistical testing with the generalized logit model.  
 
 
Table 44:  Outcome Variable and Independent Variables 
Variables for Testing Hypothesis I 
 Multinomial Logistic Regression Model (MLR1) 
 
Outcome Variable* Independent Variables** 
Treatment Group Gender  
I. Radiation Therapy 
II. Chemotherapy 
III. No Treatment Assignment (No 
Radiation, Chemotherapy and/or 
Surgery) 
IV. Radiation + Surgery 
V. Radiation  + Chemotherapy 
VI. Surgery + Chemotherapy 
VII. Radiation + Chemotherapy + Surgery 
VIII. Surgery 
Stage  
Grade 
Morphology 
Race 
Marital Status at Diagnosis 
Age Group at Diagnosis 
 
* Outcome Variable Reference Group: Treatment Group = Surgery 
** Independent Variable Reference: Gender = 2 (Male), Stage = IV, Grade = IV, Morphology = 4 (SCLC), 
Race = 3   (Other, Non-White), Marital Status = 5 (Widowed), and Age Group = 5 (> 80 - < 90 yrs) 
 
 
The outcome variable profile given previously in Table 36 had a total frequency 
of 44,863 lung cancer cases; there was one outcome variable, treatment group, with eight 
treatment groups.  The total frequency of each treatment group of lung cancer cases were 
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also given in Table 36 with the minimum number of cases in treatment group IV 
(Radiation and Surgery) with 1,063 cases and a maximum of 12,728 lung cancer cases in 
treatment group VIII (Surgery).        
 
Potential Confounders, Multicollinearity and Interactions  
This next section reviews three topics of interest: potential confounders, 
multicollinearity and interaction as each can impact the study by biasing the results due to 
the design and in the analysis phase.  First, a potential source of error affecting the 
validity of study can be confounding variables.  Confounding can cause a distortion in the 
measure of association due to an unequal distribution of a determinant of the outcome 
73, 
224
.  Confounding is a problem of comparison, a problem that arises when important 
extraneous factors are differentially distributed across groups being compared.  A 
confounding variable is related to the outcome variable and the independent variable but 
not on the direct causal pathway between the outcome and independent variable of 
interest 
73, 224
.  The following methods were utilized to control for confounding in the 
design phase of the study.  In the study design phase, two methods selected to reduce any 
confounding were 1) randomization in the selection of the states and 2) restriction: some 
of the restrictions included selecting only primary lung cancer cases and cases from 
NAACCR cancer registries.   
Smoking is a major confounding variable for lung cancer but smoking was not 
addressed as a variable in this study due to several reasons.  There was difficulty in 
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studying the variable ―smoking‖ as cancer registry procedures and methods in the coding 
and collection of smoking history can be dissimilar and are listed below: 
I. Smoking was coded differently, e.g. the NAACCR standard code format 
was not followed in each state cancer registry. 
II. The data for smoking or smoking history were not collected in similar 
manner across all states, e.g. different start/inception dates to begin the 
collection of smoking information. 
III. No smoking history was collected or the information was not available 
from two state cancer registries under study, therefore a complete 
assessment could not be made. 
IV. Whether a person smokes or not is not a variable of interest in this 
research.  In the opinion of the researcher, smoking or not smoking is not 
associated or rather will not determine if a lung cancer case receives a 
particular treatment modality, e.g. radiation, surgery, and or any 
combination of treatment modalities.  
 
Next, a second possible source of error could be in the case of collinearity or 
highly collinear values between two independent variables that could affect the 
relationship of either or both variables on the research outcome, i. e. the lung cancer 
treatment received. This is commonly referred to as ―multicollinearity‖.  When there is a 
high level of intercorrelation between the independent variables, the effects of the 
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independent variables may not be separated resulting in statistical inferences made about 
the data that could be unreliable.  For the research data set, a similar method described by 
Hosmer and Lemeshow
1
 for categorical variables was utilized to test for 
multicollinearity.   First, a logistic regression model was run or generated with all seven 
independent variable: gender, stage, grade, morphology, marital status, age group, and 
race.  Then seven logistic regression models (variable subsets) were generated, i.e. each 
model dropped one of the independent variables that were originally included in the full 
model.  The full model coefficients and standard errors were examined and then 
compared to the coefficients and standard errors for the seven other logistic regression 
models (Model I all variables, Model II stage excluded, Model III grade excluded, Model IV morphology 
excluded, Model V gender excluded, Model VI marital status excluded, Model VII race excluded, Model VIII 
age group excluded).  There were no appreciable differences between the standard errors and 
the coefficients. An appreciable difference as noted by Hosmer and Lemeshow could be a 
change in the beta coefficients or standard errors by an order of magnitude.  For example, 
in Table 45 the data extracted from the full model, Model I and Model II (morphology 
removed from the other independent variables) does not display such a change.  From 
this assessment in combination all other ―subset‖ model comparisons, multicollinearity 
was deemed minimal; therefore the coefficients were assumed to be unbiased. 
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Table 45:  Multicollinearity Assessment via Logistic Regression 
Comparison of Coefficients and Standard Error 
Extracted from the Logistic Regression Models 
  Parameter  Coefficient Standard Error   
 
 
 
 
 
 
 
MODEL I
*
 
(Full Model) 
    
Morphology 1 -0.285 0.017 
Morphology 2 0.007 0.018 
Morphology 3 -0.016 0.019 
Grade 1 -0.221 0.029 
Grade 2 -0.198 0.020 
Grade 3 0.189 0.016 
Stage 1 -1.364 0.018 
Stage 2 -0.381 0.023 
 Stage 3 0.321 0.016 
 Gender 1 -0.037 0.009 
 Race 1 -0.097 0.035 
 Race 2 0.103 0.039 
 Marital Status 1 0.061 0.030 
 Marital Status 2 -0.162 0.023 
 Marital Status 3 0.071 0.077 
 Marital Status 4 -0.021 0.029 
 Age Group 4 -0.212 0.032 
 Age Group 5 -0.162 0.020 
 Age Group 6 -0.127 0.017 
 Age Group 7 0.013 0.016 
  
Grade 1 -0.324 0.027 
Grade 2 -0.301 0.017 
Grade 3 0.121 0.014 
Stage 1 -1.363 0.018 
Stage 2 -0.379 0.023 
MODEL II
*
 
(Morphology Excluded) 
Stage 3 0.328 0.016 
Gender 1 -0.047 0.009 
Race 1 -0.091 0.035 
Race 2 0.110 0.039 
Marital Status 1 0.063 0.030 
Marital Status 2 -0.170 0.023 
 Marital Status 3 0.074 0.077 
 Marital Status 4 -0.022 0.029 
 Age Group 4 -0.232 0.032 
 Age Group 5 -0.166 0.020 
 Age Group 6 -0.121 0.017 
 Age Group 7 0.025 0.016 
*Model I included the independent variables of gender, stage, grade, morphology, marital 
status, race, and age group 
** Model II included the independent variables of gender, stage, grade, morphology, marital 
status, race, and age group 
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Another area of importance in the testing of the hypothesis was the evaluation of 
possible interaction or effect modification that might significantly affect the relationship 
between the outcome and the independent variables.  An effect modifier is a variable that 
changes the relationship between the independent variable and the outcome variable.  A 
variable that acts as an effect modifier is contained in the interaction term and the 
outcome/independent variable relationship changes at different levels or strata 
73, 74, 226
.  
The interaction terms were evaluated for their impact on the outcome and any effect on 
the overall fit of the model equation.  In the statistical testing and analysis stage, 
interaction or effect modification was addressed by evaluating the stratified multivariate 
analyses.  In summary, stratification based on the independent variables, such as stage, 
grade and morphological lung cancer type was employed in the statistical methods and 
interaction terms were included to evaluate the effects of any possible moderating 
variable on the relationship between the independent variable and outcome variable at 
different levels of that moderating variable.  
 
Multinomial Logistic Regression 
Stepwise multinomial logistic regression (MLR) testing was used to select the 
variables (main effects and interaction terms) for the full model.  The stepwise process 
consisted of a forward selection of covariates with a backward elimination of variables 
that did not meet a specified significance level.  The stepwise procedure incorporated 
(specified in the model statement) the four primary variables (gender, stage, grade, and 
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morphology) throughout the process selection and included variables with second degree 
interaction terms in the stepwise model selection process.  The criterion for inclusion into 
a model was a significance level of 0.05 and an elimination of variable/interaction terms 
when the significance level was greater than 0.05.   In the stepwise multinomial logistic 
procedure, Type III Analysis of Effects showed the change in the model fit when an 
independent variable was dropped while keeping the other variables in the model.  In all, 
there were eleven different models generated.  The resultant multinomial logistic model 
included seven main effects for the variables of gender, morphology, stage, grade, marital 
status, race, age group and five interaction terms of gender*morphology, gender*stage, 
stage*grade,  gender*marital status and stage*age group.  Table 46 gives the results for 
the statistical test that was generated for the final model, i.e. Type III Analysis of Effects.  
The Type III test statistic is associated with the estimated coefficients in the model and 
represents an effect due to a particular variable, e.g. gender.  The statistic for the Type III 
test is the amount of variation in the response when a particular variable, e.g. gender, is 
added to the model that already contains all the other variables.  Also, the Type III test 
statistic is not depended upon the order that the independent variables (to include 
interaction terms) are specified in the model.  
In the full model, gender was not significant (p-value >0.05) as a main effect but 
was significant in the interaction terms of gender and stage (gender*stage) and gender 
and marital status (gender*marital status).  Other statistically significant interaction terms 
included stage and grade (stage*grade) and stage and age group (stage*age group).  The 
174 
interpretation of the exponentiated parameter estimates are presented as Odds Ratios with 
the associated 95% confidence intervals in the following paragraphs of this chapter.  Also 
as noted in Table 46, there are large Wald Chi Square values for several main effect 
variables and interaction terms.  Large Wald Chi-Square statistics are an indication of the 
variability of the data contained in the model.  For example, this result could be attributed 
to the multinomial nature of the output variable, treatment group.  The variability of the 
parameter estimates in the model could be increased due to the fact there are eight 
different levels of the outcome variable, treatment group.  
 
Table 46: Type III Analysis of Effects 
Main Effect and Interaction Terms* 
Multinomial Logistic Regression Model (MLR1) 
 
Effect DF 
Wald 
Chi-Square Pr > ChiSq 
Gender 7 10.63 0.156 
Morphology 21 879.88 <.0001 
Gender*Morphology  21 29.43 0.104 
Grade 21 132.55 <.0001 
Stage 21 260.73 <.0001 
Gender*Stage 21 45.31 0.002 
Stage*Grade 63 178.92 <.0001 
Marital Status 28 325.40 <.0001 
Gender*Marital Status 28 52.94 0.003 
Age Group 28 948.87 <.0001 
Stage*Age Group  84 222.51 <.0001 
Race 14 88.36 <.0001 
           Note: Age Group and Marital Status at defined on/at Date of Diagnosis 
                                   * indicates interaction term  
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  The Multinomial Logistic Regression (MLR) model (also known as the 
generalized or baseline-category logit model) with treatment group as the outcome 
variable is represented by the following equation (coefficients are not displayed):  
 
 
= 
 
Gender + Morphology + Gender*Morphology + 
Grade + Stage + Gender*Stage + Stage*Grade + 
Marital Status + Gender*Marital Status + Age 
Group + Stage*Age Group + Race 
 
There were seven categories of the response variable (treatment group) for the 
multinomial logistic regression model.  From the equation above, in the numerator Y 
represents the treatment type; when i = 1, the treatment group is radiation alone, if i = 2 
the treatment group is chemotherapy alone, i = 3 the treatment group is no treatment, i = 
4, the treatment group is radiation + chemotherapy, i =5 the treatment group is surgery + 
radiation, i = 6 the treatment group is surgery + chemotherapy, and when i = 7 the 
treatment group is radiation + chemotherapy + surgery.  Also in the equation above, in 
the denominator Y is the reference treatment group for each of the treatment groups, 1 
through 7.  For the term Y (in the denominator), Y is the reference group and is the eighth 
treatment group (surgery).  In the equation above, k + 1 is a numerical expression that 
specifies or is representative of the reference treatment group 8 (surgery); k = 7 therefore 
k +1 = Y =8. 
From Table 46, the following equation was derived from the full model (the 
interaction term of Gender*Morphology was not included because it was not statistically 
significant and therefore would not affect the outcome): 
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Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI + 
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9 
stageI* age_groupI + 10 morphologyI + 11 raceI + others 
 
The Wald statistic in Table 46 is a parameter/statistic that can be utilized to assess 
the ―goodness of fit‖ of the data to the model.  In other words, the ―goodness of fit‖ can 
be interpreted as how well a mathematical equation estimates the behavior of the data.  If 
a large variability of Wald Chi-Square (a statistic derived from the parameter estimate 
and standard error) existed, this could be interpreted that the wrong model was selected to 
examine the data.   A brief review will be presented concerning the issue of how the 
assessment of the model fit was evaluated prior to reviewing the MLR model results.   
Model fit or the assessment of the predicted results versus the truth (the actual 
results from the data) for a statistical test can be performed after the analysis because the 
researcher wishes to ensure that he/she are using the correct method to test or assess their 
data and that the results are valid.  Prior to inferences being made for the fitted model, an 
assessment of the model fit via diagnostics for the multinomial logistic regression model 
was made.  Residual testing is a common statistical approach in the evaluation of the 
error in the model equation comparing the predicted or estimated results with the data.  
Because residual analysis was not available in the SAS software for a multinomial or 
multiple outcome variable (treatment) levels; Hosmer and Lemeshow
2
 suggest assessing 
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the fit via logistic regression models for each outcome (seven logistic regression models 
in total).  The results of the residual analysis were compared and examined for any trends 
that would demonstrate a lack of model fit.  This type of assessment was made for the 
seven possible treatment outcomes of 1) radiation alone, 2) chemotherapy alone, 3) no 
treatment, 4) radiation + chemotherapy, 5) radiation + surgery, 6) surgery + 
chemotherapy, and 7) radiation + chemotherapy + surgery) with surgery as the reference 
group for each treatment group.  Examples of the residual analysis results for three of the 
treatment outcome groups are given in Tables 52 through 54.  No trends were 
demonstrated for the seven models meaning the use of the multinomial logistic regression 
model to the best of our knowledge was appropriate.   
In the next five sections, the statistical results obtained from the logistic 
regression models for the coefficient estimates, standard errors, the Odds Ratios and 95% 
confidence interval are evaluated.  The first section reviews the ORs/95% CIs for the 
statistically significant main effect variables, morphology and race (Tables 47: a - b).  
Note these main effects are reported because they are not included in any statistically 
significant interaction terms.  If morphology or race were in an interaction term that was 
statistically significant, that result due to the interaction would be reported.  As the 
outcome could change due to the interaction; the outcome could be misinterpreted if the 
main effect variables were the only variables considered.  In the second section, the 
MLRM ORs of the interaction terms (Tables 48 - 51) are evaluated.  The third section 
compares and contrasts the results of the assessment of the model fit.  The fourth section 
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presents the results of a random effect component for state in the multinomial logistic 
regression model.  The results given in the fifth section are the statistics and 
interpretation of the overall variable effect on the treatment type received.  
 
Section 1: Multinomial Logistic Regression Main Effects 
 When examining only main effect results from a statistical model, any type of 
effect modification between an independent variable and the outcome based on a 
moderating variable is not accounted for.  When two variables interact in determining the 
chance of a particular outcome, it is inappropriate to just report the main effect as it will 
give misleading results.  In this research the relationship between some of the main effect 
variables and the outcome variable changed when a moderating variable was present, as 
in the interaction term.  The only time it is appropriate to report the main effect results is 
when that main effect variable gives statistically significant results and any interaction 
term containing that main effect variable is not statistically significant.   
Table 47-a consists of non-significant and significant OR’s and 95% confidence 
intervals generated in the full model, MLR1 for the main effect of morphology.  The main 
effect of morphology is reported because this variable is significant and the interaction 
term of gender and morphology (gender*morphology) was not statistically significant 
(the results for the interaction of gender and morphology term are not reported in the final 
analysis).  When evaluating morphology in Table 47-a, lung cancer cases with 
adenocarcinoma versus other lung cancer morphological types were at a statistically 
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significant decreased risk for all treatment types (OR’s ranged from 0.03 – 0.23) with the 
exception of adenocarcinoma lung cancer cases receiving radiation therapy in 
combination with surgery (OR = 1.55, 95% CI 0.52, 2.65) as compared to receiving 
surgery after adjustment for gender, gender*morphology, grade, stage, gender*stage, 
stage*grade, marital status, gender*marital status, age group, stage*age group, and race.  
Comparing the Odds Ratios between adenocarcinoma and treatment type to lung cancer 
cases with squamous cell and treatment type, the same relationship was exhibited.  There 
was an decreased risk that lung cancer cases with squamous cell carcinoma as compared 
to other lung cancer morphological types would receive any treatments (OR’s ranging 
from 0.04 to 0.28) with the exception of radiation in combination with surgery (OR = 
1.92, 95% CI 0.64, 3.01) as compared to receiving surgery alone but this was not 
statistically significant.  
The last table for a main effect is Table 47-b, with race as the main effect with the 
outcome of treatment type.  There was one statistically significant association between 
race and treatment type; no trends were exhibited for white and black lung cancer cases 
receiving a particular treatment versus receiving surgery.  A possible limitation to this 
analysis of race was the reduced number of the reference group, other lung cancer cases 
(n = 363, 0.8%).  There was an increased number of white (n = 41,458, 92.4%) and black 
lung (n = 3,042, 6.8%) cancer cases.  This reduced number as the reference group could 
have introduced some bias into results (artificial inflation of the ORs).  As the ORs only 
demonstrated one statistically significant result and as the variability of the confidence 
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intervals was minimal, the decision was made to keep this group (other) as the referent 
group.  
Table 47-a: Main Effect for Morphology  
Extracted From the Full Model (MLR1) 
Odds Ratios and 95% Confidence Intervals by Treatment Group 
 
Treatment Type (Outcome) Main Effect Odds Ratio 95% LCI 95% UCI 
 
 Morphology    
Radiation Adenocarcinoma 0.14 0.10 0.52 
Chemotherapy Adenocarcinoma 0.03 0.02 0.37 
No Treatment Adenocarcinoma 0.07 0.05 0.41 
Radiation + Surgery Adenocarcinoma 1.55 0.52 2.65 
Radiation + Chemotherapy Adenocarcinoma 0.04 0.03 0.38 
Surgery + Chemotherapy Adenocarcinoma 0.23 0.13 0.80 
Radiation +Surgery + Chemotherapy Adenocarcinoma 0.21 0.12 0.75 
Surgery* Small Cell* 1.00 - - 
Radiation Squamous 0.28 0.19 0.66 
Chemotherapy Squamous 0.04 0.03 0.38 
No Treatment Squamous 0.11 0.08 0.45 
Radiation + Surgery Squamous 1.92 0.64 3.01 
Radiation + Chemotherapy Squamous 0.08 0.06 0.42 
Surgery + Chemotherapy Squamous 0.22 0.13 0.79 
Radiation +Surgery + Chemotherapy Squamous 0.22 0.13 0.76 
Surgery* Small Cell* 1.00 - - 
Radiation Large Cell 0.30 0.21 0.69 
Chemotherapy Large Cell 0.06 0.04 0.41 
No Treatment Large Cell 0.13 0.10 0.48 
Radiation + Surgery Large Cell 1.64 0.55 2.75 
Radiation + Chemotherapy Large Cell 0.10 0.07 0.44 
Surgery + Chemotherapy Large Cell 0.34 0.19 0.92 
Radiation +Surgery + Chemotherapy Large Cell 0.29 0.17 0.84 
Surgery* Small Cell* 1.00 - - 
* Signifies Referent or Reference Group. Adjusted for gender, gender*morphology, grade, stage, 
gender*stage, stage*grade, marital status, gender*marital status, age group, stage*age group, and 
race. 
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Table 47-b: Main Effect of Race 
Extracted From the Full Model (MLR1) 
Odds Ratios and 95% Confidence Intervals by Treatment Group 
 
Treatment Type (Outcome) Main Effect Odds Ratio 95% LCI 95% UCI 
 Race    
Radiation White 0.99 0.62 1.46 
Chemotherapy White 0.67 0.45 1.08 
No Treatment White 0.86 0.59 1.23 
Radiation + Surgery White 0.88 0.43 1.58 
Radiation + Chemotherapy White 0.83 0.56 1.23 
Surgery + Chemotherapy White 1.31 0.62 2.05 
Radiation +Surgery + Chemotherapy White 0.85 0.46 1.48 
Surgery* Other * 1 - - 
     
Radiation Black 1.74 1.06 2.23 
Chemotherapy Black 0.82 0.53 1.25 
No Treatment Black 1.32 0.89 1.72 
Radiation + Surgery Black 0.94 0.44 1.69 
Radiation + Chemotherapy Black 1.22 0.80 1.63 
Surgery + Chemotherapy Black 1.34 0.62 2.12 
Radiation +Surgery + Chemotherapy Black 0.84 0.43 1.51 
Surgery* Other * 1 - - 
* Signifies Referent or Reference Group. Adjusted for gender, morphology, gender*morphology, 
stage, grade, gender*stage, stage*grade, marital status, gender*marital status, age group, and 
stage*age group. 
 
 
 
Section 2: Multinomial Logistic Regression Interaction Terms  
The next section lists the results that contain statistically significant interaction 
terms for the full model (Tables 48 – 51).  In Table 48, the OR’s and the 95% confidence 
intervals are given for the interaction term of gender and stage.  In this research, the 
overall gender effect is reported later in this chapter which utilizes the results of the main 
effect of gender and the interaction term of gender*stage.  Also the results from Table 48 
are compared later in the next section ―Multinomial versus Binomial Logistic Regression 
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Models‖. 
The Odds Ratios and 95% Confidence Intervals are given in Table 49 for the 
treatment groups and the interaction term of gender and marital status.  The moderating 
variable of gender demonstrated the interaction effect varied according to the level of 
marital status in the interaction term (gender*marital status).  Once again the statistics 
will not be discussed for Table 49 as this is covered in section five in the ―Gender Effect‖ 
portion of this chapter 
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Table 48: Gender and Stage Interaction Terms 
Significant Terms Extracted From the Full Model (MLR1) 
Odds Ratios and 95% Confidence Intervals by Treatment Group 
 
Treatment Type (Outcome) 
Interaction Term 
Odds Ratio 
95% 
LCI 
95% 
UCI 
        Gender        Stage    
Radiation Female I 1.35 1.05 1.60 
Radiation Female II 0.91 0.65 1.23 
Radiation Female III 1.04 0.81 1.29 
Surgery* Male* IV* 1 - - 
Chemotherapy Female I 1.53 1.14 1.82 
Chemotherapy Female II 1.03 0.74 1.35 
Chemotherapy Female III 1.29 1.02 1.52 
Surgery* Male* IV* 1 - - 
No Treatment Female I 1.12 0.91 1.33 
No Treatment Female II 1.16 0.89 1.41 
No Treatment Female III 1.14 0.91 1.36 
Surgery* Male* IV* 1 - - 
Radiation + Surgery Female I 0.95 0.61 1.39 
Radiation + Surgery Female II 0.94 0.60 1.39 
Radiation + Surgery Female III 1.07 0.72 1.47 
Surgery* Male* IV* 1 - - 
Radiation + Chemotherapy Female I 1.17 0.91 1.42 
Radiation + Chemotherapy Female II 0.99 0.76 1.27 
Radiation + Chemotherapy Female III 1.26 1.02 1.48 
Surgery* Male* IV* 1 - - 
Surgery + Chemotherapy Female I 0.99 0.67 1.38 
Surgery + Chemotherapy Female II 0.84 0.53 1.30 
Surgery + Chemotherapy Female III 1.25 0.86 1.63 
Surgery* Male* IV* 1 - - 
Radiation +Surgery + Chemotherapy Female I 0.62 0.38 1.11 
Radiation +Surgery + Chemotherapy Female II 0.68 0.43 1.14 
Radiation +Surgery + Chemotherapy Female III 1.27 0.90 1.61 
Surgery* Male* IV* 1 - - 
Note: * = The reference group LCI = Lower Confidence Interval, UCI = Upper Confidence 
Interval  
** Adjusted for morphology, grade, stage*grade, marital status, gender*marital status, age group, 
stage*age group, and race 
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Table 49: Gender and Marital Status Interaction Terms 
Significant Terms Extracted From the Full Model (MLR1) 
Odds Ratios and 95% Confidence Intervals by Treatment Group 
 
Treatment Type (Outcome) Interaction Term Odds Ratio 95% LCI 95% UCI 
 
       
Gender 
       Marital 
Status    
Radiation Female Single 0.73 0.53 1.05 
Radiation Female Married 0.88 0.71 1.10 
Radiation Female Separated 1.67 0.69 2.56 
Radiation Female Divorced 0.67 0.49 0.97 
Surgery* Male* Widowed* 1 - - 
Chemotherapy Female Single 1.12 0.82 1.44 
Chemotherapy Female Married 1.10 0.89 1.32 
Chemotherapy Female Separated 2.47 1.03 3.35 
Chemotherapy Female Divorced 1.04 0.77 1.34 
Surgery* Male* Widowed* 1 - - 
No Treatment Female Single 0.76 0.58 1.02 
No Treatment Female Married 0.94 0.78 1.12 
No Treatment Female Separated 1.89 0.85 2.69 
No Treatment Female Divorced 0.75 0.58 1.00 
Surgery* Male* Widowed* 1 - - 
Radiation + Surgery Female Single 0.75 0.42 1.33 
Radiation + Surgery Female Married 0.70 0.46 1.12 
Radiation + Surgery Female Separated 0.65 0.10 2.47 
Radiation + Surgery Female Divorced 0.65 0.37 1.20 
Surgery* Male* Widowed* 1 - - 
Radiation + Chemotherapy Female Single 0.83 0.62 1.14 
Radiation + Chemotherapy Female Married 0.78 0.63 0.99 
Radiation + Chemotherapy Female Separated 1.59 0.71 2.40 
Radiation + Chemotherapy Female Divorced 0.74 0.56 1.02 
Surgery* Male* Widowed* 1 - - 
Surgery + Chemotherapy Female Single 1.50 0.83 2.08 
Surgery + Chemotherapy Female Married 0.86 0.56 1.29 
Surgery + Chemotherapy Female Separated 1.52 0.35 3.00 
Surgery + Chemotherapy Female Divorced 0.69 0.40 1.25 
Surgery* Male* Widowed* 1 - - 
Radiation +Surgery + Chemotherapy Female Single 1.38 0.78 1.95 
Radiation +Surgery + Chemotherapy Female Married 1.07 0.72 1.47 
Radiation +Surgery + Chemotherapy Female Separated 2.27 0.57 3.65 
Radiation +Surgery + Chemotherapy Female Divorced 1.42 0.84 1.93 
Surgery* Male* Widowed* 1 - - 
Note: * = The reference group LCI = Lower Confidence Interval, UCI = Upper Confidence Interval  
** Adjusted for morphology, grade, stage, stage*grade, gender*stage, age group, stage*age group, and race 
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Table 50 displays the results for the interaction term of stage and age group for 
treatment groups containing statistically significant ORs.  The moderating variable of age 
group at the time of diagnosis demonstrated interaction between stage (independent 
variable) and the treatment group (outcome) based on the level of the moderator.  Lung 
cancer cases with stage I lung cancer were 78% less likely to receiving radiation therapy 
treatments for Age Group V (OR = 0.22, 95% CI 0.13 – 0.75) and 63% less likely for 
Age Group VI (OR = 0.37, 95% CI 0.24 – 0.79) as compared to receiving surgery.  This 
result was expected as radiation alone as a treatment for early stage lung cancer would 
not be the standard of care.  For the other age groups with stage I lung cancer receiving 
radiation, the results were not statistically significant.  Clinically, it would be predicted 
that the odds ratios for the youngest age group or Age Group 4 with early stage lung 
cancer would demonstrate a statistically significant decrease in the probability of 
receiving radiation alone but the results were not statistically significant (Table 50).   
For stage I lung cancer cases receiving radiation in combination with 
chemotherapy, there was a trend demonstrated that as age increased the ORs approached 
1.00.   Overall there was a decrease likelihood of being treated with chemotherapy 
combined with radiation.  For early stage disease the youngest age group was 85% less 
likely to receive chemotherapy combined with radiation with the oldest age group (age 
group VII) being 32% less likely to receive radiation in combination with chemotherapy 
after controlling for gender, morphology, gender*morphology, grade, gender*stage, 
stage*grade, gender*marital status, marital status, and race.  As shown in Table 50, 
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overall, the younger the early stage lung cancer case was,  the less likely the lung cancer 
case had of being treated with radiation or radiation in combination with chemotherapy as 
compared to receiving surgery.  
 
Table 50: Stage and Age Group at Diagnosis Interaction Terms  
Significant Terms Extracted From the Full Model (MLR1) 
Odds Ratios and 95% Confidence Intervals by Treatment Group 
 
Treatment Type (Outcome) Interaction Term Odds Ratio 95% LCI 95% UCI 
 Stage        Age Group    
Radiation I 4 0.08 0.03 1.14 
Radiation I 5 0.22 0.13 0.75 
Radiation I 6 0.37 0.24 0.79 
Radiation I 7 0.69 0.47 1.08 
Surgery* IV* 8* 1 - - 
Radiation III 4 0.31 0.14 1.08 
Radiation III 5 0.48 0.29 0.97 
Radiation III 6 0.71 0.46 1.13 
Radiation III 7 0.87 0.58 1.28 
Surgery* IV* 8* 1 - - 
Radiation + Chemotherapy I 4 0.15 0.07 0.92 
Radiation + Chemotherapy I 5 0.27 0.16 0.79 
Radiation + Chemotherapy I 6 0.42 0.26 0.88 
Radiation + Chemotherapy I 7 0.68 0.44 1.13 
Surgery* IV* 8* 1 - - 
Note: * = The reference group; LCI = Lower Confidence Interval, UCI = Upper Confidence 
Interval  Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - 
< 80 yrs), 8 = (> 80 - < 90 yrs).** Adjusted for gender, morphology, gender*morphology, grade, 
gender*stage, stage*grade, gender*marital status, marital status, and race 
 
  
Table 51 contains the results for the interaction terms of stage and grade.  There 
were no statistically significant ORs for Stage II at any level of Grade (the moderating 
variable) and was not presented in Table 51.  Stage I and Stage III with the moderating 
variable of Grade that contained statistically significant results for a treatment group are 
listed.  After adjustment for gender, morphology,  gender*stage, stage*age group, marital 
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status, gender*marital status, age group, and race, grade II stage I lung cancer cases as 
compared to other lung cancer cases were 65% less likely to receive chemotherapy (OR = 
0.35, 95% CI 0.20 – 0.93).  This particular result was not unexpected as early stage 
disease, as the standard of care is not to receive chemotherapy as the only treatment for 
lung cancer; grade moderated the relationship between stage and the treatment received.  
Stage III grade I lung cancer cases as compared to other lung cancer cases were 7 
times more likely (OR = 7.03, 95% CI 1.50 – 8.58) to receive radiation in combination 
with surgery after adjustment for gender, morphology, gender*stage, stage*age group, 
marital status, gender*marital status, age group, and race.  The moderating effect of grade 
on the independent and the outcome relationship was highly significant for stage III grade 
I but this relationship was not significant for stage III with grade II or III.  When 
considering just the ORs and not the confidence intervals this could be suggestive of a 
treatment difference base on grade as there was a trend of decreasing ORs with an 
increasing grade. 
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Table 51: Stage and Grade at Diagnosis Interaction Terms 
Significant Terms Extracted From the Full Model (MLR1) 
Odds Ratios and 95% Confidence Intervals by Treatment Group 
 
 
Treatment Type (Outcome) 
 
Interaction Term 
Odds 
Ratio 
95% 
LCI 
95% 
UCI 
 Stage     Grade    
Chemotherapy I I 0.69 0.35 1.37 
Chemotherapy I II 0.35 0.20 0.93 
Chemotherapy I III 0.35 0.20 0.90 
Surgery* IV* IV* 1.00 - - 
      
Radiation + Chemotherapy I I 0.34 0.17 1.01 
Radiation + Chemotherapy I II 0.29 0.17 0.83 
Radiation + Chemotherapy I III 0.30 0.18 0.82 
Surgery* IV* IV* 1.00 - - 
      
Radiation + Surgery III I 7.03 1.50 8.58 
Radiation + Surgery III II 2.83 0.75 4.16 
Radiation + Surgery III III 2.45 0.66 3.76 
Surgery* IV* IV* 1.00 - - 
Note: * = The reference group; LCI = Lower Confidence Interval, UCI = Upper Confidence 
Interval  
** Adjusted by gender, morphology, gender*morphology, gender*stage, gender*marital status, 
marital status, age group, stage*age group, and race. 
 
 
Section 3: Multinomial Logistic Regression Assessment of Fit 
The comparison of the residual analysis results for the multinomial logistic 
regression models for the individual treatment are given next three tables (Figures 11 – 
13). The results are given for the treatment groups of radiation therapy, chemotherapy, no 
treatment, radiation + surgery, radiation + chemotherapy, surgery + chemotherapy, and 
radiation + chemotherapy + surgery.  The Pearson residual is the residual divided by the 
variance for a particular observation and is the individual contribution to the Pearson Chi 
Square statistic.  The deviance residuals are a measure of the amount of deviance 
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contributed by the individual observation.  In each distribution, the residuals are centered 
about zero, do not demonstrate a distinctive trend, and are similar for each treatment 
outcome.   From the observed data of the residual patterns, the determination was made 
that the multiple logistic regression model was appropriate as a model for the research 
lung cancer data set. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Pearson and Deviance Residual Analysis 
Treatment Groups I, II, III with Treatment Group VIII (Surgery) as Reference 
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Figure 12: Pearson and Deviance Residual Analysis 
Treatment Groups IV and V with Treatment Group VIII (Surgery) as Reference 
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Figure 13: Pearson and Deviance Residual Analysis 
Treatment Groups VI and VII with Treatment Group VIII (Surgery) as Reference 
 
Section 4: The Random Effect Component  
 The statistical testing and analysis used in testing Hypothesis I also included a 
multinomial logistic regression model with a random effects component to investigate 
any random effect of state may have had on the model results.  The method used in SAS 
was the Proc Glimmix procedure that utilizes statistical modeling approach to account for 
random effects.  The ―random effect‖ procedure fit a random adjustment to the intercept 
of the model for the eight states in the cancer data set and estimates the variance of those 
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adjustments separately for each level of the response variable, treatment group.  In the 
Proc Glimmix procedure, the overall random effect of state was evaluated and in Table 
52, the estimates of the variance are given.  Because the variances do not demonstrate a 
wide range of variability, the random effect of eight states with respect to which 
treatment the lung cancer cases received meaning the heterogeneity (differences) was 
minimal.   
 
Table 52: Random Effect of State 
Covariance Parameter Estimates: Intercept Method 
 
Subject  
Random Effect 
Group 
Treatment Group Estimate 
 Standard 
 Error 
    
State Radiation 0.340 0.175 
State Chemotherapy 0.247 0.126 
State No Treatment 0.094 0.050 
State Radiation + Chemotherapy 0.091 0.060 
State Radiation + Surgery 0.331 0.168 
State Surgery + Chemotherapy 0.101 0.061 
State Radiation + Chemotherapy + Surgery 0.024 0.016 
Note: Surgery is the reference treatment group 
 
When comparing the model without the random effect of state ―Type III Analysis 
of Effects‖ for the full multinomial logistic regression model (Table 46) with the 
multinomial logistic regression model ―Type III Analysis of Effects‖ (Table 53) 
generated with a random effect of state; there were no significant differences in the p-
values of the independent and interaction terms. Therefore, evaluating the Type III tests 
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for the model with and without the random effect, as the p-values did not change, the 
overall conclusions drawn during the Hypothesis I testing could be that the random effect 
is not influencing the conclusions but the random effect should be account for/assessed.   
 
Table 53: Type 3 Analysis of Effects Main Effects and Interaction Terms* 
Multinomial Logistic Regression Model (MLR2) 
(Random Effect of State) 
 
Effect DF F Value Pr > F 
Gender 7 1.24 0.2739 
Morphology 21 71.78 <.0001 
Gender*Morphology  21 1.45 0.0851 
Grade 21 21.00 <.0001 
Stage 21 150.00 <.0001 
Gender*Stage 21 2.16 0.0015 
Stage*Grade 63 2.77 <.0001 
Marital Status 28 12.76 <.0001 
Gender*Marital Status 28 1.70 0.0115 
Age Group 28 39.88 <.0001 
Stage*Age Group  84 2.67 <.0001 
Race 14 5.40 <.0001 
           Note: Age Group and Marital Status at defined on/at Date of Diagnosis 
                                   * indicates interaction term  
 
 
 
Section 5: Overall Effect of Interaction on the Outcome 
 
By convention, the Odds Ratios (ORs) for the main effects and interaction terms 
are reported in the literature as a statistic used to evaluate the effect of the independent 
variables on the outcome of interest.  In this section, the overall effect of interaction on 
the outcome of interest, treatment type received was also examined.  In this research, the 
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ORs for the interaction effect on the treatment received was also evaluated in order to 
perform a more complete assessment of the relationship between the overall effect 
variables with the outcome.  In determining the overall effect on the outcome, main 
effects and statistically significant interaction term variables that contained the variables 
of interest were included.  In the equation below, the expression used to determine the 
overall interaction effect from the full model (variables listed in Table 46) is given as: 
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI + 
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9 
stageI* age_groupI + 10 morphologyI + 11 raceI + others 
 
 Over the next section and in Appendix IV, the method used to calculate the Odds 
Ratios and 95% Confidence Internals are given for the variable combinations of gender, 
stage, marital status, grade and age group. The summary of the overall effect variable 
combinations are given in Table 54. The statistically significant results for the overall 
interaction effects are given in Tables 55 through 57-b. 
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Table 54: Overall Variable Effect on Lung Cancer (LC) Treatment Received 
Overall Interaction 
 Effect Variable 
Interaction Term      Odds Ratios 
Gender Gender1*StageI OR = exp (1 + 6) 
 Gender1*Marital Status1 OR = exp (1 + 7) 
Stage StageI*Gender1 OR = exp (2 + 6) 
 Stage1*GradeI OR = exp (2 + ) 
 StageI* Age Group1 OR = exp (2 + ) 
Marital Status Marital Status1*Gender1 OR = exp (3 + 7)  
Grade Grade1*StageI OR = exp (4 + 8).   
Age Group Age Group1*StageI OR = exp (5 + 9)  
        Note: Considering only Gender 1, Stage I, Grade I, Marital Status 1, Age Group 1 in this example; 
        where Gender 1 = female, Age Group 1 = Age Group IV, and Marital Status 1 = Single 
As previously discussed, a multinomial logistic regression model was utilized 
having eight treatment groups (Y). Surgery was the reference treatment group; therefore 
there were seven possible outcome categories or levels.  Also, there were four categories 
for stage (Stage IV = reference) and five categories for marital status (Marital Status V 
(Widowed) = reference).  An example is given next to show how the ―Gender Effect‖ 
Odds Ratios were calculated with the 95% Confidence Intervals for one of the treatment 
groups.  In the equations below, the treatment group is radiation (with surgery as the 
reference) with gender = 1 for females and gender = 0 for males given for stageI and 
marital_statusI.  The effect of gender on the probability of receiving radiation therapy as 
a treatment, given that the patient is at stageI, is determined as: 
Female: Logit (Y=Radiation|gender=1, stageI) =  + 1 + 2 stageI + 3 marital_statusI + 
4 *stageI + 5* marital_statusI 
 
Male: Logit (Y=Radiation|gender=0, stageI) =  +2 stageI + 3 marital_statusI    
By subtracting the Logit for males from Logit for females, the following equation 
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is given as: 
Logit (Y=Radiation |gender=1, stageI) = 1 + 4 *stageI     + 5* marital_statusI 
Next, at the variable stageI which is coded as 1 for stage I and 0 for stage IV 
(reference), the results are: 
   
Logit (Y=Radiation |gender=1, stageI=1) = 1 + 4      + 5* marital_statusI 
Logit (Y=Radiation |gender=1, stageI=0) = 1              + 5* marital_statusI 
 
 
Marital_statusI appears in both logits whether stageI is 1 or 0.  In other words, it 
does not matter whether the patient is single or married. This can also be stated as when 
the interaction between gender and stageI is examined, marital_status I is fixed or 
controlled for.  For estimating the effect of gender (female as compared to male) on the 
probability of receiving radiation treatment, given that the patient is at stage I (stage=1) 
and after adjusting for marital_status I , the resultant equation for the Odds Ratio is given 
as: OR = exp (1 + 4).  The Odds Ratios were calculated by exponentiating the beta 
coefficients for gender (female) plus the beta coefficient for the interaction term of 
gender (female)*stageI. The 95% lower (LCI) and upper (UCI) confidence intervals were 
calculated with the following equation: 
LCI, UCI = exp ((1 + 4) + (1.96* [(var (1) +var (4) + 2covar (1, 4)]
 0.5
)) 
  For each of the six other possible outcomes (treatment groups) remaining, each 
outcome (chemotherapy, no treatment, radiation + surgery, radiation + chemotherapy, 
surgery + chemotherapy, radiation + chemotherapy + surgery) would have twenty 
possible results (ORs and 95% CIs) based on the level of stage for a total of 21 possible 
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outcomes.  
As shown in Table 55 on the next page, females with stage I as compared with 
males with stage I are 1.71 times more likely to receive a combination of chemotherapy 
and radiation therapy versus receiving surgery alone (OR = 1.71, 95%CI 1.06 – 2.78) 
after adjustment.  In other words for patients with stage 1 lung cancer, females are 1.71 
times more likely to receive a combined chemotherapy and radiation therapy than males 
do.  After adjustment, stage 3 females as compared to males with stage 3 were 1.85 times 
more likely to receive radiation therapy in combination with chemotherapy versus 
receiving surgery alone for the treatment of lung cancer (OR = 1.854, 95%CI 1.151 – 
2.986).  The results for females with stage II versus males with stage II lung cancer were 
not statistically significant.  Also, none of the other six treatment types demonstrated 
statistically significant results.  
 
Table 55: Interaction Effect of Gender on LC Treatment Received 
Gender and Gender*Stage 
Treatment Group 5 (Radiation Therapy in Combination with Chemotherapy) 
 
    Odds Ratio 95% LCI 95% UCI 
Females with Stage I 
(Treatment Group 5) 1.71 1.06 2.78 
    
Females with Stage II 
(Treatment Group 5) 1.46 0.88 2.41 
    
Females with Stage III 
(Treatment Group 5) 1.85 1.15 2.99 
Reference for Gender = Males, Reference for Treatment Group = Surgery, Reference for Stage = Stage IV 
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Next, the effect of gender on the probability of receiving radiation therapy as a 
treatment, given that the patient is at marital_statusI, is determined as: 
Female: Logit (Y=Radiation|gender=1, marital_statusI) =  + 1 + 2 stageI + 3 
marital_statusI + 4 *stageI + 5* marital_statusI 
 
Male: Logit (Y=Radiation|gender=0, marital_statusI) =  +2 stageI + 3 marital_statusI    
By subtracting the Logit for males from Logit for females, the following equation 
is given as: 
Logit (Y=Radiation |gender=1, stageI) = 1 + 4 *stageI + 5* marital_statusI 
At the variable marital_statusI which is coded as 1 for marital_statusI and 0 for 
marital_statusI (V = reference), the results are: 
   
Logit (Y=Radiation |gender=1, marital_statusI =1) = 1  + 4 *stageI         + 5 
Logit (Y=Radiation |gender=1, marital_statusI =0) = 1  + 4 *stageI       
 
Thus, from above stageI appears in both logits whether marital_statusI is 1 or 0. 
That is, it does not matter whether the patient is stage 1 or stage III.  Another way of 
stating this fact is that when the interaction between gender and marital_statusI is looked 
at, stageI is fixed or controlled for.  For estimating the effect of gender (female as 
compared to male) on the probability of receiving radiation treatment, given that the 
patient is at marital_statusI and after adjusting for stageI (stage=1), the resultant equation 
for the Odds Ratio is given as: OR = exp (1 + 5).   
For each of the six other possible outcomes (treatment groups) remaining, each 
outcome (chemotherapy, no treatment, radiation + surgery, radiation + chemotherapy, 
surgery + chemotherapy, radiation + chemotherapy + surgery) would have OR’s and 95% 
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CIs based on the level of marital status for a total of 28 possible outcomes.  The overall 
gender effect from gender and the interaction term of gender*marital status was also 
calculated for the treatment received.  There were no statistically significant results.  
 
Overall Effect of Stage on the Treatment Received 
 In the next three tables (Tables 56-a, 56-b, 56-c), the statistically significant ORs 
and 95% CIs for the interaction effect of ―stage‖ on the outcome are given.  In Table 56-
a, the interaction between stage and gender is examined with grade and age group at the 
time of diagnosis being controlled for.  As noted in the table, all the ORs demonstrate a 
decrease probability to receive a particular treatment for females as compared to males. 
Females as compared to males with stage 1 and stage 2 lung cancer are less likely to 
receive one of the seven treatment types.  The ORs range from 0.008 to 0.137 for stage 1 
and 0.023 to 0.929 for stage II lung cancer. After adjustment, females versus males with 
stage I lung cancer are 86.3% less likely to receive a combination of surgery and 
chemotherapy (OR = 0.137, 95% CI 0.103 – 0.782).  For stage 2 lung cancer, females as 
compared to males are 73.1% less likely to receive surgery in combination with 
chemotherapy (OR = 0.269, 95% CI 0.191 – 0.380).   Stage 3 lung cancer females versus 
males after controlling for grade and age group, result in four treatment types (radiation, 
chemotherapy, no treatment and radiation in combination with chemotherapy) in which 
females can be up to 98% less likely to receive one of those four particular treatments.  
For example, females versus males with stage 3 lung cancer are 91.6% less likely to 
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receive radiation alone as their treatment for lung cancer (OR = 0.84, 95% CI 0.070 – 
0.102) after adjustment.  Also, contrary to the previous tables being presented with two 
significant figures, to see the variability between the statistics, the tables (Tables 56-a 
through Table 56-f-2) are presented to the third significant figure. 
 
 
 
Table 56-a: Interaction Effect of Stage on LC Treatment Received 
Stage and Stage*Gender 
 
Treatment Type (Outcome) Stage Gender OR 95% LCI 95% UCI 
Radiation  I  Female 0.019 0.016 0.023 
Chemotherapy   0.008 0.006 0.009 
No Treatment   0.019 0.016 0.022 
Radiation + Surgery   0.074 0.054 0.103 
Radiation + Chemotherapy   0.013 0.011 0.015 
Surgery + Chemotherapy   0.137 0.103 0.182 
Radiation +Surgery + Chemotherapy   0.032 0.022 0.046 
Radiation  II Female 0.029 0.022 0.037 
Chemotherapy   0.023 0.018 0.029 
No Treatment   0.037 0.030 0.044 
Radiation + Surgery   0.329 0.235 0.461 
Radiation + Chemotherapy   0.047 0.038 0.058 
Surgery + Chemotherapy   0.269 0.191 0.380 
Radiation +Surgery + Chemotherapy   0.189 0.133 0.267 
Radiation   III Female 0.084 0.070 0.102 
Chemotherapy   0.092 0.077 0.109 
No Treatment   0.092 0.078 0.108 
Radiation + Chemotherapy   0.019 0.016 0.023 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Gender = Males 
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 The statistically significant ORs and 95%CIs for Table 56-b-1, 56-b-2, and 56-b-3 
are given for the effect of stage on the probability of receiving a particular lung cancer 
given the lung cancer case is at a specific grade.  After adjustment, for stage 1 grade 1 
lung cancer cases as compared to stage 4 grade 4 lung cancer cases, stage 1 grade 1 lung 
cancer cases are 98.9% less likely to receive chemotherapy alone (OR = 0.011, 95% CI 
0.007 – 0.017) or 88.1% less likely to receive radiation in combination with surgery (OR 
= 0.119, 95% CI 0.050 – 0.286).   For grade 2 stages 1 though 3 (Table 56-b-2), once 
again there is a decreased probability to receive a particular treatment based on the ―stage 
effect‖ as compared to receiving surgery alone as the treatment for lung cancer.  For stage 
1 grade 2 and stage 2 grade 2, there are seven treatment types given as possible outcomes 
with four treatment types (radiation chemotherapy no treatment and radiation in 
combination with chemotherapy) for stage 3 grade 2.  In Table 56-b-3, there are seven 
treatment type outcomes for stage 1 grade 3 and stage 2 grade 3 and five treatment 
outcomes for stage 3 grade 3.  For all ―Stage Effects‖ in Tables 56-b-1through 56-b-3 
there is a decrease probability to receive the particular treatment type listed, in other 
words for effect of stage does not increase the probability of receiving a treatment type.  
Also as the stage of the lung cancer patient increases there is a trend of increasing ORs. 
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Table 56-b-1: Overall Interaction Effect of Stage on LC Treatment Received 
Stage and Stage*Grade (Grade I) 
 
Treatment Type (Outcome) Stage Grade OR 95% LCI 95% UCI 
Radiation   I I 0.025 0.017 0.037 
Chemotherapy   0.011 0.007 0.017 
No Treatment   0.032 0.024 0.045 
Radiation + Surgery   0.119 0.050 0.286 
Radiation + Chemotherapy   0.012 0.008 0.020 
Surgery + Chemotherapy   0.126 0.067 0.238 
Radiation +Surgery + Chemotherapy   0.070 0.028 0.172 
Radiation   II   I 0.047 0.027 0.083 
Chemotherapy   0.028 0.015 0.053 
No Treatment   0.050 0.032 0.076 
Radiation + Chemotherapy   0.061 0.037 0.101 
Surgery + Chemotherapy   0.312 0.146 0.668 
Radiation +Surgery + Chemotherapy   0.150 0.044 0.503 
Radiation  III  I 0.221 0.138 0.352 
Chemotherapy   0.129 0.077 0.215 
No Treatment   0.184 0.123 0.274 
Radiation + Chemotherapy   0.474 0.314 0.716 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV 
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Table 56-b-2: Interaction Effect of Stage on LC Treatment Received 
Stage and Stage* Grade (Grade II) 
 
Treatment Type (Outcome) Stage Grade OR 95% LCI 95% UCI 
Radiation I II 0.016 0.013 0.019 
Chemotherapy   0.005 0.004 0.007 
No Treatment   0.018 0.015 0.021 
Radiation + Surgery   0.081 0.057 0.116 
Radiation + Chemotherapy   0.010 0.008 0.013 
Surgery + Chemotherapy   0.095 0.068 0.133 
Radiation +Surgery + Chemotherapy   0.038 0.025 0.058 
Radiation II II 0.039 0.030 0.050 
Chemotherapy   0.023 0.017 0.031 
No Treatment   0.037 0.030 0.046 
Radiation + Surgery   0.340 0.234 0.495 
Radiation + Chemotherapy   0.051 0.040 0.065 
Surgery + Chemotherapy   0.277 0.190 0.402 
Radiation +Surgery + Chemotherapy   0.247 0.165 0.369 
Radiation III II 0.086 0.069 0.106 
Chemotherapy   0.065 0.052 0.082 
No Treatment   0.077 0.064 0.094 
Radiation + Chemotherapy   0.183 0.151 0.222 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
    Reference for Treatment Group = Surgery, Reference for Stage = Stage IV Reference for Grade = Grade IV 
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Table 56-b-3: Interaction Effect of Stage on LC Treatment Received 
Stage and Stage* Grade (Grade III) 
 
Treatment Type (Outcome) Stage Grade OR 95% LCI 95% UCI 
Radiation I III 0.016 0.014 0.019 
Chemotherapy   0.005 0.004 0.006 
No Treatment   0.017 0.015 0.020 
Radiation + Surgery   0.069 0.050 0.094 
Radiation + Chemotherapy   0.010 0.009 0.012 
Surgery + Chemotherapy   0.169 0.128 0.224 
Radiation +Surgery + Chemotherapy   0.039 0.028 0.054 
Radiation II III 0.023 0.018 0.028 
Chemotherapy   0.019 0.015 0.024 
No Treatment   0.030 0.025 0.036 
Radiation + Surgery   0.315 0.233 0.426 
Radiation + Chemotherapy   0.041 0.034 0.049 
Surgery + Chemotherapy   0.298 0.215 0.414 
Radiation +Surgery + Chemotherapy   0.237 0.178 0.316 
Radiation III III 0.072 0.061 0.085 
Chemotherapy   0.072 0.061 0.084 
No Treatment   0.081 0.070 0.095 
Radiation + Surgery   0.665 0.513 0.863 
Radiation + Chemotherapy   0.162 0.139 0.188 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV 
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Next in Tables 56-c-1 through 56-c-3, the effect of stage on the probability of the 
treatment received given the patient is at age group I are given.  For stage 1, there are 
seven possible outcomes with ORs ranging from 0.003 to 0.324 for age group 4, six 
outcomes for age group 5 (ORs range from 0.007 to 0.084), and 7 possible treatment 
outcomes for age group 6 and 7.  Note that these results are based on comparing the 
reference group of surgery for the treatment type, age group 8 as the reference for the age 
group at the time of diagnosis and stage 4 as the reference group for stage.  Table 56-c-2 
gives the statistics for stage 2 and age groups 4 through 7. There are 5 treatment 
outcomes dependent upon the effect of stage (Stage 2 and age groups 4, 5, and 6) and 
four treatment groups for stage 2 in age group 7 with the ORs ranging from 0.038 to 
0.080.  Stage 2 age group 7 lung cancer cases have a 92.0% less likely probability to 
receive radiation therapy alone (OR = 0.080, 95% CI 0.35 = 0.182) versus receiving 
surgery after controlling for gender and grade.  For stage 3, there are five possible 
treatment outcomes for age group 4 and 5 with age group 6 and 7 having four treatment 
types given with statistically significant ORs (Table 56-c-3).  For age groups 6 and 7, the 
treatment types are radiation, chemotherapy, no treatment and radiation in combination 
with chemotherapy.  The effect of stage on the treatment type received was to decrease 
the probability of receiving the treatment given in the tables.  It is interesting to report 
that the effect of stage does not increase the probability of receiving a particular treatment 
type given stage 1, 2 or 3.   
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Table 56-c-1: Interaction Effect of Stage on LC Treatment Received 
Stage and Stage*Age Group (Stage I) 
 
Treatment Type (Outcome) Age Group Stage Odds Ratio 95% LCI 95% UCI 
Radiation 4 I 0.003 0.001 0.010 
Chemotherapy   0.004 0.002 0.011 
No Treatment   0.016 0.007 0.033 
Radiation + Surgery   0.079 0.018 0.354 
Radiation + Chemotherapy   0.010 0.004 0.022 
Surgery + Chemotherapy   0.324 0.107 0.979 
Radiation + Chemotherapy + Surgery   0.073 0.021 0.258 
Radiation 5  0.008 0.004 0.017 
Chemotherapy   0.007 0.004 0.013 
No Treatment   0.017 0.009 0.030 
Radiation + Surgery   0.075 0.021 0.271 
Radiation + Chemotherapy   0.018 0.010 0.032 
Radiation + Chemotherapy + Surgery   0.084 0.030 0.235 
Radiation 6  0.014 0.007 0.026 
Chemotherapy   0.013 0.007 0.022 
No Treatment   0.024 0.014 0.040 
Radiation + Surgery   0.129 0.038 0.443 
Radiation + Chemotherapy   0.027 0.016 0.047 
Surgery + Chemotherapy   0.308 0.132 0.716 
Radiation + Chemotherapy + Surgery   0.104 0.039 0.279 
Radiation 7  0.026 0.014 0.049 
Chemotherapy   0.014 0.008 0.025 
No Treatment   0.024 0.014 0.041 
Radiation + Surgery   0.130 0.038 0.445 
Radiation + Chemotherapy   0.045 0.027 0.076 
Surgery + Chemotherapy   0.315 0.133 0.744 
Radiation + Chemotherapy + Surgery   0.137 0.052 0.365 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV 
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 
80 - < 90 yrs) 
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Table 56-c-2: Interaction Effect of Stage on LC Treatment Received 
Stage and Stage*Age Group (Stage II) 
 
Treatment Type (Outcome) Age Group Stage Odds Ratio 95% LCI 95% UCI 
Radiation 4 II 0.009 0.003 0.034 
Chemotherapy   0.012 0.004 0.040 
No Treatment   0.024 0.010 0.060 
Radiation + Chemotherapy   0.014 0.005 0.038 
Radiation + Chemotherapy + Surgery   0.092 0.011 0.739 
Radiation 5  0.025 0.010 0.062 
Chemotherapy   0.020 0.008 0.050 
No Treatment   0.026 0.012 0.055 
Radiation + Chemotherapy   0.025 0.011 0.058 
Radiation + Chemotherapy + Surgery   0.106 0.015 0.746 
Radiation 6  0.043 0.018 0.098 
Chemotherapy   0.037 0.015 0.087 
No Treatment   0.037 0.018 0.076 
Radiation + Chemotherapy   0.039 0.017 0.086 
Radiation + Chemotherapy + Surgery   0.131 0.019 0.906 
Radiation 7  0.080 0.035 0.182 
Chemotherapy   0.042 0.018 0.099 
No Treatment   0.038 0.019 0.077 
Radiation + Chemotherapy   0.064 0.029 0.141 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV 
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = 
(> 80 - < 90 yrs) 
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Table 56-c-3: Interaction Effect of Stage on LC Treatment Received 
Stage and Stage*Age Group (Stage III) 
 
Treatment Type (Outcome) Age Group Stage Odds Ratio 95% LCI 95% UCI 
Radiation 4 III 0.013 0.004 0.043 
Chemotherapy   0.034 0.012 0.098 
No Treatment   0.061 0.027 0.139 
Radiation + Chemotherapy   0.048 0.019 0.119 
Radiation + Chemotherapy + Surgery   0.168 0.032 0.874 
Radiation 5  0.034 0.016 0.073 
Chemotherapy   0.055 0.025 0.119 
No Treatment   0.066 0.034 0.126 
Radiation + Chemotherapy   0.087 0.043 0.177 
Radiation + Chemotherapy + Surgery   0.193 0.044 0.849 
Radiation 6  0.058 0.029 0.115 
Chemotherapy   0.101 0.050 0.205 
No Treatment   0.094 0.051 0.172 
Radiation + Chemotherapy   0.135 0.070 0.261 
Radiation 7  0.109 0.056 0.212 
Chemotherapy   0.116 0.058 0.232 
No Treatment   0.096 0.053 0.175 
Radiation + Chemotherapy   0.222 0.116 0.426 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV 
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 
80 - < 90 yrs) 
 
 
 
Overall Effect of Marital Status on the Treatment Received 
 For the effect of marital status on the probability of receiving a particular 
treatment given that the patient is female, Table 56-d demonstrates statistically significant 
ORs and 95% CIs for married, separated and divorced patients.  Females versus males 
that were married were 48.2% less likely to receive radiation (OR = 0.518, 95%CI 0.388 
– 0.690) or 45.3% less likely to receive no treatment (OR = 0.547, 95% CI 0.433 – 
0.691).  Married females versus married males were 2.144 more likely to receive surgery 
in combination with chemotherapy after adjustment.  Also divorced females as compared 
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to males that were divorced were 1.738 time more likely to receive surgery in 
combination with chemotherapy.  There was a probability of receiving no treatment for 
females versus males that were separated by as much as 72.8% (OR = 0.493, 95% CI 
0.274 – 0.887). 
 
Table 56-d: Interaction Effect of Marital Status on LC Treatment Received 
Marital Status and Marital Status *Gender 
 
Treatment Type (Outcome) Gender Marital Status Odds Ratio 95% LCI 95% UCI 
Radiation Female Married 0.518 0.388 0.690 
No Treatment   0.547 0.433 0.691 
Surgery + Chemotherapy   2.144 1.335 3.444 
      
No Treatment Female Separated 0.493 0.274 0.887 
      
Surgery + Chemotherapy Female Divorced 1.738 1.012 2.985 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Marital Status = 
Widowed 
 
 
Overall Effect of Grade on the Treatment Received 
In examining the effect of grade on the probability of receiving a particular 
treatment type, for stage 1, 2, and 3, there is a decreased probability in all instances listed 
in Table 56-e-1.   For stages 1, 2 and 3, there are seven possible treatment outcomes for 
grade 1.  As the severity of the grade increase, there are less treatment types given as 
outcomes that are statistically significant.  For grade 2 stage 1, there are two statistically 
significant ORs/95% CIs for the treatment types of chemotherapy and radiation in 
combination with chemotherapy. In Table 56-e-3, the effect of grade 3 on the probability 
210 
of the treatment type received are given. For grade 3 stage 1 there 1 treatment type listed 
that is statistically significant (radiation in combination with chemotherapy) and three 
treatment types for stage 2 grade 3 and stage 3 grade 3.  The ORs for grade 3 range from 
a minimum 0.385 to a maximum of 0.570. 
 
Table 56-e-1: Overall Interaction Effect of Grade on LC Treatment Received 
Grade and Stage*Grade (Grade I) 
 
Treatment Type (Outcome) Stage Grade Odds Ratio 95% LCI 95% UCI 
Radiation I I 0.445 0.267 0.741 
Chemotherapy   0.254 0.157 0.411 
No Treatment   0.526 0.372 0.744 
Radiation + Surgery   0.320 0.113 0.901 
Radiation + Chemotherapy   0.127 0.080 0.202 
Surgery + Chemotherapy   0.331 0.179 0.613 
Radiation + Chemotherapy + Surgery   0.300 0.118 0.761 
Radiation II  0.297 0.168 0.528 
Chemotherapy   0.129 0.076 0.218 
No Treatment   0.299 0.191 0.469 
Radiation + Surgery   0.224 0.065 0.765 
Radiation + Chemotherapy   0.107 0.066 0.173 
Surgery + Chemotherapy   0.247 0.108 0.565 
Radiation + Chemotherapy + Surgery   0.158 0.053 0.472 
Radiation III  0.327 0.187 0.572 
Chemotherapy   0.130 0.079 0.211 
No Treatment   0.295 0.191 0.457 
Radiation + Surgery   0.190 0.056 0.644 
Radiation + Chemotherapy   0.112 0.071 0.178 
Surgery + Chemotherapy   0.434 0.193 0.973 
Radiation + Chemotherapy + Surgery   0.159 0.055 0.462 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV 
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Table 56-e-2: Overall Interaction Effect of Grade on LC Treatment Received 
Grade and Stage*Grade (Grade II) 
 
Treatment Type (Outcome) Stage Grade Odds Ratio 95% LCI 95% UCI 
Chemotherapy I II 0.380 0.211 0.682 
Radiation + Chemotherapy   0.210 0.118 0.373 
Radiation II  0.496 0.313 0.786 
Chemotherapy   0.193 0.128 0.290 
No Treatment   0.431 0.312 0.596 
Radiation + Chemotherapy   0.177 0.125 0.251 
Surgery + Chemotherapy   0.343 0.197 0.600 
Radiation + Chemotherapy + Surgery   0.322 0.145 0.716 
Radiation III  0.545 0.331 0.897 
Chemotherapy   0.194 0.127 0.296 
No Treatment   0.426 0.293 0.618 
Radiation + Chemotherapy   0.186 0.126 0.273 
Radiation + Chemotherapy + Surgery   0.326 0.139 0.765 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV 
 
 
 
 
 
 
Table 56-e-3: Overall Interaction Effect of Grade on LC Treatment Received 
Grade and Stage*Grade (Grade III) 
 
 
Treatment Type (Outcome) Stage Grade Odds Ratio 95% LCI 95% UCI 
Radiation + Chemotherapy I III 0.434 0.246 0.765 
Chemotherapy II  0.401 0.255 0.632 
Radiation + Chemotherapy   0.366 0.245 0.547 
Surgery + Chemotherapy   0.325 0.168 0.627 
Chemotherapy III  0.403 0.278 0.584 
Radiation + Chemotherapy   0.385 0.277 0.533 
Surgery + Chemotherapy   0.570 0.331 0.982 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV 
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Overall Effect of Age Group on the Treatment Received 
In the next two tables, Tables 57-a and 57-b, the effect of age group of the 
probability of receiving a particular treatment type given the patient is at stageI are given.  
These tables display statistics that show not only a decreased probability of receiving a 
specific treatment but also an increased probability to receive a particular treatment based 
on the overall interaction effect of age group.  For age group 4 and 5, there is an 
increased probability to receive surgery + chemotherapy as well as radiation + 
chemotherapy + surgery for all stages (stages 1, 2, and 3).   For stage 1 age group 4 
patients, there is a 5.716 times increased in the risk to receive surgery in combination 
with chemotherapy and a 7.975 increase risk to receive radiation in combination with 
surgery plus chemotherapy.  Of all age groups, the maximum risk (OR = 11.377, 95% CI 
3.387 – 38.214) to receive a particular treatment (radiation + chemotherapy + surgery) is 
for age group 4 stage 3 lung cancer patients.  There is a decrease probability to receive 
radiation or no treatment for age groups 4, 5, 6, and 7 for all three stages of lung cancer 
(Tables 57-a and 57-b) after adjustment.  The ORs range from 0.044 for age group 6 
stage 1 to 0.382 for age group 4 stage 3.  Age group seven is the only age group that lists 
ORs that a show a decreased risk to receive a given treatment type.  This could be 
indicative of that as patients’ age - patients are not treated as aggressively.   
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Table 57-a: Interaction Effect of Age Group on LC Treatment Received 
Age Group and Stage*Age Group (Age Group 4 and Age Group 5) 
 
Treatment Type (Outcome) Stage Age Group OR 95% LCI 95% UCI 
Radiation I 4 0.085 0.035 0.210 
No Treatment   0.278 0.191 0.406 
Surgery + Chemotherapy    5.716 2.930 11.150 
Radiation + Chemotherapy + Surgery    7.975 2.419 26.285 
Radiation II 4 0.225 0.118 0.429 
No Treatment   0.299 0.171 0.525 
Radiation + Surgery   3.260 1.136 9.356 
Surgery + Chemotherapy   7.375 2.851 19.082 
Radiation + Chemotherapy + Surgery   9.164 2.650 31.688 
Radiation III 4 0.382 0.219 0.667 
No Treatment   0.426 0.255 0.712 
Radiation + Surgery   5.636 2.084 15.245 
Radiation + Chemotherapy   2.313 1.313 4.074 
Surgery + Chemotherapy   5.429 2.212 13.328 
Radiation + Chemotherapy + Surgery   11.377 3.387 38.214 
Radiation I 5 0.057 0.020 0.161 
Chemotherapy   0.340 0.138 0.837 
No Treatment   0.211 0.112 0.397 
Radiation + Chemotherapy   0.409 0.195 0.859 
Surgery + Chemotherapy   3.110 1.140 8.488 
Radiation + Chemotherapy + Surgery   4.624 1.194 17.914 
Radiation II 5 0.150 0.103 0.217 
Chemotherapy    0.542 0.339 0.867 
No Treatment   0.226 0.179 0.286 
Surgery + Chemotherapy   4.013 2.243 7.181 
Radiation + Chemotherapy + Surgery   5.314 1.841 15.343 
Radiation III 5 0.254 0.173 0.371 
No Treatment   0.322 0.233 0.445 
Radiation + Surgery   4.125 1.822 9.338 
Surgery + Chemotherapy   2.954 1.427 6.116 
Radiation + Chemotherapy + Surgery   6.597 2.162 20.129 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV 
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs) 
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Table 57-b: Interaction Effect of Age Group on LC Treatment Received 
Age Group and Stage*Age Group (Age Group 6 and Age Group 7) 
 
Treatment Type (Outcome) Stage Age Group OR 95% LCI 95% UCI 
Radiation I 6 0.044 0.016 0.122 
Chemotherapy   0.252 0.104 0.611 
No Treatment   0.187 0.101 0.345 
Radiation + Chemotherapy   0.250 0.121 0.516 
Surgery + Chemotherapy   2.915 1.111 7.650 
Radiation II 6 0.115 0.072 0.184 
Chemotherapy   0.402 0.233 0.692 
No Treatment   0.201 0.141 0.288 
Radiation + Chemotherapy   0.457 0.292 0.714 
Surgery + Chemotherapy   3.762 1.793 7.892 
Radiation III 6 0.196 0.152 0.251 
No Treatment   0.286 0.241 0.340 
Radiation + Chemotherapy   0.705 0.520 0.954 
Surgery + Chemotherapy   2.769 1.579 4.856 
Radiation + Chemotherapy + Surgery   3.002 1.063 8.476 
Radiation I 7 0.045 0.016 0.125 
Chemotherapy   0.206 0.085 0.500 
No Treatment   0.220 0.120 0.403 
Radiation + Chemotherapy   0.161 0.078 0.331 
Radiation II 7 0.119 0.075 0.188 
Chemotherapy   0.329 0.192 0.564 
No Treatment   0.236 0.166 0.335 
Radiation + Chemotherapy   0.294 0.189 0.457 
Radiation III 7 0.201 0.145 0.280 
Chemotherapy   0.608 0.395 0.938 
No Treatment   0.336 0.258 0.438 
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV 
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs) 
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Hypothesis I Conclusion 
 
In conclusion, in testing Hypothesis I, the null hypothesis of no differences in 
treatment outcomes between men and women, was rejected as there were statistically 
significant results when the overall gender effect was examined.  A multinomial logistic 
regression model was used to test Hypothesis I for differences between men and women 
with the same histological type, stage, and grade of lung cancer and the treatment they 
received.   
When considering the random effect that state may have made on the conclusions, 
the reported estimates of the variances demonstrated that there was minimal 
heterogeneity due to the states with regard to which treatment modality the lung cancer 
cases received.  Also when comparing the p-values for the Type III tests for the model 
with and without the random effect, the overall conclusions drawn during Hypothesis I 
testing did not change.  Although it could be said the random effect was not influencing 
the overall conclusions, the random effect should be assessed for the possible impact on 
the resultant analyses.  
Lastly, when the overall interaction effect of gender, stage, grade, marital status 
and age groups on the treatment received was examined, a complete assessment of the 
outcome was given.  For example, utilizing gender and the interaction terms of 
gender*stage and gender*marital status, statistically significant ORs and 95% CIs were 
demonstrated for an increased or risk to receive a particular treatment modality based on 
gender and a specific stage classification.   
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Hypothesis II  
There is a statistically significant difference in survival between women with lung 
cancer as compared to the survival of men with lung cancer.  
Introduction and Survival Analysis 
During hypothesis testing, the purpose for Hypothesis 2 was to examine if there 
was or was not an association between gender and survival without adjustment for the 
other research covariates in the lung cancer data set.  To test Hypothesis II and assess the 
relationship between gender groups and survival, a non-parametric survival method, the 
Life Table (Actuarial) method was utilized.   The life table method is appropriate for 
large data sets with grouped data and the observation times are subdivided into intervals 
of fixed length.  Table 58 lists the results of the survival distribution function generated 
by the Life Table method.   Although three test statistics (the log-rank, the Wilcoxon, and 
-2Log (LR)) were generated for the survival distribution function, the log-rank test 
statistic was selected as the standard reporting statistic.  This particular statistic gives 
equal weight to every lung cancer case death time.  The other two statistics adjust for 
differences in the survival distribution function depending upon the time of the death in 
the time, i.e. the event (death) will be weighted.  The log-rank test statistic was 
significant with a p-value less than 0.0001 which could be interpreted as a difference 
existed in survival between men and women.   
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Table 58: Lung Cancer Survival 
Survival Distribution Function 
              Testing the Equality over Gender 
 
Life Table Method 
Test 
Chi-
Square DF* 
Chi-Square 
P Value 
Log-Rank 213.70 1 <.0001 
*DF = Degrees of Freedom 
 
The graph of the survival function or cumulative survival, S(t) for Life Table 
method is shown below in Figure 14.  As displayed in the graph, with no adjustment, 
females had an increased probability of survival and survived longer than males.  The 
shape of the curves for the survival probability for males and females in Figure 14 were 
not the same, i.e. the curves did not overlay and did not cross.  ―If‖ the survival curves for 
females and males did overlay, this would suggest that there was no difference with a 
resultant ―failure to reject‖ the null hypothesis.  In Figure 14, any crossing of the gender-
specific survival curves could indicate changes in the survival patterns between males 
and females or possible interaction.  Also shown in Figure 14 after 10 months, the 
difference between the curves were approximately parallel over the 5 year time period; 
this suggested that the proportionality assumption was not violated meaning the hazard or 
risk of death did not change over time between the male and female lung cancer cases.  
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Figure 14: Life Table Method 
Survival Distribution Function 
 
 
Table 59 displays the summary of the number of lung cancer case that lived (no 
event = censored) and the number of lung cancer cases that died (event occurred = 
uncensored).  During survival statistical testing it was important to evaluate the number 
of cases that died and the number of cases that lived in the data set because if the number 
of lung cancer cases that lived were disproportional between the two groups (females and 
males) the resultant statistics could be biased and subsequent interpretations for 
Hypothesis II could be limited.   Table 59 gives the total number of females and male 
lung cancer cases in the lung cancer data set; overall 33.31% of the female lung cancer 
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cases did not die and 25.47% of the male lung cancer cases did not die over the study 5 
year time period.  In Table 59, although fewer males lived as compared to females 
(6333males vs. 6661females) when examining Table 59-a, the differences in the number of 
females and males that lived in time intervals (1 month intervals) was not 
disproportionate.  Overall,  the survival time consisted of 60 time intervals of one month, 
examples (Table 59-a) for the early time intervals and later time intervals are given for 
number of cases that died (d), the number of cases that survived (c) and the effective 
number of lung cancer cases at risk (n) in each time interval, I (one month).  Therefore, 
the difference between the number of female and male lung cancer cases that lived (c) 
would not impact or limit the interpretation of the survival results from Hypothesis II 
testing. 
 
 
Table 59: Survival Data for Lung Cancer Cases  
             Lung Cancer Distribution Summary 
 
   Total Total Percent 
Gender Total Died Lived Lived 
Female 19994 13333 6661 33.31 
Male 24869 18536 6333 25.47 
 Total 44863 31869 12994 28.96 
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Table 59-a: Extracted Life Table Survival Parameter Results   
Life Table Model for the Lung Cancer Data Set 
 
 Time Interval 
(months) 
Lower, Upper 
Number  
Failed 
(Died) 
Number  
Censored 
(Lived) 
Effective  
Sample 
Size 
   d c n 
 
 
 
Females 
 
 
 
 
 
0 1 2665 1436 19276.0 
1 2 1310 656 15565.0 
2 3 1082 452 13701.0 
3 4 967 379 12203.5 
4 5 821 363 10865.5 
56 57 7 12 1926.0 
57 58 4 11 1907.5 
58 59 4 10 1893.0 
59 60 1265 619 1574.5 
      
 
 
 
Males 
 
 
 
 
 
0 1 3672 1278 24230.0 
1 2 1877 641 19598.5 
2 3 1617 459 17171.5 
3 4 1445 375 15137.5 
4 5 1215 360 13325.0 
56 57 7 3 1971.5 
57 58 5 18 1954.0 
58 59 9 11 1934.5 
59 60 1394 526 1657.0 
Note: Originally there were 60 time intervals of 1 month 
 
In Table 60, the results for the quartile estimates and the 95% confidence intervals 
for the survival probabilities with the mean survival times are given for males and 
females lung cancer cases.  The confidence intervals are reported because each estimate 
of the survival probability contains random variation resulting in an inherent imprecision.  
When evaluating the ―Quartile Percents‖, the 50th percentile is of the greatest of interest 
as it represents the median survival time. The median survival time is defined as the 
survival time for a cumulative survival function of 0.5.  The median survival time for the 
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data set cannot be interpreted as that ―point in time‖ where 50% of the lung cancer cases 
survived; this would only be true if there were no censored observations prior to that 
―point in time‖, which was not the case.  Females had a median survival of 7.69 months 
with a 95% confidence interval of 7.46 to 7.95 months.  The median survival time for 
males was 6.30 months with a 95% confidence interval of 6.17 to 6.44 months; this was 
1.39 months less than the female median survival time.  Also shown in Table 60, the 
mean survival time for females is 19.83 months whereas the mean (or average) survival 
time for males was 16.37 months; females for this data set ―on average‖ lived 
approximately 3.01 months longer than the males.  
 
Table 60: Gender Survival Estimates (in months) 
             Summary Statistics of the Lung Cancer Distribution 
 
 Quartile 
Percent 
Point 
Estimate 
95% LCI 95% UCI Mean Standard 
Error 
Female 75 34.29 31.56 37.41   
 50 7.69 7.46 7.95 19.83 0.19 
 25 2.63 2.53 2.73   
       
Male 75 19.70 18.85 20.46   
 50 6.31 6.17 6.44 16.37 0.15 
 25 2.23 2.14 2.30   
 
 *LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
 
Another test statistic generated with the Life Table Method is the cumulative 
hazard function, CHF.  The cumulative hazard function corresponds to the total number 
of deaths over an interval of time.   In Figure 15, the graph of the cumulative hazard 
function is representative for the overall study time of 60 months.  The x-axis for the 
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overall time is annotated in ten month time intervals which are further subdivided into 
one month survival time intervals as noted on the graph as a circle (o) for females and a 
plus (+) for males.  The cumulative hazard function illustrates the probability for the 
outcome of interest, death and how that probability changes with time.  The cumulative 
probability of death increased for both females and males over the time interval in Figure 
15 with males having an increase in the probability of death as compared to females.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Cumulative Hazard Function for the Life Table Model 
Female and Males Lung Cancer Cases 
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When examining the cumulative hazard function plot a comprehensive 
representation of how the hazard is changing over time cannot be completely ascertained.   
Survival data are not normal and therefore to view the cumulative hazard function 
transforming the data with a logarithmic function allows for a more complete 
examination of the hazard between males and females.  As shown in Figure 16, after the 
6transformation of the data, the hazard is shown to remain constant between males and 
females over the time under study (see Figure 16).  This was important to examine 
(constant hazard) to ensure the assumption of proportionality was not violated, i.e. the 
probability of death was constant over the study time period between males and females.   
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Transformation of the Cumulative Hazard Function  
Female and Males Lung Cancer Cases 
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Hypothesis II Conclusion 
In conclusion, for Research Question Two, the null hypothesis was rejected as 
there were statistically significant differences in gender specific survival.  Women lung 
cancer cases had an increased probability of survival (a survival advantage) versus men 
with lung cancer.  It is reported in the literature that there is a distinct survival advantage 
for women with lung cancer as compared to men with lung cancer.  This result of 
increased survival for women was verified during Hypothesis II testing and analyses; 
these results are consistent with published literature.  
 
Hypothesis III  
Women with the same histological type, stage, grade of lung cancer, and the same 
treatment modality differ significantly in survival as compared to men with the same 
histological type, stage, and grade of lung cancer, and the same treatment modality.  
Introduction 
The third aim in testing the hypothesis of this research study was to expand the 
investigation of lung cancer treatment differences for females versus males in order to 
answer the research question of whether differences in treatment assignment based on 
gender altered survival.  For lung cancer cases, females have been shown to have a 
distinct survival advantage relative to males
8, 15,
 
17
.  The statistical modeling approaches 
that demonstrate this survival advantage for females do not account for any effects due to 
moderating variables on the relationship or association between the independent variable 
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of gender and survival.  The intent was to determine under which conditions females 
demonstrated or did not demonstrate a survival advantage as compared to males by 
investigating differences in gender-specific survival for men and women lung cancer 
cases grouped or stratified by treatment modality, histologic type, stage, grade and other 
research covariates and by expanding the modeling approach to include interaction terms.  
The research statistical approach to test Hypothesis 3 was to employ Survival 
Analysis or ―Time-to-Event‖ Analysis.  This technique can be applied to evaluate data 
that are censored (the research study event is not observed) and are not normal (lack of 
normality) due to censoring.  Under the conditions described in this research, the lung 
cancer data from the eight cancer registries were right censored.  Right censoring is 
defined as the non-observance of the study event, i.e. death, during a specified time 
range.  During the specified time frame (1-1-2000 through 12-31-2004) under study, any 
non-observed event (death) would classify that individual lung cancer case as censored.  
As stated in Chapter Three, the model selected to examine the relationship 
between survival and the covariates was the Cox Proportional Hazards model.  This 
particular model is categorized as semi-parametric as the baseline hazard is not specified 
but other assumptions such as time-invariant covariates across the study period are 
assumed.  Time-invariant covariates imply that the ratio of the hazard for any two 
observations is similar across the period of study.  Prior to hypothesis testing with the 
Cox Proportional Hazards statistical model, the first step to answer Research Question 
Three was to perform a preliminary ―Exploratory Univariate Survival Analysis‖ for the 
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individual categorical independent variables.  Commonly the ―Kaplan-Meier Survival 
Method’ is utilized but due to the large number of lung cancer cases with many failures in 
the data set (N =44,863) the ―Life Table Survival Method‖ was selected for the 
preliminary analyses
3
.  This initial or preliminary testing was done to evaluate the 
survival function and shape of the survival curves for each covariate over survival time.  
The survival curves for the groups or strata of the individual covariates were utilized to 
examine the proportionality between the strata (groups) for each variable.  When the 
groups or strata for the independent variable are proportional, the curves of the survival 
function graphs between the strata appear approximately parallel (the lines of the graphs 
do not diverge or do not cross).  After evaluating the survival function curves between 
gender vs. survival time, stage vs. survival time, grade vs. survival time, and morphology 
vs. survival time for the lung cancer cases diagnosed over the 5 year study period, it was 
determined that utilization of the Cox Proportional Hazard model was appropriate as the 
proportionality assumption held for gender, stage, grade, and morphology over survival 
time.  There were some overlapping survival curves for independent variables of age 
group at diagnosis, marital status at diagnosis, race, and treatment group over time which 
could have been problematic as the assumption of proportionality (constant hazard) could 
possibly be violated making the Cox Proportional Hazard model inappropriate to use with 
the lung cancer data set.  The initial non-proportionality concern was addressed later in 
this section with the variables (age group at diagnosis, marital status at diagnosis, race, 
                                                 
3
 Information from ―Analyzing Survival Data from Clinical Trials and Observational Studies‖ by Ettore 
Marubini and Maria Grazia Valsecchi; section 3.3.2., page 54. 
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and treatment group) being tested via residual analysis (results are shown in Figures 13 
and 14).   
During the initial phase of univariate survival analysis, the statistics generated by 
the ―Test of Equality over Strata‖ were used to evaluate any inequality across the strata 
for each independent categorical variable.  The lifetest procedure generated log-rank test 
statistic, with the p-values (<0.0001) being significant for gender, stage, grade, 
morphology, race, marital status at diagnosis, age group at diagnosis, and treatment 
group.  Table 61 contains the some of the results for the Life Table Method ―Tests of 
Equality over the Strata‖ and as noted above the p-values are significant.  A possible 
limitation of the statistical analysis for this data set for the highly significant p-values 
may not just be a result of a true null hypothesis (no difference) but rather may be 
attributed to the extremely large sample size (N = 44,863) influencing the statistics.  
 
Table 61: Life Table - Test of Equality over Strata 
 
Parameter Test Chi-Square Pr > Chi-Square 
    
Gender Log-Rank 206.90 < 0.0001 
Stage Log-Rank 502.70 < 0.0001 
Grade Log-Rank 844.80 < 0.0001 
Morphology Log-Rank 417.80 < 0.0001 
 
The next phase in testing Hypothesis 3 was assessing the research question by 
fitting the data to the Cox Proportional Hazard model which is a semi-parametric 
mathematical equation (the procedure in SAS is referred to as ―PROC PHREG‖).  During 
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the model build or selection of the covariates and interaction terms to be included in the 
final model, the ―Stepwise‖ procedure was utilized in a forward selection (alpha = 0.05) 
and backward elimination of the variable or interaction term if the significance level of 
0.05 was not met.  Four variables (gender, stage, grade, and morphology) were coded to 
remain in the model during the stepwise procedure without having to meet the entry and 
exit specifications of 0.05 as these were the primary variables under study.  At the 
completion of the stepwise procedure, the final model was assessed by examining the p-
values for the main effect variables and the variable combinations for the interaction 
terms.  Interaction terms were included in the final model so the effect of moderating 
variables that could impact the relationship between the independent variables and 
survival were identified.  Below in Table 61-a, the results of the Type III testing for the 
final model are given.  As shown Table 61-a, there were a total of six main effects 
variables and ten interaction terms.   
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Table 61-a: The Cox Proportional Hazards Model (CPHM1)  
Type 3 Tests - Final Model  
 
Effect DF 
Wald  
       Chi-Square Pr > ChiSq 
Gender 1 34.54 <.0001 
Morphology 3 17.21 0.0006 
Gender * Morphology 3 8.61 0.0350 
Grade 3 3.81 0.2823 
Grade * Morphology 9 29.34 0.0006 
Stage 3 92.72 <.0001 
Stage * Morphology 9 20.69 0.0141 
Age Group 4 64.69 <.0001 
Stage * Age Group 12 22.99 0.0278 
Race 2 4.14 0.1259 
Treatment Type 7 20.54 0.0045 
Gender * Treatment Type 7 23.01 0.0017 
Treatment Type * Morphology  21 73.18 <.0001 
Treatment Type * Grade  21 61.24 <.0001 
Treatment Type *  Stage  21 147.33 <.0001 
Treatment Type * Age Group  28 104.76 <.0001 
Treatment Type * Race  14 34.35 0.0018 
Note: Age Group at defined on/at Date of Diagnosis 
                * indicates interaction term  
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The extracted equation or expression from the Cox Proportional Hazards model would 
be: 
 
Hazard Rate = exp (1genderI + 2morphologyI + 3gradeI + 4stageI + 5age_groupI + 
6raceI + 7treatment_typeI + 8 genderI * morphologyI   + 9 gradeI * morphologyI + 
10 stageI * morphologyI + 11 stageI * age_groupI    + 12 genderI*treatment_typeI   + 
13 treatment_typeI * morphologyI+ 14 treatment_typeI * grade I   + 
15treatment_typeI* stageI    + 16treatment_typeI* age_groupI   + 
17treatment_typeI*raceI + others) 
 
The next three sections for Hypothesis III include 1) the interaction terms 
analysis, 2) the residuals analysis (model assessment), and 3) gives the results for the 
overall interaction effect on the probability of survival.  It was important to include the 
interaction terms analysis so a comparison of the results could be made to the overall 
interaction effect on the outcome.  
 
Section 1: Cox Proportional Hazards Model Interaction Terms 
In the next six tables (Tables 62- 67), the results of the final Cox Proportional 
Hazards Model (CPHM1) are given for the interaction terms extracted from the full 
model that contained statistically significant results.  When there were associations 
between the independent variable and the outcome of interest, survival, the relationship 
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varied at different levels dependent upon the effect modifier.  Interaction terms included 
in the statistical model (when appropriate) allowed for the opportunity to examine a more 
complete overview of the relationship between an independent variable and the outcome 
and how that relationship changes based on the moderating variable (effect modifier).  As 
stated previously during Hypothesis II testing, in the majority of the currently published 
literature of gender-specific survival, gender is evaluated as a main effect without 
interaction terms.  The survival estimates based on the information presented in that 
literature are reported favorably for women relative to men
8, 15,
 
17
.  In testing Hypothesis 
II, the results were consistent with the published literature that found females have a 
survival advantage over men.  Part of the research investigation of gender-specific 
survival was to verify that the results obtained from the lung cancer data set were 
consistent with other research results published in the current literature.  
The investigation of gender-specific survival was expanded during Hypothesis III 
testing. After adjustment for covariates, the relationship between gender-specific survival 
and the treatment received was analyzed.  As shown in the following tables (Tables 62 
through 67), there were increased hazard or increase risk of death based on treatment 
received.  The overall gender effect reported later in this section on survival will include 
the results for the terms containing gender; therefore the statistics for Table 62 will not be 
reviewed here. 
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Table 62: Hazard Ratios and 95% Confidence Intervals  
Interaction Term of Treatment Group and Gender 
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1) 
 
 
Interaction Terms** Hazard Ratio 95% LCI 95% UCI  
Gender 
(Moderator) 
Treatment Group 
    
Female Radiation 1.18 1.09 1.29 
Female Chemotherapy 1.16 1.07 1.26 
Female No Treatment 1.13 1.05 1.21 
Female Radiation + Surgery 1.13 0.96 1.34 
Female Radiation + Chemotherapy 1.18 1.09 1.27 
Female Surgery + Chemotherapy 1.11 0.93 1.33 
Female Radiation + Surgery + Chemotherapy 1.07 0.92 1.25 
Male* Surgery* 1.00* - - 
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference 
** Adjusted for morphology, gender * morphology, grade, grade * morphology, stage,  stage * 
morphology, age group, stage * age group, race, morphology * treatment type, grade * treatment type, 
stage * treatment type,  age group * treatment type, and  race * treatment type 
 
 
The results displayed in Table 63 are for the interaction term of treatment group 
and stage; stage is the moderator in this interaction term extracted from the full CPH 
model.  For the first treatment group of radiation therapy, lung cancer cases with stage 3 
were at a 20.0% decreased risk for death than those lung cancer cases receiving surgery 
after controlling for gender, morphology, gender * morphology, grade, grade * 
morphology, stage * morphology, age group, stage * age group, race, gender * treatment 
type, morphology * treatment type, grade * treatment type, age group * treatment type, 
and race * treatment type.  There are no trends or overall significant findings 
demonstrated for an increased or decreased risk in this treatment group (radiation) based 
on stage 1 or stage 2 for this disease.  In the case of chemotherapy (treatment group 2), 
233 
there is a decreasing risk of death as stage increases.  For stage 1 lung cancer cases 
receiving chemotherapy the risk of death was 1.68 times greater than those lung cancer 
cases receiving surgery after controlling for gender, morphology, gender * morphology, 
grade, grade * morphology, stage * morphology, age group, stage * age group, race, 
gender * treatment type, morphology * treatment type, grade * treatment type, age group 
* treatment type, and race * treatment type.   
Stage 2 lung cancer cases receiving chemotherapy were 1.44 times more likely to 
die than those lung cancer cases receiving surgery after adjustment.  Later stage lung 
cancer cases (stage 3) receiving chemotherapy were 7.0% less likely to die than those 
lung cancer cases receiving surgery after adjustment, although this was not statistically 
significant (HR = 0.93, 95% CI 0.81 - 1.06).  After controlling for gender, morphology, 
gender * morphology, grade, grade * morphology, stage * morphology, age group, stage 
* age group, race, gender * treatment type, morphology * treatment type, grade * 
treatment type, age group * treatment type, and race * treatment type, stage 1 (HR = 1.68, 
95% CI 1.41 - 1.99) and stage 2 (HR = 1.44, 95% CI 1.19 - 1.74) lung cancer cases were 
shown to be at a greater risk or hazard for death as opposed to lung cancer cases 
receiving surgery alone.  These findings are of particular interest as clinically early stage 
disease is associated with a decreased hazard for death and later stage disease has 
decreased survival.  Evaluation of the effects of the moderator (stage) in the relationship 
between treatment and survival after adjustment in the full model for this data set 
demonstrated that early stage lung cancer cases receiving chemotherapy had decreased 
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survival.   
For the next treatment group of ―no treatment‖, early stage lung cancer cases 
(stage 1) that received no treatment were 16.0% more likely to die (HR = 1.16, 95 % CI 
1.02 - 1.32) than those lung cancer cases receiving surgery alone after controlling for 
gender, morphology, gender * morphology, grade, grade * morphology, stage * 
morphology, age group, stage * age group, race, gender * treatment type, morphology * 
treatment type, grade * treatment type, age group * treatment type, and race * treatment 
type.  The risk of death increased by 46.0% for stage 2 lung cancer cases as compared to 
other lung cancer cases (HR = 1.46, 95 %CI 1.25 - 1.70) versus receiving surgery alone 
after adjustment.  Although the hazard ratio decreased for stage 3 disease, the result 
shown in Table 63 for stage 3 lung cancer cases receiving no treatment was not 
statistically significant (HR = 0.93, 95% CI = 0.82 - 1.06).  Once again it would be 
expected that later stage disease would have increased mortality; this was association was 
not demonstrated for those lung cancer cases in the no treatment group.  
The only statistically significant hazard ratio in treatment group 4 (radiation in 
combination with surgery) in Table 63, was for stage 3 lung cancer cases.  Lung cancer 
cases receiving radiation plus surgery were 26.0% less likely to die than those lung 
cancer cases receiving surgery after controlling for gender, morphology, gender * 
morphology, grade, grade * morphology, stage * morphology, age group, stage * age 
group, race, gender * treatment type, morphology * treatment type, grade * treatment 
type, age group * treatment type, and race * treatment type.  This result indicated that for 
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later stage disease the treatment combination of radiation and surgery improved survival.  
For early stage disease (Stage 1 and 2) lung cancer cases receiving chemotherapy plus 
radiation did not demonstrate a decrease in the risk of death (Table 63).  On the contrary, 
stage 1 lung cancer cases receiving this treatment combination were 43.0% more likely to 
die with stage 2 lung cancer cases being 31.0% more likely to die than those lung cancer 
cases receiving surgery after adjustment.  The trend of increasing stage having a 
decreased risk for death for the radiation plus chemotherapy treatment group was further 
demonstrated as stage 3 had an 11.0% decrease in the risk for death versus lung cancer 
cases receiving surgery after adjustment.  These results suggest that stage moderated the 
relationship between the treatment group and survival: earlier stage lung cancer cases 
have decreased survival when the treatment for the disease consists of radiation in 
combination with chemotherapy.  For the last two treatment groups (surgery + 
chemotherapy and radiation + chemotherapy + surgery) in Table 63, the only significant 
hazard ratio was for stage 1 lung cancer cases receiving all three treatment modalities of 
radiation, chemotherapy and surgery (HR = 1.79, 95% CI 1.31 – 2.44) as compared to 
lung cancer cases receiving surgery after controlling for gender, morphology, gender * 
morphology, grade, grade * morphology, stage * morphology, age group, stage * age 
group, race, gender * treatment type, morphology * treatment type, grade * treatment 
type, age group * treatment type, and race * treatment type.  This treatment group 
(radiation + surgery + chemotherapy) with stage 1 disease had the highest risk for death 
(79.0%) as compared to all the other treatment groups as shown in Table 63.    
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Table 63: Hazard Ratios and 95% Confidence Intervals  
Interaction Term of Treatment Group and Stage 
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1) 
 
Interaction Terms**  
Hazard 
Ratio 95% LCI 95% UCI  
 
Treatment Group 
 Stage 
(Moderator)    
Radiation I 1.03 0.89 1.19 
Chemotherapy I 1.68 1.41 1.99 
No Treatment I 1.16 1.02 1.32 
Radiation + Surgery I 1.28 0.97 1.68 
Radiation + Chemotherapy I 1.43 1.22 1.66 
Surgery + Chemotherapy I 1.25 0.95 1.64 
Radiation + Surgery + Chemotherapy I 1.79 1.31 2.44 
Surgery* IV* 1.00 - - 
Radiation II 1.10 0.92 1.32 
Chemotherapy II 1.44 1.19 1.74 
No Treatment II 1.46 1.25 1.70 
Radiation + Surgery II 1.07 0.82 1.41 
Radiation + Chemotherapy II 1.31 1.11 1.54 
Surgery + Chemotherapy II 1.01 0.72 1.41 
Radiation + Surgery + Chemotherapy II 1.27 0.95 1.71 
Surgery* IV* 1.00 - - 
Radiation III 0.80 0.69 0.92 
Chemotherapy III 0.93 0.81 1.06 
No Treatment III 0.93 0.82 1.06 
Radiation + Surgery III 0.74 0.59 0.92 
Radiation + Chemotherapy III 0.89 0.78 1.01 
Surgery + Chemotherapy III 0.90 0.71 1.14 
Radiation + Chemotherapy III 1.31 1.11 1.54 
Radiation + Surgery + Chemotherapy III 0.95 0.77 1.17 
Surgery* IV* 1.00 - - 
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference 
** Adjusted for gender, morphology, gender * morphology, grade, grade * morphology, stage * 
morphology, age group, stage * age group, race, gender * treatment type, morphology * treatment 
type, grade * treatment type,  age group * treatment type, and  race * treatment type 
 
 
Table 64 exhibits only one statistically significant hazard ratio for the interaction 
term of treatment group and grade.  Grade I lung cancer cases receiving chemotherapy 
had an increased risk of death with a hazard ratio of 1.51 (95% CI 1.12 - 2.03) relative to 
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lung cancer cases receiving surgery after controlling for gender, morphology, gender * 
morphology, grade * morphology, stage, stage * morphology, age group, stage * age 
group, race, gender * treatment type, morphology * treatment type, grade * treatment 
type, age group * treatment type, and race * treatment type.     For this data set and as 
shown in Table 64, there was only one statistically significant hazard ratio which may 
have been due to chance alone versus being truly significant for the relationship between 
treatment modality of chemotherapy and decreased survival moderated by the grade of 
disease. 
The hazard ratios and the 95% confidence intervals for the interaction term of 
treatment group and morphology are displayed in Table 65.  Morphology moderated the 
relationship between the independent variable treatment group and the outcome, survival.  
The finding that morphology acted as a moderator was consistent with clinical practices 
of treating a disease based on cell type with a particular treatment regimen. The statistics 
demonstrated that the treatment selection based on cell type could decrease survival or 
may not increase survival.  There were only three treatment groups (radiation, 
chemotherapy, and radiation in combination with chemotherapy) with statistically 
significant results meaning for a particular treatment group the hazard ratio and the 
confidence interval for that hazard ratio did not include 1.  For each of those three 
treatment groups, the hazard ratios demonstrated an increased risk for death or decreased 
survival for the lung cancer cases.  Lung cancer cases with adenocarcinoma receiving 
radiation were 45.0% more likely to die (HR = 1.45, 95% CI 1.03 – 2.04) as compared to 
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the other treatment groups with adenocarcinoma after controlling for gender, gender * 
morphology, grade, grade * morphology, stage, stage * morphology, age group, stage * 
age group, race, gender * treatment type, stage * treatment type, grade * treatment type, 
age group * treatment type, and race * treatment type.  The hazard ratio increased by 65% 
(HR = 1.65, 95% CI 1.17 – 2.33) for squamous cell lung cancer cases receiving radiation 
with a hazard ratio for large cell carcinoma increasing by 61% (HR = 1.61, 95% CI 1.14 
– 2.28) relative to lung cancer cases receiving surgery after adjustment.  For 
adenocarcinoma lung cancer cases receiving chemotherapy, the risk of death increased by 
42.0% than those lung cancer cases receiving surgery after adjustment.  The hazard ratio 
for squamous cell lung cancer receiving chemotherapy was 1.51 meaning there was a 
51.0% increase in the risk of death as compared to lung cancer cases receiving surgery 
after controlling for gender, gender * morphology, grade, grade * morphology, stage, 
stage * morphology, age group, stage * age group, race, gender * treatment type, stage * 
treatment type, grade * treatment type, age group * treatment type, and race * treatment 
type.  Radiation in combination with chemotherapy demonstrated the same trend of 
decreased survival for the lung cancer morphological types of adenocarcinoma, 
squamous cell, and large cell carcinoma.  Adenocarcinoma lung cancer cases receiving 
radiation plus chemotherapy were 48.0% (HR = 1.48, 95% CI 1.08 – 2.02) more likely to 
die with large cell lung cancer cases having a 62.0% increase risk for death (HR = 1.62, 
95% CI 1.18 – 2.24) than those lung cancer cases receiving surgery after adjustment.  
According to the statistics, chemotherapy, radiation, and chemotherapy in combination 
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with radiation decreased survival for all three lung cancer types.  In Table 65, the hazard 
ratios for radiation in combination with surgery was the one treatment group that did 
increase in survival (HR’s less than 1.00) for all three NSCLC types (adenocarcinoma, 
squamous, and large cell) as compared lung cancer cases receiving surgery but these 
results were not statistically significant as the 95% confidence intervals did include 1.  
For all other treatment groups (no treatment, surgery plus chemotherapy, and radiation in 
combination with surgery plus chemotherapy) listed in Table 65, the results were not 
statistically significant therefore an association between the treatment group and survival 
moderated by morphology was not demonstrated.    
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Table 64: Hazard Ratios and 95% Confidence Intervals  
Interaction Term of Treatment Group and Grade 
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1) 
 
Interaction Terms**  
Hazard 
Ratio 95% LCI 95% UCI  
 
Treatment Group 
 Grade 
(Moderator)    
Radiation I 1.03 0.76 1.41 
Chemotherapy I 1.51 1.12 2.03 
No Treatment I 1.05 0.81 1.38 
Radiation + Surgery I 0.66 0.34 1.27 
Radiation + Chemotherapy I 1.26 0.94 1.67 
Surgery + Chemotherapy I 1.22 0.69 2.17 
Radiation + Surgery + Chemotherapy I 0.92 0.5 1.71 
Surgery* IV* 1 - - 
Radiation II 0.93 0.71 1.23 
Chemotherapy II 1.09 0.84 1.41 
No Treatment II 1.06 0.84 1.36 
Radiation + Surgery II 0.89 0.52 1.53 
Radiation + Chemotherapy II 1.12 0.88 1.44 
Surgery + Chemotherapy II 0.97 0.6 1.59 
Radiation + Surgery + Chemotherapy II 0.97 0.61 1.54 
Surgery* IV* 1 - - 
Radiation III 0.92 0.7 1.2 
Chemotherapy III 0.89 0.7 1.14 
No Treatment III 1 0.79 1.26 
Radiation + Surgery III 0.91 0.54 1.55 
Radiation + Chemotherapy III 0.98 0.77 1.24 
Surgery + Chemotherapy III 0.98 0.61 1.56 
Radiation + Surgery + Chemotherapy III 0.82 0.52 1.28 
Surgery* IV* 1 - - 
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference 
** Adjusted for gender, morphology, gender * morphology, grade * morphology, stage,  stage * 
morphology, age group, stage * age group, race, gender * treatment type, morphology * 
treatment type, stage * treatment type,  age group * treatment type, and  race * treatment type 
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Table 65: Hazard Ratios and 95% Confidence Intervals  
Interaction Term of Treatment Group and Morphology 
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1) 
 
Interaction Terms**  
Hazard 
Ratio 95% LCI 95% UCI  
 
Treatment Group 
Morphology 
(Moderator)    
     
Radiation Adenocarcinoma 1.45 1.03 2.04 
Chemotherapy Adenocarcinoma 1.42 1.04 1.95 
No Treatment Adenocarcinoma 1.07 0.79 1.46 
Radiation + Surgery Adenocarcinoma 0.72 0.31 1.65 
Radiation + Chemotherapy Adenocarcinoma 1.48 1.08 2.02 
Surgery + Chemotherapy Adenocarcinoma 1.03 0.61 1.72 
Radiation + Surgery + Chemotherapy Adenocarcinoma 1.53 0.92 2.55 
Surgery* Small Cell* 1 - - 
Radiation Large Cell 1.61 1.14 2.28 
Chemotherapy Large Cell 1.43 1.03 1.97 
No Treatment Large Cell 1 0.72 1.37 
Radiation + Surgery Large Cell 0.82 0.35 1.91 
Radiation + Chemotherapy Large Cell 1.62 1.18 2.24 
Surgery + Chemotherapy Large Cell 0.97 0.57 1.66 
Radiation + Surgery + Chemotherapy Large Cell 1.43 0.84 2.42 
Surgery* Small Cell* 1 - - 
Radiation Squamous 1.65 1.17 2.33 
Chemotherapy Squamous 1.51 1.1 2.07 
No Treatment Squamous 1.16 0.85 1.58 
Radiation + Surgery Squamous 0.84 0.36 1.93 
Radiation + Chemotherapy Squamous 1.63 1.19 2.23 
Surgery + Chemotherapy Squamous 1.04 0.62 1.77 
Radiation + Surgery + Chemotherapy Squamous 1.58 0.94 2.64 
Surgery* Small Cell* 1 - - 
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference 
** Adjusted for gender, gender * morphology, grade, grade * morphology, stage,  stage * morphology, 
age group, stage * age group, race, gender * treatment type, grade * treatment type, stage * treatment 
type,  age group * treatment type, and  race * treatment type 
 
 
The hazard ratios for the interaction term of treatment group and age group in 
Table 66 displayed that age was a moderator in the association between the treatment 
received and survival.  Also in Table 66, the hazard ratios did not exhibit an increasing or 
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decreasing trend between the type of treatment received and survival.   For all levels of 
age group (4, 5, 6, and 7) lung cancer cases receiving radiation therapy as a treatment 
modality were at increased risk for death as compared to lung cancer cases receiving 
surgery after controlling for gender, morphology, gender * morphology, grade, grade * 
morphology, stage, stage * morphology, stage * age group, race, gender * treatment type, 
stage * treatment type, grade * treatment type, morphology * treatment type, and race * 
treatment type.  Lung cancer cases in age group 4 that received radiation were 1.38 times 
more likely to die than those lung cancer cases receiving surgery after adjustment.  All 
other age groups, 5 (HR = 1.51, 95% CI 1.27 – 1.81), 6 (HR = 1.27, 95% CI 1.10 – 1.46), 
and 7 (HR = 1.19, 95% CI 1.05 – 1.36) were at increased risk for death versus lung 
cancer cases receiving surgery after adjustment.   
The risk of death increased by 22.0% for lung cancer cases in age group 5 
receiving chemotherapy (HR = 1.22, 95% CI 1.03 – 1.45) versus lung cancer cases 
receiving surgery after adjustment (Table 66).  The variation of that risk was as small as 
3.0% to a maximum risk for death of 45.0%.  In Table 66, the no treatment group 
demonstrated a trend of decreasing risk of death with the HRs ranging from 1.65 to 1.23; 
as the lung cancer case became older the hazard ratio decreased but this was not 
statistically significant.  The only other treatment group with a statistically significant 
hazard ratio was the treatment group of radiation in combination with chemotherapy 
(Table 66).  Lung cancer cases that received radiation in combination with chemotherapy 
were 31.0% more likely to die (HR = 1.31, 95% CI 1.11 - 1.56) relative to lung cancer 
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cases receiving surgery after adjustment.  For all age groups in the other three treatment 
groups of 1) radiation plus surgery, 2) surgery in combination with chemotherapy, and 3) 
radiation plus surgery plus chemotherapy, the risk of death or hazard ratio was not 
statistically significant as compared to lung cancer cases receiving surgery after 
controlling for gender, morphology, gender * morphology, grade, grade * morphology, 
stage, stage * morphology, stage * age group, race, gender * treatment type, stage * 
treatment type, grade * treatment type, morphology * treatment type, and race * treatment 
type.  Age group moderated the relationship between treatment group and survival with 
the no treatment group overall having the highest risk of death.  Possible explanations of 
the no treatment group having the highest risk would include 1) those particular lung 
cancer cases did not receive one of the seven treatments for lung cancer because they 
were too sick for treatment or 2) the lung cancer case may have refused treatment for 
their disease.   Of the last four treatment groups (Radiation + Surgery, Radiation + 
Chemotherapy, Surgery + Chemotherapy, and Radiation + Chemotherapy + Surgery) 
shown in Table 66, the only treatment group moderated by age group that demonstrated a 
statistically significant hazard ratio was for the radiation in combination with 
chemotherapy treatment group.  Lung cancer cases in age group 5 were at a 31.0 % 
increased risk versus lung cancer cases receiving surgery after adjustment.    
The last table (Table 67) in the Hypothesis 3 section 1 lists the hazard ratios for 
the interaction term of treatment group and race extracted from the full model.  After 
controlling for gender, morphology, gender * morphology, grade, grade * morphology, 
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stage,  stage * morphology, age group, stage * age group, gender * treatment type, 
morphology * treatment type, grade * treatment type, stage * treatment type,  and  age 
group * treatment type, white and black lung cancer cases receiving radiation had an 
increased hazard for death or decreased survival with white lung cancer cases having a 
38.0% (HR = 1.38, 95% CI 1.04 – 1.84) increased risk for death and black lung cancer 
cases having a 27.0%  (HR = 1.51, 95% CI 1.27 – 1.81)  increased risk for death than 
other lung cancer cases receiving surgery.  For lung cancer cases receiving 
chemotherapy, black lung cancer cases demonstrated the only statistically significant 
relationship between the treatment type and survival.  After adjustment, black lung cancer 
cases receiving chemotherapy alone were 22.0% more likely to die as compared to other 
lung cancer cases receiving surgery alone (HR = 1.22, 95% CI 1.03 – 1.45). 
 For white lung cancer cases receiving no treatment there was a 65.0% increase in 
the risk of death (HR = 1.65, 95%CI 1.28 - 2.14) and for black lung cancer cases 
receiving no treatment the hazard ratio was 1.60 (95%CI 1.37 - 1.87) as compared to 
other lung cancer cases receiving surgery after controlling for gender, morphology, 
gender * morphology, grade, grade * morphology, stage,  stage * morphology, age group, 
stage * age group, gender * treatment type, morphology * treatment type, grade * 
treatment type, stage * treatment type,  and  age group * treatment type.  Once again as 
demonstrated in Table 66 (interaction term of treatment group and age group), the ―no 
treatment group‖ had the highest risk of death but in this case (Table 67) race was the 
moderator between treatment group and survival.   
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Black lung cancer cases receiving a combination of radiation and chemotherapy 
had a 1.31 times increase in the risk of death with a hazard ratio varying as low as 11.0% 
to a maximum of 56.0% (95% confidence interval of 1.11 to 1.56) versus other lung 
cancer cases receiving surgery after adjustment.  For all other treatment groups, i.e. 
radiation + surgery, surgery + chemotherapy, and radiation + surgery + chemotherapy, 
the results were not statistically significant.  Although when just evaluating the hazard 
ratios for radiation in combination with surgery and chemotherapy, there was a decreased 
risk of death for both white (HR = 0.73, 95%CI 0.39 – 1.35) and black lung (HR = 0.72, 
95%CI 0.41 – 1.27) cancer cases.  
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Table 66: Hazard Ratios and 95% Confidence Intervals  
Interaction Term of Treatment Group and Age Group 
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1) 
 
Interaction Terms**  
Hazard 
Ratio 95% LCI 95% UCI  
 
Treatment Group 
Age Group 
(Moderator)    
Radiation 4 1.38 1.04 1.84 
Chemotherapy 4 1.1 0.84 1.43 
No Treatment 4 1.65 1.28 2.14 
Radiation + Surgery 4 0.93 0.56 1.54 
Radiation + Chemotherapy 4 1.24 0.96 1.61 
Surgery + Chemotherapy 4 0.99 0.57 1.72 
Radiation + Surgery + Chemotherapy 4 0.73 0.39 1.35 
Surgery* 8* 1 - - 
Radiation 5 1.51 1.27 1.81 
Chemotherapy 5 1.22 1.03 1.45 
No Treatment 5 1.6 1.37 1.87 
Radiation + Surgery 5 1.23 0.87 1.73 
Radiation + Chemotherapy 5 1.31 1.11 1.56 
Surgery + Chemotherapy 5 1.05 0.67 1.65 
Radiation + Surgery + Chemotherapy 5 0.72 0.41 1.27 
Surgery* 8* 1 - - 
Radiation 6 1.27 1.1 1.46 
Chemotherapy 6 1.1 0.95 1.28 
No Treatment 6 1.53 1.35 1.73 
Radiation + Surgery 6 1.04 0.77 1.41 
Radiation + Chemotherapy 6 1.13 0.98 1.32 
Surgery + Chemotherapy 6 1.01 0.66 1.54 
Radiation + Surgery + Chemotherapy 6 0.75 0.43 1.3 
Surgery* 8* 1 - - 
Radiation 7 1.19 1.05 1.36 
Chemotherapy 7 1 0.87 1.15 
No Treatment 7 1.23 1.1 1.38 
Radiation + Surgery 7 1.07 0.8 1.44 
Radiation + Chemotherapy 7 1.08 0.93 1.24 
Surgery + Chemotherapy 7 0.88 0.57 1.34 
Radiation + Surgery + Chemotherapy 7 0.64 0.37 1.11 
Surgery* 8* 1 - - 
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference 
Age Groups: 4 ( > 40 - < 50 years old) , 5 ( > 50 - < 60 years old), 6 (> 60 - < 70 years old), 7 ( > 
70 - < 80 years old), 8 ( > 80 - < 90 years old) 
** Adjusted for gender, morphology, gender * morphology, grade, grade * morphology, stage,  
stage * morphology, stage * age group, race, gender * treatment type, morphology * treatment 
type, grade * treatment type, stage * treatment type,  and  race * treatment type 
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Table 67: Hazard Ratios and 95% Confidence Intervals  
Interaction Term of Treatment Group and Race 
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1) 
 
Interaction Terms**  
Hazard 
Ratio 95% LCI 95% UCI  
 
Treatment Group 
Race 
(Moderator)    
Radiation White 1.38 1.04 1.84 
Chemotherapy White 1.1 0.84 1.43 
No Treatment White 1.65 1.28 2.14 
Radiation + Surgery White 0.93 0.56 1.54 
Radiation + Chemotherapy White 1.24 0.96 1.61 
Surgery + Chemotherapy White 0.99 0.57 1.72 
Radiation + Surgery + Chemotherapy White 0.73 0.39 1.35 
Surgery* Other* 1 - - 
Radiation Black 1.51 1.27 1.81 
Chemotherapy Black 1.22 1.03 1.45 
No Treatment Black 1.6 1.37 1.87 
Radiation + Surgery Black 1.23 0.87 1.73 
Radiation + Chemotherapy Black 1.31 1.11 1.56 
Surgery + Chemotherapy Black 1.05 0.67 1.65 
Radiation + Surgery + Chemotherapy Black 0.72 0.41 1.27 
Surgery* Other* 1 - - 
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference 
** Adjusted for gender, morphology, gender * morphology, grade, grade * morphology, stage,  stage 
* morphology, age group, stage * age group, gender * treatment type, morphology * treatment type, 
grade * treatment type, stage * treatment type,  and age group * treatment type 
 
 
 
Section 2: Residuals 
 
The next two figures are the residual plots for the independent variables versus 
the log of time in months (Figures 13 and 14).  A residual for a ―variable‖ is defined as 
the difference between the actual value and the estimated value for all units or individuals 
given for that particular ―variable‖ contained in the model equation.  These plots were 
generated to assess the overall fit of the Cox Proportional Hazard model to the lung 
cancer data.  When the requirements or assumptions for the semi-parametric Cox-
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proportional Hazards model are met, the model would be appropriate or correctly 
estimate the behavior of the data.  Validating or corroborating the final Cox Proportional 
Hazard model results via residual analysis established that the initial non-proportional 
covariates (age group at diagnosis, race, and treatment group) were independent of 
survival time for that period under study.  If the residuals exhibited a trend, e.g. increased 
over time for the covariates of interest, the hazard ratio or relative risk could be 
overestimated (overestimation could lead to inflated coefficient estimates) and those 
covariates would not be time-invariant across the study period.  As the residual plots for 
the covariates over survival time for the 5 year study time did not demonstrate any trends, 
the use of the Cox Proportional Hazards model was appropriate.  Residual analysis was 
also performed to evaluate the proportionality and constant hazard assumptions for the 
remaining covariates and interaction terms - no trends were seen with residuals and the 
values fell about zero (Figures 17 and 18).   
In Figure 17, the Schoenfeld residuals for the independent variable (gender) 
versus the log of survival time in months are displayed; the residuals produced during the 
statistical testing were weighted and smoothed over time.  There is no trend of increasing 
or decreasing residual patterns for gender over the log of survival time meaning the 
requirement of time-invariance held true; the model accurately estimated the lung cancer 
data behavior for females and males.  As noted on the x-axis for Figure 17, time was 
transformed into the log of survival time due to the nature of survival data (non-
normalcy) due to the effects of censoring.  If the transformation of survival time was not 
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done, the residual pattern could be inappropriately displayed and interpreted incorrectly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Residual Testing of the Lung Cancer Distribution 
Gender versus the Log of Time in Months 
 
 
The next figure (Figure 18) includes the Schoenfeld residuals plots for all eight 
independent research variables.  Although the displays in Figure 18 of the residual plots 
are minimized as compared to the display of the single variable, gender as shown in 
Figure 17, the intent was to illustrate any overall trend in the residual plots for gender, 
stage, grade, morphology, race, age group, treatment group, and marital status versus the 
log of survival time. The residual patterns did not increase or decrease over time (no 
slope) and were centered about zero as expected; the difference on average between the 
estimated and actual data point for the residual should fall or be located along the zero 
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axis value. There is no trend of increasing or decreasing residual patterns for the 
individual independent variables over the log of survival time meaning the assumption of 
proportionality and constant hazard was not violated and that the model accurately 
estimated the lung cancer data behavior for females and males. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Residual Testing for the Lung Cancer Distribution 
Independent Variables versus the Log of Time in Months 
 
Section 3: Overall Effect of Interaction on Survival 
The final assessment for the overall effect on survivorship is presented in this 
section.  Utilizing the SAS command ―contrast‖ in the PHREG model statement, the 
Hazard Ratios and 95% Confidence Intervals were calculated for the variables of gender, 
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morphology, stage, grade, race, and treatment type and the statistically significant 
interaction terms.  In the following equation, the variables that were evaluated for the 
overall effect are given.  The variables given in the equation were extracted from the full 
Cox’ Proportional Hazards model (Table 61-a) that contained statistically significant 
interaction terms: 
 
Hazard Rate = exp (1genderI + 2morphologyI + 3gradeI + 4stageI + 5age_groupI + 
6raceI + 7treatment_typeI + 8 genderI * morphologyI   + 9 gradeI * morphologyI + 
10 stageI * morphologyI + 11 stageI * age_groupI    + 12 genderI*treatment_typeI   + 
13 treatment_typeI * morphologyI+ 14 treatment_typeI * grade I   + 
15treatment_typeI* stageI    + 16treatment_typeI* age_groupI   + 
17treatment_typeI*raceI + others) 
 
In Table 68, the statistically significant Hazard Ratio combinations for the 
statistically significant interaction terms are listed by gender, morphology, stage, grade, 
race, and treatment type.  Following Table 68, an example of the method used to 
calculate the Hazard Ratios for the overall effect of gender on the probability or risk for 
death for a given morphological lung cancer type is reviewed.   
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Table 68: Overall Effect on Survival 
          Hazard Ratio Combinations 
 
Overall Effect Variable Interaction Term      Hazard Ratios 
Gender Gender1*Morphology1 HR = exp (1 + 8) 
 
 
Morphology 
Gender1 and Treatment Type1 
 
Morphology1 and Gender1 
Morphology1 and Grade1 
 
HR = exp (1 + 12)  
 
HR = exp (2 + 8) 
HR = exp (2 + 9) 
Grade Grade1 and Morphology1 
Grade1 and Treatment Type1 
 
HR = exp (3 + 9) 
HR = exp (3 + 17) 
Stage Stage1 and Morphology1 HR = exp (4 + 10) 
 Stage1 and Treatment Type1 
Stage1 and Age Group1 
 
HR = exp (4 + 15) 
HR = exp (4 + 11) 
 
 
Age Group1and Treatment Type1 
Age Group1 and Stage1 
HR = exp (5 + 16) 
HR = exp (5 + 11) 
   
Race Race1 and Treatment Type1 HR = exp ( + 17) 
   
Treatment Type Treatment Type1 and Gender1 
Treatment Type1 and Morphology1 
Treatment Type1 and Grade1 
 
Treatment Type1 and Stage1 
Treatment Type1 and Age Group1 
Treatment Type1 and Race1 
HR = exp (7 + 12) 
HR = exp (7 + 13) 
HR = exp (7 + 14) 
 
HR = exp (7 + 15) 
HR = exp (7 + 16) 
HR = exp (7 + 17) 
   
Note: Considering only Gender 1 (female), Stage I, Grade I, Race I (white), Age Group 1 (Age Group IV 
(> 40 - < 50 yrs. old)), Morphology 1,  Treatment Type 1(radiation) in this example. 
 
 
 
253 
Evaluating the Overall Effect of Gender on Survival 
 
From the equation below, the gender and the statistically significant interaction terms 
containing gender are identified (bolded).  
Hazard Rate = exp (1genderI + 2morphologyI + 3gradeI + 4stageI + 5age_groupI + 
6raceI + 7treatment_typeI + 8 genderI * morphologyI   + 9 gradeI * morphologyI + 
10 stageI * morphologyI + 11 stageI * age_groupI    + 12 genderI*treatment_typeI   + 
13 treatment_typeI * morphologyI+ 14 treatment_typeI * grade I   + 
15treatment_typeI* stageI    + 16treatment_typeI* age_groupI   + 
17treatment_typeI*raceI + others) 
 From the equation above, the following equation results when examining of the 
overall effect of gender on survival: 
Hazard Rate = exp (1genderI + 2morphologyI + 7treatment_typeI + 8 genderI * 
morphologyI + 12 genderI*treatment_typeI)  
 
Gender and Morphology 
 
Female: HR (gender =1, morphologyI) = exp (1 + 2morphologyI + 7treatment_typeI + 
8 * morphologyI + 12 *treatment_typeI   )  
 
Male: HR (gender =0, morphologyI) = exp (       + 2morphologyI + 7treatment_typeI   ) 
 
Subtracting male from female given morphologyI, the following equation is given as: 
 
Female: HR (gender =1, morphologyI) = exp (1 + 8 * morphologyI + 12 
*treatment_typeI)  
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Then looking at morphologyI for morphology 1 = 1 and morphologyI for morphology 4 = 
0, the following equation is given as: 
 
 
Female: HR (gender =1, morphologyI = 1) = exp (1 + 8 + 12 *treatment_typeI)  
Female: HR (gender =1, morphologyI = 0) = exp (1         + 12 *treatment_typeI)  
 
 
Note that any treatment type does not affect the outcome under the conditions as 
stated above.  The Hazard Ratio is then calculated for females as compared to males 
adjusting for morphology and controlling for treatment group as: 
HR = exp (1 + 8)  
        
 In Table 69-a the effect of gender on the probability of survival based on the 
morphological lung cancer type demonstrate an increase survival for all three non-small 
cell lung cancer types for females as compared to males controlling for treatment type. 
After adjustment, females versus males with large cell lung cancer are 25% more likely 
to survive (HR = 0.75, 95% CI 0.70 – 0.81), whereas females with squamous cell 
carcinoma are 18% more likely to survive as compared to males with squamous cell 
carcinoma (HR = 0.82, 95% CI 0.76 – 0.87).   
 The effect of gender on the probability of survival (Table 69-b) shows an overall 
increase in survival given the treatment types of chemotherapy, no treatment, radiation + 
chemotherapy, and radiation + chemotherapy + surgery.  The hazard ratios range from a 
minimum of 0.83 to a maximum of 0.92.  Females versus males receiving radiation in 
combination with chemotherapy and surgery are 17% more likely to survive (HR = 0.83, 
95% CI 0.72 – 0.97) and 8% more likely to die when females as compared to males 
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receive radiation plus chemotherapy after adjustment.  The statistics demonstrate that for 
a particular treatment combination statistically significant survivorship is exhibited for 
females versus males.    
 
Table 69-a: Overall Effect of Gender on Survival 
Hazard Ratios and 95% Confidence Intervals 
Gender and Gender*Morphology 
 
Gender Morphology HR 95% LCI 95% UCI 
Female Adenocarcinoma 0.76 0.71 0.80 
 Squamous Cell 0.82 0.76 0.87 
 Large Cell 0.75 0.70 0.81 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Gender = Male, Reference for Morphology = Small Cell Lung Cancer 
 
 
 
 
Table 69-b: Overall Effect of Gender on Survival 
Hazard Ratios and 95% Confidence Intervals 
Gender and Gender* Treatment Type 
 
Gender Treatment Type HR 95% LCI 95% UCI 
Female Chemotherapy 0.91 0.85 0.97 
 No Treatment 0.88 0.82 0.94 
 Radiation + Chemotherapy 0.92 0.86 0.98 
 Radiation + Chemotherapy + Surgery 0.83 0.72 0.97 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Gender = Male, Reference for Treatment Type = Surgery 
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Evaluating the Overall Effect of Morphology  on Survival 
 
 In Tables 69-c through 69-e the overall effect of morphology on the risk of 
survival are given.  After adjustment, the risk of death is decreased for squamous cell 
carcinoma lung cancer cases by 425% and 40% for large cell lung cancer cases as 
compared to small cell lung cancer cases that are female (Table 69-c).  In Table 69-d, 
large cell (HR = 0.50, 95% CI 0.28 – 0.88) and squamous cell carcinoma (HR = 0.51, 
95% CI 0.29 – 0.89) are at an increase risk for survival given that those patients are grade 
1.    For the overall effect of morphology on the probability of survival in Table 69-e, 
four of five the treatment types are statistically significant for an increased survival with 
the HRs ranging from a minimum of 0.44 to a maximum HR of 0.65.  The only HR in 
Table 69-e that demonstrates a decreased survival or increase risk of death is the 
morphologic lung cancer type of adenocarcinoma when those patients receive radiation in 
combination with chemotherapy (HR = 1.24, 95% CI 1.04 – 1.49) after adjustment.   
 
 
Table 69-c: Overall Effect of Morphology on Survival 
Hazard Ratios and 95% Confidence Intervals 
Morphology and Morphology *Gender 
 
Morphology Gender HR 95% LCI 95% UCI 
Squamous Cell Female 0.59 0.42 0.82 
Large Cell   0.60 0.43 0.83 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, 
Reference for Morphology = Small Cell Lung Cancer, Reference for Gender = Male 
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Table 69-d: Overall Effect of Morphology on Survival 
Hazard Ratios and 95% Confidence Intervals 
Morphology and Morphology*Grade 
 
Morphology Grade HR 95% LCI 95% UCI 
Squamous Cell I 0.50 0.28 0.88 
Large Cell I 0.51 0.29 0.89 
Large Cell III 0.54 0.32 0.92 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence 
Interval, Reference for Morphology = Small Cell Lung Cancer, Reference for Grade = IV 
 
 
 
Table 69-e: Overall Interaction Effect of Morphology on Survival 
Hazard Ratios and 95% Confidence Intervals 
Morphology and Morphology*Treatment Type 
 
Morphology Treatment Type HR 95% LCI 95% UCI 
Adenocarcinoma Radiation + Chemotherapy 1.24 1.04 1.49 
Squamous Cell No Treatment 0.65 0.53 0.80 
Squamous Cell Radiation + Surgery 0.44 0.20 0.97 
Squamous Cell Surgery + Chemotherapy 0.62 0.39 0.99 
Large Cell Radiation + Surgery 0.45 0.20 0.99 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, 
Reference for Morphology = Small Cell Lung Cancer, Reference for Treatment Type = Surgery 
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Evaluating the Overall Effect of Grade on Survival 
In the next two tables (Table 69-f and Table 69-g) the effect of grade on the risk 
of death are given based on morphology and treatment type.  Grade I (HR = 0.64, 95% CI 
0.49 – 0.83) and grade III (HR = 0.68, 95% CI 53 – 0.88) demonstrate an increase risk of 
survival for patients that have adenocarcinoma as compared to small cell lung cancer 
after adjustment. The HR for Grade II adenocarcinoma lung cancer cases was not 
statistically significant.   In Table 69-g, the effect of grade given the treatment type 
received shows a decrease survival for grade II and III lung cancer cases receiving 
chemotherapy and a decrease survival for grade III patients receiving radiation in 
combination with chemotherapy.  The risk of death ranges from a minimum HR of 1.38 
to a maximum HR of 1.66.   Grade II versus grade IV lung cancer patients are 1.414 
times more likely to die when they receive chemotherapy (HR = 1.41, 95% CI 1.03 – 
1.95) versus receiving surgery for the treatment of their lung cancer.  After adjustment, 
for patients with Grade II lung cancer, the risk of death increases by 38% when receiving 
radiation in combination with chemotherapy and 66% when receiving chemotherapy 
(Table 69-g).   
Table 69-f: Overall Effect of Grade on Survival 
Hazard Ratios and 95% Confidence Intervals 
Grade and Grade*Morphology 
 
Grade Morphology HR 95% LCI 95% UCI 
I Adenocarcinoma 0.64 0.49 0.84 
III Adenocarcinoma 0.68 0.53 0.88 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, 
Reference for Morphology = Small Cell Lung Cancer, Reference for Grade = IV 
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Table 69-g: Overall Effect of Grade on Survival 
Hazard Ratios and 95% Confidence Intervals 
Grade and Grade*Treatment Type 
 
Grade Treatment Type HR 95% LCI 95% UCI 
II Chemotherapy 1.41 1.03 1.95 
III Chemotherapy 1.66 1.34 2.05 
III Radiation + Chemotherapy 1.38 1.12 1.69 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, 
Reference for Treatment Type = Surgery, Reference for Grade = IV 
 
 
 
Evaluating the Overall Effect of Stage on Survival 
 
 In Tables 69-h, 69-i, and 69-j, the statistics for the effect of stage on the 
probability of survival given morphology, treatment type and age group at the time of 
diagnosis are given.  In Table 69-h, for all stages of lung cancer (stages 1 through 3) there 
is an increase risk of survival for the morphologic types of adenocarcinoma, squamous 
cell, and large cell lung cancer as compared to small cell carcinoma after adjustment.  
The HRs range from a minimum of 0.41 for stage 1 adenocarcinoma patients to a 
maximum of 0.78 for stage 2 large cell lung cancer patients.  Also for all stages of cases 
with squamous cell lung carcinoma the risk of an increased survival ranges from an HR 
of 0.52 to a maximum HR of 0.61 (Table 69-h).  There is an increase risk of survival for 
stage 1 lung cancer cases receiving six of the seven possible treatment types based on 
surgery as the reference group and after adjustment (Table 69-i).  Stage 1 lung cancer 
patients versus stage 4 lung cancer patients are 57% more likely to survive when they 
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receive radiation therapy alone and 31% more likely to survive when they (stage I lung 
cancer patients) receive chemotherapy for the treatment of their lung cancer.  Comparing 
the effect of stage II lung cancer patients receiving radiation therapy alone, there is a 45% 
increased risk of survival (HR 0.55, 95% CI 0.44 – 0.69) after adjustment.  Also for stage 
III versus stage IV lung cancer cases, there is a 29% increased risk of survival when 
receiving radiation therapy alone.  Noted in Table 69-i, the percent increased risk of 
survival decreases with increasing stage; this same trend is exhibited for the no treatment 
group.  The HRs for the no treatment group increase from 0.48 for stage 1, 0.62 for stage 
II and 0.79 for stage III lung cancer cases.  This can be interpreted as the percent increase 
in survivorship values decreases with increasing stage. For stage I lung cancer case 
receiving no treatment there is a 52% increased risk of survival, stage II lung cancer cases 
have a 38% increased risk of survival and for stage III lung cancer cases there is a 21% 
increased risk of survival (table 69-i).  
 The statistically significant hazard ratios and 95% confidence intervals for the 
overall effect of stage on the risk of death given an age group is shown in Table 69-j.  For 
all stage of lung cancer, there is a decrease risk of death or increased survivorship for the 
four age groups 4 though 7 as compared to age group 8 and after adjustment.  The HRs in 
Table 69-j range from 0.33 to 0.67 with a trend of increasing HRs with increasing age 
group for each of the four age groups listed.   
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Table 69-h: Overall Effect of Stage on Survival 
Hazard Ratios and 95% Confidence Intervals 
Stage and Stage*Morphology 
 
Stage Morphology HR 
95% 
LCI 
95% 
UCI 
I Adenocarcinoma 0.41 0.35 0.47 
II   0.47 0.41 0.55 
III   0.43 0.37 0.50 
I Squamous Cell 0.52 0.41 0.67 
II   0.61 0.47 0.78 
III   0.55 0.43 0.71 
I Large Cell 0.67 0.55 0.81 
II   0.78 0.64 0.95 
III   0.70 0.57 0.86 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence 
Interval, Reference for Morphology = Small Cell Lung Cancer, Reference for Stage = IV 
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Table 69-i: Overall Effect of Stage on Survival 
Hazard Ratios and 95% Confidence Intervals 
Stage and Stage*Treatment Type 
 
Stage Treatment Group HR 
95% 
LCI 
95% 
UCI 
I Radiation 0.43 0.36 0.51 
 Chemotherapy 0.70 0.58 0.83 
 No Treatment 0.48 0.41 0.56 
 Radiation +Surgery 0.53 0.39 0.71 
 Radiation + Chemotherapy 0.59 0.50 0.70 
 Surgery + Chemotherapy 0.52 0.39 0.69 
II Radiation 0.55 0.44 0.69 
 No Treatment 0.62 0.51 0.77 
 Radiation +Surgery 0.68 0.50 0.94 
 Radiation + Chemotherapy 0.76 0.61 0.96 
 Surgery + Chemotherapy 0.67 0.48 0.92 
III Radiation 0.70 0.60 0.83 
 No Treatment 0.79 0.69 0.91 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence 
Interval, Reference for Treatment Group = Surgery, Reference for Stage = Stage IV 
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Table 69-j: Overall Effect of Stage on Survival 
Hazard Ratios and 95% Confidence Intervals 
Stage and Stage*Age Group 
 
Stage Age Group HR 95% LCI 95% UCI 
1 4 0.35 0.26 0.47 
 5 0.33 0.28 0.40 
 6 0.36 0.30 0.43 
 7 0.41 0.35 0.49 
2 4 0.45 0.33 0.63 
 5 0.43 0.34 0.55 
 6 0.46 0.37 0.58 
 7 0.53 0.42 0.67 
3 4 0.58 0.43 0.77 
 5 0.55 0.45 0.67 
 6 0.59 0.49 0.70 
 7 0.67 0.57 0.80 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, 
Reference for Stage = Stage 4, Reference for Age Group = 8, Age Groups: 4 = (> 40 - < 50 yrs), 
5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs) 
 
 
 
 
Evaluating the Overall Effect of Age Group at Time of Diagnosis  on Survival 
 
In the next tables, 69-k and 69-l, the effect of age group on the risk of survival is 
given for treatment type and stage.    
 
 
 
 
264 
Table 69-k: Overall Effect of Age Group on Survival 
Hazard Ratios and 95% Confidence Intervals 
Age Group and Age Group*Treatment Type 
 
Age Group Treatment Type HR 
95% 
LCI 
95% 
UCI 
4 Radiation 0.83 0.69 0.99 
 Chemotherapy 0.66 0.57 0.75 
 Radiation +Surgery 0.56 0.35 0.89 
 Radiation + Chemotherapy 0.74 0.65 0.86 
 Radiation + Chemotherapy + Surgery 0.44 0.24 0.79 
5 Chemotherapy 0.64 0.48 0.84 
 Radiation +Surgery 0.54 0.33 0.91 
 Radiation + Chemotherapy 0.72 0.55 0.95 
 Radiation + Chemotherapy + Surgery 0.43 0.23 0.80 
6 Radiation + Chemotherapy + Surgery 0.51 0.28 0.95 
7 No Treatment 1.35 1.05 1.74 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Age Groups: 4 = (> 40 - 
< 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs) 
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Table 69-l: Overall Effect of Age Group on Survival 
Hazard Ratios and 95% Confidence Intervals 
Age Group and Age Group*Stage 
 
Age Group Stage HR 95% LCI 95% UCI 
4 I 0.51 0.40 0.64 
 II 0.48 0.37 0.63 
 III 0.52 0.40 0.66 
5 I 0.49 0.37 0.65 
 II 0.47 0.41 0.53 
 III 0.50 0.43 0.59 
6 I 0.59 0.46 0.77 
 II 0.56 0.48 0.66 
 III 0.61 0.55 0.67 
7 I 0.69 0.53 0.90 
 III 0.66 0.56 0.76 
 III 0.71 0.62 0.80 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Stage = Stage 4, Reference for Age Group = 8, Age Groups: 4 = (> 40 - < 50 yrs), 5 
= (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs) 
 
 
 
Evaluating the Overall Effect of Race on Survival 
 
 In Table 69-m, the statistically significant HRs and 95%CIs for the overall effect 
of race on the probability of survival given treatment type are given.  For white versus 
other lung cancer cases, there is a 1.43 times increased risk of death when the patient 
receives chemotherapy and a 1.91 times increase in the risk of death when that case 
receives no treatment.  For black lung cancer cases versus other lung cancer cases, the 
risk of death increases from 1.57 times when they receive chemotherapy alone to a 2.10 
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times increase in the risk of death when the patient receives no treatment. 
 
Table 69-m: Overall Effect of Race on Survival 
Hazard Ratios and 95% Confidence Intervals 
Race and Race*Treatment Type 
 
Race Treatment Type HR 95% LCI 95% UCI 
White Chemotherapy 1.43 1.07 1.90 
  No Treatment 1.91 1.46 2.50 
Black Chemotherapy 1.57 1.15 2.14 
  No Treatment 2.10 1.57 2.82 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Race = 3 (or Other), Reference for Treatment Group = Surgery 
 
 
  
 
Evaluating the Overall Effect of Treatment Type on Survival 
 
In the next five tables, the effect of treatment type received for the probability of survival 
given morphology, grade, stage, age group and race. There were no statistically 
significant HRs and 95% CIs when the overall effect of treatment on the risk of survival 
was evaluated for gender.  For the treatment type of chemotherapy (Table 69-n), the risk 
of survival was increased by 48% when the patient had large cell lung cancer versus 
small cell lung cancer (HR = 0.52, 95% CI 0.30 – 0.91).  In Table 69-o, for the treatment 
type effect of chemotherapy, there was a decrease in the risk of death for both grade 1 
and grade 3 lung cancer.  There was an increase in survivorship of 49.8% for grade 1 
patients receiving chemotherapy (HR = 0.50, 95% CI 0.27 – 0.94) and a 49% increase in 
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survival for grade 3 patients receiving chemotherapy.  All other  
treatment types did not present statistically significant HRs with 95%CIs.  The effect of 
treatment type on the risk of death given the stage (Table 69-p) of lung cancer 
demonstrated an decreased risk of survival for those stage 1 cases receiving 
chemotherapy alone (HR = 0.51, 95% 0.28 - 0.90) but a 2.10 times increased risk for 
death when stage 2 lung cancer cases received radiation alone as their treatment for lung 
cancer.  For those lung cancer patient receiving chemotherapy in age groups 5 and 7, the 
risk of survival increased  by as much as 79% (Table 69-q).  In age group 6, when the 
treatment was radiation therapy alone versus surgery, the risk of death increased 2.07 
times (HR = 2.07, 95% CI 1.04 – 4.13) after adjustment.  In the last table (Table 69-r), 
the overall effect of treatment type on the risk of survival given raceI, shows that for 
black and white lung cancer cases, when the treatment was chemotherapy the risk of 
death decreases by as much as 77%.   
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Table 69-n: Overall Effect of Treatment Type on Survival 
Hazard Ratios and 95% Confidence Intervals 
Treatment Type and Treatment Type*Morphology 
 
Treatment Type Morphology HR 95% LCI 95% UCI 
Chemotherapy Large Cell 0.52 0.30 0.91 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence 
Interval, Reference for Treatment Group = Surgery, Reference for Morphology = Small Cell 
Lung Cancer 
 
 
 
 
 
Table 69-o: Overall Effect of Treatment Type on Survival 
Hazard Ratios and 95% Confidence Intervals 
Treatment Type and Treatment Type*Grade 
 
Treatment Type Grade HR 95% LCI 95% UCI 
Chemotherapy I 0.50 0.27 0.94 
Chemotherapy III 0.51 0.28 0.94 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence 
Interval, Reference for Treatment Group = Surgery, Reference for Grade =  Grade IV 
 
 
 
 
Table 69-p: Overall Effect of Treatment Type on Survival 
Hazard Ratios and 95% Confidence Intervals 
Treatment Type and Treatment Type*Stage 
 
Treatment Type Stage HR 95% LCI 95% UCI 
Chemotherapy I 0.51 0.28 0.90 
Radiation II 2.10 1.08 4.06 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, 
Reference for Treatment Group = Surgery, Reference for Stage = Stage 4 
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Table 69-q: Overall Effect of Treatment Type on Survival 
Hazard Ratios and 95% Confidence Intervals 
Treatment Type and Treatment Type*Age Group 
 
Treatment Type Age Group HR 95% LCI 95% UCI 
Chemotherapy 5 0.53 0.29 0.98 
Radiation 6 2.07 1.04 4.13 
Chemotherapy 7 0.45 0.21 0.97 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Stage = Stage 4, Reference for Age Group = 8, Age Groups: 4 = (> 40 - < 50 yrs), 5 
= (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs) 
 
 
 
Table 69-r: Overall Effect of Treatment Type on Survival 
Hazard Ratios and 95% Confidence Intervals 
Treatment Type and Treatment Type*Race 
 
Treatment Type Race HR 95% LCI 95% UCI 
Chemotherapy White 0.41 0.23 0.75 
Chemotherapy Black 0.53 0.38 0.75 
Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval 
Reference for Race = 3, Reference for Treatment Group = Surgery 
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Hypothesis III Conclusion 
 
After evaluating the results generated during Hypothesis 3 testing, the decision 
was made to reject the null hypothesis because statistically significant differences existed 
in survival between women and men after controlling for covariates and interaction 
terms.  The final CPH model included stratification based on gender, stage, grade, 
morphology and treatment type as well as investigating main effects and the effect of 
moderating variables on the association  between independent variables and survival.  
The additional information obtained by utilizing a statistical model that included 
interaction terms served to reveal increased hazard ratios that demonstrated female and 
male lung cancer cases had survival patterns that were moderated by the treatment type 
received.  When the overall effect was examined, survival differences were exhibited.  
Females as compared to males had an increased risk of survivorship specific to different 
treatment types and lung cancer type.  Of all the treatment groups, the greatest increased 
survival was for women versus men being treated with radiation in combination with 
surgery and chemotherapy (HR = 0.83, 95% CI 0.72 – 0.98).  The hazard ratios based on 
the gender effect demonstrated an increase in survivorship for females versus males. But 
when the hazard ratios for the interaction term for gender and treatment type received 
were examined, females were at a decreased survival by as much as 18%. Without 
consideration of the overall effect of gender this survival advantage would not have been 
identified and the results could have been misinterpreted.  
In conclusion, female lung cancer cases have been reported in the literature to 
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have increased survival as well as decreased survival as compared to males with lung 
cancer. Without the modeling approach presented in this research, specific treatment 
regimens and the importance of that treatment on survivorship would not have been 
ascertained for females as compared to males.  The answer to the research question of 
―Does the lung cancer treatment received impact gender-specific survival‖ has been 
presented for this data set.  The research results found that gender does play a role in 
some of the lung cancer treatment selected and that selection impacts gender specific 
survival.  
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CHAPTER V: DISCUSSION 
 Introduction  
Chapter 5 summarizes the results of this research with 1) an assessment of the 
major findings for the statistical analyses of the three hypotheses tested, 2) comparison of 
the key findings with current literature for consistency 3) an evaluation of the key 
findings for inconsistencies with current literature, 4) a review of the strengths and the 
weakness of the research study, 5) a presentation of the significant research findings as it 
relates to the importance in Public Health and lastly, 6) and future directions.  The 
purpose of this research was to investigate if any differences in lung cancer treatment 
received were based on gender, and whether any associated treatment differences 
impacted gender-specific survival.  To examine the relationship between gender-specific 
treatment and survival, the first research question to answer was if differences in lung 
cancer treatment (the outcome variable) existed based on gender (an independent 
variable).  The question of gender-specific lung cancer treatments was important to 
address as a first step in the investigation as there are no published quantitative results 
that show whether there is a statistically significant difference regarding the lung cancer 
treatment received by women as compared to men
12, 40-45
.  The selection of a particular 
lung cancer treatment is a clinical decision based on standardized recommendations 
which considers several parameters including morphologic type, stage, and grade of lung 
cancer
4, 9, 13
.  Each morphologic type of lung cancer has its own medical intervention that 
can include any combination of surgery, radiation therapy, and/or chemotherapy.  A 
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particular lung cancer treatment may vary depending upon other differences such as co-
morbidities or regional differences, e.g. physician preferences, physician training, 
insurance.   
 
Assessment of the Major Findings  
The procedures and methods presented in this research concerning gender-
specific treatment differences, to the author’s knowledge, have not been published in the 
literature.  Any differences in lung cancer treatment for females relative to males were 
important to ascertain as those differences could affect survival.  The research questions 
were designed to investigate if gender-specific treatment differences changed the 
relationship between female survival and male survival for the data analyzed in this 
dissertation.  A novel approach was used to evaluate the overall interaction effect and that 
impact on the treatment received and survival.  To the author’s knowledge this approach 
has not been published in the literature as it pertains to lung cancer treatment and 
survival.  For example, the overall gender effect was calculated from the beta coefficients 
for the main effect of gender plus the beta coefficients of the statistically significant 
interaction term containing gender. When the beta coefficients were added and 
exponentiated the Odds Ratios for treatment received and Hazard Ratios for survival 
were generated.  From this information, differences in specific lung cancer treatments and 
gender specific survival could be ascertained.    
Upon examination of the Odds Ratios from the Multinomial Logistic Regression 
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model, it was determined that the recommended standard of care for the treatment of 
primary lung cancer was not always adhered to for females versus males.  For example, 
the ORs were statistically significant for stage I female lung cancer cases; those patients 
had as much as a 2.78 times increased probability of receiving radiation in combination 
with chemotherapy versus the standard of care, surgery.  Surgery is the primary modality 
for the treatment of early stage lung cancer (stage I); radiation plus chemotherapy is an 
adjunct or secondary treatment and the treatment modality could vary based on gender.   
When the hazard ratios were assessed some of the treatment decisions for the lung 
cancer cases affected males’ survival by increasing their risk for death relative to females.  
Depending upon the treatment received and morphologic lung cancer type, males as 
compared to females could have an increased hazard for death with the hazard ranging 
from 8 % to 29%.  These results demonstrated that males had a statistically significant 
decrease in survival when the overall gender effect was taken into account.  Without the 
statistical approach utilized in this research, misinterpretation of gender specific 
treatment and survival could have been made.  Evaluating just the main effects and/or 
interaction effects can give results that conflict with the overall effect a variable 
contributes to the outcome. 
 
Hypothesis I 
Hypothesis I stated that there was a treatment difference based on gender when 
adjusted for the research covariates.  The outcome variable of interest was treatment 
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group which included eight different lung cancer treatment options.  The eight lung 
cancer treatment groups were classified as 1) radiation therapy, 2) chemotherapy, 3) no 
treatment received, 4) radiation plus surgery, 5) radiation in combination with 
chemotherapy, 6) surgery plus chemotherapy, 7) radiation plus chemotherapy plus 
surgery and 8) surgery.   
The statistics for the data analyzed in this dissertation demonstrated that some 
females as compared to males depending upon stage and marital status did not receive the 
same lung cancer treatment modality.  The standard of care as outlined in the article by 
Collins, et. al. (2007) is to treat a later stage lung cancer with chemotherapy or a 
combination of chemotherapy and radiation.  Treatment decisions are based on the 
standards of care established by the medical community are overseen by several 
organizations such as the American Medical Association, the American College of 
Surgeons, the National Cancer Institute, and the American College of Radiology 
33
.   The 
statistical analyses found that some of the treatment selection for stage I and III was 
gender dependent.  The null hypothesis of no differences in treatment outcomes between 
men and women was rejected as there were statistically significant differences between 
gender and the lung cancer treatment received.  
 
 
Hypothesis II 
The major finding for Hypothesis II (there was a statistically significant 
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difference in survival for female lung cancer cases as compared to the survival for male 
lung cancer cases) was the unadjusted gender-specific survival patterns were comparable 
to the published literature 
14-17
.   Female lung cancer cases had an increased probability of 
survival (increased survivorship) as compared to males.  The mean survival time for 
females was 19.8 months whereas the mean survival time for males was 16.4 months; 
females for this data set ―on average‖ lived approximately 3.0 months longer than the 
males; these results were statistically significant.  Women were at a lower risk to 
experience the event (death) as compared to men for the selected five year time range 
under study.  Comparing these results to the literature, Ouellette et. al. (1998), ―Lung 
Cancer in Women as Compared to Men: Stage, Treatment, and Survival‖ 8, also found 
gender differences in survival.  Women were found to live, on average, 12 months longer 
than men.  The authors concluded there was a significant survival difference between 
men and women with lung cancer with women having a survival advantage over men.  
For the data analyzed in this dissertation, the null hypothesis of no difference was 
rejected as it was determined that there was a statistically significant increase in survival 
in women with lung cancer as compared to the survival of men with lung cancer. 
 
Hypothesis III 
Univariate and multivariate survival analysis were included in the statistical 
methods to test Hypothesis Three.   Hypothesis III stated that women with the same 
histological type, stage, grade of lung cancer, and the same treatment modality differ 
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significantly in survival as compared to men with the same histological type, stage, and 
grade of lung cancer, and the same treatment modality.  The gender effect demonstrated a 
decreased risk of death for females versus males dependent upon the treatment received 
and the morphologic lung cancer type.   After adjustment, females versus males with 
large cell lung cancer could exhibit a 30% increase in the probability of survival (HR = 
0.75, 95% CI 0.70 – 0.81) and a 29% increase in survival for females versus males with 
adenocarcinoma.  Based on the statistical analyses with the overall gender effect, females 
exhibited a distinct survival advantage when the type of treatment received and 
morphological lung cancer type was examined.  The majority of the literature
17, 27, 40
 that 
was reviewed males are at increased risk of death as compared to females with lung 
cancer.  The cited articles do not take into account any effect of gender on survival.  
Comparisons were made to the statistics generated by models cited in the literature that 
did not mention any adjustment for interaction terms demonstrated females had a survival 
advantage as compared to males
17, 27, 41
.  For example, in the article by Ringer, et. al. 
(2005), the statistics used for the primary outcome of survival were given as the Chi-
Square and Student t test.  Although survival rates (%) were given for lung cancer 
patients by stage of disease, histologic type, and by gender, there was no mention of 
interaction.   Fu, et. al. (2007)
 12
 reported on a model that included interaction terms; the 
only interaction term that was statistically significant was gender and age.  The authors 
found that women and men that were age 50 or greater demonstrated increased survival 
as compared to women less than 50 years of age.   
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For Hypothesis III, the null hypothesis of no difference was rejected as the results 
of the statistical testing supported statistically significant differences in gender specific 
survival.    
 
Comparison and Consistency of Key Findings with the Current Literature 
When comparing the characteristics of the lung cancer cases, Radzikowska, et. al., 
(2002), investigated demographic factors (gender, age, and smoking) and factors 
connected with the disease (histology, performance status, stage, treatment and survival) 
for lung cancer patients.  Women were found to be more likely to have adenocarcinoma 
and SCLC as compared to men.  Squamous cell cancer was the predominant type of lung 
cancer among men, and less than ten percent of men had adenocarcinoma.  This was 
consistent with research findings of this dissertation, Kowski, et al., (2010); 
adenocarcinoma was the most prevalent histological type for women (17.8%) whereas 
squamous cell lung cancer included the greatest number of males (19.4%).  Radzikowska, 
et. al., (2002) found that 21.6% of all females had adenocarcinoma of the lung.  There 
was a 2.2% difference for the number of females with adenocarcinoma when both lung 
cancer data sets were compared.    
Fu, et. al. (2007)
12
 evaluated the survival rates for men and women who received 
one of five treatment groups (surgery alone, radiotherapy alone, surgery + radiotherapy, 
no surgery or radiotherapy, unknown)  utilizing the life table method.  With this method, 
for patients receiving surgery as part of their treatment, females had an increased survival 
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as compared to men
12
.  For females and males that underwent surgery in combination 
with radiation therapy, females had an increase in survival by as much as 66%.  This 
increase in survivorship for women receiving radiotherapy in combination with surgery 
was also demonstrated by Kowski, et. al. (2010) with the Cox Proportional Hazards 
model.  Women as compared to men receiving radiotherapy in combination with surgery 
were 1.08 times more likely to survive (HR = 0.92, 95% CI 0.86 – 0.98).  Although each 
of the authors utilized different statistical methods, both found similar results of a 
decrease survivorship for men versus females when treatment type was evaluated.  
There were other areas of agreement (consistency) in this research with cited 
literature
8, 15,
 
17, 27, 167
 that reported women with lung cancer survive longer than men with 
lung cancer.  Analyses of data among females demonstrated statistically significant 
increased survivorship in the unadjusted survival rates as compared to males utilizing the 
Life Table method (non-parametric).  Lung cancer mortality rates are higher in men as 
compared to women 
3, 10
.  This was consistent with the research findings during 
Hypothesis II testing.  
 
Comparison of the Key Findings with the Current Literature for Inconsistency  
The article, Ouellette, et. al. (1998), ―Lung Cancer in Women as Compared to 
Men: Stage, Treatment, and Survival‖ 8, found gender differences in survival were not 
significant.  This was inconsistent with the statistical analyses addressing Hypothesis II in 
this research which found females having a survival advantage.  When stratified analysis 
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based on stage of disease was assessed by Ouellette, et. al. (1998); women were found to 
live, on average, 12 months longer than men.  The authors concluded there was a 
statistically significant survival difference after adjusting by stage between men and 
women with lung cancer with women having a survival advantage over men.  In 
comparison to the increased survivorship of women after adjustment for stage, published 
by Ouellette, et. al. (1998), this dissertation, Kowski, et. al. (2010) did not find a 
statistically significant relationship between gender, stage and survival when the overall 
gender effect was considered.  These differences in survival were demonstrated utilizing 
a semi-parametric statistical model - the Cox Proportional Hazards model.  When the 
statistics were assessed for the overall gender effect on survival, there were no 
statistically significant hazard ratios that included gender and stage. 
 Ringer, et al. (2005) in the article "Influence of sex on lung cancer histology, 
stage, and survival in a Midwestern United States Tumor Registry." identified differences 
between men and women with regard to lung cancer type, stage at diagnosis, and 
survival.  Women were found to have a decreased survival with late stage lung cancer as 
compared to men 
27
 but there was no expansion of the results based on any analysis that 
included the type of treatment received for women and men.  Kowski, et. al. (2010) 
research results for the lung cancer cases demonstrated an inconsistency based on the 
treatment received.  Females versus males with lung cancer were at a statistically 
significant increased risk of survival when they were treated with radiation in 
combination with surgery (HR = 0.92, 95% CI 0.86 – 0.98), chemotherapy alone (HR = 
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0.91, 95% CI 0.85 – 0.97), radiation in combination with chemotherapy and surgery (HR 
= 0.83, 95% CI 0.72 – 0.97) or if no treatment was received (HR = 0.88, 95% CI 0.82 – 
0.94) as compared to receiving surgery alone.     
Survival rates were shown to be independent of lung cancer morphology as cited 
in the article by Visbal, et. al. (2004)
17
.   The survival rates presented in this dissertation 
demonstrated a statistically significant difference for the 4 major lung cancer 
morphologic types.  When the gender effect was considered, females versus males with 
squamous cell lung cancer receiving surgery alone demonstrated an increase risk of 
survival (HR = 0.82, 95% CI 0.76 – 0.87).  Also, females versus males with large cell 
lung cancer receiving radiation therapy alone were 1.11 times more likely to survive (HR 
= 0.89, 95% CI 0.82 – 0.96).  This research expanded the investigation to include the 
possible effect of stage, grade, treatment type, age group, marital status, and race for each 
morphologic lung cancer type.   
The article ―Women and Lung Cancer: Epidemiology, tumor biology, and 
emerging trends in clinical research‖ by Belani, et.al. (2007), noted gender specific 
differences in cancer prognosis 
41
.  Belani compared several studies examining 
histological types of lung cancer and gender differences.  For example, the authors noted 
that the major histologic type of lung cancer was adenocarcinoma with ratio between 
males to females being 1.0 to 1.3
41
.  Belani, et. al. (2007) further reported that males as 
compared to females have a greater proportion of squamous cell carcinoma 
approximately 1.7 to 1.0.  As reported in the previous section, adenocarcinoma was the 
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most prevalent histological type for females (17.8%) whereas squamous cell lung cancer 
included the greatest number of males (19.4%).  The difference in the distribution for the 
morphologic types could have resulted from differences in the data analyzed in this 
dissertation for Kowski, et. al. (2010) versus the data sets Belani, et. al. (2007) examined 
as those lung cancer cases were from different studies.   
 
Study Limitations 
Different types of bias or systematic error can be initiated in the design phase, the 
data collection phase, the analysis phase or during the publication phases for the research 
study.  Several possible limitations in this research were experienced in the initial phase 
of data collection.  The data that were collected was secondary data.  Secondary data can 
be subject to measurement error.  This bias could have been introduced by errors made 
during data collection by the cancer registries.  As the cancer registries collected the data 
in a standardized format, this particular limitation was considered to be minimal.   
Initially, all cancer registries that were members of NAACCR from the four 
geographic regions of the US were possible candidates for inclusion into the study.  From 
the NAACCR cancer registries, cancer registries were selected that met and maintained 
quality standards for the years of study (2000 – 2004).  Once it was established that a 
cancer registry followed the standardized procedures for NAACCR, two state cancer 
registries were randomly selected from each geographic region.  Also, there were 
differences for each state cancer registry IRB protocol for the release of data.  This may 
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have introduced a selection bias in that some of the states that were selected randomly 
from each geographic region would not release the data; another state had to be selected 
from the region.  Selection bias is minimal when the samples are selected randomly and 
although this was the intent for this research, a completely random selection of the cancer 
registries that supplied lung cancer cases for the data set was not achievable; this may 
have limited the external validity of the study results due to a systematic or random error 
bias.   
Another limitation was the limited access over which variables could be obtained 
from the cancer registries.  Patient anonymity was a major concern limiting the number 
of variables that could be obtained for the research study.  Also variations due to changes 
in the characteristics of the lung cancer population may have been introduced by 
geographic differences, e.g. different patterns of care specific to a region, environmental 
differences, e.g. an increase in lung cancer cases due to radon and these random 
variations may have limited the interpretation of the study results.  
When evaluating the statistical analyses, one of the limitations could be identified 
as some of the lower bounds of the confidence intervals were minimally statistically 
significant, i.e. some of the lower bounds of the confidence intervals did approach one.  
The statistics were reported and standardized on the level of significance to the hundreds; 
therefore these results were still reported as statistically significant.  Not all subgroup 
analyses resulted in statistically significant findings, which could be interpreted as a 
possible limitation if statistically significant results for all subgroups were anticipated.  
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Without the subgroup analyses, the information on treatment and gender specific survival 
differences between could not be determined or examined.  
One of the major limitations for comparative purposes was that the current 
literature
8, 15,
 
17, 27, 167
  does not addressed treatment differences based on gender.   
Contrary to the current literature, gender specific survival differences, were demonstrated 
when females and males were stratified by lung cancer type (morphology), stage, grade 
and treatment type and when the effect of moderating variables were accounted for in the 
statistical models.  The authors Belani, et. al. (2007) expressed an urgent need to increase 
research and funding to improve lung cancer care, in particular for women 
41
, their 
recommendation was based on limited information as difference in treatment modality by 
gender only included studies focused on surgery alone or radiation therapy alone.  For 
this research presented in this dissertation, the major treatment types for lung cancer were 
critical for a valid assessment.  As demonstrated in the statistical analyses, there are 
statistically significant differences in the treatments women receive as compared to men 
based on stage for the data analyzed in this dissertation.   
 
Study Strengths 
 The data from the eight cancer registries for this research was acquired over a 
year and a half time period.  Strength in the study design included the large population 
size (power) and quality of data.  Each cancer registry that was included in the data set 
met national standards as outlined by NAACCR decreasing any discrepancies with data 
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collection and data quality.  In the design phase, strength of this study was in the protocol 
for the selection of the state cancer registries which minimized selection bias by the 
random selection of the cancer registries.  Error due to random variations in the 
characteristics of lung cancer cases was accounted for by assessing random effects during 
the statistical testing phase.  Possible random variations in the lung cancer cases due to 
geographic or environmental differences that may have invalidated the results were 
addressed comparing a random effects model to a fixed effects model.  No effect on the 
association between for the outcome and independent variables were seen for the data 
analyzed in this dissertation when the two models were compared.  A particular strength 
of the study statistical testing included a more complete assessment of gender-specific 
survival adjusted for treatment type, stage, morphology, grade and interaction terms.  
Studies have not been published in the literature (to the author’s knowledge) utilizing a 
statistical modeling approach which included these variables with interaction terms.  
Temporal differences due to changes in treatment regimens for the treatment of lung 
cancer were minimized as the time range of this study was 5 years (01-01-2000 though 
12-31-2004), as the standards of care did not change over this time period.  Also there 
were no coding changes introduced by NACCR for lung cancer during the study time 
range, so any misclassification error would be thought as minimal. 
Expanding upon the strength of the methods utilized, initially, during the model 
criteria development, different classifications (strata) for lung cancer treatments were 
identified.  Other independent variables were selected for inclusion into the statistical 
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model (the Multinomial Logistic Regression model) to answer question one.  
Stratification based on the independent variables of gender, morphology, stage, grade, 
age, race and marital status was utilized in the statistical model but this approach is unlike 
statistical models in other currently published studies
12, 40-45
.  This research model 
identified possible moderating variables that could have affected a lung cancer treatment 
based on the overall gender effect.  The fixed effects were accounted for in the first 
model for the multinomial logistic regression model (MLR1).  Another important aspect 
in answering Research Question I was to investigate possible random effects.  A random 
effects component was included in a second multinomial logistic regression (MLR2) 
model.  The decision to test for possible changes in the associations between the outcome 
and independent variables due to random effects was based on previous risk factors cited 
in the literature (Chapter Two) which included the environment
10, 172
 and geographic 
variations
10
.  Possible random effects due to these and other risk factors may have 
introduced differences in the lung cancer cases from the state cancer registries located in 
the four geographic regions of the United States.  Any differences in the association 
between the outcome and covariates due to the fixed effects versus random effects would 
have to be identified as the resultant statistics could be biased and could have included 
invalid interpretations.  
After the assessment of gender-specific treatment differences as outlined in 
Question One during Hypothesis I testing, Research Questions Two and Three then 
expanded the study of survival based on gender differences and other covariates.  Other 
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covariates included the treatment received, age, morphologic lung cancer type, grade and 
stage.  Research Question Two examined survival rates between males and females 
without any statistical adjustment for additional covariates in the model.  The 
investigation of the unadjusted lung cancer survival for the data analyzed in this 
dissertation over the five year time interval served a two-fold purpose.  First, an initial 
assessment of the unadjusted gender-specific survival associated with these data had to be 
made without the effects of the covariates on the outcome.  Secondly, an evaluation of 
the survivorship for these data was necessary so a comparison of the gender specific 
survival patterns reported in the literature could be made.  In the literature, females with 
lung cancer have been reported to have a survival advantage relative to males with lung 
cancer
3, 10
; consistency with the published literature would add to the external validity of 
the findings for this research.  For example, although interpretations of the unadjusted 
results were limited in scope, the individuals comprising the research lung cancer data set 
could be representative of the lung cancer cases in the US if the lung cancer data set 
survival patterns were consistent with gender-specific lung cancer survival results 
published in the literature
3, 10
.   
Other study’s strengths in the methodology to answer to the final research 
question during Hypothesis III statistical testing utilized univariate and multivariate 
survival analysis.  Univariate survival analysis was comprised of evaluating the statistics 
and graphs generated during the non-parametric technique for the Life Table Method.  
Each independent variable was tested separately to evaluate the proportionality 
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assumption between the strata of the independent variable versus survival time.  The 
proportionality assumption infers that the hazard or risk of failure (death) is constant over 
survival time.  For the assumption of proportionality to hold true, the graphs between the 
survival curves and the strata of the independent variable will be parallel; any 
overlapping, diverging or converging lines of the graphs can be cause for concern as this 
could violate the basic statistical assumptions for a semi-parametric model.    
The semi-parametric method, the Cox’s Proportional Hazards model, was selected 
to assess the multivariable relationship between the outcome (survival time) and the 
independent variables with the inclusion of interaction terms.  In order to obtain a model 
with the inclusion and exclusion of variables and variable combination for second order 
interaction terms, the stepwise procedure was used.  Included in the evaluation of the 
model fit, any non-proportionality concerns for a non-constant hazard over survival time 
were addressed via residual analysis.  Residual analysis was used to test for trends; any 
resultant trends in the residual plots for the individual variables would be displayed as 
increasing or decreasing slopes over the log of survival time.  If a trend was displayed for 
a variable over the log of survival time, the model would be inappropriate for the variable 
selected or the model would ―not fit the data‖ properly as the associated hazard for the 
variable was not constant over the survival time.  
The reported relationship in the literature between gender and survival is 
inconsistent.   Contrary to some of the articles published in the literature
8, 15,
 
17, 27, 167
 , 
with women having increased survivorship as compared to men, in some circumstances 
289 
this research found female had a survival disadvantage as compared to males.  Treatment 
differences based on gender were demonstrated and that those treatment differences 
changed the association for gender-specific survival when adjustments for the covariates 
and interaction terms were taken into account in the model.  When the overall gender 
effect was considered for the treatment received, morphologic lung cancer type and 
survival, this research design and resultant findings  supports the literature
27
 in which 
females have an increased survivorship as compared to men. 
 
Public Health Importance 
Finding the most effective treatment for increasing lung cancer survival has 
immense public health consequences.  Finding the most effective treatment includes 
many factors that must be accounted for but can be difficult to ascertain.  Prior to 
investigating effective treatments that increase survival, the examination of treatment 
differences based on key factors for lung cancer would have to be made.  This would 
include any treatment for lung cancer that differed on the basis of gender.  The clinical 
pathways for the care of lung cancer patients is standardized but when quantifiable 
techniques were utilized, differences in the standard of care for lung cancer patients were 
demonstrated to be gender dependent.  For example, the standard of care for early stage 
lung cancer is surgery.  For this data set, surgery was not consistently shown to be the 
first treatment choice for early stage lung cancer.  For example, separated females with 
stage I lung cancer versus separated males with stage I were 2.82 times more likely to 
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receive chemotherapy alone (OR = 2.82, 95% CI 1.17 – 6.80) as compared to receiving 
surgery alone.  For later stage disease, divorced females as compared to divorced males 
with stage III lung cancer were 1.57 times more likely to receive radiation in combination 
with surgery and chemotherapy (OR = 1.57, 95% CI 1.07 – 2.30) versus receiving 
surgery alone.  For later stage disease, radiation therapy in combination with 
chemotherapy or chemotherapy alone is the standard treatment recommendation. 
Building on this information of gender differences in lung cancer treatments, 
when the overall gender effect was assessed for survival, lung cancer type and the 
treatment received, males versus females had a statistically significant decrease in 
survival.  Gender specific survivorship was demonstrated to be statistically significant 
when adjusted for grade, grade*morphology, stage, stage*morphology, age group, 
stage*age group, race, treatment type*morphology, treatment type*grade, treatment 
type*stage, treatment type*age group, and treatment type*race.  When the gender effect 
for survival was assessed, females compared to males had a statistically significant 
survival advantage for six of the seven treatment groups.  For the other treatment group 
of radiation therapy in combination with chemotherapy, the result for the gender effect on 
survival was not statistically significant.  Generally, lung cancer cases receive a specific 
treatment for lung cancer regardless of gender; this was not the case for the data analyzed 
for this dissertation.  For males versus female lung cancer cases, differences in the type of 
treatment received could increase the risk of death or decrease survival time.  The 
associated gender differences with treatment selection were tested with multiple 
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modeling techniques resulting in the same conclusion, there is a statistically significant 
difference in the way female and male lung cancer cases are treated.  The methods and 
statistical analyses outlined in this research identify the impact of treatment decisions on 
female and male survival in particular for early stage lung cancer.   
The costs associated with lung cancer care are enormous according to the 
National Heart Lung & Blood Institute (NHLBI).   Lung cancer costs shows medical 
expenditures as approximately 10 billion annually, according to the Centers for Medicare 
and Medicaid Services (CMS) 
115
.  Over 13% of the total cancer care costs for 2006 were 
attributed to lung cancer.  The non-medical total or personal care exceeded 250 billion for 
the same time period.  If it is possible to assess the most effective treatment, there could 
be an increase in survival and a decrease in healthcare costs, thereby improving Public 
Health.   
 
Future Directions 
A first step in the future direction of this research would be a comparative 
analysis of an active versus passive cancer registry such as SEER.  These data are 
collected and compiled independently by SEER registries.  Further, the data are publicly 
available and issues of patient confidentiality will be minimized.  An independent 
comparison and verification of the study results would be a necessary next step to verify 
that treatment differences based on gender exist.  Lastly, a possible future direction, after 
validation of the research results presented in this dissertation would be the development 
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of a task group to investigate treatment differences based on gender and the subsequent 
impact on gender specific survivorship.   Several scientific and medical associations such 
as the American Medical Association, the American College of Surgeons, the National 
Cancer Institute, or the American College of Radiology might possibly accept this role. 
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Appendix I: State Demographics 
Table 70: Geographic Area:  Florida 
Profile of Sex and Age Characteristics: 2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Number Percent 
Total population 15,982,378 100.0 
SEX AND AGE  
Male 7,797,715 48.8 
Female 8,184,663 51.2 
 
Under 5 years 945,823 5.9 
5 to 9 years 1,031,718 6.5 
10 to 14 years 1,057,024 6.6 
15 to 19 years 1,014,067 6.3 
20 to 24 years 928,310 5.8 
25 to 34 years 2,084,100 13.0 
35 to 44 years 2,485,247 15.5 
45 to 54 years 2,069,479 12.9 
55 to 59 years 821,517 5.1 
60 to 64 years 737,496 4.6 
65 to 74 years 1,452,176 9.1 
75 to 84 years 1,024,134 6.4 
85 years and over 331,287 2.1 
 
Median age (years) 38.7 (X) 
 
18 years and over 12,336,038 77.2 
     Male 5,926,729 37.1 
     Female 6,409,309 40.1 
21 years and over 11,736,378 73.4 
62 years and over 3,245,806 20.3 
65 years and over 2,807,597 17.6 
     Male 1,216,647 7.6 
     Female 1,590,950 10.0 
Legend: (X) Not Applicable 
Source:  U.S. Census Bureau, Census 2000. 
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Table 71: Geographic Area:  Idaho 
Profile of Sex and Age Characteristics: 2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Number Percent 
Total population 1,293,953 100.0 
SEX AND AGE  
Male 648,660 50.1 
Female 645,293 49.9 
 
Under 5 years 97,643 7.5 
5 to 9 years 100,756 7.8 
10 to 14 years 104,608 8.1 
15 to 19 years 110,858 8.6 
20 to 24 years 93,994 7.3 
25 to 34 years 169,433 13.1 
35 to 44 years 192,968 14.9 
45 to 54 years 170,248 13.2 
55 to 59 years 60,024 4.6 
60 to 64 years 47,505 3.7 
65 to 74 years 75,970 5.9 
75 to 84 years 51,889 4.0 
85 years and over 18,057 1.4 
 
Median age (years) 33.2 (X) 
 
18 years and over 924,923 71.5 
     Male 458,934 35.5 
     Female 465,989 36.0 
21 years and over 860,220 66.5 
62 years and over 173,097 13.4 
65 years and over 145,916 11.3 
     Male 64,161 5.0 
     Female 81,755 6.3 
 
Legend: (X) Not Applicable 
Source:  U.S. Census Bureau, Census 2000. 
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Table 72: Geographic Area:  Indiana 
Profile of Sex and Age Characteristics: 2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Number Percent 
Total population 6,080,485 100.0 
SEX AND AGE  
Male 2,982,474 49.0 
Female 3,098,011 51.0 
 
Under 5 years 423,215 7.0 
5 to 9 years 443,273 7.3 
10 to 14 years 443,416 7.3 
15 to 19 years 453,482 7.5 
20 to 24 years 425,731 7.0 
25 to 34 years 831,125 13.7 
35 to 44 years 960,703 15.8 
45 to 54 years 816,865 13.4 
55 to 59 years 294,169 4.8 
60 to 64 years 235,675 3.9 
65 to 74 years 395,393 6.5 
75 to 84 years 265,880 4.4 
85 years and over 91,558 1.5 
 
Median age (years) 35.2 (X) 
 
18 years and over 4,506,089 74.1 
     Male 2,174,756 35.8 
     Female 2,331,333 38.3 
21 years and over 4,221,426 69.4 
62 years and over 888,688 14.6 
65 years and over 752,831 12.4 
     Male 303,797 5.0 
     Female 449,034 7.4 
 
Legend: (X) Not Applicable 
Source:  U.S. Census Bureau, Census 2000. 
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Table 73: Geographic Area:  Massachusetts 
Profile of Sex and Age Characteristics: 2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Number Percent 
Total population 6,349,097 100.0 
SEX AND AGE  
Male 3,058,816 48.2 
Female 3,290,281 51.8 
 
Under 5 years 397,268 6.3 
5 to 9 years 430,861 6.8 
10 to 14 years 431,247 6.8 
15 to 19 years 415,737 6.5 
20 to 24 years 404,279 6.4 
25 to 34 years 926,788 14.6 
35 to 44 years 1,062,995 16.7 
45 to 54 years 873,353 13.8 
55 to 59 years 310,002 4.9 
60 to 64 years 236,405 3.7 
65 to 74 years 427,830 6.7 
75 to 84 years 315,640 5.0 
85 years and over 116,692 1.8 
 
Median age (years) 36.5 (X) 
 
18 years and over 4,849,033 76.4 
     Male 2,289,671 36.1 
     Female 2,559,362 40.3 
21 years and over 4,587,935 72.3 
62 years and over 997,277 15.7 
65 years and over 860,162 13.5 
     Male 341,539 5.4 
     Female 518,623 8.2 
 
Legend: (X) Not Applicable 
Source:  U.S. Census Bureau, Census 2000. 
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Table 74: Geographic Area:  Nebraska  
Profile of Sex and Age Characteristics 2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Number Percent 
Total population 1,711263 100.0 
SEX AND AGE  
Male 843,351 49.3 
Female 867,912 50.7 
 
Under 5 years 117,048 6.8 
5 to 9 years 123,445 7.2 
10 to 14 years 128,934 7.5 
15 to 19 years 134,909 7.9 
20 to 24 years 120,331 7.0 
25 to 34 years 223,273 13.0 
35 to 44 years 263,834 15.4 
45 to 54 years 225,754 13.2 
55 to 59 years 77,584 4.5 
60 to 64 years 63,956 3.7 
65 to 74 years 115,699 6.8 
75 to 84 years 82,543 4.8 
85 years and over 33,953 2.0 
 
Median age (years) 35.3 (X) 
 
18 years and over 1,261,021 73.7 
     Male 612,965 35.8 
     Female 648,056 37.9 
21 years and over 1,180,859 69.0 
62 years and over 269,893 15.8 
65 years and over 232,195 13.6 
     Male 95,630 5.6 
     Female 136,565 8.0 
 
Legend: (X) Not Applicable 
Source:  U.S. Census Bureau, Census 2000. 
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Table 75: Geographic Area:  Oregon 
Profile of Sex and Age Characteristics: 2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Number Percent 
Total population 3,421,399 100.0 
SEX AND AGE  
Male 1,696,550 49.6 
Female 1,724,849 50.4 
 
Under 5 years 223,005 6.5 
5 to 9 years 234,474 6.9 
10 to 14 years 242,098 7.1 
15 to 19 years 244,427 7.1 
20 to 24 years 230,406 6.7 
25 to 34 years 470,695 13.8 
35 to 44 years 526,574 15.4 
45 to 54 years 507,155 14.8 
55 to 59 years 173,008 5.1 
60 to 64 years 131,380 3.8 
65 to 74 years 219,342 6.4 
75 to 84 years 161,404 4.7 
85 years and over 57,431 1.7 
 
Median age (years) 36.3 (X) 
 
18 years and over 2,574,873 75.3 
     Male 1,262,405 36.9 
     Female 1,312,468 38.4 
21 years and over 2,429,348 71.0 
62 years and over 513,663 15.0 
65 years and over 438,177 12.8 
     Male 186,477 5.5 
     Female 251,700 7.4 
 
Legend: (X) Not Applicable 
Source:  U.S. Census Bureau, Census 2000. 
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Table 76: Geographic Area:  Rhode Island 
Profile of Sex and Age Characteristics: 2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Number Percent 
Total population 1,048,319 100.0 
SEX AND AGE  
Male 503,635 48.0 
Female 544,684 52.0 
 
Under 5 years 63,896 6.1 
5 to 9 years 71,905 6.9 
10 to 14 years 71,370 6.8 
15 to 19 years 75,445 7.2 
20 to 24 years 71,813 6.9 
25 to 34 years 140,326 13.4 
35 to 44 years 170,310 16.2 
45 to 54 years 141,863 13.5 
55 to 59 years 49,982 4.8 
60 to 64 years 39,007 3.7 
65 to 74 years 73,684 7.0 
75 to 84 years 57,821 5.5 
85 years and over 20,897 2.0 
 
Median age (years) 36.7 (X) 
 
18 years and over 800,497 76.4 
     Male 376,436 35.9 
     Female 424,061 40.5 
21 years and over 748,445 71.4 
62 years and over 175,111 16.7 
65 years and over 152,402 14.5 
     Male 60,002 5.7 
     Female 92,400 8.8 
 
Legend: (X) Not Applicable 
Source:  U.S. Census Bureau, Census 2000. 
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Table 77: Geographic Area:  South Carolina 
Profile of Sex and Age Characteristics: 2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Number Percent 
Total population 4,012,012 100.0 
SEX AND AGE  
Male 1,948,929 48.6 
Female 2,063,083 51.4 
 
Under 5 years 264,679 6.6 
5 to 9 years 285,243 7.1 
10 to 14 years 290,479 7.2 
15 to 19 years 295,377 7.4 
20 to 24 years 281,714 7.0 
25 to 34 years 560,831 14.0 
35 to 44 years 625,124 15.6 
45 to 54 years 550,321 13.7 
55 to 59 years 206,762 5.2 
60 to 64 years 166,149 4.1 
65 to 74 years 270,048 6.7 
75 to 84 years 165,016 4.1 
85 years and over 50,269 1.3 
 
Median age (years) 35.4 (X) 
 
18 years and over 3,002,371 74.8 
     Male 1,432,413 35.7 
     Female 1,569,958 39.1 
21 years and over 2,814,131 70.1 
62 years and over 581,573 14.5 
65 years and over 485,333 12.1 
     Male 196,734 4.9 
     Female 288,599 7.2 
 
Legend: (X) Not Applicable 
Source:  U.S. Census Bureau, Census 2000. 
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Appendix II: Lung Cancer Distribution Tables 
Table 41:  Lung Cancer Distribution - Treatment Group versus Race 
 
Treatment Group Race Frequency Percent 
 Radiation White  3921 90.1 
 I Black 401 9.2 
  Other 29 0.7 
 Chemotherapy White  6026 93.1 
 II Black 383 5.9 
  Other 63 1.0 
 Surgery White  11967 94.0 
 III Black 659 5.2 
  Other 102 0.8 
 Radiation + Surgery White  990 93.1 
 IV Black 64 6.0 
  Other 9 0.9 
 Radiation + Chemotherapy White  7262 91.3 
 V Black 627 7.9 
  Other 66 0.8 
 Surgery + Chemotherapy White  1166 93.4 
VI  Black 75 6.0 
  Other 8 0.6 
 Radiation + Surgery +  White  1254 93.0 
 Chemotherapy Black 81 6.0 
 VII Other 13 1.0 
 No Radiation, Surgery, White  8872 91.5 
and/or Chemotherapy Black 752 7.8 
 VIII  Other 73 0.8 
 
There were no obvious differences in treatment groups versus and distribution of 
race – see Table 41 in Appendix B. The majority of lung cancer cases are White ranging 
from 91.3% of all lung cancer cases in Group V (Radiation and Chemotherapy) to 94% of 
all lung cancer cases in Group III (Surgery). The classification of ―Other‖ for race 
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contained the least amount of lung cancer cases for each treatment group with each 
Treatment Group having a minimum of approximately one percent within each treatment 
classification (I – VIII). 
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Table 42:  Lung Cancer Distribution - Treatment Group vs. Marital Status at Diagnosis 
Treatment Group Marital Status Frequency Percent 
 Single 482 11.1 
  Radiation Married 2309 53.1 
 I Separated 46 1.1 
  Divorced 486 11.2 
  Widowed 1028 23.6 
  Single 652 10.1 
Chemotherapy  Married 3879 59.9 
II  Separated 63 1.0 
  Divorced 734 11.3 
  Widowed 1144 17.7 
  Single 1014 8.0 
Surgery Married 8014 63.0 
 III  Separated 76 0.6 
  Divorced 1301 10.2 
  Widowed 2323 18.3 
  Single 93 8.8 
Radiation + Surgery  Married 693 65.2 
IV  Separated 6 0.6 
  Divorced 108 10.2 
  Widowed 163 15.3 
Radiation +   Single 784 9.9 
Chemotherapy  Married 4991 62.7 
V  Separated 86 1.1 
  Divorced 982 12.3 
  Widowed 1112 14.0 
 Surgery + Single 103 8.3 
Chemotherapy  Married 873 69.9 
VI  Separated 9 0.7 
  Divorced 122 9.8 
 Radiation + Surgery + Single 98 7.3 
 Chemotherapy Married 934 69.3 
 VII Separated 11 0.8 
  Divorced 148 11.0 
  Widowed 157 11.7 
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 No Radiation, Surgery, Single 1201 12.4 
 and/or Chemotherapy Married 5066 52.2 
 VIII Separated 70 0.7 
  Divorced 1039 10.7 
  Widowed 2321 23.9 
 
 
For all treatment groups in Table 42 (Treatment Group vs. Marital Status at 
Diagnosis), the greatest percentage of the lung cancer cases were married at the time of 
diagnosis ranging from 52.2 percent for Treatment Group VIII to maximum percentage 
of 69.9 percent for surgical and chemotherapy, Group VI. 
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Table 43: Lung Cancer Distribution - Treatment Group vs. Age Group at Diagnosis 
 
Treatment 
Group 
Age Group at  
Diagnosis Frequency Percent 
       
  > 40 - < 50 189 4.3 
 Radiation > 50 - < 60 573 13.2 
 I > 60 - < 70 1093 25.1 
  > 70 - < 80 1675 38.5 
  > 80 - < 90 821 18.9 
       
  > 40 - < 50 404 6.2 
 Chemotherapy > 50 - < 60 1192 18.4 
 II > 60 - < 70 2061 31.8 
  > 70 - < 80 2225 34.4 
  > 80 - < 90 590 9.1 
       
  > 40 - < 50 442 3.5 
 Surgery > 50 - < 60 1662 13.1 
  III > 60 - < 70 3893 30.6 
 > 70 - < 80 5366 42.2 
  > 80 - < 90 1365 10.7 
  > 40 - < 50 59 5.6 
 Radiation + Surgery > 50 - < 60 178 16.8 
 IV > 60 - < 70 358 33.7 
  > 70 - < 80 395 37.2 
  > 80 - < 90 73 6.9 
 Radiation + > 40 - < 50 666 8.4 
Chemotherapy  > 50 - < 60 1743 21.9 
V  > 60 - < 70 2705 34.0 
  > 70 - < 80 2361 29.7 
  > 80 - < 90 480 6.0 
 Surgery + > 40 - < 50 92 7.4 
Chemotherapy  > 50 - < 60 287 23.0 
VI  > 60 - < 70 479 38.4 
  > 70 - < 80 350 28.0 
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  > 80 - < 90 41 3.3 
Radiation + Surgery +  > 40 - < 50 133 9.9 
 Chemotherapy > 50 - < 60 345 25.6 
VII  > 60 - < 70 485 36.0 
  > 70 - < 80 366 27.2 
  > 80 - < 90 19 1.4 
No Radiation, Surgery,  > 40 - < 50 367 3.8 
 and/or Chemotherapy > 50 - < 60 1199 12.4 
VIII  > 60 - < 70 2462 25.4 
  > 70 - < 80 3666 37.8 
  > 80 - < 90 2003 20.7 
 
The greatest percentage for age group IV (> 70 - < 80) were found in Treatment 
Groups I (38.5), II (34.4), III (42.2), IV (37.2), V (29.7), and VIII (37.8). The remaining 
two treatment groups had the highest percentage in the third age group, > 60 - < 70, 
Treatment Group VI (38.4) and Treatment Group VII (36.0). 
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Appendix III: Chemotherapy Agents 
Table 78: Chemotherapy Agents for Lung Cancer 
 
Source: Alexander Spira, M.D., Ph.D., and David S. Ettinger, M.D.; N Engl J Med 2004; 
350:379-92. 
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Appendix IV: Calculation of the Overall Interaction Effect 
Calculation of the overall effect for the treatment type received (variables extracted for 
the Multinomial Logistic Regression Model). 
 
Stage 
The interaction terms containing stage with the main effects are included in the following 
equation that was originally extracted from the full model.  
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI + 
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9 
stageI* age_groupI + 10 morphologyI + 11 raceI 
The terms that contain stage are identified and include the main effect: 
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI + 
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 
9 stageI* age_groupI + 10 morphologyI + 11 raceI 
 
The following equation results: 
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 4 gradeI + 5age_groupI + 6 
genderI*stageI + 8 stageI*gradeI + 9 stageI* age_groupI 
 
These terms must be evaluated separately to assess the effect of stage on the outcome.  In 
other words, as there are three interaction terms with stage, three separate equations 
containing stage are calculated for gender, grade and age group.  In Part I below, the 
example treatment is radiation, stageI (stageI = stage 1 coded as 1 and stage IV coded as 
0 (reference).  Part II will examine stage and grade and Part III will assess stage and age 
group. 
 
Part I: Evaluating stage and gender 
 
Stage I: Logit (Y= Radiation | stageI = 1, genderI) =  + 1 genderI + 2 + 4 gradeI + 
5age_groupI + 6 genderI* + 8 *gradeI + 9 * age_groupI 
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Stage IV: Logit (Y= Radiation | stageI = 0, genderI) =  + 1 genderI + 4 gradeI + 
5age_groupI  
 
Subtracting stage I from stage IV, the following is given: 
 
Logit (Y= Radiation | stageI = 1, genderI) = 2 + 6 genderI* + 8 *gradeI + 9 * 
age_groupI 
 
Looking at females as compared to males with gender = 1 for females and gender = 0 for 
males. 
 
Logit (Y= Radiation | stageI = 1, genderI = 1) = 2 + 6 + 8 *gradeI + 9 * age_groupI 
Logit (Y= Radiation | stageI = 1, genderI = 0) = 2            + 8 *gradeI + 9 * age_groupI 
 
The Odds Ratio for females with stage 1 lung cancer (grade and age group are fixed or 
controlled for) is given as:  OR = exp (2 + 6)  
 
Part II: Evaluating stage and grade 
 
Stage I: Logit (Y= Radiation | stageI = 1, genderI) =  + 1 genderI + 2 + 4 gradeI + 
5age_groupI + 6 genderI* + 8 *gradeI + 9 * age_groupI 
 
Stage IV: Logit (Y= Radiation | stageI = 0, genderI) =  + 1 genderI + 4 gradeI + 
5age_groupI  
 
Subtracting stage I from stage IV, the following is given: 
 
Logit (Y= Radiation | stageI = 1, genderI) = 2 + 6 genderI* + 8 *gradeI + 9 * 
age_groupI 
 
Looking at grade I as compared to grade IV with gradeI = 1 for grade I and gradeI = 0 for 
grade IV. 
 
Logit (Y= Radiation | stageI = 1, gradeI = 1) = 2 + 6 genderI* + 8 + 9 * age_groupI  
Logit (Y= Radiation | stageI = 1, gradeI = 0) = 2 + 6 genderI*         + 9 * age_groupI  
 
The Odds Ratio for stage 1 grade 1 lung cancer (gender and age group are fixed or 
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controlled for) is given as:  OR = exp (2 + )  
 
Part III: Evaluating stage and age group 
 
Stage I: Logit (Y= Radiation | stageI = 1, age_groupI) =  + 1 genderI + 2 + 4 gradeI + 
5age_groupI + 6 genderI* + 8 *gradeI + 9 * age_groupI 
 
Stage IV: Logit (Y= Radiation | stageI = 0, age_groupI =  + 1 genderI + 4 gradeI + 
5age_groupI  
 
Subtracting stage I from stage IV, the following is given: 
 
Logit (Y= Radiation | stageI = 1, age_groupI) = 2 + 6 genderI* + 8 *gradeI + 9 * 
age_groupI 
 
Looking at grade I as compared to grade IV with gradeI = 1 for grade I and gradeI = 0 for 
grade IV. 
 
Logit (Y= Radiation | stageI = 1, age_groupI = 1) = 2 + 6 genderI* + 8 *gradeI + 9  
Logit (Y= Radiation | stageI = 1, age_groupI = 0) = 2 + 6 genderI* + 8 *gradeI +  
 
The Odds Ratio for stage 1 in age group I (gender and grade are fixed or controlled for) is 
given as:  OR = exp (2 + )  
 
Grade 
Given the equation extracted from the full model: 
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI + 
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9 
stageI* age_groupI + 10 morphologyI + 11 raceI 
 
The terms that contain grade are identified and include the main effect: 
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI + 
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9 
stageI* age_groupI 
 
The following equation results: 
329 
Logit (Y= Treatment | X) =  + 2 stageI + 4 gradeI + 8 stageI*gradeI  
 
Next, the effect of grade on the probability of receiving radiation therapy as a 
treatment, given that the patient is at stageI, is determined as: 
 
Grade I:    Logit (Y=Radiation|grade=1, stageI) =  + 2 stageI + 4 + 8 *stageI  
Grade IV: Logit (Y=Radiation|grade=0, stageI) =  + 2 stageI  
By subtracting the Logit for grade IV from Logit for grade I, the following 
equation is given as: 
 
Logit (Y=Radiation |grade=1, stageI) = 4 + 8 *stageI 
 
At the variable stageI which is coded as 1 for stageI and 0 for stageI (V = 
reference), the results are given as: 
   
Logit (Y=Radiation |grade=1, stageI =1) = 4  + 8        
Logit (Y=Radiation |grade=1, stageI =0) = 4         
 
Estimating the overall effect of grade (grade I as compared to grade IV) on the 
probability of receiving radiation treatment, after adjusting for stageI (stage=1) results in 
the following equation for the Odds Ratio is given as:  
 
OR = exp (4 + 8).   
 
Marital Status 
The interaction terms containing marital status with the main effects are included in the 
following equation that was originally extracted from the full model.  
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI + 
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9 
stageI* age_groupI + 10 morphologyI + 11 raceI 
 
The terms that contain stage are identified and include the main effect: 
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI 
+ 5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 
9 stageI* age_groupI 
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The following equation results: 
 
Logit (Y= Treatment | X) =  + 1 genderI + 3 marital_statusI + 7 genderI* 
marital_statusI  
 
Evaluating marital_statusI for marital status = I (single) and marital_statusI for marital 
status = V (widowed), the following is given: 
 
Marital Status I: Logit (Y= Radiation | marital_statusI = 1, genderI) =  + 1 genderI + 
3 + 7 genderI*  
 
Marital Status V: Logit (Y= Radiation | marital_statusI = 0, genderI) =  + 1 genderI  
 
 
Subtracting marital status I from marital status IV, the following equation results: 
 
Logit (Y= Radiation | marital_statusI = 1, genderI) = 3 + 7 genderI*  
 
Looking at females as compared to males with genderI = 1 for females and gradeI = 0 for 
males. 
 
Logit (Y= Radiation | marital_statusI = 1, genderI = 1) = 3 + 7   
Logit (Y= Radiation | marital_statusI = 1, genderI = 0) = 3   
 
 
The Odds Ratio for the overall interaction effect given marital status for females as 
compared to males is given as:  OR = exp (3 + 7)  
 
 
Age Group 
The interaction terms containing age group with the main effects are included in the 
following equation that was originally extracted from the full model.  
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI + 
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9 
stageI* age_groupI + 10 morphologyI + 11 raceI 
 
The terms that contain age group are identified and include the main effect: 
 
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI + 
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5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9 
stageI* age_groupI 
 
The following equation results: 
 
Logit (Y= Treatment | X) =  + 2 stageI + 5age_groupI + 9 stageI* age_groupI 
 
For the next example, the treatment group still remains as Radiation alone.  Evaluating 
age_groupI for age group I = 1 (> 40 - < 50 year) and age_groupI for age group V = 0 (> 
80 - < 90 years), the following is given: 
 
Marital Status I: Logit (Y= Radiation | age_groupI = 1, stageI) =  + 2 stageI + 5 + 9 
stageI*  
 
Marital Status V: Logit (Y= Radiation | age_groupI = 0, stageI) =  + 2 stageI  
 
 
Subtracting age group I from age group V, the following equation results: 
 
Logit (Y= Radiation | age_groupI = 1, stageI) = 5 + 9 stageI* 
 
Looking at stage I and stage IV with stageI = 1 for stage I and stageI = 0 for stage IV. 
 
Logit (Y= Radiation | marital_statusI = 1, stageI = 1) = 5 + 9  
Logit (Y= Radiation | marital_statusI = 1, stageI = 0) = 5  
 
 
 
The Odds Ratio for the overall interaction effect given age group I controlling for stage is 
given as:  OR = exp (5 + 9)  
 
 
Logit (Y= Radiation | stageI = 1, grade =1) =  + 1 gender + 2 stageI + 4 gradeI + 
5age_groupI + 6 gender*stageI + 8 stageI*gradeI + 9 stage* age_groupI 
 
Logit (Y= Radiation | stageI = 1, age_group =1) =  + 1 gender + 2 stageI + 4 gradeI + 
5age_groupI + 6 gender*stageI + 8 stageI*gradeI + 9 stage* age_groupI 
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